<SEC-DOCUMENT>0000719135-23-000027.txt : 20230511
<SEC-HEADER>0000719135-23-000027.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230511150623
ACCESSION NUMBER:		0000719135-23-000027
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apyx Medical Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		23910484

	BUSINESS ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760
		BUSINESS PHONE:		7273842323

	MAIL ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL Corp
		DATE OF NAME CHANGE:	20150319

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>apyx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:28fd0711-76c0-4c99-9948-92d9f912ad78,g:c54375b6-2eb5-4e7e-b289-a9d1feaf728d,d:81be52fe8a3444dab77580d4782f59cd--><html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:apyx="http://apyxmedical.com/20230331" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>apyx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN18xLTEtMS0xLTI3ODUy_400a54fe-4da9-4a46-83fc-2e6835158cdd">0000719135</ix:nonNumeric><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN18yLTEtMS0xLTI3ODUy_a04ed26e-72bb-4779-94a2-a0c84fd09e2d">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN18zLTEtMS0xLTI3ODUy_8fc8e637-ebf3-47b9-95a1-1026c9d66197">December 31</ix:nonNumeric><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN180LTEtMS0xLTI3ODUy_f1c0b744-ab9c-4298-99e8-1e586045cf64">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN181LTEtMS0xLTI3ODUy_49117a52-0375-4794-a0a2-b74808a9809a">2023</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="apyx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45bd55a6ca54408a973dca3478244f79_I20230510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="icea0a6dbf6c34a688351e2f5840efa13_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd413f451a2b4d84baf891bc120bef43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700d97178d1c46b7bec5f0372efea304_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9633d667b894c12a7a3c33ec5e248c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf286c1d1ac4c6a9c53a9c75c20d4fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc8cd3754b8424cbe8a8f678d790982_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19af6f40a56e4da7be4be449774e9c38_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9497de4ef599443782493d1d3dbc6609_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6931ca2b85e4446925ba4947ddbe1f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4434306a747741429a540f6a76d96647_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9fa3089458f42aaa023258bbce7b89b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f3a4fe886c472bb7f4d921600ce418_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8e01e3706a4c1a911c23a654ab59de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i791bf538170f41c58addc94c2a446640_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f633cacdd140aa9bab43f887b78a2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11e1edafd25048a898c12ed311d1309e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2ed1527d7c4ddf9a25ba44fc615c47_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fe44f8091664b47a7bff608e2b30703_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d048bc9f0341638ec692b0b8f93ca7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3301b75ad88b4456ac3325aa744427ee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bdfda32745048c198232e04864a2e0c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c5d633167d49f083a557d93bdab57d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i302145e8cbf54af2abc2a3fd7137c26e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i188f6d41df7e4eb08c173022c9d1302e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d14b67a6cb40a08208352f01687ae9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4329db9485b349278676f47f9db880a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf0f4361aaa413daa96a1cde208b376_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9396d3bd36c8431da99d9d9421e5af7b_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3932728fc7a04ebaa43fed7736e1c40c_D20221122-20221122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apyx:ShelfRegistrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i842683acc0a34f84893c61d6455c84bd_D20221122-20221122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apyx:AtTheMarketFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7ad3b30f9045f4a940c5dd6e62909f_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22587808ca5d48bab5471ce1b3d5871d_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4a9c2aec01046399022caa446b9ec13_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e46158015eb4aec901c105c23099f18_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9789c9d226394206be51a46193f836c3_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32fcb27739a44c999f32b3a61c449f6_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-14</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26213cf5bc234af691fd6ad429fc40cf_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02d47ac09b44377974655e36339723e_D20230109-20230109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6a3f2eb674df41a2ae74e07a8d73a59c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i444e3d03e8b34aea95597bd9077be349_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d67f218c964b66aa874fbba351e483_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d4a532478246d4bf4d795e035840ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e80aa911f544e7a99cf80274b923c6a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c447b579b144bf96d49d5e10b32eee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52498e454d8e4e4a9cc70ff49ba56436_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67f1d0dccbc94a32bfdc2e93912d45e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b3a3086a39456d82fe6d3a37c11a9b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0311da46d2f74bb18fbfe7861fcd1a6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb80eb1f91e44c0eaf61e0cd23a39e01_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c7b33ceee847c4b00c7492e4b509f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5534ca1fb36e45c69f14c9ee7219b0e5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:MoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ef5925e82e463ca7c4bf42717d5767_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:MoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if55075181de3450781da931211bae736_D20230508-20230508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i099455fbc1dc4ad496d841a9e2cbc539_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="monthlypayment"><xbrli:measure>apyx:monthlyPayment</xbrli:measure></xbrli:unit><xbrli:context id="i5d5ece174ab94a1db32622d52c60a23c_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if473b8c0c1e64a71aaa04d5e033d18a5_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i326c0815b32647328b23564b770a38b5_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9fbd2dc730476f8a383e982377fba4_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id84b5b8ace5c47e0ab7d98a27c878c5a_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8727fd78b5f49719ede74e72b308e36_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6475488d296841caa68cd47c85e020e8_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959de39370604cf7aad3380d9347c61e_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f997a25acb43b78c977a49616ca9cb_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d5b6ac44ade4700b26334526cfe5f12_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b5c4f206324a52b8b01adbfe778760_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb361a5c665a4bcbb5b44abe46d8fc2b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6338653760b44614b5950f6458c874e5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4271a8fb9da64a4789ce96b320c25e39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f9fa1ecfdb48119493afdf30b2022a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa4190bc3674f469e5b158e6869197c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb98c8ff23e49bc88f698fa56afd8ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4980f0f2ab4be298429e6c68c4337c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i994301f8b554452584f2e4a03b35f7ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie30ce932627140d1a2b179341ef78232_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ce5d204aa7344c59e93d632a33eef74_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857f1353ae2c4ec3bc1c0d6d91f7e28c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib96384db7fff41dbb63293f4abff78af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd237ef53a384e9e80d9d797d4712603_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3163fe51e869499585757dba371b5390_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968a4cfb77a54232afc8b80ea39ad52b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59716d0f60c45d9aded6f41b3e4a29f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c3ed228146b4231874ddd7a84ecf89c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b520559f24c441e931060ece6becb9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1fa5e6669544a54afa2eccf6e04c7a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i429b0f131ab543fbb23ba8b453c39589_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2994bfe0e594059a28c66ab8010af39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc25d1761ff44d87a5e3cce964599c64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>apyx:lease</xbrli:measure></xbrli:unit><xbrli:context id="i03f055d56d024c43ab76ceb69016f0cc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42273566c1174b14a4e8392f80ba2427_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d07b00814b44846ae29c9126733b0ab_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e994b58a5f469cb23af8692f7bf53f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead2dc3eba5e47188eea66a730ec7ba2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe7f3502b4347be9913b0ff042c7661_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8478849b5317485ba002f297876ef34b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>apyx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef61e5dd37545a3ad7e31b677f88c1d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5569b815eaea4f9d9cdfcb8f7e5f0209_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6176a8f8df744f2b97ab2568640c4a9d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic12b47ef6b0e48508323229d60109300_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i81be52fe8a3444dab77580d4782f59cd_1"></div><div style="min-height:31.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ1_97f719d9-8fcb-40e9-874f-bffd5aaeea8e">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6ZDYwYzFkOGQyNDAzNDY4NWJmNTNmNjY4ODExODBjYmYvdGFibGVyYW5nZTpkNjBjMWQ4ZDI0MDM0Njg1YmY1M2Y2Njg4MTE4MGNiZl8wLTItMS0xLTI3ODUy_f9860a47-3022-4a38-b7be-2a0e8e375315">&#9746;</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the quarterly period ended</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6ZDYwYzFkOGQyNDAzNDY4NWJmNTNmNjY4ODExODBjYmYvdGFibGVyYW5nZTpkNjBjMWQ4ZDI0MDM0Njg1YmY1M2Y2Njg4MTE4MGNiZl8xLTQtMS0xLTI3ODUy_2b345f4b-d684-49ab-9d55-cad6f3d7321d">March 31, 2023</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">or</span></td></tr><tr style="height:3pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6ZDYwYzFkOGQyNDAzNDY4NWJmNTNmNjY4ODExODBjYmYvdGFibGVyYW5nZTpkNjBjMWQ4ZDI0MDM0Njg1YmY1M2Y2Njg4MTE4MGNiZl81LTItMS0xLTI3ODUy_c7761172-599a-4c8d-b76b-078cb19af5a7">&#9744;</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from _____ to _____</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6ZDYwYzFkOGQyNDAzNDY4NWJmNTNmNjY4ODExODBjYmYvdGFibGVyYW5nZTpkNjBjMWQ4ZDI0MDM0Njg1YmY1M2Y2Njg4MTE4MGNiZl83LTQtMS0xLTI3ODUy_1ffe6cc7-a783-4b38-8f67-810e960919e2">0-12183</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:114pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="apyx-20230331_g1.jpg" alt="apyxmedicallogotagline.jpg" style="height:145px;margin-bottom:5pt;vertical-align:text-bottom;width:223px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NDcxZTg2Yjc3MmQxNDBkOTk1ZGZiMTA0MGZjNzE1NzEvdGFibGVyYW5nZTo0NzFlODZiNzcyZDE0MGQ5OTVkZmIxMDQwZmM3MTU3MV8xLTAtMS0xLTI3ODUy_188efc5f-19f2-4d87-87a2-8a3b1fbe274a">APYX MEDICAL CORPORATION</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NDIzMzVjZDY5MjgyNDVlNDg5OGM0ZjRjNzE4YmM4OGIvdGFibGVyYW5nZTo0MjMzNWNkNjkyODI0NWU0ODk4YzRmNGM3MThiYzg4Yl8wLTAtMS0xLTI3ODUy_d66174c5-217a-40a7-bb5a-208431e52eff">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NDIzMzVjZDY5MjgyNDVlNDg5OGM0ZjRjNzE4YmM4OGIvdGFibGVyYW5nZTo0MjMzNWNkNjkyODI0NWU0ODk4YzRmNGM3MThiYzg4Yl8wLTItMS0xLTI3ODUy_bee6e10d-0387-44c4-814e-685196f4e452">11-2644611</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ2_570509d1-01df-4671-8a0f-37a32400757e">5115 Ulmerton Road,</ix:nonNumeric> <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTUy_375d0697-6687-42fa-ba44-564a9f969a44">Clearwater</ix:nonNumeric>, <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTUz_9dd8f5c2-c004-4095-beaf-3ddbcbfe01a7">FL</ix:nonNumeric> <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ3_8bf03cea-d573-4a74-9f76-3425efcbafdf">33760</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ4_7aeb0e60-a576-41c9-a916-7a0e0c53325e">727</ix:nonNumeric>) <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ5_715189b8-297a-4687-8623-99043b821da4">384-2323</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities Registered Pursuant to Section 12 (b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6YzNiNTc4MzMwYTNmNDBiOGExYTMwNjk5ZjkzMTMyNGIvdGFibGVyYW5nZTpjM2I1NzgzMzBhM2Y0MGI4YTFhMzA2OTlmOTMxMzI0Yl8xLTAtMS0xLTI3ODUy_5a9a48aa-c738-4a63-bda6-3ab268a5060e">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6YzNiNTc4MzMwYTNmNDBiOGExYTMwNjk5ZjkzMTMyNGIvdGFibGVyYW5nZTpjM2I1NzgzMzBhM2Y0MGI4YTFhMzA2OTlmOTMxMzI0Yl8xLTEtMS0xLTI3ODUy_11682321-17bd-48a8-9755-e7765d7c4136">APYX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6YzNiNTc4MzMwYTNmNDBiOGExYTMwNjk5ZjkzMTMyNGIvdGFibGVyYW5nZTpjM2I1NzgzMzBhM2Y0MGI4YTFhMzA2OTlmOTMxMzI0Yl8xLTItMS0xLTI3ODUy_da6c84c4-75b4-4d79-aad5-66562610c6b3">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTUw_ce13948c-2293-4930-942f-299fb7686141">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTUx_cf664d52-441c-45d3-9ffa-519e010737b9">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NTI5MDJkNzZjZWRlNGM0ZDk2NjY5NGI4NTllZTJlZWQvdGFibGVyYW5nZTo1MjkwMmQ3NmNlZGU0YzRkOTY2Njk0Yjg1OWVlMmVlZF8xLTAtMS0xLTI3ODUy_4bd575f0-5d57-499c-8ba4-6dcf0438d9ee">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NTI5MDJkNzZjZWRlNGM0ZDk2NjY5NGI4NTllZTJlZWQvdGFibGVyYW5nZTo1MjkwMmQ3NmNlZGU0YzRkOTY2Njk0Yjg1OWVlMmVlZF8xLTQtMS0xLTI3ODUy_525c9051-70be-4ac9-8e46-103f96baf2de">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NTI5MDJkNzZjZWRlNGM0ZDk2NjY5NGI4NTllZTJlZWQvdGFibGVyYW5nZTo1MjkwMmQ3NmNlZGU0YzRkOTY2Njk0Yjg1OWVlMmVlZF8yLTQtMS0xLTI3ODUy_4f6b2590-e286-42e7-99d3-767a0bca1953">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQz_f9970786-1d73-4fad-a24b-a59dc9454a27">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">s of May&#160;10, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i45bd55a6ca54408a973dca3478244f79_I20230510" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8yNzQ4Nzc5MDcxMDIy_84f23e2b-bcf8-4445-8fca-9d8e7cf37a5a">34,597,822</ix:nonFraction> shares of the registrant&#8217;s $0.001 par value common stock were outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO QUARTERLY REPORT ON FORM 10-Q</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended March 31, 2023</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_10">Financial Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_10">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_13">Financial Statements</a> (Unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_16">Consolidated Balance Sheets at </a>March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_19">Consolidated Statements of Operations for </a>the three months ended March 31, 2023 and 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_22">Consolidated Statements of Changes in Equity for the</a> three months ended March 31, 2023 and 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_28">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_67">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_76">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_76">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_79">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_79">30</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_82">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_82">31</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_85">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_85">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_88">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_88">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_94">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_94">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_97">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_97">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_100">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_103">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_103">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_106">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_106">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_109">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i81be52fe8a3444dab77580d4782f59cd_109">35</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_10"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. &#160;&#160;&#160;&#160;Financial Information</span></div><div><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_13"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMy0xLTEtMS0yNzg1Mg_5da3d28e-93e6-4e49-b453-e5007acffd31">16,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMy0zLTEtMS0yNzg1Mg_e909998d-37a7-4963-a1e2-55235ffcda9e">10,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Trade accounts receivable, net of allowance of $<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNC0wLTEtMS0yNzg1Mi90ZXh0cmVnaW9uOjc5Y2Y1YTAyOTE4MTQ0OWRiNGIyNjc1YjlkZDM4MDM5XzU0_02cdd8c6-f03a-42fe-892c-b7397ff7b9d0">359</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNC0wLTEtMS0yNzg1Mi90ZXh0cmVnaW9uOjc5Y2Y1YTAyOTE4MTQ0OWRiNGIyNjc1YjlkZDM4MDM5XzYx_27f54d05-265a-4587-a80c-f7b5aa91f312">668</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNC0xLTEtMS0yNzg1Mg_988054b9-a757-4f52-ae5e-affc2974d5e6">9,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNC0zLTEtMS0yNzg1Mg_6a7b58da-8017-40fa-953f-11f9f10dc0e2">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNS0xLTEtMS0yNzg1Mg_e9ee9afe-3255-4fc8-a6f3-c3c835969be1">7,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNS0zLTEtMS0yNzg1Mg_e82d42be-5630-4948-9ed7-6cd9dd9bdea0">7,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNi0xLTEtMS0yNzg1Mg_2158a497-94e3-4aef-83c1-aa3ddc7f8019">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNi0zLTEtMS0yNzg1Mg_0e5efda5-2fa3-426f-beba-e06d33db4aa8">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net of provision for obsolescence of $<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNy0wLTEtMS0yNzg1Mi90ZXh0cmVnaW9uOjlmMzk4YzJmMWE3NzQxNTNhMWVkY2UxMDczNWY2ZDg5XzU0_e57a1197-26da-4f1a-a54b-280d5673de59">428</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNy0wLTEtMS0yNzg1Mi90ZXh0cmVnaW9uOjlmMzk4YzJmMWE3NzQxNTNhMWVkY2UxMDczNWY2ZDg5XzYx_8aec5397-ecce-4d8f-9087-d4b5abce2cc4">457</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNy0xLTEtMS0yNzg1Mg_f53e83e7-c12c-4830-8864-75a91eab0f2e">10,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNy0zLTEtMS0yNzg1Mg_1997e1e5-0acf-4883-a586-63d54e344129">11,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOS0xLTEtMS0yODM2Nw_23744043-79dc-40fe-83c9-d6b67f1c8de2">4,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOS0zLTEtMS0yODM2Nw_b23084a2-3910-4ea7-a790-91a0e131dd33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOC0xLTEtMS0yNzg1Mg_abf99352-4d8e-45d6-aae9-50ce328ee43d">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOC0zLTEtMS0yNzg1Mg_97d5a67b-644e-4f6b-b720-a87bcdddb790">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOS0xLTEtMS0yNzg1Mg_3a18f716-5002-492c-b6e2-35ad363c48ac">52,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOS0zLTEtMS0yNzg1Mg_09a13594-fcd0-4472-882b-6ec0a3646e9e">42,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTAtMS0xLTEtMjc4NTI_0d345193-37e5-4678-b0b6-bed2c3fcf717">2,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTAtMy0xLTEtMjc4NTI_f27874bb-4424-48c6-be38-321271687c31">6,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTEtMS0xLTEtMjc4NTI_656c8907-41ee-4eb6-a0e2-4770dcaa225b">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTEtMy0xLTEtMjc4NTI_b65fd126-34fc-412f-8e1f-83d9b5512f62">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTItMS0xLTEtMjc4NTI_b1d52d39-6f95-4c12-a858-e6c9df4620cd">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTItMy0xLTEtMjc4NTI_2c5c3cee-5605-48fe-9b22-baffe8be9a42">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTQtMS0xLTEtMjc4NTI_907b414b-b6f9-47bc-841d-ae0a579986d2">1,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTQtMy0xLTEtMjc4NTI_e642c8e6-41ef-41eb-946c-d63e82ff1cfb">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTUtMS0xLTEtMjc4NTI_4b9eb2cb-7852-49bf-a345-12035be367e4">56,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTUtMy0xLTEtMjc4NTI_40884312-d85c-4229-a129-c271935caefb">51,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjEtMS0xLTEtMjc4NTI_75da868f-6427-48e0-aed0-cb4743c447f6">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjEtMy0xLTEtMjc4NTI_b4f8d663-3d8f-4440-97ca-26345322f58c">2,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjItMS0xLTEtMjc4NTI_abb3d8bf-84aa-471f-aa3c-996292ffe08f">7,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjItMy0xLTEtMjc4NTI_174849c3-1e95-4084-ab4e-ba4d6275d458">8,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjMtMS0xLTEtMjc4NTI_57d6da1f-3391-4bf9-be64-c5ccbed4721c">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjMtMy0xLTEtMjc4NTI_9a6e475e-f8ed-47b4-937a-0569f3c358bf">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjQtMS0xLTEtMjc4NTI_3b501793-e849-4e72-812c-6b53e6bc859e">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjQtMy0xLTEtMjc4NTI_2eeec5c7-3bf8-463a-87a6-6dd0adeab83d">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjUtMS0xLTEtMjc4NTI_40f92877-fe55-4e92-a44d-dcb0f49cc412">8,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjUtMy0xLTEtMjc4NTI_6acc2b30-8ba5-4d39-b309-8d7f7f4c4170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjYtMS0xLTEtMjc4NTI_50ac7fee-ffe5-433e-b0d8-8fdcf48db8c4">18,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjYtMy0xLTEtMjc4NTI_952604de-19f2-44c2-b734-0376dd38a141">11,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjctMS0xLTEtMjc4NTI_e07bb3f0-09f6-4516-a6b8-35c5cc81b17d">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjctMy0xLTEtMjc4NTI_44723e23-a9ef-4660-95e4-7ce449383501">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjgtMS0xLTEtMjc4NTI_258569c2-775d-4341-a910-7061b82a3eae">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjgtMy0xLTEtMjc4NTI_09413ea9-25fc-42ed-99bf-70c13a380157">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjktMS0xLTEtMjc4NTI_6f1d4b7d-b42f-44c0-8c33-4afff456264e">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjktMy0xLTEtMjc4NTI_e8159c43-0e84-4448-b875-4e79f4cb99a3">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzAtMS0xLTEtMjc4NTI_fb38f39c-2825-4ed7-9c1d-e5f8be98e73c">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzAtMy0xLTEtMjc4NTI_2c9fdf57-781e-4762-b0dd-ea77e7b63aff">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzEtMS0xLTEtMjc4NTI_0229fe77-38d7-434d-bd82-aa71811c4126">20,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzEtMy0xLTEtMjc4NTI_c566555b-3a00-45bd-85db-1ebbeb4a378d">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV8yMQ_3b723a1a-c367-4760-b1f0-27ef38548e6c"><ix:nonFraction unitRef="usdPerShare" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV8yMQ_d3c71c07-8b22-4bf4-945a-f22004895183">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV8zNQ_183bcfab-c8ea-4e80-b6ad-ae7866c20d94"><ix:nonFraction unitRef="shares" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV8zNQ_c94bb00a-003c-411a-b517-bc227462f783">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV81Nw_2e1899cc-bd17-4abf-9b50-2b11a33d31c6"><ix:nonFraction unitRef="shares" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV81Nw_85d9c793-564f-46d2-8dfe-dc08eed9cced"><ix:nonFraction unitRef="shares" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV81Nw_a4f274eb-4ac5-41f8-99c9-1fe411028dd8"><ix:nonFraction unitRef="shares" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV81Nw_ccf4e7ef-a0c5-4513-8d98-60a5f4339c35">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding as of March 31, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzUtMS0xLTEtMjk1NTE_b26437ea-e9ea-4650-b701-3b6253d0004f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzUtMy0xLTEtMjk1NTM_76f350d4-c186-4552-b830-978694d18dc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl8xOA_642585e2-12fe-48d7-8312-67a6ab2b2ea7"><ix:nonFraction unitRef="usdPerShare" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl8xOA_98617d48-b20c-492e-9cdc-e07ce82fda68">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl8zMg_aaffd130-8a8f-4495-b49b-85b3e77c0b9a"><ix:nonFraction unitRef="shares" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl8zMg_d2ac7c8b-d434-4a8f-858a-39b7fd56e47b">75,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl81NA_5e27ac52-0250-434d-9131-491de344286c"><ix:nonFraction unitRef="shares" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl81NA_d61029e1-4d50-4b26-9aaf-9b8a87b923da">34,597,822</ix:nonFraction></ix:nonFraction> issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMS0xLTEtMjc4NTI_cb1c8e24-e28d-41dd-ad9e-28a221c5f89a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMy0xLTEtMjc4NTI_3eaacb42-20c3-4690-b0fe-0154ebecab0a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzQtMS0xLTEtMjc4NTI_26026e45-d660-4692-a99b-4d43b8874746">75,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzQtMy0xLTEtMjc4NTI_c4dc9e48-04d0-4897-92a0-7e163c156e09">73,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzUtMS0xLTEtMjc4NTI_a74a421f-c435-4b08-959f-2bba2b478104">39,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzUtMy0xLTEtMjc4NTI_923c12a8-f158-4fe2-8af8-6baa7ba8f371">35,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzYtMS0xLTEtMjc4NTI_d10a89f0-8aee-4c5d-9d36-c9bd856cff70">36,052</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzYtMy0xLTEtMjc4NTI_e29f6968-c8f0-4eb6-99b4-ab3d9bd06d29">37,582</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzctMS0xLTEtMjc4NTI_22a49511-e0bd-4893-8064-ae89424392e8">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzctMy0xLTEtMjc4NTI_236a3c91-c343-401a-ac3e-a032abc751c8">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzgtMS0xLTEtMjc4NTI_ca1b5580-5558-4b1d-bece-66ef89c48953">36,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzgtMy0xLTEtMjc4NTI_049b3b50-4fed-42bf-bf00-4d9ec1f0228a">37,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzktMS0xLTEtMjc4NTI_2a098edf-0a63-48da-8a1f-b3dfe6f07545">56,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzktMy0xLTEtMjc4NTI_d1913908-b0c5-4fb7-84dc-1ce6de5d12f6">51,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data) </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMi0xLTEtMS0yNzg1Mg_47d477cb-736d-4452-90c5-691766d76371">12,142</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMi0zLTEtMS0yNzg1Mg_db20eef5-50ca-4645-8344-8919e783c961">12,493</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMy0xLTEtMS0yNzg1Mg_4ba73c09-dd08-4d18-bed1-5eeb1d345e5e">4,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMy0zLTEtMS0yNzg1Mg_1cc02982-4508-4503-86d9-baa96a1a90cf">4,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNC0xLTEtMS0yNzg1Mg_30e7b242-85ec-4cb1-b2b3-edf00e75d8a6">7,573</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNC0zLTEtMS0yNzg1Mg_ae8356dc-8d05-4178-bfd5-0316ef05f16d">8,219</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNi0xLTEtMS0yNzg1Mg_3721da6a-8bd6-434c-a67b-4b98f34c1c6c">1,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNi0zLTEtMS0yNzg1Mg_f649cec1-ae39-4ceb-a7b5-1035d12984b6">1,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNy0xLTEtMS0yNzg1Mg_19eece4f-a392-495f-9d8c-76cd9a7aadf0">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNy0zLTEtMS0yNzg1Mg_80fa33e0-4069-4603-8fb3-d8a412ec5412">2,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:SalariesAndWages" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfOC0xLTEtMS0yNzg1Mg_7bc4e2ed-af27-49a7-957a-7d2ab3ccc2a5">5,068</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:SalariesAndWages" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfOC0zLTEtMS0yNzg1Mg_7a18870f-01e6-4eaa-b98c-831221bd784f">5,181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfOS0xLTEtMS0yNzg1Mg_67dea5ba-67cc-44cc-9c87-07c2bea3c09f">5,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfOS0zLTEtMS0yNzg1Mg_eb6c9993-0319-4016-bfce-9731b05f3d59">5,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTAtMS0xLTEtMjc4NTI_e19da63d-be57-4a9d-b8bf-72c78a5c5010">13,184</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTAtMy0xLTEtMjc4NTI_98f1cac1-4d7d-477e-9980-938b4d969395">14,090</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTEtMS0xLTEtMjc4NTI_93985a87-9f7f-4afb-b555-f1284eb0249e">5,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTEtMy0xLTEtMjc4NTI_83df6372-59f3-4b56-9294-3a9cdf4deb9d">5,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTItMS0xLTEtMjc4NTI_abbab44d-85ce-44e1-941e-855b75cddbe9">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTItMy0xLTEtMjc4NTI_38ea9ced-f882-4bbb-bb34-0ff186e8a958">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTMtMS0xLTEtMjc4NTI_03c153f0-8054-4168-a4ae-cc4ad2dbbf48">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTMtMy0xLTEtMjc4NTI_2fc67e03-55e6-4e74-ad7a-07239000c599">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTQtMS0xLTEtMjc4NTI_892d8189-9240-4eee-b4ac-854e0cbb1e54">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTQtMy0xLTEtMjc4NTI_58fd4126-8692-41d2-b996-9c41188b5c2e">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other loss, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTUtMS0xLTEtMjc4NTI_8d55164e-d4ca-4a8c-b30f-7e7c440bf61c">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTUtMy0xLTEtMjc4NTI_8fcbde53-eef1-421a-bc74-a06f5429acc5">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTYtMS0xLTEtMjc4NTI_964c9071-92de-40ba-8c0f-2be876d570c1">5,799</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTYtMy0xLTEtMjc4NTI_9049c4bd-5bbd-4295-aef1-efb102bdfa88">5,898</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTctMS0xLTEtMjc4NTI_835b2e11-ba5f-43ef-be89-884c059cf452">2,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTctMy0xLTEtMjc4NTI_576ee45e-7d74-4442-b209-f327e04ea8c5">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTgtMS0xLTEtMjc4NTI_5b187a7b-264e-480a-9b52-72b2f5b101d8">3,532</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTgtMy0xLTEtMjc4NTI_33489982-cac7-4b6b-bee9-7337c0d47286">5,968</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net loss attributable to non-controlling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTktMS0xLTEtMjc4NTI_392e02f0-dc3f-4db6-88ad-fcbe5481a0ae">49</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTktMy0xLTEtMjc4NTI_9439347c-0b35-4849-894f-5f5aadb07a89">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to stockholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjAtMS0xLTEtMjc4NTI_72510674-5004-4069-8be6-595197bb4250">3,483</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjAtMy0xLTEtMjc4NTI_f79e3914-8fc1-4900-9b81-794d32f67d07">5,945</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjQtMS0xLTEtMjc4NTI_9e581336-963e-45cc-86ce-26b764e13000"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjQtMS0xLTEtMjc4NTI_e5b30bc6-d305-412d-a66e-1ccf42f58ff7">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjQtMy0xLTEtMjc4NTI_a33078ff-e486-40b0-a870-2c0a989f5c96"><ix:nonFraction unitRef="usdPerShare" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjQtMy0xLTEtMjc4NTI_ca3d06c3-9312-48f1-abe2-fb31d35ae86b">0.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023 and 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Accumulated Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy0xLTEtMS0yNzg1Mg_6f90889a-ca1c-4cb6-9dab-fc32afd52d94">34,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy0zLTEtMS0yNzg1Mg_9b8b0685-51f0-4bea-b93d-95c947e07a8f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd413f451a2b4d84baf891bc120bef43_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy01LTEtMS0yNzg1Mg_16bdcd55-09c4-46af-929a-20dc8117fe51">66,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i700d97178d1c46b7bec5f0372efea304_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy03LTEtMS0yNzg1Mg_367a277b-d03e-4a5b-8349-d133cf00b753">12,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9633d667b894c12a7a3c33ec5e248c2_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy05LTEtMS0yNzg1Mg_75978fb9-6bef-41c4-ae24-aacd352858d9">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf286c1d1ac4c6a9c53a9c75c20d4fd_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy0xMS0xLTEtMjc4NTI_88e91095-0e1c-41df-a5e0-f70df3cd6a85">54,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbc8cd3754b8424cbe8a8f678d790982_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNS0xLTEtMS0yNzg1Mg_43f17d23-1919-4c29-bbc2-1dc9c2ab08b9">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19af6f40a56e4da7be4be449774e9c38_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNS01LTEtMS0yNzg1Mg_bf362841-2fa1-41c3-9c30-92fdbe6e32ba">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNS0xMS0xLTEtMjc4NTI_00ee20be-fce2-428f-ab3a-d137566d81c0">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19af6f40a56e4da7be4be449774e9c38_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNi01LTEtMS0yNzg1Mg_e480912e-225e-45a5-9595-54c85dc37e18">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNi0xMS0xLTEtMjc4NTI_c34299a8-fd97-4d63-b9a1-c00f045e9410">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbc8cd3754b8424cbe8a8f678d790982_D20220101-20220331" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNy0xLTEtMS0yNzg1Mg_39c76f10-9a17-4a04-b8d1-9ebfad8b540a">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9497de4ef599443782493d1d3dbc6609_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfOS03LTEtMS0yNzg1Mg_adfec92b-3de5-46c5-8b00-cb590d8b5c79">5,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6931ca2b85e4446925ba4947ddbe1f2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfOS05LTEtMS0yNzg1Mg_cde4e9c7-a8a1-4ffc-8943-585af4af644c">23</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfOS0xMS0xLTEtMjc4NTI_bfe029df-40f9-4bcd-b785-404c4cabbc12">5,968</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4434306a747741429a540f6a76d96647_I20220331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtMS0xLTEtMjc4NTI_20d73901-706d-4207-823d-b1b2d4b12a8a">34,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434306a747741429a540f6a76d96647_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtMy0xLTEtMjc4NTI_339e8ba4-db91-45e3-b8c3-271a2ef1b372">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9fa3089458f42aaa023258bbce7b89b_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtNS0xLTEtMjc4NTI_3d01cfa3-5b24-4f00-b657-4c2fc0f4196f">68,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f3a4fe886c472bb7f4d921600ce418_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtNy0xLTEtMjc4NTI_39099b02-ec9c-4586-a040-b81cacf9c8e3">18,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8e01e3706a4c1a911c23a654ab59de_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtOS0xLTEtMjc4NTI_e6fd0a92-6df9-46f1-bf61-eb325ca383d7">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791bf538170f41c58addc94c2a446640_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtMTEtMS0xLTI3ODUy_5b48e356-5269-40c5-8bad-61c8f0d35b69">49,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87f633cacdd140aa9bab43f887b78a2e_I20221231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItMS0xLTEtMjc4NTI_9b335511-35c7-49f4-92e5-8aebf70c812d">34,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f633cacdd140aa9bab43f887b78a2e_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItMy0xLTEtMjc4NTI_b8415fe8-210b-4f52-875e-74092ca5b093">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e1edafd25048a898c12ed311d1309e_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItNS0xLTEtMjc4NTI_091ab952-2282-4f32-87ec-f9316e5350aa">73,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f2ed1527d7c4ddf9a25ba44fc615c47_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItNy0xLTEtMjc4NTI_455941fe-c8bf-47e9-b9b1-ae9108dc970f">35,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe44f8091664b47a7bff608e2b30703_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItOS0xLTEtMjc4NTI_a4d9a90a-9e25-47a9-8965-2cf71dcec863">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItMTEtMS0xLTI3ODUy_af9ef9c2-1b1c-40a5-a395-41c63d63f022">37,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d048bc9f0341638ec692b0b8f93ca7_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTUtNS0xLTEtMjc4NTI_cc103ebf-caeb-4dd2-ad56-ae6584e3dab6">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTUtMTEtMS0xLTI3ODUy_8d8ad942-7c06-4312-b94f-f6510fcbd00a">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds received from issuance of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d048bc9f0341638ec692b0b8f93ca7_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTctNS0xLTEtMjc4NTI_ed416aa9-9444-48a1-bfc7-2dd80195ba4b">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTctMTEtMS0xLTI3ODUy_842bb8be-6e17-4a04-9e96-7fd65681b170">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3301b75ad88b4456ac3325aa744427ee_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTgtNy0xLTEtMjc4NTI_ce3e317c-2744-4d87-8d51-895108d216f9">3,483</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bdfda32745048c198232e04864a2e0c_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTgtOS0xLTEtMjc4NTI_97a01174-4788-402f-a9a8-b5fe7c96d2cd">49</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTgtMTEtMS0xLTI3ODUy_7064fdc6-64d6-463f-b623-a94a00abf1ee">3,532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1c5d633167d49f083a557d93bdab57d_I20230331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktMS0xLTEtMjc4NTI_d3c891f0-6ce2-4bfe-bf83-c03c461833ff">34,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c5d633167d49f083a557d93bdab57d_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktMy0xLTEtMjc4NTI_a59f6a15-fa06-41b0-b672-3ec106a58717">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i302145e8cbf54af2abc2a3fd7137c26e_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktNS0xLTEtMjc4NTI_f576d0e5-94f9-48a1-8d50-1695bd0bc84b">75,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i188f6d41df7e4eb08c173022c9d1302e_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktNy0xLTEtMjc4NTI_d89e4218-b416-42cf-b874-98d2d3400dbf">39,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d14b67a6cb40a08208352f01687ae9_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktOS0xLTEtMjc4NTI_b6f11ff5-3e13-4478-986d-041e3f9b5d7c">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktMTEtMS0xLTI3ODUy_ad102ef2-31ec-4b51-aa79-7a192ed6a9ae">36,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMy0xLTEtMS0yNzg1Mg_4b73681d-2abe-4a2a-9b47-83e1596e0206">3,532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMy0zLTEtMS0yNzg1Mg_0cbd694e-f127-40fa-8171-46c7aaef587e">5,968</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfNS0xLTEtMS0yNzg1Mg_4a6933dc-6eb1-424b-a91d-b95cb30bafb1">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfNS0zLTEtMS0yNzg1Mg_1c8d9f5d-906a-42d2-ac2d-4aaba163bf76">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for inventory obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfNi0xLTEtMS0yNzg1Mg_743af969-4528-49b9-a360-edf9f1adfe30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfNi0zLTEtMS0yNzg1Mg_bd3db15e-9da9-4ad6-9baa-7f7c7157e935">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfOC0xLTEtMS0yNzg1Mg_f07c97da-bd34-4baf-9e95-b5d102b622fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfOC0zLTEtMS0yNzg1Mg_64fcde23-0ecb-4ad7-bc0a-1b68a05c525c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfOS0xLTEtMS0yNzg1Mg_2f5aa4ed-938b-4d83-9b44-23844eb2ef57">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfOS0zLTEtMS0yNzg1Mg_cc48a936-e6d7-4760-abce-92536ed80b5f">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTAtMS0xLTEtMjc4NTI_562eeaf6-b851-4052-9810-a7d92900464d">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTAtMy0xLTEtMjc4NTI_c6aebc0c-7ca0-4cc2-aa7a-076d3a3f63bf">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTEtMS0xLTEtMjc4NTI_c9c02a2a-9a37-4cb7-b159-d869d6475eb7">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTEtMy0xLTEtMjc4NTI_4e47cf14-a2b9-4574-b547-8638ff2e9718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTMtMS0xLTEtMjc4NTI_b717ad92-065d-4a60-b041-c963e42dbadf">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTMtMy0xLTEtMjc4NTI_7a406807-a645-4d99-b59b-7e756a708c9e">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTQtMS0xLTEtMjc4NTI_64af65ad-90d4-4c66-bead-fd3af27d3793">858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTQtMy0xLTEtMjc4NTI_8acb7d89-2023-4f18-90f0-7a6d50411950">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTUtMS0xLTEtMjc4NTI_c3a5fd39-e461-4879-a702-840d6d366fa6">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTUtMy0xLTEtMjc4NTI_8f69da3f-c676-435f-9b39-37a4d3e1c243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTYtMS0xLTEtMjc4NTI_22bf96d9-682a-49d0-89a1-f384bff30c4a">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTYtMy0xLTEtMjc4NTI_a79b69f6-d7c8-445a-9b2c-202b83965cfc">371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTctMS0xLTEtMjc4NTI_0b9ca07e-0af3-4277-b24c-dc74a6f56860">776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTctMy0xLTEtMjc4NTI_7aa21959-6538-4bbc-9088-9eda28301689">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTgtMS0xLTEtMjc4NTI_165ca53b-e7c2-41ab-a0da-47e3034b87b1">1,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTgtMy0xLTEtMjc4NTI_4c1ead7e-fe41-4cec-a66e-ef8aa4f3d242">1,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTktMS0xLTEtMjc4NTI_8044ac7a-3f8f-44f9-af4c-5c41c979aeb3">1,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTktMy0xLTEtMjc4NTI_b4c20489-20e6-4fc1-9020-20b084c7ed52">4,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjEtMS0xLTEtMjc4NTI_8002e8e9-2d75-4678-a4d3-3f58f9086c80">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjEtMy0xLTEtMjc4NTI_005d9545-04a4-47ae-87b9-5b0e3a88f77b">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjQtMS0xLTEtMjc4NTI_45e2b2a6-9a04-48c8-8b90-42d5c1f7f754">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjQtMy0xLTEtMjc4NTI_55e50844-dabb-4ec4-9f91-efb29506c246">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjYtMS0xLTEtMjc4NTI_83b4b8d1-0e82-488f-b976-bbfbaba3fe24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjYtMy0xLTEtMjc4NTI_eb0e1c64-ddbd-4e85-a04b-3dae31add61b">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjctMS0xLTEtMjc4NTI_2388f146-48a1-4305-8ff4-116c7db1bb6e">9,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjctMy0xLTEtMjc4NTI_f2cf1284-3e20-443a-a5b1-4f52546edec1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjgtMS0xLTEtMjgxNjY_544a7ffe-944e-4832-8000-a449b70f9048">1,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjgtMy0xLTEtMjgxNjY_3558e762-d21e-4422-9aed-8a00d78bd78b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjktMS0xLTEtMzA2Njk_70d7129e-d487-4dc7-b85e-d3c5c0f13bd1">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjktMy0xLTEtMzA2NzY_6e84a038-7af1-4fd3-99ec-279b0fe0885d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="apyx:RepaymentofFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjgtMS0xLTEtMjc4NTI_0b9ff6f9-09e9-49f0-b0a7-f0634ecf36b3">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="apyx:RepaymentofFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjgtMy0xLTEtMjc4NTI_d610a6e2-3c84-49bc-903e-2b3e19914141">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzAtMS0xLTEtMjc4NTI_27dbc242-cdad-450c-9af4-f1adb5f92ce0">8,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzAtMy0xLTEtMjc4NTI_f6d7a417-ec38-406b-b131-9287fcc891b3">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzEtMS0xLTEtMjc4NTI_ba0ab695-3b5e-44cd-bbe6-70b1a6f0154a">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzEtMy0xLTEtMjc4NTI_8e47ef5b-8cee-4581-be99-d9cd9ece5763">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzItMS0xLTEtMjc4NTI_ffc1ac84-250d-4d80-816b-32cfa70317d2">6,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzItMy0xLTEtMjc4NTI_3fae79f2-b3c6-475e-b180-82e8f9c97b4c">4,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzMtMS0xLTEtMjc4NTI_e8770eb5-f634-40c7-8b69-50070927b0ad">10,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf286c1d1ac4c6a9c53a9c75c20d4fd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzMtMy0xLTEtMjc4NTI_3a884525-8d20-4f3b-a2f5-30505b1f3214">30,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzQtMS0xLTEtMjc4NTI_ddb52913-9de7-49cb-a308-2489845be091">16,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791bf538170f41c58addc94c2a446640_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzQtMy0xLTEtMjc4NTI_0dc108df-9369-4932-9660-6b154c5f632b">26,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzctMS0xLTEtMjc4NTI_548c23e4-f600-4f61-bbd8-7fcc76298ebe">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzctMy0xLTEtMjc4NTI_e1a0561f-ab7c-4ed2-8c5f-fe18347bec1c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzgtMS0xLTEtMjc4NTI_f6e3c0e9-c819-4047-84e6-ffa65d3ff5a9">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzgtMy0xLTEtMjc4NTI_6ae1c1c4-4115-4b5d-85e1-28c50ef01543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMzA2Nw_0919c1d8-1589-4ae9-a278-0385158af5ef" continuedAt="i21eefc83726c4ebfb69c84c88ed90e3c" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i21eefc83726c4ebfb69c84c88ed90e3c" continuedAt="icb0420d8218a4b2c9af2df17c16b56ae"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company&#8221;, &#8220;Apyx&#8221;, &#8220;it&#8221; and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its plan to accelerate and fully fund the development of its advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, the Company sold its Core business in 2018 for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i4329db9485b349278676f47f9db880a6_D20180101-20181231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODIwNjg3_9c89341b-648d-4f98-afd0-375396f5d35f">97</ix:nonFraction>&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Medical Device Safety Communication (&#8220;Safety Communication&#8221;). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as &#8220;tightening&#8221;). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#174; Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion&#174; device system for certain dermal resurfacing procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion&#174; APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers  about the clearance for the Renuvion&#174; APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="icb0420d8218a4b2c9af2df17c16b56ae" continuedAt="i251ba56eecdd49aab339bfa6a7c4b37a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Financial Accounting Standards Board&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#8217;s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term.  During the year ended December 31, 2022, the Company incurred an operating loss of $<ix:nonFraction unitRef="usd" contextRef="ibbf0f4361aaa413daa96a1cde208b376_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMzI5ODUzNDkwNDM4Ng_30e4336f-148d-43c6-9c7d-53814776e870">23.6</ix:nonFraction>&#160;million and used $<ix:nonFraction unitRef="usd" contextRef="ibbf0f4361aaa413daa96a1cde208b376_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMzI5ODUzNDkwNDQwMQ_4cc929f1-a2b8-49a7-b745-5e6115844c51">20.3</ix:nonFraction>&#160;million of cash in operations. During the three months ended March 31, 2023, the Company incurred an operating loss of $<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2Mzk3_a8b17725-3694-4d78-b6fa-848a5615150e">5.6</ix:nonFraction>&#160;million and used $<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2NDEw_aca96ec9-c88c-4712-93ee-1fc2fd907183">1.9</ix:nonFraction>&#160;million of cash in operations. As of March 31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2NTA3_944cf7c1-ff66-4c86-8438-e34d9150c467">16.3</ix:nonFraction>&#160;million, of which the Company must maintain $<ix:nonFraction unitRef="usd" contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217" decimals="-5" name="apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMjc0ODc3OTA5MTQ3NA_62618fac-0bef-4f5a-940e-8f725387e31e">10.0</ix:nonFraction>&#160;million under its Credit Agreement. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $<ix:nonFraction unitRef="usd" contextRef="i3932728fc7a04ebaa43fed7736e1c40c_D20221122-20221122" decimals="-6" name="apyx:SecuritiesRegisteredNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2OTg5_2e63c08c-dffc-493f-9ba6-565dcd0ae98a"><ix:nonFraction unitRef="usd" contextRef="i3932728fc7a04ebaa43fed7736e1c40c_D20221122-20221122" decimals="-6" name="apyx:SecuritiesRegisteredNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2OTg5_379f5d2b-b356-4e1b-9ac0-5ba6da25991d">100</ix:nonFraction></ix:nonFraction>&#160;million. The shelf registration included an embedded ATM facility for up to $<ix:nonFraction unitRef="usd" contextRef="i842683acc0a34f84893c61d6455c84bd_D20221122-20221122" decimals="-6" name="apyx:SecuritiesRegisteredNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3MDYx_1828c93b-6edf-4bef-8288-ec768335292f"><ix:nonFraction unitRef="usd" contextRef="i842683acc0a34f84893c61d6455c84bd_D20221122-20221122" decimals="-6" name="apyx:SecuritiesRegisteredNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3MDYx_a9669397-6125-40f4-9adc-c02e1b83c2cc">40</ix:nonFraction></ix:nonFraction>&#160;million. To date, the Company has not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $<ix:nonFraction unitRef="usd" contextRef="i9f7ad3b30f9045f4a940c5dd6e62909f_I20230217" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3NDE5_531bedb5-ea39-4ef1-976b-eea2b3d5c4b9">35</ix:nonFraction>&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $<ix:nonFraction unitRef="usd" contextRef="i22587808ca5d48bab5471ce1b3d5871d_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3NTc2_0a1841f3-f5d1-42f7-9761-43b0fc7eb589">25</ix:nonFraction>&#160;million, comprised of (i) an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="ic4a9c2aec01046399022caa446b9ec13_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3NjIw_7c659f2c-6bca-4393-85eb-79b6baaf6d18">10</ix:nonFraction>&#160;million, (ii) a second tranche of $<ix:nonFraction unitRef="usd" contextRef="i0e46158015eb4aec901c105c23099f18_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3NjUw_90b0c99e-8caf-4eae-8a4b-0682b2bd6d89">5</ix:nonFraction>&#160;million, and (iii) a third tranche of $<ix:nonFraction unitRef="usd" contextRef="i9789c9d226394206be51a46193f836c3_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3Njg0_4b188167-f308-4955-9de8-3e5b1ca64f87">10</ix:nonFraction>&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ia32fcb27739a44c999f32b3a61c449f6_I20230217" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3Nzgx_04becdd9-a0fc-4d6c-bf56-f7a17d27a95b">10</ix:nonFraction>&#160;million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement, see Note 6.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, the Company&#8217;s Board of Directors approved a plan to sell and leaseback the Company&#8217;s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of the Company&#8217;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i251ba56eecdd49aab339bfa6a7c4b37a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314" decimals="-4" name="apyx:SaleLeasebackPurchaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI4NTUw_bb27c763-430a-46da-878f-1462390d26a7">7,650,000</ix:nonFraction>. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement, see Note 4.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company&#8217;s tax refunds were approved for approximately $<ix:nonFraction unitRef="usd" contextRef="i26213cf5bc234af691fd6ad429fc40cf_D20230101-20230131" decimals="-5" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMjc0ODc3OTA5MDU5Ng_a92f1248-ecac-4326-b665-4eb72ee92a01">0.2</ix:nonFraction>&#160;million more than the amount recorded in the Company&#8217;s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company&#8217;s U.S. headcount by <ix:nonFraction unitRef="number" contextRef="ib02d47ac09b44377974655e36339723e_D20230109-20230109" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI5Njgx_200fd990-60a1-4906-a0e7-58723257474b">14</ix:nonFraction>%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations and its debt covenants for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNC9mcmFnOjY2OGZjYzRkOTk2MDRmMDE4MTNkOTU3N2Q0ZTc5ZDA3L3RleHRyZWdpb246NjY4ZmNjNGQ5OTYwNGYwMTgxM2Q5NTc3ZDRlNzlkMDdfMTU3MA_c48367c7-5214-4633-8327-0c330a72a5f3" continuedAt="i717a18d5fe2b4275b5c71942b1a1836a" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i717a18d5fe2b4275b5c71942b1a1836a"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNC9mcmFnOjY2OGZjYzRkOTk2MDRmMDE4MTNkOTU3N2Q0ZTc5ZDA3L3RleHRyZWdpb246NjY4ZmNjNGQ5OTYwNGYwMTgxM2Q5NTc3ZDRlNzlkMDdfMTU3Ng_8ba55403-7e45-459d-968d-7985d62658ad" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RleHRyZWdpb246M2Q5MDEwZDRlNzFkNGEzZTlhMTFkNzY4ODhlYWYyMzVfMzk0_0867486a-b90a-4aa6-8701-c248b92fbee9" continuedAt="ie6b50361a1cd4687b6f4ae73415ffb5d" escape="true">INVENTORIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie6b50361a1cd4687b6f4ae73415ffb5d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RleHRyZWdpb246M2Q5MDEwZDRlNzFkNGEzZTlhMTFkNzY4ODhlYWYyMzVfNDA3_0c62eb38-972c-4dd4-ac44-93093fdba07e" escape="true">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RleHRyZWdpb246M2Q5MDEwZDRlNzFkNGEzZTlhMTFkNzY4ODhlYWYyMzVfNDAx_9f2c2cef-cb12-4ac9-9611-000caf3c4e6c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMS0xLTEtMS0yNzg1Mg_8841de79-b0b7-48a1-b55a-d191505f3880">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMS0zLTEtMS0yNzg1Mg_4affcaf0-e6e7-48ab-b20a-645aeab8ebc5">4,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMi0xLTEtMS0yNzg1Mg_eb466ff5-25a6-4a4d-9670-ef8478df276f">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMi0zLTEtMS0yNzg1Mg_91899dc2-ec5e-4b71-830d-55803c7a9f1b">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMy0xLTEtMS0yNzg1Mg_6e15ab01-6116-445a-ab2b-fc65a554481e">4,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMy0zLTEtMS0yNzg1Mg_13ccefd4-1889-41c4-a72a-e406b16ee1a0">5,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNC0xLTEtMS0yNzg1Mg_ce229317-05d6-4a96-b95c-988ea54def5c">11,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNC0zLTEtMS0yNzg1Mg_f33fd9d6-9f09-46d1-8a58-93c9205a08da">12,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNS0xLTEtMS0yNzg1Mg_9e712a58-c02a-4567-b8db-ac12ff644b0c">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNS0zLTEtMS0yNzg1Mg_bf9a4f74-6a2c-4e45-a110-865591d3b471">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNi0xLTEtMS0yNzg1Mg_4344f53d-b520-4440-8474-09483632ee5d">10,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNi0zLTEtMS0yNzg1Mg_547a703a-198b-42e3-947f-5eaa5ee5da18">11,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMTI4Nw_a96d1d82-8493-47a5-912e-d8273b64c668" continuedAt="i05dd0f52c9234f40ab2d9b5f3126796b" escape="true">ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i05dd0f52c9234f40ab2d9b5f3126796b" continuedAt="ied30daf694574da0b6d2b05d689cfb29"><div style="text-align:justify"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMzI5ODUzNDg5MjM0NA_7c47c026-523b-45e2-b3b6-c093d644f9ca" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a3f2eb674df41a2ae74e07a8d73a59c_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMS0xLTEtMS0yOTkwMw_2af1b2fa-ab38-4ae4-b1c9-a99e5ad3af2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444e3d03e8b34aea95597bd9077be349_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMS0zLTEtMS0yOTkwNA_fba62408-ff1a-4439-ac8f-359fa4c12dbc">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d67f218c964b66aa874fbba351e483_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMi0xLTEtMS0yOTkwMw_bf54a742-6b4b-4917-8215-ebb84731222d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d4a532478246d4bf4d795e035840ec_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMi0zLTEtMS0yOTkwNA_f96e40b0-1cdf-4762-9d15-0050f4d74056">4,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e80aa911f544e7a99cf80274b923c6a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMy0xLTEtMS0yOTkwMw_82133042-5f4b-4274-ade5-26b5cfefa1b6">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c447b579b144bf96d49d5e10b32eee_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMy0zLTEtMS0yOTkwNA_f88178a2-e784-4036-8257-3c3000a17dfd">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52498e454d8e4e4a9cc70ff49ba56436_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNC0xLTEtMS0yOTkwMw_bffa413e-92cd-4b12-aadc-e6fba446cf39">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f1d0dccbc94a32bfdc2e93912d45e2_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNC0zLTEtMS0yOTkwNA_a5424529-c2ff-49da-b0a4-4d6d3f8c2664">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b3a3086a39456d82fe6d3a37c11a9b_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNS0xLTEtMS0yOTkwMw_570cfb6d-1a0e-476d-9f3e-c2577971f78f">1,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0311da46d2f74bb18fbfe7861fcd1a6b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNS0zLTEtMS0yOTkwNA_884236cf-cc22-4f78-a4c4-899f6438f6b2">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb80eb1f91e44c0eaf61e0cd23a39e01_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNi0xLTEtMS0yOTkwMw_4438ea9f-fda6-4730-81a8-34ae800730f6">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c7b33ceee847c4b00c7492e4b509f0_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNi0zLTEtMS0yOTkwNA_ea2def3d-0ccb-474d-9b70-36eef882ebb6">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5534ca1fb36e45c69f14c9ee7219b0e5_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNy0xLTEtMS0yOTkwMw_674f9972-51b3-4479-8b4d-1e8e4f8906a3">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ef5925e82e463ca7c4bf42717d5767_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNy0zLTEtMS0yOTkwNA_7ae44436-1a85-495e-a5d5-43c9e8c5a8ca">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfOC0xLTEtMS0yOTkwMw_3acdfd3d-e9dc-4579-b3c5-7e099f3f21b0">4,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfOC0zLTEtMS0yOTkwNA_ac95d17d-a228-4bf7-a678-1e2f8cc26fac">11,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfOS0xLTEtMS0yOTkwMw_72acc73b-510f-4472-84b0-fa7ce474b7f2">3,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfOS0zLTEtMS0yOTkwNA_ad5a8515-09cf-4435-91cd-cf6276672f41">5,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="apyx:PropertyPlantAndEquipmentInService" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTAtMS0xLTEtMjk5MDM_6809e47a-d473-4509-a40c-98278d09aabe">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="apyx:PropertyPlantAndEquipmentInService" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTAtMy0xLTEtMjk5MDQ_2c6d61fd-3bd4-4273-9d86-2884b055df0c">6,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTEtMS0xLTEtMjk5MDM_ede0f480-5cdf-4b7d-bca9-44768fbcd0b8">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTEtMy0xLTEtMjk5MDQ_797bffcf-58c6-4acc-b1d3-8a50d9149d7a">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTItMS0xLTEtMjk5MDM_c2a44098-7c17-40c2-b0a3-ea4687bc141f">2,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTItMy0xLTEtMjk5MDQ_23f2ebce-fe8c-4e58-9c9d-cdde22156867">6,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTQtMS0xLTEtMjk4OTU_d5c916c6-abe6-467c-ab38-75c5aee9d136">4,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTQtMy0xLTEtMjk5MDE_ac885a5d-5b9f-4151-9849-d80243b6c775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company&#8217;s unencumbered real property. On February 27, 2023, the Company&#8217;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of the Company&#8217;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314" decimals="-4" name="apyx:SaleLeasebackPurchaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE3NDk0_d238407c-9d5f-4462-8af6-e99e7ec07f32">7,650,000</ix:nonFraction>. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ied30daf694574da0b6d2b05d689cfb29" continuedAt="i296170a8271f4318bc82bd98f21b8e43"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the requirements of ASC Topic 360,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Property, Plant, and Equipment, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Company has determined that the real property to be sold meets the requirements to be presented as held for sale. Accordingly, the Company has presented the associated assets as held for sale in the accompanying unaudited condensed consolidated balance sheet and the table above at March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the &#8220;Lease&#8221;) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (<ix:nonNumeric contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314" name="apyx:SaleLeasebackTermOfLease" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4NTI2_293419ae-8e5a-4022-84a9-0f253b32c1e8">10</ix:nonNumeric>) years commencing from the closing (the &#8220;Initial Term&#8221;), and a renewal term of five (<ix:nonNumeric contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314" name="apyx:SaleLeasebackRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4NjE1_c28d1bdc-6eb8-4722-9176-e9ff0b66da17">5</ix:nonNumeric>) years, exercisable at the Company&#8217;s option. The annual fixed rent will be $<ix:nonFraction unitRef="usd" contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314" decimals="-2" name="apyx:SaleLeasebackAnnualRentPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4Njk0_2274fd1e-0880-418b-95c3-39310259b57c">619,500</ix:nonFraction> for the first year of the Initial Term, and will be subject to a <ix:nonFraction unitRef="number" contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314" decimals="2" name="apyx:SaleLeasebackAnnualRentIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4NzYz_493d8e63-d590-41ac-979a-f08e33ebc5dc">4</ix:nonFraction>% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a <ix:nonFraction unitRef="number" contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314" decimals="2" name="apyx:SaleLeasebackManagementFeeOnRentPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4OTQ1_108d1866-51be-4ffd-a08c-7cbdba295a51">3</ix:nonFraction>% management fee on rent payments throughout the Initial Term and optional renewal term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i296170a8271f4318bc82bd98f21b8e43">On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a <ix:nonNumeric contextRef="if55075181de3450781da931211bae736_D20230508-20230508" name="apyx:SaleLeasebackTermOfLease" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMjc0ODc3OTA3OTI3NQ_2bdcc53c-93d6-475a-a3ff-eb7b675f5188">10-year</ix:nonNumeric> agreement to leaseback the underlying Property from the Purchaser. The Company received net cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="if55075181de3450781da931211bae736_D20230508-20230508" decimals="-5" name="apyx:SaleLeasebackNetCashProceeds" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMjc0ODc3OTA4MDc5Mg_a3e4af63-51dc-4c2f-880e-da4a036a2de8">6,600,000</ix:nonFraction>, after withholding the security deposit equal to <ix:nonNumeric contextRef="if55075181de3450781da931211bae736_D20230508-20230508" name="apyx:SaleLeasebackSecurityDepositEqualToAnnualRent" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMjc0ODc3OTA4MDgxNg_ad95761c-55c1-44e4-82e1-39692c500990">one year</ix:nonNumeric>s rent, taxes, first months rent, expenses, and fees. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital to its operations.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RleHRyZWdpb246NzM2NDQ2MDQ2NWY3NGU4MWIzNWRlYTEyZDM3ZjJiYzNfMzE4_c5b7a2a8-88a1-49e0-bf4f-1ce5a64ec87f" continuedAt="i5897eeafe1df4721bd02bb268026cd9d" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5897eeafe1df4721bd02bb268026cd9d" continuedAt="i8a1963839fb04485b31e9abb0d2026f5"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RleHRyZWdpb246NzM2NDQ2MDQ2NWY3NGU4MWIzNWRlYTEyZDM3ZjJiYzNfMzIy_fc9b7f9b-c236-47d6-bf7e-d50589eaa4da" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMS0xLTEtMS0yNzg1Mg_42cf0591-bd70-4f94-a0a8-ce4a3b74c65b">848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMS0zLTEtMS0yNzg1Mg_155c1bef-9b0f-434a-97ce-aa8dafae705e">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMi0xLTEtMS0yNzg1Mg_38799e41-3702-4daa-b1e6-2a08c64e7084">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMi0zLTEtMS0yNzg1Mg_f956ea1d-fd73-45e0-bcda-c2ca77499904">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMy0xLTEtMS0yNzg1Mg_d05d2403-c5a8-405d-ba72-33c3d807a73c">790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMy0zLTEtMS0yNzg1Mg_38219a41-200b-4390-8ba3-77f114312ec6">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNC0xLTEtMS0yNzg1Mg_9040acdd-9b9a-44d9-8b60-a3ceb39fece9">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNC0zLTEtMS0yNzg1Mg_e36d365f-4b37-4793-bbd6-b80c9ad94da8">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNS0xLTEtMS0yNzg1Mg_38cb699e-45fb-4761-8d81-c0249bfa7183">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNS0zLTEtMS0yNzg1Mg_2d6d118f-95ef-491b-8b52-8892f8c00b3f">1,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNi0xLTEtMS0yNzg1Mg_a0177d72-49d2-49fe-93ec-abc7bd04cc95">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNi0zLTEtMS0yNzg1Mg_9c68cbd3-9ee9-41e3-bc95-b6c4ee2157e4">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNy0xLTEtMS0yNzg1Mg_31909e1f-776d-46d0-b9eb-db80bfb896d3">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNy0zLTEtMS0yNzg1Mg_18ce188b-4401-45c2-92a0-770098a5044c">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfOC0xLTEtMS0yNzg1Mg_93ac79c1-dbe6-44ae-995e-d35e5112119b">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfOC0zLTEtMS0yNzg1Mg_04bece26-d9a3-4c68-a63e-048f945c79e1">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="apyx:UncertainTaxPositionsLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfOS0xLTEtMS0yNzg1Mg_ed152f81-0657-4713-8eb2-b054c1af468e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="apyx:UncertainTaxPositionsLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfOS0zLTEtMS0yNzg1Mg_f4dfb0e5-c335-4f77-95dc-8f333415250a">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTAtMS0xLTEtMjc4NTI_fa176f86-02f0-40ea-af14-2a6a2b42723b">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTAtMy0xLTEtMjc4NTI_e54412ea-16ee-4a88-85fd-ce27eb8de8df">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTEtMS0xLTEtMjc4NTI_2dfa38e0-b9ed-41f3-b1b0-9514796dc0b8">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTEtMy0xLTEtMjc4NTI_47ab82de-764b-4466-84e4-1df28cba020b">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTItMS0xLTEtMjc4NTI_abb3d8bf-84aa-471f-aa3c-996292ffe08f">7,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="-3" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTItMy0xLTEtMjc4NTI_2c041c70-291c-4dad-93d6-98d03be238b7">8,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a1963839fb04485b31e9abb0d2026f5">During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations on the liability.</ix:continuation> </span></div><div style="text-align:center"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_1004"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjQy_117f330e-e3e0-4787-9a35-435fa5b91aee" continuedAt="i3473e6960c6b479790c29b71de44bc81" escape="true">CREDIT AGREEMENT</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i3473e6960c6b479790c29b71de44bc81" continuedAt="i59fe8e4f29d74993a4428439ddbc7182">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;), by and among the Company (as borrower) and Apyx China Holding Corp., the Company&#8217;s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively &#8220;MidCap&#8221;).</ix:continuation></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i59fe8e4f29d74993a4428439ddbc7182" continuedAt="ia10d7916f665441999929768e9c7f14d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement provides for an up to $<ix:nonFraction unitRef="usd" contextRef="i9f7ad3b30f9045f4a940c5dd6e62909f_I20230217" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzE5_e57b5d6c-9080-4169-a05f-932774c0f1d9">35</ix:nonFraction>&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $<ix:nonFraction unitRef="usd" contextRef="i22587808ca5d48bab5471ce1b3d5871d_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMjkz_1e3fa01c-3da3-459a-9961-1c891ff581ee">25</ix:nonFraction>&#160;million, comprised of (i) an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="ic4a9c2aec01046399022caa446b9ec13_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzA2_01d0340b-8c0a-4d46-8d26-da3658f551e2">10</ix:nonFraction>&#160;million, (ii) a second tranche of $<ix:nonFraction unitRef="usd" contextRef="i0e46158015eb4aec901c105c23099f18_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzU4_fd542869-59e7-47a9-93c9-1c10018a6aa4">5</ix:nonFraction>&#160;million, and (iii) a third tranche of $<ix:nonFraction unitRef="usd" contextRef="i9789c9d226394206be51a46193f836c3_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTc0_137fb466-0f55-4519-a1c8-a61bef2bb5c2">10</ix:nonFraction>&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ia32fcb27739a44c999f32b3a61c449f6_I20230217" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzMy_0853be1f-7ca8-4b81-94fa-6eed125e1896">10</ix:nonFraction>&#160;million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the Credit Agreement. The Credit Agreement matures on February 1, 2028.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Term Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The initial tranche of $<ix:nonFraction unitRef="usd" contextRef="ic4a9c2aec01046399022caa446b9ec13_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzQ1_f74247bd-65ee-4602-bc97-36a7cdbcdbdb">10</ix:nonFraction>&#160;million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company&#8217;s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each term loan bears interest at a floating rate reset monthly based on an adjusted  one month SOFR plus <ix:nonFraction unitRef="number" contextRef="i099455fbc1dc4ad496d841a9e2cbc539_D20230217-20230217" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzcw_a861a6a0-9442-4693-b6ba-a842a640161e">0.1</ix:nonFraction>%, subject to a floor of <ix:nonFraction unitRef="number" contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217" decimals="3" name="apyx:DebtInstrumentInterestRateFloorPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzc2_a92ba963-2e04-4beb-baaf-4d090dc64838">2.5</ix:nonFraction>%, plus <ix:nonFraction unitRef="number" contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217" decimals="4" name="apyx:DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTg3_d25dd8dc-485c-4f8e-9e03-9f5ccc597505">7.35</ix:nonFraction>% calculated on a 360 day basis (<ix:nonFraction unitRef="number" contextRef="ic4a9c2aec01046399022caa446b9ec13_I20230217" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0Mjc4_a55a4da8-a5bf-4866-9a9f-912b47f86b05">12.1</ix:nonFraction>% at March 31, 2023). Interest is payable monthly in arrears on the first day of each month.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The first twenty-four (<ix:nonNumeric contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217" name="apyx:DebtInstrumentPeriodOfInterestOnly" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjAy_7387f6a8-a9f7-4d78-8673-9b7f169d9c49">24</ix:nonNumeric>) months of the term loans constitute an interest-only period (with a possible twelve (<ix:nonNumeric contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217" name="apyx:DebtInstrumentExtensionPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjE4_65eacc1e-5ff4-4b37-91bd-bb3744a573bd">12</ix:nonNumeric>) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (<ix:nonFraction unitRef="monthlypayment" contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217" decimals="INF" name="apyx:DebtInstrumentNumberOfMonthlyPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjA4_d76ccab0-09fe-44d3-8e30-df5b5631f956">36</ix:nonFraction>) equal monthly payments (or twenty-four (<ix:nonFraction unitRef="monthlypayment" contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217" decimals="INF" name="apyx:DebtInstrumentNumberOfMonthlyPaymentsExtension" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0MzIy_90b9efaa-4b3d-4bfc-a9d0-81ead5f9a1d7">24</ix:nonFraction>) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity on February 1, 2028. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment fees, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of <ix:nonFraction unitRef="number" contextRef="i5d5ece174ab94a1db32622d52c60a23c_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzgy_0e07e3f2-57fe-499a-a05d-bb51ccc1af69">3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="if473b8c0c1e64a71aaa04d5e033d18a5_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzg2_73a2207a-1286-405b-a441-66289943f979">2</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i326c0815b32647328b23564b770a38b5_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzkw_62457637-9bb5-45b3-bd7b-597c1f946e83">1</ix:nonFraction>% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of <ix:nonFraction unitRef="number" contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentExitFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzk0_8a689bd5-026b-4789-a2da-4051d3f0c413">4</ix:nonFraction>% of the total amount funded thereunder. The exit fee is being accreted over the life of the Credit Agreement utilizing the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the Credit Agreement contains a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet at March 31, 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Revolving Facility</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. Borrowings are limited to the lesser of the Company&#8217;s borrowing base and the revolving commitment of $<ix:nonFraction unitRef="usd" contextRef="i8a9fbd2dc730476f8a383e982377fba4_I20230217" decimals="-6" name="apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDE1_1bf64806-008f-44e3-ada3-9e2be21a7dac">10,000,000</ix:nonFraction>. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the revolving facility, the Company is required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account will be swept daily to MidCap and applied to outstanding borrowings under the revolving agreement <ix:nonNumeric contextRef="id84b5b8ace5c47e0ab7d98a27c878c5a_D20230217-20230217" name="apyx:DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTEwMTA0_6b8aa698-7718-46fd-9ea9-02750b4ee3f0">5</ix:nonNumeric> days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings will be promptly returned to the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Loans made under the revolving facility bear interest at a floating rate based on an adjusted one month SOFR plus <ix:nonFraction unitRef="number" contextRef="ia8727fd78b5f49719ede74e72b308e36_D20230217-20230217" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDMz_f20ebd73-1af4-4feb-992a-a685979ea7a4">0.1</ix:nonFraction>%, subject to a floor of <ix:nonFraction unitRef="number" contextRef="i6475488d296841caa68cd47c85e020e8_D20230217-20230217" decimals="3" name="apyx:DebtInstrumentInterestRateFloorPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDM5_1410ba69-e7a6-4a89-b06c-89320e299bc3">2.5</ix:nonFraction>%, plus <ix:nonFraction unitRef="number" contextRef="i6475488d296841caa68cd47c85e020e8_D20230217-20230217" decimals="4" name="apyx:DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTEwMTEw_44521f68-f97c-4d94-a6ae-42b9dd3ca4ec">4.00</ix:nonFraction>% calculated on a 360 day basis (<ix:nonFraction unitRef="number" contextRef="i8a9fbd2dc730476f8a383e982377fba4_I20230217" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0Mjg2_53d32c14-2d13-4635-b08f-1cb5ed89ee51">8.8</ix:nonFraction>% at March 31, 2023). The Company is obligated to pay a fee equal to <ix:nonFraction unitRef="number" contextRef="i6475488d296841caa68cd47c85e020e8_D20230217-20230217" decimals="3" name="apyx:DebtInstrumentAnnualFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTMw_d28032e5-8501-437e-8eb1-4b936a54aa96">0.5</ix:nonFraction>%  per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee. Terminations and reductions of the commitments are subject to fees of <ix:nonFraction unitRef="number" contextRef="id84b5b8ace5c47e0ab7d98a27c878c5a_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentTerminationFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjI1_a4f2d366-011f-416e-a364-64a42d682920">3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i959de39370604cf7aad3380d9347c61e_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentTerminationFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTY2_a43898a7-9b50-41be-8a6b-8b0d53beb8b2">2</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="if7f997a25acb43b78c977a49616ca9cb_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentTerminationFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTcw_c251c7eb-8521-434a-b368-ce960067b3c7">1</ix:nonFraction>% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is also required to maintain a minimum balance of <ix:nonFraction unitRef="number" contextRef="id84b5b8ace5c47e0ab7d98a27c878c5a_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDU4_55055cd2-fee6-43fb-ad6d-472be5dc3777">30</ix:nonFraction>% of the lesser of the borrowing base or $<ix:nonFraction unitRef="usd" contextRef="i8a9fbd2dc730476f8a383e982377fba4_I20230217" decimals="-6" name="apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDQ1_83c6c303-9b88-4902-a6b5-2ee0c57a9535">10</ix:nonFraction>&#160;million under the revolving facility. If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, the Company has drawn no amounts on the revolving facility. As of March 31, 2023, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="ia32fcb27739a44c999f32b3a61c449f6_I20230217" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0Mjky_28f7ff2a-b50a-476a-be04-ddeda86abe53">5,700,000</ix:nonFraction> available to be drawn on the revolving facility. As the Credit Agreement contains a subjective acceleration clause and the Company is required to maintain a lockbox, any amounts drawn on the revolving facility will be presented as a current liability in the consolidated financial statements. </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ia10d7916f665441999929768e9c7f14d" continuedAt="i4f76e79b9e574665b8f22736a1f31b11"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Collateral</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Covenants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $<ix:nonFraction unitRef="usd" contextRef="i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217" decimals="-6" name="apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTM2_54aa59b3-cebf-4514-a73b-ac92b5b05ce7">49</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217" decimals="-6" name="apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDYz_13fc9f0c-7f40-416f-912a-9ff2717f6e19">60</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217" decimals="-6" name="apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDc2_b07819a5-e0d3-49c5-9045-157f39559d83">70</ix:nonFraction>&#160;million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $<ix:nonFraction unitRef="usd" contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217" decimals="-6" name="apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDg5_40849602-8637-44f9-94b7-32820fc37b90">10</ix:nonFraction>&#160;million in cash and cash equivalents during the duration of the Credit Agreement&#8217;s term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023, the Company was in compliance with the financial covenants contained within the Credit Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Events of Default</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement also contains customary Events of Default</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to <ix:nonFraction unitRef="number" contextRef="i5d5b6ac44ade4700b26334526cfe5f12_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentDefaultApplicableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTAy_8dbaaa2f-1124-4aa6-af38-87abe51b8c8f">2</ix:nonFraction>% in excess of the applicable interest rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the Credit Agreement. The bifurcated derivative is de minimis to the Company's unaudited condensed consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Issuance of Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company&#8217;s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTA2_9886e561-3cd9-45f3-b12f-1c1ec56d0f0c">250,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTE1_cae81284-677c-40c0-a462-9355057540d5">0.001</ix:nonFraction>, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTIz_54fd2aab-561b-4ee7-8815-520ecda847ec">3.40</ix:nonFraction> per share.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The warrants have a <ix:nonNumeric contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjQw_e94eec9d-b9db-4dcf-bd81-74d6a96df9f5">10</ix:nonNumeric> year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering  warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Debt Issuance Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with entering into the Credit Agreement, the Company incurred debt issuance costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0MzA2_1bf07c62-0180-4837-b9cb-44789d7c6299">1.8</ix:nonFraction>&#160;million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan will be amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and will be amortized over the life of the term loans starting at the issuance date. If these loans are not issued, the Company will recognize </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i4f76e79b9e574665b8f22736a1f31b11"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the deferred costs at the point that the Company's rights to borrow on the term loans expires. The costs allocated to the revolving facility will be recognized on a straight-line basis over the term of the Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Included in interest expense for the three months ended March 31, 2023 are $<ix:nonFraction unitRef="usd" contextRef="i52b5c4f206324a52b8b01adbfe778760_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI4NzA5_0e5e52b7-37d6-4b0e-9134-3c6bf28a7844">17,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i52b5c4f206324a52b8b01adbfe778760_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI4NzE4_6a844c9d-60b5-4c65-8ad0-c2652ff89657">37,000</ix:nonFraction>, respectively, of amortization of the debt issuance costs and amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three months ended March 31, 2023 are $<ix:nonFraction unitRef="usd" contextRef="idb361a5c665a4bcbb5b44abe46d8fc2b_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI4NzI3_ec798470-837a-47ab-8279-362adadc4b4d">12,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idb361a5c665a4bcbb5b44abe46d8fc2b_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI4NzM4_576e1f45-fcb8-4237-938d-367802024552">1,000</ix:nonFraction>, respectively, of amortization of the debt issuance costs and amortization of the debt discount on the revolving facility. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0MzAz_59295b91-fad1-4b63-a697-e25000917a44" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s term loan, net consists of the following at March 31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6338653760b44614b5950f6458c874e5_I20230331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ZTk4YWJjNTNjNjNjNDQzNzliOTMzNTQxN2U0YzNkOTEvdGFibGVyYW5nZTplOThhYmM1M2M2M2M0NDM3OWI5MzM1NDE3ZTRjM2Q5MV8xLTItMS0xLTMwNzE0_ff7830e2-a8ac-46e0-af0f-03b0e05de929">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ZTk4YWJjNTNjNjNjNDQzNzliOTMzNTQxN2U0YzNkOTEvdGFibGVyYW5nZTplOThhYmM1M2M2M2M0NDM3OWI5MzM1NDE3ZTRjM2Q5MV8yLTItMS0xLTMwNzE0_417b29a3-9e0e-4e28-9f2d-7f73c3da0a04">485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount, including accretion of exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ZTk4YWJjNTNjNjNjNDQzNzliOTMzNTQxN2U0YzNkOTEvdGFibGVyYW5nZTplOThhYmM1M2M2M2M0NDM3OWI5MzM1NDE3ZTRjM2Q5MV8zLTItMS0xLTMwNzE0_4c621e5a-a797-414a-9889-a654fbb3d956">737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ZTk4YWJjNTNjNjNjNDQzNzliOTMzNTQxN2U0YzNkOTEvdGFibGVyYW5nZTplOThhYmM1M2M2M2M0NDM3OWI5MzM1NDE3ZTRjM2Q5MV80LTItMS0xLTMwNzE0_1cee06d4-3fbf-428b-a29a-229f75424ef6">8,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0MzA0_b599af2b-54ac-49b6-b8f4-f22b0848400e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, principal repayments on the term loan are as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:86.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV8xLTEtMS0xLTMwNzI5_fd257e22-44e0-4791-b323-1f7061d1fb9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV8yLTEtMS0xLTMwNzI5_7142ce9c-96fe-4629-9f7b-30203f394254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV8zLTEtMS0xLTMwNzI5_b489bbfc-d172-4c3f-81c9-c3d351c42aeb">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV80LTEtMS0xLTMwNzI5_d21e4ab5-b8da-409b-b7eb-aea15a158dc1">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV81LTEtMS0xLTMwNzI5_f6ff1e0a-324a-4e2e-a5b3-644c50a456cf">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="apyx:LongTermDebtMaturityAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV82LTEtMS0xLTMwNzI5_10392987-502a-4ded-9bd9-77701965a917">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV83LTEtMS0xLTMwNzI5_e7997bd2-cfc2-4375-9c04-92de3015dd22">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfNjIx_1f3d67ac-4361-4711-bb77-b597a28370d2" continuedAt="i6bb21e322c9444efa484e11ba9c4b758" escape="true">INTEREST IN JOINT VENTURE INVESTMENT</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6bb21e322c9444efa484e11ba9c4b758"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier (&#8220;China JV&#8221;) whereby the Company has a <ix:nonFraction unitRef="number" contextRef="i4271a8fb9da64a4789ce96b320c25e39_I20191231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfMTU2_e3c59f74-cf4d-43fe-aac9-cb4f3a18c6a6">51</ix:nonFraction>% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="if3f9fa1ecfdb48119493afdf30b2022a_I20191231" decimals="-3" name="apyx:NoncontrollingInterestRequiredCapitalContribution" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfMzY5_ac20b183-a613-4254-8091-22386b8ce08b">357,000</ix:nonFraction>, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i6aa4190bc3674f469e5b158e6869197c_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfMzI5ODUzNDg4NDQ2OQ_6c074e93-1c68-4f67-b54c-343994059baf">203,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9eb98c8ff23e49bc88f698fa56afd8ce_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfMzI5ODUzNDg4NDQ3OQ_00a5c1b0-4c8f-4103-b0f3-11881b471399">154,000</ix:nonFraction>, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="apyx:NoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfNjIy_7c3e7825-b7f4-43cf-b54a-1ac9c4dd75e9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.159%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4980f0f2ab4be298429e6c68c4337c_I20221231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfMi0yLTEtMS0yNzg1Mg_614b3ba0-7a8d-4803-bf05-e4f3d4ae7ace">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i994301f8b554452584f2e4a03b35f7ac_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfMi00LTEtMS0yNzg1Mg_536f2a19-8904-43ad-a7f7-28335af98464">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie30ce932627140d1a2b179341ef78232_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfNC0yLTEtMS0yNzg1Mg_190cb1a9-477b-4330-9979-f0dfb4002997">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ce5d204aa7344c59e93d632a33eef74_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfNC00LTEtMS0yNzg1Mg_80bd60bd-ce04-4f6a-8575-b5f04220c068">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857f1353ae2c4ec3bc1c0d6d91f7e28c_I20230331" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfNS0yLTEtMS0yNzg1Mg_71ae5524-01b7-45d6-b443-87b947413657">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96384db7fff41dbb63293f4abff78af_I20220331" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfNS00LTEtMS0yNzg1Mg_04ccb972-e271-4f3f-bcb9-4785d7954d92">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RleHRyZWdpb246ZjY3YTRhZmM0ZDZlNGNlNTk0YjFiNzRiNzMwYmYwYTBfNTM0_d3099f62-e9bf-48d9-8d9d-25ff2730f231" continuedAt="ibfad237b7c6247a7bd84ecd77b6e4f1a" escape="true">EARNINGS (LOSS) PER SHARE </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibfad237b7c6247a7bd84ecd77b6e4f1a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RleHRyZWdpb246ZjY3YTRhZmM0ZDZlNGNlNTk0YjFiNzRiNzMwYmYwYTBfNTM4_394adbf3-dec0-4f25-8fda-0a692e6b6f0b" continuedAt="i168f936152f4455f982c6870b33d9c1f" escape="true">The following table provides the computation of basic and diluted loss per share.</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i168f936152f4455f982c6870b33d9c1f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.159%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMy0yLTEtMS0yNzg1Mg_572125aa-8124-4ac3-89a2-6c7e289a2ab9"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMy0yLTEtMS0yNzg1Mg_dc228632-f94f-4b73-bea6-49b738360845">3,483</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMy00LTEtMS0yNzg1Mg_09eb75f7-962e-4bc1-886c-9e427e6d2dec"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMy00LTEtMS0yNzg1Mg_883918a2-ffe5-47c7-92db-3427d638832c">5,945</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfNi0yLTEtMS0yNzg1Mg_72475432-9e5e-4dfc-aca9-4de3ee5a5180"><ix:nonFraction unitRef="shares" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfNi0yLTEtMS0yNzg1Mg_86228d8c-f815-466b-ab87-38d947f61401">34,598</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfNi00LTEtMS0yNzg1Mg_4ea220da-529d-4abb-a65d-15ed0b148fc4"><ix:nonFraction unitRef="shares" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfNi00LTEtMS0yNzg1Mg_f886c8f1-6b7f-484b-bb77-c2bffb108d77">34,429</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfOS0yLTEtMS0yNzg1Mg_c337521e-6346-447d-8890-e1f07a12b257"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfOS0yLTEtMS0yNzg1Mg_d4195e92-d9bf-49cb-a4ee-49151d13048e">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfOS00LTEtMS0yNzg1Mg_27a296f0-44da-4d65-9d0c-c80e404c151b"><ix:nonFraction unitRef="usdPerShare" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfOS00LTEtMS0yNzg1Mg_9986b3e0-4585-4d69-84bd-832052dd07af">0.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd237ef53a384e9e80d9d797d4712603_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMTMtMi0xLTEtMjc4NTI_a99f1e2e-bc5e-4d1f-ba43-ce6b4f1d8bbc">7,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3163fe51e869499585757dba371b5390_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMTMtNC0xLTEtMjc4NTI_2213f821-dff8-45b0-95c5-d77bd4106fbd">6,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i968a4cfb77a54232afc8b80ea39ad52b_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMTQtMi0xLTEtMjk4ODg_d951411f-f2f5-4131-8d28-3e78a892e315">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie59716d0f60c45d9aded6f41b3e4a29f_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMTQtNC0xLTEtMjk4ODk_7e22e700-9ac2-4f6b-a11d-55a0ebdbbc7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTUxMg_253306c0-ec3c-4359-973b-ebb250e76b38" continuedAt="ic6b95a47d96b41ae9b69afb4eac2270e" escape="true">STOCK-BASED COMPENSATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic6b95a47d96b41ae9b69afb4eac2270e"><div style="text-align:justify"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTUxNA_ade53ef1-ca93-41f7-871b-589af35c4d6f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfNjUw_292020ec-3d76-4040-a496-6b35326e5f79">1,367,000</ix:nonFraction> in stock-based compensation expense for the three months ended March 31, 2023, as compared with $<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfNzE4_b00c0d9a-2ec7-4ba9-8c37-2a71223fa55f">1,650,000</ix:nonFraction> for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTUxOA_7342c07f-bd35-40a7-a522-3ae6508d44be" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNS0xLTEtMS0yNzg1Mg_7a70e3c7-d42b-4f32-8c45-b4edfba6c95e">6,520,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNS0zLTEtMS0yNzg1Mg_a6c7a994-9df8-41cc-91cd-522a2cdf78b0">7.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNi0xLTEtMS0yNzg1Mg_8bd365ba-23ae-445d-b77a-8853dc7f96d9">1,408,865</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNi0zLTEtMS0yNzg1Mg_a182348b-269b-4f7b-9dc9-7847563d956d">2.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNy0xLTEtMS0yNzg1Mg_1f887bc6-654a-4d11-bb4d-14e6ad4f6874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNy0zLTEtMS0yNzg1Mg_b6dda139-1fa1-4dee-8d10-7c85f944e842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfOC0xLTEtMS0yNzg1Mg_74db3f76-12ef-4413-af44-0e3da501e38d">146,164</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfOC0zLTEtMS0yNzg1Mg_2368c203-b498-4033-b500-67f3562ff17e">8.08</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfOS0xLTEtMS0yNzg1Mg_2276cbe8-0c35-4e1f-b7cd-cb5999fd70cb">7,783,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfOS0zLTEtMS0yNzg1Mg_a873518f-32bf-428b-a711-bc264d635376">6.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended March 31, 2022, we received <ix:nonFraction unitRef="shares" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTE4NA_21e98b8f-6fd5-48b7-9193-db3fbb1e3bbf">22,654</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTIzMg_571894ba-ba89-4dc7-bd53-0bdfb6f7430e">19,013</ix:nonFraction> options. There were no such exercises for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. <ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTUyMQ_41e8d161-61e6-4fab-9e61-4e98493fcd7b" continuedAt="ib1986f1e97c6461c80f13f4a17f37f5a" escape="true">The Company calculated the grant date fair value of options granted in 2023 (&#8220;2023 Grants&#8221;) utilizing a Black Scholes model.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="ib1986f1e97c6461c80f13f4a17f37f5a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"></td><td style="width:71.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.589%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfMS0xLTEtMS0yNzg1Mg_2a535307-1356-4a33-a8ee-137ba6dd2386">2.50</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfMi0xLTEtMS0yNzg1Mg_3d09d32b-503c-43cf-9ffc-ad7c4f4065d8">3.6</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfMy0xLTEtMS0yNzg1Mg_c2ef20da-e4a0-4e4a-b246-822c1ee3c35c">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfNC0xLTEtMS0yNzg1Mg_94ece69c-22a8-4b43-a886-8e8218c53d8f">85.8</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfNS0xLTEtMS0yNzg1Mg_9aaa71a6-a0cd-4788-a685-c11cd6774ca2">6</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfMTI3OQ_bad1d9a8-778a-442d-940d-32a8a4539e27" continuedAt="i393ed557e91144d78b3ed10cf65287d7" escape="true">INCOME TAXES </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i393ed557e91144d78b3ed10cf65287d7">Income tax (benefit) expense was approximately $(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfNjY_cd555d65-0fd8-4b06-80f5-2177e62e741f">2,267,000</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfNzM_4f3bfbdb-b232-4846-84ca-6125b23926b9">70,000</ix:nonFraction> with effective tax rates of <ix:nonFraction unitRef="number" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfMTA0_533923bb-47d6-42ad-a569-16a25f4f9118">39.1</ix:nonFraction>% and (<ix:nonFraction unitRef="number" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfMTEx_95b8c9b9-d726-4cfd-b09e-63d2dfcc3940">1.2</ix:nonFraction>)% for the three months ended March&#160;31, 2023 and 2022, respectively. For the three months ended March&#160;31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company&#8217;s liability for uncertain tax positions, including accrued interest and penalties of approximately $<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfMzI5ODUzNDg4OTk5Ng_b4ab9fe9-fe4a-4f0d-919e-8fa2e6bc588d">2.1</ix:nonFraction>&#160;million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on the net operating loss (&#8220;NOL&#8221;) and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMzE3Mg_12f6808e-691e-49bc-99e3-31a34d10d708" continuedAt="ie9af3a702c7f42e0a25778f1d5815309" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie9af3a702c7f42e0a25778f1d5815309" continuedAt="i73d06ecec9184fbbb5fa8226f25070f7"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $<ix:nonFraction unitRef="usd" contextRef="i4c3ed228146b4231874ddd7a84ecf89c_I20211231" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMjYwMw_02cd6945-6a1b-490d-b65c-758dfa744eaa">250,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i1b520559f24c441e931060ece6becb9b_I20211231" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMjYwOQ_487fa2f0-be30-4ca1-8981-d791759e12d8">1,000,000</ix:nonFraction>. The Company recorded an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMjY1OQ_0e1e2bfc-6001-4795-b308-b641fad09913">250,000</ix:nonFraction> related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed with the U.S. Securities and Exchange Commission on the Company&#8217;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#8220;Hattaway Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#8220;Goodwin&#8221;), the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, and Tara Semb (&#8220;Semb&#8221;), the Company&#8217;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#8217;s Advanced Energy products and the impact such usage would have on the Company&#8217;s business, operations and prospects. The Hattaway Complaint seeks an unspecified amount of damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Hattaway Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $<ix:nonFraction unitRef="usd" contextRef="ib1fa5e6669544a54afa2eccf6e04c7a5_I20221231" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIxOTMz_df7c32a5-8d37-45d8-8408-96bc48df323b">475,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i429b0f131ab543fbb23ba8b453c39589_I20221231" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIxOTQw_a204e7f6-a23c-45b8-a440-b42f9ff0b2aa">2,500,000</ix:nonFraction>. The Company recorded an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="ib2994bfe0e594059a28c66ab8010af39_I20221231" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIxOTkx_f698cd6f-3c1b-4069-91a0-6cc908d4b536">475,000</ix:nonFraction> related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of <ix:nonFraction unitRef="lease" contextRef="idc25d1761ff44d87a5e3cce964599c64_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyNDYy_0db17e9d-e207-4f50-b1b8-f34e5ecfc769">two</ix:nonFraction> related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the <ix:nonFraction unitRef="lease" contextRef="idc25d1761ff44d87a5e3cce964599c64_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyNjE3_f8a8d708-d171-421d-9698-7d18b18668ea">ten</ix:nonFraction> individual plaintiff&#8217;s allegations could be subject to separate </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i73d06ecec9184fbbb5fa8226f25070f7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $<ix:nonFraction unitRef="usd" contextRef="i03f055d56d024c43ab76ceb69016f0cc_I20230331" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyODY1_9daad6b0-ecf3-4ad6-99e7-dd604c63d0d9">1,450,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i42273566c1174b14a4e8392f80ba2427_I20230331" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyODcy_26b4b3bf-74a4-4691-ab93-f1f1ac7c24c1">2,400,000</ix:nonFraction>. The Company recorded an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="i5d07b00814b44846ae29c9126733b0ab_I20230331" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyOTIz_9562c7bb-7187-4012-909c-e2da83379a36">1,450,000</ix:nonFraction> related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the &#8220;Stein Suit&#8221;) against individual members of the Company&#8217;s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the &#8220;Pritchard Case&#8221;).  The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing.  The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously.  The outcome of the action is not within the Company&#8217;s control and may not be known for a prolonged period of time.  In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company&#8217;s financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the Company had purchase commitments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMzA4MQ_402b9976-d46e-4d07-83a2-974278e72c07">4.0</ix:nonFraction>&#160;million, substantially all of which is expected to be purchased within the next twelve months.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNzI2_9ffa9a52-5a0b-4171-87fa-6fb674772ded" continuedAt="i93a0defee400417bb874bc3cb70aefc8" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i93a0defee400417bb874bc3cb70aefc8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China JV is also a supplier to the Company. For the three months ended March&#160;31, 2023 and 2022, the Company made purchases from this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7e994b58a5f469cb23af8692f7bf53f_D20230101-20230331" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNjE4_102323cc-56b7-4741-87b1-a4dc029d3011">44,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iead2dc3eba5e47188eea66a730ec7ba2_D20220101-20220331" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNjI1_c8d9d1a9-3b46-4ea5-a46c-24b8eddcc04f">124,000</ix:nonFraction>, respectively. At March&#160;31, 2023 and December&#160;31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $<ix:nonFraction unitRef="usd" contextRef="iabe7f3502b4347be9913b0ff042c7661_I20230331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNzE2_68d2fdf1-a386-4f24-9fb3-5fdd90cf63e4">2,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8478849b5317485ba002f297876ef34b_I20221231" decimals="-3" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNzIz_7f5df988-53b7-427f-be05-d873907ce3b6">8,000</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTYxMQ_e3dc2771-67f0-494c-8d72-6c4698ec33b9" continuedAt="i32c7e78d09ad42498110307e81bb3a64" escape="true">GEOGRAPHIC AND SEGMENT INFORMATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i32c7e78d09ad42498110307e81bb3a64" continuedAt="i479f81cd0a0340ebac0a077e62ebc401"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are disclosed as principally organized and managed as <ix:nonFraction unitRef="segment" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfODYy_88af0a16-a31c-4ebd-9c02-69f6c5d9657a"><ix:nonFraction unitRef="segment" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfODYy_c86b0e30-aec4-468e-a621-ed2496352a4a">two</ix:nonFraction></ix:nonFraction> operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTYyMA_ffc54475-d23a-4a58-98c2-87ba7b77b825" continuedAt="ibd8f9072fff0414dae8c7ca6b802bfe8" escape="true">Summarized financial information with respect to reportable segments is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i479f81cd0a0340ebac0a077e62ebc401"><ix:continuation id="ibd8f9072fff0414dae8c7ca6b802bfe8"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMi0zLTEtMS0yNzg1Mg_c5a01ca5-c4a3-41be-bbbb-202297aa4ca3">9,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMi01LTEtMS0yNzg1Mg_6b56bf20-d74e-44cf-950d-e92183d0c425">2,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMi03LTEtMS0yNzg1Mg_f9f6e8c0-408a-42b7-855f-7e45e63a1b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMi05LTEtMS0yNzg1Mg_1a1c238a-8627-44f9-9941-aa1c846cc9b8">12,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTQtMy0xLTEtMjc4NTI_76c46548-eb49-4c3e-9adc-e389737dff1d">1,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTQtNS0xLTEtMjc4NTI_e7882d92-dcb9-46eb-b6f5-7f0fb15470c4">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTQtNy0xLTEtMjc4NTI_af63c46f-6de1-471a-b6ed-a2ae7bac02c8">5,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTQtOS0xLTEtMjc4NTI_1d31d349-1f50-4820-b7ef-f3722724352e">5,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTYtMy0xLTEtMjc4NTI_8bca8eb7-b7b5-4a6d-847c-949db05434bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTYtNS0xLTEtMjc4NTI_9c9a9a8e-e32c-4432-823e-9cae70063cf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTYtNy0xLTEtMjc4NTI_d30b76fd-50c9-4bd7-8a0e-df1a6bff62b3">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTYtOS0xLTEtMjc4NTI_d2f2414c-89a4-4d66-a09e-2293bcc3e721">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTctMy0xLTEtMjc4NTI_7958b89c-07b3-42ce-b0c1-f1697c2113dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTctNS0xLTEtMjc4NTI_7842da07-7abd-4dbc-bb08-f951fb5a05f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTctNy0xLTEtMjc4NTI_080edf8a-6e80-4ce2-90be-a7cc14e75c06">234</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTctOS0xLTEtMjc4NTI_31a3a69b-3f52-4e8f-afe2-fd01b1cc8aa3">234</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTgtMy0xLTEtMjc4NTI_95f8f7d2-3d1f-4b9b-ba6c-d09b06db5754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTgtNS0xLTEtMjc4NTI_3f2783f5-fe70-4302-b37c-e7edd7e465fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTgtNy0xLTEtMjc4NTI_3a3f4782-9b12-4e48-8925-73d5a82ccfd7">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTgtOS0xLTEtMjc4NTI_2749b959-8b2a-42ef-b680-b50f65497b14">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMjItMy0xLTEtMjc4NTI_d6d4d8a1-711d-43f6-bebb-da381e19b0f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMjItNS0xLTEtMjc4NTI_77bc3513-6666-455e-ab7c-7b447d37e416">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMjItNy0xLTEtMjc4NTI_060a882e-03ce-4bb0-b62b-4c4c1a297fed">2,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMjItOS0xLTEtMjc4NTI_1ebb1a2a-10a6-4139-a95e-a7a356742349">2,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMi0zLTEtMS0yNzg1Mg_7a34dbb5-16da-4e22-9b7d-c2024318833a">10,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMi01LTEtMS0yNzg1Mg_687137fa-f26d-4fd9-a3c2-5af5f09af48a">1,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMi03LTEtMS0yNzg1Mg_88f003e8-7b6e-4eca-9bc3-042c3476ce1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMi05LTEtMS0yNzg1Mg_9b19104e-527d-489a-86eb-c67412243e6e">12,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTQtMy0xLTEtMjc4NTI_b44b57a6-8610-4f2e-b0fe-1dcd4ef52567">1,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTQtNS0xLTEtMjc4NTI_0eb068f6-7dff-4cf9-9f8d-dce222e6be79">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTQtNy0xLTEtMjc4NTI_9df79c86-45ee-4d17-824f-728f89742405">4,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTQtOS0xLTEtMjc4NTI_d5d28630-9228-4fee-80d6-b85f4957c349">5,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTYtMy0xLTEtMjc4NTI_953cb192-5c16-448b-ad96-1bcb456bf76e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTYtNS0xLTEtMjc4NTI_0b7a740f-5c10-4ee1-a7fa-fab5b7fa9bd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTYtNy0xLTEtMjc4NTI_1e212ae6-9924-4801-9274-43d5cedaf196">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTYtOS0xLTEtMjc4NTI_296b2bc5-09e3-4629-9e96-15864da88ef3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTgtMy0xLTEtMjc4NTI_bda339cf-e56a-438e-8169-231f01123b86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTgtNS0xLTEtMjc4NTI_a324eb4d-a2ed-4732-92b5-aa4aec8e4b5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTgtNy0xLTEtMjc4NTI_b534959b-5980-4725-a642-bc6dcc885361">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTgtOS0xLTEtMjc4NTI_c09f3186-d867-4b58-9742-38ba627058ad">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTktMy0xLTEtMjc4NTI_7b746a31-2a52-4344-b231-b1eebcc5cb1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTktNS0xLTEtMjc4NTI_4cd111f4-97d8-4b7e-9470-57cec26f695d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTktNy0xLTEtMjc4NTI_8e71cd55-03ae-496d-bd15-46b8ce0d95db">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTktOS0xLTEtMjc4NTI_00cab033-8c4b-495a-b804-4fe14fb28d38">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMjMtMy0xLTEtMjc4NTI_f94a68df-0ae2-473f-83bf-5b927e506f41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMjMtNS0xLTEtMjc4NTI_f58370fb-00fe-4866-9839-4a15d0a8014d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMjMtNy0xLTEtMjc4NTI_1c8373c7-aeb9-4d3f-a72a-a0e14017d91e">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMjMtOS0xLTEtMjc4NTI_26f69397-aa20-4474-ba1b-82b4119f8cd7">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately <ix:nonFraction unitRef="number" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTQwMA_6a9c4bd1-4c51-4487-a163-b122d6f9c6de">26.9</ix:nonFraction>% of total revenues for the three months ended March 31, 2023,  as compared with approximately <ix:nonFraction unitRef="number" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTQ2NQ_0b965f77-06fc-4eba-b51c-ce958d21c42c">39.6</ix:nonFraction>% of total revenues for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTYxMg_b39d86e0-bb2d-415d-9ef7-93a482050c97" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"><tr><td style="width:1.0%"></td><td style="width:63.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef61e5dd37545a3ad7e31b677f88c1d_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfMy0xLTEtMS0yNzg1Mg_565563a0-5fff-4702-9580-9da0c8caff5d">8,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5569b815eaea4f9d9cdfcb8f7e5f0209_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfMy0zLTEtMS0yNzg1Mg_c8229cfe-eca9-42ba-8c99-262bf3a52d16">7,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6176a8f8df744f2b97ab2568640c4a9d_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfNC0xLTEtMS0yNzg1Mg_3bb8f0b6-c723-4c1d-a77a-ec05db224cf5">3,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12b47ef6b0e48508323229d60109300_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfNC0zLTEtMS0yNzg1Mg_13739e98-b8bf-4aa9-8d2d-83a18b5bae31">4,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfNS0xLTEtMS0yNzg1Mg_01e3bf2f-6d3d-4e02-9cc8-ba2ca5dfe88d">12,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfNS0zLTEtMS0yNzg1Mg_a4116004-4ef9-4a29-8f3b-982d974d39f8">12,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Level Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including our Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our plan to accelerate and fully fund the development of our advanced energy business, with a focus in the cosmetic  surgery market, we sold our Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, we had and still have, some significant non-recurring discretionary expenditures associated with completing our multi-year marketing initiatives related to our dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Medical Device Safety Communication (&#8220;Safety Communication&#8221;). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as &#8220;tightening&#8221;). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, we experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion&#174; Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion&#174; device system for certain dermal resurfacing procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion&#174; APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 28, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion&#174; APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, we believe that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of our sale of the Core business segment to Symmetry Surgical during 2018, we have incurred recurring net losses and cash outflows from operations and we anticipate that losses will continue in the near term. During the year ended December 31, 2022, the we incurred an operating loss of $23.6&#160;million and used $20.3&#160;million of cash in operations. During the three months ended March 31, 2023, the we incurred an operating loss of $5.6&#160;million and used $1.9&#160;million of cash in operations. As of March 31, 2023, the we had cash and cash equivalents of $16.3&#160;million, of which we must maintain $10.0 million under our Credit Agreement. These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, we have not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement, see Note 6 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. On May 8, 2023, we closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement, see Note 4 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the our tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company&#8217;s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations and our debt covenants for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to drive sales in our Advanced Energy business by increasing the adoption and utilization of our handpieces by surgeons in the U.S. and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 60 countries. As of March&#160;31, 2023, we had a direct sales force of 35 field-based selling professionals and utilized 3 independent sales agencies. We also had 4 sales managers. This selling organization is focused on the use of Renuvion&#174; in the cosmetic surgery market, supported by our global medical affairs team. This global team of clinical support specialists focuses on supporting our users to ensure optimal outcomes for their patients. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174; into physicians&#8217; practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regards to our operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the global supply chain instability and inflationary cost increases, we continue to take action to minimize, as much as possible, any potential adverse impacts by working closely with our suppliers to closely monitor the availability of raw material components (i.e. semiconductors and plastics), lead times, and freight carrier availability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect global supply chain instability will continue to have an impact on our business, but to date that has not been material to our financial performance. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly encourage investors to visit our website: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.apyxmedical.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to view the most current news and to review our filings with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:47.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Reportable Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Energy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OEM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or approximately $0.4&#160;million, for the three months ended March 31, 2023 when compared with the three months ended March 31, 2022. Advanced Energy segmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t sales decreased 10.4%, or approximately $1.1&#160;million, for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023 when compared with the three months ended March 31, 2022. The Advanced Energy sales decrease was driven by decreases in adoption of our generator technology in international markets and in global utilization based demand for our handpieces following the FDA Safety Communication on March 14, 2022. These decreases were partially offset by domestic customers, who upgraded their generator to our new Apyx One Console, which we launched in January 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OEM segmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t sales increased 46.0%, or approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when compared with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in OEM sales was due to increases in sales volume to existing customers as well as incremental new sales upon the commencement of the supply arrangement related to the completion of the development portion of some of our OEM development agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 26.9% of total revenues for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared with 39.6% of total revenues for the same prior year period.  Management estimates our products have been sold in more than 60 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:47.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:47.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the three months ended March&#160;31, 2023, decreased 7.9% to $7.6 million, compared to $8.2 million for the same period in the prior year. Gross margin for the three months ended March&#160;31, 2023, was 62.4%, compared to 65.8% for the same period in 2021. </span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in gross profit margins for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the prior year period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is primarily attributable to changes in the sales mix between our two segments, with our OEM segment comprising a higher percentage of total sales and product mix within our Advanced Energy segment. These decreases were partially offset by geographic mix within our Advanced Energy segment, with domestic sales comprising a higher percentage of total sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Expenses</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:47.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased 3.2% for the three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily due to lower spending on ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r two investigational device exemption (IDE) clinical studies and other product development initiatives ($0.1 million). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This decrease was partially offset by increased labor and benefit costs from the same period in the prior year ($0.1 million). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:47.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional ser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vices expense decreased 23.9% for the three months ended March&#160;31, 2023 as compared to the same period in the prior year, primarily attributable to decreases in legal expenses ($0.3 million), physician consulting fees ($0.2 million) and accounting and audit fees ($0.1 million). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and related costs</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:47.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, salaries and related expenses decreased 2.2%, primarily driven by lower stock based compensation expense ($0.2 million). This increase was partially offset by higher compensation and benefits ($0.1 million) as compared to the same period in the prior year.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:47.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, selling, general and administrative expense decreased 3.8%, primarily driven by decreased advertising expense, including trade show fees and related costs ($0.5 million), lower bad debt expenses ($0.3 million) and employee training and other meeting expenses ($0.2 million). These decreases were partially offset by increases in travel and entertainment expense ($0.5 million) and insurance expense ($0.3 million).</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income (Expense)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.596%"><tr><td style="width:1.0%"></td><td style="width:73.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2023, compared with same period in the prior year. This increase is due to higher yields on our investments in money market funds and U.S. Treasury securities included in cash, cash equivalents and restricted cash, partially offset by a lower average balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2023, compared with same period in the prior year. This increase is due to cash and noncash interest expense on the Credit Agreement executed on February 17, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.508%"><tr><td style="width:1.0%"></td><td style="width:57.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.845%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.846%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March&#160;31, 2023 and 2022, respectively. For the three months ended March&#160;31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of our liability for uncertain tax positions, including accrued interest and penalties, of approximately $2.1 million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on our NOL and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, we had approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash, cash equivalents and restricted cash as compared to approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash and cash equivalents at December 31, 2022.  Our working capital at March 31, 2023 was approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$34.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $31.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at December 31, 2022. The increase in working capital at March 31, 2023 was primarily due to the reclassification of assets held for sale from long term assets to current assets in March 2023 and the reversal of our liability for uncertain tax positions upon the completion in January 2023 of the IRS examination of our 2018, 2019 and 2020 income tax returns. This increase was partially offset by the net loss incurred by the Company in the first quarter of 2023, excluding non-cash activity, comprised primarily of stock-based compensation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, net cash used in operating activities was approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which principally funded our los</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s from operations of $5.6 million, compared with net cash used in operating activities of approximately $4.5 million in 2022. As discussed in the Executive Level Overview, our operating loss, cash used in operations and current cash and cash equivalents balance of $16.3 million, of which we must maintain $10.0 million under our Credit Agreement,  raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of our unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, we have not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement, see Note 6 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $7,650,000. On May 8, 2023, we closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement, see Note 4 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations and our debt covenants for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March 31, 2023 and 2022, were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, related to purchases of property and equipment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March 31, 2023 was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.1 million related to proceeds received upon the execution of the Credit Agreement ($9.9 million) less debt issuance costs incurred in the transaction ($1.8 million). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, our borrowing availability under the revolving facility was approximately $5.7 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, we had purchase commitments for inventories totaling approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, substantially all of which is expected to be purchased by the end of 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on March 16, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model, which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the estimates of expected life and volatility used in the calculations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. The SEC allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable Allowance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze historical bad debt experience, the composition of outstanding receivables by customer class, and the age of outstanding balances, and we make estimates in connection with establishing the allowance for doubtful accounts, including the expected impacts of changes in the operating environment and other trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory Obsolescence Allowance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of historical losses and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on our net deferred tax assets. Exclusive of the carryback provisions of the CARES Act and the associated income tax benefit recognized in 2020, we do not anticipate recording an income tax benefit related to our deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent our results of operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., we continued to record a valuation allowance on the net deferred tax assets balance as of March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty. Inflation has not, to date, materially impacted our operations or financial performance. However, as these trends continue for raw materials, freight, and labor costs, our future financial performance could be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements at this time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_34">See Note 2 of the Notes to Condensed Consolidated Financial Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_76"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:4.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures </span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March&#160;31, 2023, the Company's disclosure controls and procedures were effective.</span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="margin-top:4.59pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we entered into a Credit, Security and Guaranty Agreement ("Credit Agreement"). We are in the process of developing new control activities around the accounting for the Credit Agreement, including the review and compliance with debt covenants. There were no other changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by the Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_82"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#160;&#160;&#160;&#160;Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_58">See Note 1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_58">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_58"> of Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.</a></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. Risk factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no material changes to the risk factors described under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_94"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. Defaults Upon Senior Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i81be52fe8a3444dab77580d4782f59cd_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 8, 2023, Apyx Medical Corporation (the &#8220;Company&#8221;) closed the previously announced sale and leaseback of its facility located </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">at 5115 Ulmerton Road, Clearwater, Florida, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">VK Acquisitions VI, LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for a purchase price of $7,650,000.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Following the closing, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">net cash proceeds of approximately $6,600,000 after withholding the security deposit equal to one years rent, taxes, first months rent, expenses and fees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_106"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Articles of Incorporation of the Registrant (</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Incorporated by reference to </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Exhibit 3.1 to </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">By laws of the Registrant (</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">Incorporated by reference to </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">Exhibit 3.2 to </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q3exhibit35.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant (</a>Incorporated by reference to Exhibit 3.5 to the Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s Quarterly Report on Form 10-Q filed on November 3, 2017<a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q3exhibit35.htm">)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx_201805xex31certificate.htm">Certificate of Elimination (</a>Incorporated by reference to Exhibit 3.1 to the Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s Current Report on Form 8-K filed on May 3, 2018<a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx_201805xex31certificate.htm">)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000086/0000719135-18-000086-index.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant (</a>Incorporated by reference to Exhibit 3.1 to the Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s Current Report on Form 8-K filed on December 28, 2018<a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000086/0000719135-18-000086-index.htm">)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2023q110-kexhibit311.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2023q110-kexhibit312.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2023q110-qexhibit321.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2023q110-kexhibit322.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Presentation Document</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration&#160;statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i81be52fe8a3444dab77580d4782f59cd_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i81be52fe8a3444dab77580d4782f59cd_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apyx Medical Corporation</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 11, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 11, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasurer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2023q110-kexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic268d7cd3ffa4d369d770ff56e7e11ab_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2023q110-kexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idd552afc9f2b40b7b26ef0d1b43ac130_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tara Semb, the Registrant's Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:42.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2023q110-qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0610e21479a444699a6d598901e2c45f_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a2023q110-kexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1474b2f771554677a8d625a1afda4ea9_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>apyx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:28fd0711-76c0-4c99-9948-92d9f912ad78,g:c54375b6-2eb5-4e7e-b289-a9d1feaf728d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:apyx="http://apyxmedical.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://apyxmedical.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://apyxmedical.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION">
        <link:definition>0000007 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://apyxmedical.com/role/INVENTORIES">
        <link:definition>0000009 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT" roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT">
        <link:definition>0000010 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>0000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CREDITAGREEMENT" roleURI="http://apyxmedical.com/role/CREDITAGREEMENT">
        <link:definition>0000012 - Disclosure - CREDIT AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENT" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT">
        <link:definition>0000013 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>0000014 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000015 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://apyxmedical.com/role/INCOMETAXES">
        <link:definition>0000016 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000018 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATION" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION">
        <link:definition>0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPolicies" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies">
        <link:definition>0000020 - Disclosure - BASIS OF PRESENTATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://apyxmedical.com/role/INVENTORIESTables">
        <link:definition>0000021 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables" roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables">
        <link:definition>0000022 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://apyxmedical.com/role/DebtTables">
        <link:definition>0000024 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTTables" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables">
        <link:definition>0000025 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>0000026 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>0000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONTables" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables">
        <link:definition>0000028 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONDetails" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONDetails">
        <link:definition>0000029 - Disclosure - BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESDetails" roleURI="http://apyxmedical.com/role/INVENTORIESDetails">
        <link:definition>0000030 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails">
        <link:definition>0000031 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>0000032 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CREDITAGREEMENTNarrativeDetails" roleURI="http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails">
        <link:definition>0000034 - Disclosure - CREDIT AGREEMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CREDITAGREEMENTScheduleOfLongTermDebtDetails" roleURI="http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails">
        <link:definition>0000035 - Disclosure - CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" roleURI="http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails">
        <link:definition>0000036 - Disclosure - CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails">
        <link:definition>0000037 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails">
        <link:definition>0000038 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000040 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails">
        <link:definition>0000041 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails">
        <link:definition>0000042 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESDetails">
        <link:definition>0000043 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>0000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>0000045 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
        <link:definition>0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
        <link:definition>0000048 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" abstract="false" name="DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodTwoMember" abstract="true" name="DebtInstrumentPrepaymentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_OtherAccruedExpensesAndLiabilitiesCurrent" abstract="false" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodThreeMember" abstract="true" name="DebtInstrumentPrepaymentPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentFeePercent" abstract="false" name="DebtInstrumentPrepaymentFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" abstract="false" name="StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodOneMember" abstract="true" name="DebtInstrumentPrepaymentPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_NoncontrollingInterestRequiredCapitalContribution" abstract="false" name="NoncontrollingInterestRequiredCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SaleLeasebackTermOfLease" abstract="false" name="SaleLeasebackTermOfLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" abstract="false" name="DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodDomain" abstract="true" name="DebtInstrumentTerminationPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantsDomain" abstract="true" name="DebtInstrumentCovenantsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationFees" abstract="false" name="DebtInstrumentTerminationFees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_SaleLeasebackManagementFeeOnRentPayment" abstract="false" name="SaleLeasebackManagementFeeOnRentPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" abstract="false" name="DebtInstrumentCovenantCashAndCashEquivalentsBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ChineseSupplierMember" abstract="true" name="ChineseSupplierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_UncertainTaxPositionsLiability" abstract="false" name="UncertainTaxPositionsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" abstract="false" name="DebtInstrumentNumberOfMonthlyPaymentsExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" abstract="false" name="ProceedsFromStockOptionsExercisedAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_JointAndSeveralPayrollLiability" abstract="false" name="JointAndSeveralPayrollLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentNumberOfMonthlyPayments" abstract="false" name="DebtInstrumentNumberOfMonthlyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantsAxis" abstract="true" name="DebtInstrumentCovenantsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodOneMember" abstract="true" name="DebtInstrumentTerminationPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SuitsFiledIn2022Member" abstract="true" name="SuitsFiledIn2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackSecurityDepositEqualToAnnualRent" abstract="false" name="SaleLeasebackSecurityDepositEqualToAnnualRent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_ProvisionForInventoryObsolescence" abstract="false" name="ProvisionForInventoryObsolescence" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SaleLeasebackAnnualRentPayment" abstract="false" name="SaleLeasebackAnnualRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_NoncontrollingInterestTableTextBlock" abstract="false" name="NoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTrancheThreeMember" abstract="true" name="DebtInstrumentCovenantTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackRenewalTerm" abstract="false" name="SaleLeasebackRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_PropertyPlantAndEquipmentInService" abstract="false" name="PropertyPlantAndEquipmentInService" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" abstract="false" name="DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_RepaymentofFinanceLeaseLiabilities" abstract="false" name="RepaymentofFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTrancheOneMember" abstract="true" name="DebtInstrumentCovenantTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SuitAgainstGoodwinAndSimbMember" abstract="true" name="SuitAgainstGoodwinAndSimbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTrancheTwoMember" abstract="true" name="DebtInstrumentCovenantTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_MoldsMember" abstract="true" name="MoldsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackPurchaseAgreement" abstract="false" name="SaleLeasebackPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentExitFee" abstract="false" name="DebtInstrumentExitFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwaps" abstract="false" name="StockIssuedDuringPeriodSharesStockSwaps" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" abstract="true" name="AdjustedTermSecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_AdvancedEnergyMember" abstract="true" name="AdvancedEnergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentExtensionPeriod" abstract="false" name="DebtInstrumentExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_DebtInstrumentPeriodOfInterestOnly" abstract="false" name="DebtInstrumentPeriodOfInterestOnly" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_DebtInstrumentAnnualFeePercent" abstract="false" name="DebtInstrumentAnnualFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentInterestRateFloorPercent" abstract="false" name="DebtInstrumentInterestRateFloorPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" abstract="false" name="DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ProvisionForObsolescenceInventory" abstract="false" name="ProvisionForObsolescenceInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_TotalRevenuePercent" abstract="false" name="TotalRevenuePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_ShelfRegistrationMember" abstract="true" name="ShelfRegistrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" abstract="false" name="DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodAxis" abstract="true" name="DebtInstrumentPrepaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="apyx_OEMMember" abstract="false" name="OEMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" abstract="false" name="DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" abstract="false" name="DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodTwoMember" abstract="true" name="DebtInstrumentTerminationPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodDomain" abstract="true" name="DebtInstrumentPrepaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodAxis" abstract="true" name="DebtInstrumentTerminationPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="apyx_DebtInstrumentDefaultApplicableInterestRate" abstract="false" name="DebtInstrumentDefaultApplicableInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_StockSwapToAcquireOptionsShares" abstract="false" name="StockSwapToAcquireOptionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_SaleLeasebackNetCashProceeds" abstract="false" name="SaleLeasebackNetCashProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SecuritiesRegisteredNewIssues" abstract="false" name="SecuritiesRegisteredNewIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SaleLeasebackAnnualRentIncrease" abstract="false" name="SaleLeasebackAnnualRentIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_AtTheMarketFacilityMember" abstract="true" name="AtTheMarketFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodThreeMember" abstract="true" name="DebtInstrumentTerminationPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>apyx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:28fd0711-76c0-4c99-9948-92d9f912ad78,g:c54375b6-2eb5-4e7e-b289-a9d1feaf728d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4afc5d11-3fb1-446f-874a-949c563da23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cc536b6c-fbab-4478-b09e-56031127c687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4afc5d11-3fb1-446f-874a-949c563da23a" xlink:to="loc_us-gaap_Liabilities_cc536b6c-fbab-4478-b09e-56031127c687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_646044a7-ec23-416d-8bd9-35d4f27a7093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4afc5d11-3fb1-446f-874a-949c563da23a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_646044a7-ec23-416d-8bd9-35d4f27a7093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_567f9aeb-0a44-468e-816c-f8ff511b6ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1aa93a08-9d5a-4771-9b23-6bab7567f53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_567f9aeb-0a44-468e-816c-f8ff511b6ff6" xlink:to="loc_us-gaap_AccountsPayableCurrent_1aa93a08-9d5a-4771-9b23-6bab7567f53c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_a8b1d629-1f62-49b5-ba11-bede574fed76" xlink:href="apyx-20230331.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_567f9aeb-0a44-468e-816c-f8ff511b6ff6" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_a8b1d629-1f62-49b5-ba11-bede574fed76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e89b2ca0-b3fe-41c3-ba1b-711f76463154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_567f9aeb-0a44-468e-816c-f8ff511b6ff6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e89b2ca0-b3fe-41c3-ba1b-711f76463154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_fdbb609f-8b45-4acf-b05a-109089059eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_567f9aeb-0a44-468e-816c-f8ff511b6ff6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_fdbb609f-8b45-4acf-b05a-109089059eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_6b7ca0ba-8fe8-42af-84c7-f7e01e60f82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_567f9aeb-0a44-468e-816c-f8ff511b6ff6" xlink:to="loc_us-gaap_LongTermDebtCurrent_6b7ca0ba-8fe8-42af-84c7-f7e01e60f82b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7cc7d6e8-a355-4196-8b15-7ae674753c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a3a8e71f-a246-45ff-93f3-67729e94ba98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7cc7d6e8-a355-4196-8b15-7ae674753c33" xlink:to="loc_us-gaap_CommonStockValue_a3a8e71f-a246-45ff-93f3-67729e94ba98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e2d0d2df-a161-4cdc-aae7-a93e1eb1fb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7cc7d6e8-a355-4196-8b15-7ae674753c33" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e2d0d2df-a161-4cdc-aae7-a93e1eb1fb5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c1c22778-c701-4e1a-af9b-c9236b1a4ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7cc7d6e8-a355-4196-8b15-7ae674753c33" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c1c22778-c701-4e1a-af9b-c9236b1a4ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_07aa17ea-5483-4dd1-9d27-86b98fc6bee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7cc7d6e8-a355-4196-8b15-7ae674753c33" xlink:to="loc_us-gaap_PreferredStockValue_07aa17ea-5483-4dd1-9d27-86b98fc6bee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a2a2a263-2c5f-4382-b7f9-1709051bcaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb0bc86f-528e-49d0-b0c6-0071cfbc1739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a2a263-2c5f-4382-b7f9-1709051bcaa3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb0bc86f-528e-49d0-b0c6-0071cfbc1739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_78ecfeb3-29e6-48e1-910f-26e7ad64f614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a2a263-2c5f-4382-b7f9-1709051bcaa3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_78ecfeb3-29e6-48e1-910f-26e7ad64f614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_1908e0a8-190f-4d61-aa79-57663c9d0663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a2a263-2c5f-4382-b7f9-1709051bcaa3" xlink:to="loc_us-gaap_IncomeTaxesReceivable_1908e0a8-190f-4d61-aa79-57663c9d0663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_2943d894-cacc-4b63-a8a8-314dcb47475c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a2a263-2c5f-4382-b7f9-1709051bcaa3" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_2943d894-cacc-4b63-a8a8-314dcb47475c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6b6afe1a-e97e-473e-8c42-99a10c44f758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a2a263-2c5f-4382-b7f9-1709051bcaa3" xlink:to="loc_us-gaap_InventoryNet_6b6afe1a-e97e-473e-8c42-99a10c44f758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a957381f-f8f2-437f-8642-6bbce803cee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a2a263-2c5f-4382-b7f9-1709051bcaa3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a957381f-f8f2-437f-8642-6bbce803cee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_9148ef7c-6ab1-447a-9340-0468fdbd5f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a2a263-2c5f-4382-b7f9-1709051bcaa3" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_9148ef7c-6ab1-447a-9340-0468fdbd5f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_19a9a1fe-54d6-40d8-85f3-834c801977d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7537842b-c956-4fd3-a386-b57c1241c458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_19a9a1fe-54d6-40d8-85f3-834c801977d2" xlink:to="loc_us-gaap_AssetsCurrent_7537842b-c956-4fd3-a386-b57c1241c458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e6dddc3a-56b7-434f-b3d3-9c3e7da4458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_19a9a1fe-54d6-40d8-85f3-834c801977d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e6dddc3a-56b7-434f-b3d3-9c3e7da4458e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_81c78015-e622-4ef9-8781-0c6e8e3d0ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_19a9a1fe-54d6-40d8-85f3-834c801977d2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_81c78015-e622-4ef9-8781-0c6e8e3d0ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_b209d45a-0580-4a25-afd1-43cb27ef3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_19a9a1fe-54d6-40d8-85f3-834c801977d2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_b209d45a-0580-4a25-afd1-43cb27ef3a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2ebdf776-ff5f-4c48-83b3-3d6a772f85e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_19a9a1fe-54d6-40d8-85f3-834c801977d2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2ebdf776-ff5f-4c48-83b3-3d6a772f85e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cabda54c-0600-45ab-b6c5-072af6f1cc75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd809f09-e5d5-43bf-80b5-64e335328990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cabda54c-0600-45ab-b6c5-072af6f1cc75" xlink:to="loc_us-gaap_StockholdersEquity_dd809f09-e5d5-43bf-80b5-64e335328990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a3b7308a-444a-4a89-968a-23edf29fce3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cabda54c-0600-45ab-b6c5-072af6f1cc75" xlink:to="loc_us-gaap_MinorityInterest_a3b7308a-444a-4a89-968a-23edf29fce3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ab2ad9f1-893b-4234-8d4d-749ad3ddde34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_192a7cb3-4092-4d77-adfb-d10dc5867d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ab2ad9f1-893b-4234-8d4d-749ad3ddde34" xlink:to="loc_us-gaap_LiabilitiesCurrent_192a7cb3-4092-4d77-adfb-d10dc5867d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_fba4d2ed-0509-4bed-8293-162adb9467f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ab2ad9f1-893b-4234-8d4d-749ad3ddde34" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_fba4d2ed-0509-4bed-8293-162adb9467f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_23b951cf-4eff-436b-bac3-7eddec51a675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ab2ad9f1-893b-4234-8d4d-749ad3ddde34" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_23b951cf-4eff-436b-bac3-7eddec51a675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4cc9b2a2-0ca2-4291-9f4f-88c77631e022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ab2ad9f1-893b-4234-8d4d-749ad3ddde34" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4cc9b2a2-0ca2-4291-9f4f-88c77631e022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d963e533-a6d5-4df0-914e-cc343e57bfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ab2ad9f1-893b-4234-8d4d-749ad3ddde34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d963e533-a6d5-4df0-914e-cc343e57bfed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b4d7a461-b03a-450c-b4b1-c58c06612890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_fc0ea6b1-e8ad-453f-b344-7d9d45e49a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b4d7a461-b03a-450c-b4b1-c58c06612890" xlink:to="loc_us-gaap_InterestIncomeOperating_fc0ea6b1-e8ad-453f-b344-7d9d45e49a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ae526ec1-ef1b-4b55-9ab7-b24b53afea19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b4d7a461-b03a-450c-b4b1-c58c06612890" xlink:to="loc_us-gaap_InterestExpense_ae526ec1-ef1b-4b55-9ab7-b24b53afea19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2f8d57a6-803b-4c78-b05a-be2339e6e104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b4d7a461-b03a-450c-b4b1-c58c06612890" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2f8d57a6-803b-4c78-b05a-be2339e6e104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_96f7c845-b6b9-463a-bc03-a4c7716478ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8be3ec0a-e341-40b9-879c-9c6cac4fb9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_96f7c845-b6b9-463a-bc03-a4c7716478ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8be3ec0a-e341-40b9-879c-9c6cac4fb9a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_26e109b7-0191-4148-970b-ed9fdb9c148a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_96f7c845-b6b9-463a-bc03-a4c7716478ac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_26e109b7-0191-4148-970b-ed9fdb9c148a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_df3060f1-d855-43f6-bbdb-a112b57a8a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2e76e44d-ef86-4e77-92cc-cfba9075bbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_df3060f1-d855-43f6-bbdb-a112b57a8a81" xlink:to="loc_us-gaap_ProfitLoss_2e76e44d-ef86-4e77-92cc-cfba9075bbaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3f33cab3-19bc-4da5-b8b1-8f096706894e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_df3060f1-d855-43f6-bbdb-a112b57a8a81" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3f33cab3-19bc-4da5-b8b1-8f096706894e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0fecd735-e5f9-41a6-a1f5-6d7bd99e4be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ee724120-146e-4064-a228-bf6c004e589e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0fecd735-e5f9-41a6-a1f5-6d7bd99e4be8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ee724120-146e-4064-a228-bf6c004e589e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_83d0ef16-6c5d-4198-bce3-2c26066cf79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0fecd735-e5f9-41a6-a1f5-6d7bd99e4be8" xlink:to="loc_us-gaap_ProfessionalFees_83d0ef16-6c5d-4198-bce3-2c26066cf79c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_d6e2922c-080c-455f-a702-3471291c395f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0fecd735-e5f9-41a6-a1f5-6d7bd99e4be8" xlink:to="loc_us-gaap_SalariesAndWages_d6e2922c-080c-455f-a702-3471291c395f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5fe284ad-0486-4d03-99a2-f60cb17ce0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0fecd735-e5f9-41a6-a1f5-6d7bd99e4be8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5fe284ad-0486-4d03-99a2-f60cb17ce0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_032b3f54-4120-4abb-9a0f-be2378eb3139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb72df3d-8146-4e41-a57d-af6ee44695d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_032b3f54-4120-4abb-9a0f-be2378eb3139" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb72df3d-8146-4e41-a57d-af6ee44695d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_845aa68b-b723-497b-a97a-ed3e2c0ae5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_032b3f54-4120-4abb-9a0f-be2378eb3139" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_845aa68b-b723-497b-a97a-ed3e2c0ae5b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37d8e719-ad5d-4d1e-8ceb-1b7744097f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85af7904-f862-496d-b5ff-48bf27b215f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37d8e719-ad5d-4d1e-8ceb-1b7744097f1f" xlink:to="loc_us-gaap_OperatingIncomeLoss_85af7904-f862-496d-b5ff-48bf27b215f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3a6e267a-b236-43fb-ab5f-a6e8ffb75ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37d8e719-ad5d-4d1e-8ceb-1b7744097f1f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3a6e267a-b236-43fb-ab5f-a6e8ffb75ed0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_362b6f48-5510-434e-9e4d-fb1e3281c32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1db0560-a6d6-4ae5-bac4-aa129d449dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_362b6f48-5510-434e-9e4d-fb1e3281c32f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1db0560-a6d6-4ae5-bac4-aa129d449dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c488ae0e-0ca8-474d-961f-b4d3e866e8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a19141f9-d8e0-498f-95b0-9a81a6378bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c488ae0e-0ca8-474d-961f-b4d3e866e8e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a19141f9-d8e0-498f-95b0-9a81a6378bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_66daeb78-e077-4c47-86c1-ec341123ba30" xlink:href="apyx-20230331.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c488ae0e-0ca8-474d-961f-b4d3e866e8e6" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_66daeb78-e077-4c47-86c1-ec341123ba30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_4b1cfe34-88e4-4b08-bf94-1d7c5040a4ee" xlink:href="apyx-20230331.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c488ae0e-0ca8-474d-961f-b4d3e866e8e6" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_4b1cfe34-88e4-4b08-bf94-1d7c5040a4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b64fd79f-7058-4891-bb5b-c2eba45f9b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c488ae0e-0ca8-474d-961f-b4d3e866e8e6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b64fd79f-7058-4891-bb5b-c2eba45f9b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_fcdc8005-a70d-495b-801d-afac160386f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c488ae0e-0ca8-474d-961f-b4d3e866e8e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_fcdc8005-a70d-495b-801d-afac160386f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05297518-6095-46da-95b3-dd8ff92143dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e3b0b-4d2f-4746-b37e-a51d390db12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05297518-6095-46da-95b3-dd8ff92143dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e3b0b-4d2f-4746-b37e-a51d390db12f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_404b368c-f119-4def-86a7-7ccacf6c5f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05297518-6095-46da-95b3-dd8ff92143dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_404b368c-f119-4def-86a7-7ccacf6c5f2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_96f6ac9e-b3f2-4004-a0cb-f662a19af5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05297518-6095-46da-95b3-dd8ff92143dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_96f6ac9e-b3f2-4004-a0cb-f662a19af5cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_295946d7-d7dc-4342-be7a-9000252b6a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05297518-6095-46da-95b3-dd8ff92143dd" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_295946d7-d7dc-4342-be7a-9000252b6a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_816346a6-7c71-453d-8cfd-3f67a4f602d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_ProfitLoss_816346a6-7c71-453d-8cfd-3f67a4f602d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b756de70-5c2c-48c3-bd58-d7dd8c14dd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b756de70-5c2c-48c3-bd58-d7dd8c14dd1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_f5546aad-7acc-45fd-a566-0df7accf8fa8" xlink:href="apyx-20230331.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_f5546aad-7acc-45fd-a566-0df7accf8fa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_77c60113-ca04-4469-a194-8b4081a8b9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_ShareBasedCompensation_77c60113-ca04-4469-a194-8b4081a8b9e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5ea0f02a-0150-4140-a8a3-0de40a97ec6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5ea0f02a-0150-4140-a8a3-0de40a97ec6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4347fb5f-5adc-4d54-bf1b-8b30a9c9cbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4347fb5f-5adc-4d54-bf1b-8b30a9c9cbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_59b7df2c-fa31-454f-a3b2-674e9062e314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_59b7df2c-fa31-454f-a3b2-674e9062e314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_66f0a5a8-8c03-4f6e-9692-df5088488daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_66f0a5a8-8c03-4f6e-9692-df5088488daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d5392c98-f818-47a1-82fa-20cbbec71818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d5392c98-f818-47a1-82fa-20cbbec71818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a8daada7-7dc4-4cb2-9b82-d8080e39a968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a8daada7-7dc4-4cb2-9b82-d8080e39a968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9d303431-f176-41b6-88d7-16599ad33cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9d303431-f176-41b6-88d7-16599ad33cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2f9bc11c-081f-4500-9f85-6f51742e4b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2f9bc11c-081f-4500-9f85-6f51742e4b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_cfceae1e-0481-4df0-83d2-a950d174b0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b5e6f16-058d-4b04-8d62-c7cca22819b0" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_cfceae1e-0481-4df0-83d2-a950d174b0e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#INVENTORIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f7f6b0a2-5d71-4dc7-b194-c1d98715e9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_193cfbcc-c015-4c34-960a-3ff360932576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f7f6b0a2-5d71-4dc7-b194-c1d98715e9b1" xlink:to="loc_us-gaap_InventoryGross_193cfbcc-c015-4c34-960a-3ff360932576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_d74201f8-0110-46ce-9ed4-15df448e8095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f7f6b0a2-5d71-4dc7-b194-c1d98715e9b1" xlink:to="loc_us-gaap_InventoryValuationReserves_d74201f8-0110-46ce-9ed4-15df448e8095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_ee7c9c63-3250-43d2-8983-61fdb0914c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_b0640109-ddcf-4991-a27a-06640feff2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_ee7c9c63-3250-43d2-8983-61fdb0914c29" xlink:to="loc_us-gaap_InventoryRawMaterials_b0640109-ddcf-4991-a27a-06640feff2f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_64b030a7-bef2-480b-b113-2d601832f76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_ee7c9c63-3250-43d2-8983-61fdb0914c29" xlink:to="loc_us-gaap_InventoryWorkInProcess_64b030a7-bef2-480b-b113-2d601832f76c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_f5838d1c-a5a0-4806-bdda-44b2e32441c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_ee7c9c63-3250-43d2-8983-61fdb0914c29" xlink:to="loc_us-gaap_InventoryFinishedGoods_f5838d1c-a5a0-4806-bdda-44b2e32441c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PropertyPlantAndEquipmentInService_027ae8fb-f284-4818-9b1f-58b7571c5994" xlink:href="apyx-20230331.xsd#apyx_PropertyPlantAndEquipmentInService"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66cda617-1507-4be5-966b-1b5ba4518665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_PropertyPlantAndEquipmentInService_027ae8fb-f284-4818-9b1f-58b7571c5994" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66cda617-1507-4be5-966b-1b5ba4518665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ea260018-b7f9-4343-91a0-6a8b54600a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_PropertyPlantAndEquipmentInService_027ae8fb-f284-4818-9b1f-58b7571c5994" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ea260018-b7f9-4343-91a0-6a8b54600a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1c4ab784-6a80-491d-9d87-6aee6aa2f96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_da998b96-11aa-4f2a-b857-edec28ed06ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1c4ab784-6a80-491d-9d87-6aee6aa2f96a" xlink:to="loc_us-gaap_ConstructionInProgressGross_da998b96-11aa-4f2a-b857-edec28ed06ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PropertyPlantAndEquipmentInService_ef8ef3ed-db9e-48a8-8cf5-23a4454788f6" xlink:href="apyx-20230331.xsd#apyx_PropertyPlantAndEquipmentInService"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1c4ab784-6a80-491d-9d87-6aee6aa2f96a" xlink:to="loc_apyx_PropertyPlantAndEquipmentInService_ef8ef3ed-db9e-48a8-8cf5-23a4454788f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:href="apyx-20230331.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_8b90d7db-df89-42b7-b820-3df2e349ac4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_us-gaap_AccruedSalariesCurrent_8b90d7db-df89-42b7-b820-3df2e349ac4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_c6504aa2-9fbe-412f-aaa0-38684b89d1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_us-gaap_AccruedBonusesCurrent_c6504aa2-9fbe-412f-aaa0-38684b89d1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_45c56b20-6bde-48ff-91cf-b78300b85ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_45c56b20-6bde-48ff-91cf-b78300b85ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3d57e167-6be9-47e5-a1a0-1d9ea5ca6a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3d57e167-6be9-47e5-a1a0-1d9ea5ca6a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_22023a2e-55a0-4e3b-ad40-c61dec675631" xlink:href="apyx-20230331.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_apyx_UncertainTaxPositionsLiability_22023a2e-55a0-4e3b-ad40-c61dec675631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_85ca585f-fa67-48d3-88c2-d14decc8faac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_85ca585f-fa67-48d3-88c2-d14decc8faac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_532e555e-d286-4af6-a2c5-1a214a5efc7e" xlink:href="apyx-20230331.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_532e555e-d286-4af6-a2c5-1a214a5efc7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_e35e3b6b-bb68-49bd-8dc2-aa723fab583d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_e35e3b6b-bb68-49bd-8dc2-aa723fab583d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_1a04bdbe-cc4c-4376-b9de-cf35d828e656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_1a04bdbe-cc4c-4376-b9de-cf35d828e656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_0a60c118-e7b5-47ed-bbb6-704a7d43c580" xlink:href="apyx-20230331.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_0a60c118-e7b5-47ed-bbb6-704a7d43c580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_38d4f92b-f92b-496c-8f03-f3584e900ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_2f726433-bbcf-45c2-ab1c-1e70b5e61657" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_38d4f92b-f92b-496c-8f03-f3584e900ef7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#CREDITAGREEMENTScheduleOfLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9c893e61-d0e6-4bd2-a68c-2165a9a50482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_6306d95b-fd56-486d-a63a-9efb7956fd89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9c893e61-d0e6-4bd2-a68c-2165a9a50482" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_6306d95b-fd56-486d-a63a-9efb7956fd89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_32469d3c-90d9-4755-bf2e-0d214de85d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9c893e61-d0e6-4bd2-a68c-2165a9a50482" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_32469d3c-90d9-4755-bf2e-0d214de85d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e7ed483-62f5-456a-9312-42bfaf8a5b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9c893e61-d0e6-4bd2-a68c-2165a9a50482" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e7ed483-62f5-456a-9312-42bfaf8a5b9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c75d53fe-fbcc-4c36-8116-68afaf4e9593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_295268b4-610b-4f0a-812d-36835682a1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c75d53fe-fbcc-4c36-8116-68afaf4e9593" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_295268b4-610b-4f0a-812d-36835682a1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_377f820d-9271-4fc4-935c-71f1508b912e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c75d53fe-fbcc-4c36-8116-68afaf4e9593" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_377f820d-9271-4fc4-935c-71f1508b912e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_c1819970-2f25-440a-b70f-9bf99546525d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c75d53fe-fbcc-4c36-8116-68afaf4e9593" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_c1819970-2f25-440a-b70f-9bf99546525d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_72638f6a-d8c6-4d23-9bf6-72b6d1dbcb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c75d53fe-fbcc-4c36-8116-68afaf4e9593" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_72638f6a-d8c6-4d23-9bf6-72b6d1dbcb4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LongTermDebtMaturityAfterYearFour_70089278-05c7-46bc-82a4-180a77c6ad68" xlink:href="apyx-20230331.xsd#apyx_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c75d53fe-fbcc-4c36-8116-68afaf4e9593" xlink:to="loc_apyx_LongTermDebtMaturityAfterYearFour_70089278-05c7-46bc-82a4-180a77c6ad68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4759873a-7f87-4b4f-b0be-ab015cd087e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c75d53fe-fbcc-4c36-8116-68afaf4e9593" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4759873a-7f87-4b4f-b0be-ab015cd087e7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>apyx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:28fd0711-76c0-4c99-9948-92d9f912ad78,g:c54375b6-2eb5-4e7e-b289-a9d1feaf728d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended" id="ic2730cbc84094212a8254a4187ad0b78_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_832e668f-f821-4482-96ed-01c0ce7ba6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_832e668f-f821-4482-96ed-01c0ce7ba6bd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8bb84d60-bea0-4640-ba40-67d4cdda0953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_SharesIssued_8bb84d60-bea0-4640-ba40-67d4cdda0953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd2c4ec6-3b1a-4731-aa1f-190013687df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd2c4ec6-3b1a-4731-aa1f-190013687df1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3ae512f7-58e8-46bb-9f51-8188f136db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3ae512f7-58e8-46bb-9f51-8188f136db6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0972cda2-e8b0-452b-97a0-5a059d765f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0972cda2-e8b0-452b-97a0-5a059d765f1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ac58914-4322-406d-b036-c1ffa40388a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ac58914-4322-406d-b036-c1ffa40388a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_0ac74ad9-7894-4779-b35f-cac02499ea81" xlink:href="apyx-20230331.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_0ac74ad9-7894-4779-b35f-cac02499ea81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c03abddb-6c43-4ba2-ba45-c65cb6fc930b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c03abddb-6c43-4ba2-ba45-c65cb6fc930b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_93c531b3-8bbb-4b0c-8a31-7529f45e0d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_ProfitLoss_93c531b3-8bbb-4b0c-8a31-7529f45e0d02" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_059c1833-9aef-47de-97b0-3f8b357c4bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af583317-3813-4072-b302-eb1d27654fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7ac59082-0cd7-4fcc-8981-f814e5ee665e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_832e668f-f821-4482-96ed-01c0ce7ba6bd" xlink:to="loc_us-gaap_StatementTable_7ac59082-0cd7-4fcc-8981-f814e5ee665e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fd2d0342-7373-4b20-8b76-5fee7ee0ec21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7ac59082-0cd7-4fcc-8981-f814e5ee665e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fd2d0342-7373-4b20-8b76-5fee7ee0ec21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fd2d0342-7373-4b20-8b76-5fee7ee0ec21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd2d0342-7373-4b20-8b76-5fee7ee0ec21" xlink:to="loc_us-gaap_EquityComponentDomain_fd2d0342-7373-4b20-8b76-5fee7ee0ec21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd2d0342-7373-4b20-8b76-5fee7ee0ec21" xlink:to="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f740e96f-d6da-4943-b5d4-de1acca6107b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:to="loc_us-gaap_CommonStockMember_f740e96f-d6da-4943-b5d4-de1acca6107b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e6560ea1-bd77-45bf-a626-3de8473993c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e6560ea1-bd77-45bf-a626-3de8473993c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3f35d29e-5a7c-4315-b13b-12e6b9f37d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:to="loc_us-gaap_RetainedEarningsMember_3f35d29e-5a7c-4315-b13b-12e6b9f37d3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_74bd599f-5c01-4d43-929d-4744bd828f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:to="loc_us-gaap_NoncontrollingInterestMember_74bd599f-5c01-4d43-929d-4744bd828f05" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#BASISOFPRESENTATIONDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" xlink:type="extended" id="i2c324e8bc2334055b8f0a040de0aca56_BASISOFPRESENTATIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_16dd525b-d850-492c-a781-e0c061d12b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_16dd525b-d850-492c-a781-e0c061d12b80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_53bbdc14-0951-4c02-8aae-98d29dd9f94d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_OperatingIncomeLoss_53bbdc14-0951-4c02-8aae-98d29dd9f94d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ef17787-9f01-4cdb-b344-61925be2435b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ef17787-9f01-4cdb-b344-61925be2435b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a2cbe0c-9b22-428b-ad84-f803c229e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a2cbe0c-9b22-428b-ad84-f803c229e9e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_51c9289f-a14f-48d8-a615-b1c11c5515a6" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_51c9289f-a14f-48d8-a615-b1c11c5515a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SecuritiesRegisteredNewIssues_202f7745-00eb-4184-ad67-a0369aab12e6" xlink:href="apyx-20230331.xsd#apyx_SecuritiesRegisteredNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_apyx_SecuritiesRegisteredNewIssues_202f7745-00eb-4184-ad67-a0369aab12e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_aab227ff-209a-4506-a31d-51dff4fef711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_aab227ff-209a-4506-a31d-51dff4fef711" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_45f3535b-226a-4f0b-a504-9c3ac93bb29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_45f3535b-226a-4f0b-a504-9c3ac93bb29e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_123ee860-20f0-4c45-ba9a-f6b1be7dcb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_123ee860-20f0-4c45-ba9a-f6b1be7dcb99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement_28bd102b-7ab5-4983-ba6b-0696344898fc" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_apyx_SaleLeasebackPurchaseAgreement_28bd102b-7ab5-4983-ba6b-0696344898fc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_3e97fee5-eea9-48f3-9d90-59532d13815d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_3e97fee5-eea9-48f3-9d90-59532d13815d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7f131701-c767-4e1c-b637-647c2dbe038b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7f131701-c767-4e1c-b637-647c2dbe038b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f131701-c767-4e1c-b637-647c2dbe038b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7f131701-c767-4e1c-b637-647c2dbe038b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f131701-c767-4e1c-b637-647c2dbe038b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20ff6947-1525-4565-bddd-d45c7a60418c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7f131701-c767-4e1c-b637-647c2dbe038b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20ff6947-1525-4565-bddd-d45c7a60418c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AtTheMarketFacilityMember_fa619541-c227-451e-b1ad-1d20c7bff902" xlink:href="apyx-20230331.xsd#apyx_AtTheMarketFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20ff6947-1525-4565-bddd-d45c7a60418c" xlink:to="loc_apyx_AtTheMarketFacilityMember_fa619541-c227-451e-b1ad-1d20c7bff902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShelfRegistrationMember_44f7ddf4-8cc1-4347-807a-dc120434afeb" xlink:href="apyx-20230331.xsd#apyx_ShelfRegistrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20ff6947-1525-4565-bddd-d45c7a60418c" xlink:to="loc_apyx_ShelfRegistrationMember_44f7ddf4-8cc1-4347-807a-dc120434afeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_54549fb3-5050-45ea-938d-45139ae8f1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_DebtInstrumentAxis_54549fb3-5050-45ea-938d-45139ae8f1af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_54549fb3-5050-45ea-938d-45139ae8f1af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_54549fb3-5050-45ea-938d-45139ae8f1af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_54549fb3-5050-45ea-938d-45139ae8f1af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c3a792cb-9c42-41cd-8a32-a20359dfafba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_54549fb3-5050-45ea-938d-45139ae8f1af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c3a792cb-9c42-41cd-8a32-a20359dfafba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember_f1264cf0-2066-4449-9483-e6ffcb82af2e" xlink:href="apyx-20230331.xsd#apyx_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c3a792cb-9c42-41cd-8a32-a20359dfafba" xlink:to="loc_apyx_CreditAgreementMember_f1264cf0-2066-4449-9483-e6ffcb82af2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1ce8074e-7c1d-4c69-863c-e9c80f2644db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1ce8074e-7c1d-4c69-863c-e9c80f2644db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1ce8074e-7c1d-4c69-863c-e9c80f2644db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1ce8074e-7c1d-4c69-863c-e9c80f2644db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1ce8074e-7c1d-4c69-863c-e9c80f2644db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d4136d91-8257-405a-987c-761ed3114fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1ce8074e-7c1d-4c69-863c-e9c80f2644db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d4136d91-8257-405a-987c-761ed3114fb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c4d72914-8d62-43f0-8d23-f3fcaae60e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d4136d91-8257-405a-987c-761ed3114fb6" xlink:to="loc_us-gaap_LineOfCreditMember_c4d72914-8d62-43f0-8d23-f3fcaae60e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_da4f1e8a-211d-4004-b721-4239bdcb85b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_CreditFacilityAxis_da4f1e8a-211d-4004-b721-4239bdcb85b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_da4f1e8a-211d-4004-b721-4239bdcb85b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_da4f1e8a-211d-4004-b721-4239bdcb85b4" xlink:to="loc_us-gaap_CreditFacilityDomain_da4f1e8a-211d-4004-b721-4239bdcb85b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_80085029-6bfa-4124-bd30-044286082382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_da4f1e8a-211d-4004-b721-4239bdcb85b4" xlink:to="loc_us-gaap_CreditFacilityDomain_80085029-6bfa-4124-bd30-044286082382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_92e18f9b-e565-49f8-b657-658ec73acee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_80085029-6bfa-4124-bd30-044286082382" xlink:to="loc_us-gaap_SecuredDebtMember_92e18f9b-e565-49f8-b657-658ec73acee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f16e5aba-dabf-4b8d-a30e-55feda341b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_80085029-6bfa-4124-bd30-044286082382" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f16e5aba-dabf-4b8d-a30e-55feda341b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis_6b32d165-6634-427b-bb8a-bb77eff31c82" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_apyx_DebtInstrumentCovenantsAxis_6b32d165-6634-427b-bb8a-bb77eff31c82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_6b32d165-6634-427b-bb8a-bb77eff31c82_default" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_6b32d165-6634-427b-bb8a-bb77eff31c82" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_6b32d165-6634-427b-bb8a-bb77eff31c82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_6b32d165-6634-427b-bb8a-bb77eff31c82" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember_832db15f-92cb-496c-8704-356a056cd688" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheOneMember_832db15f-92cb-496c-8704-356a056cd688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_9ebf9c00-aaa4-4fce-aee5-7be024bde965" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_9ebf9c00-aaa4-4fce-aee5-7be024bde965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_642a8cf1-2705-4989-9ad1-05f543e3af50" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_642a8cf1-2705-4989-9ad1-05f543e3af50" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" xlink:type="extended" id="i4818a5561b5b4f2e9d88aff307e2ac44_ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4659e9a3-e265-4841-a413-215ff6625770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4659e9a3-e265-4841-a413-215ff6625770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_25c37d95-3ad1-40ca-8d7f-3bd9be52325d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_25c37d95-3ad1-40ca-8d7f-3bd9be52325d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PropertyPlantAndEquipmentInService_b4e70567-2a37-4067-9dbd-77e417abf019" xlink:href="apyx-20230331.xsd#apyx_PropertyPlantAndEquipmentInService"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_apyx_PropertyPlantAndEquipmentInService_b4e70567-2a37-4067-9dbd-77e417abf019" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_d507491a-f55a-4a03-b485-324cbcb3b9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_ConstructionInProgressGross_d507491a-f55a-4a03-b485-324cbcb3b9cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_51d2126c-536f-45dc-93dc-52e4aeb5baad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_51d2126c-536f-45dc-93dc-52e4aeb5baad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_e46697b4-03ea-4bba-87a0-11c2fbbb45e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_e46697b4-03ea-4bba-87a0-11c2fbbb45e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59aac55d-ee1e-4494-b435-0a5431deb1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59aac55d-ee1e-4494-b435-0a5431deb1a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59aac55d-ee1e-4494-b435-0a5431deb1a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_56e54cc1-73fe-41ae-a092-e7e9715ed71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_LandMember_56e54cc1-73fe-41ae-a092-e7e9715ed71b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_61cf66b8-9ef0-4089-bd68-6d6b29bacdb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_61cf66b8-9ef0-4089-bd68-6d6b29bacdb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_dd796264-3021-4eff-bc4c-3031e0943886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_dd796264-3021-4eff-bc4c-3031e0943886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_197260a2-c573-431a-b728-278bfebe50c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_197260a2-c573-431a-b728-278bfebe50c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentAndSoftwareMember_82a436ba-15ec-400e-9d73-1b19d186e48d" xlink:href="apyx-20230331.xsd#apyx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_apyx_ComputerEquipmentAndSoftwareMember_82a436ba-15ec-400e-9d73-1b19d186e48d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e695c995-07a2-426e-959f-f0179ccbed87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e695c995-07a2-426e-959f-f0179ccbed87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MoldsMember_39128efb-61b4-443b-8c46-6c4cf346253e" xlink:href="apyx-20230331.xsd#apyx_MoldsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_apyx_MoldsMember_39128efb-61b4-443b-8c46-6c4cf346253e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended" id="i5b537f318e95433f90039d6ecfe37bc8_ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement_05e0958d-2235-4f9e-9134-690a69f37dd9" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackPurchaseAgreement_05e0958d-2235-4f9e-9134-690a69f37dd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackTermOfLease_6eeb365f-cd24-4e36-8fc1-3e6f558cb9db" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackTermOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackTermOfLease_6eeb365f-cd24-4e36-8fc1-3e6f558cb9db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackRenewalTerm_16ad753f-5d2f-4010-be0e-5d34606668e7" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackRenewalTerm_16ad753f-5d2f-4010-be0e-5d34606668e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentPayment_027de48d-a9e7-453c-9030-57f3e6d7fabd" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackAnnualRentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackAnnualRentPayment_027de48d-a9e7-453c-9030-57f3e6d7fabd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentIncrease_14dbc90b-3494-4273-8092-d1826b71da44" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackAnnualRentIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackAnnualRentIncrease_14dbc90b-3494-4273-8092-d1826b71da44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackManagementFeeOnRentPayment_6e6d3c92-4036-4cef-b339-68df553514a5" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackManagementFeeOnRentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackManagementFeeOnRentPayment_6e6d3c92-4036-4cef-b339-68df553514a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackNetCashProceeds_5189758c-9b82-4ac5-afc2-cc692a50ddf3" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackNetCashProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackNetCashProceeds_5189758c-9b82-4ac5-afc2-cc692a50ddf3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent_1cc99dcb-b0ab-4f09-bbfe-0551b61faff3" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackSecurityDepositEqualToAnnualRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent_1cc99dcb-b0ab-4f09-bbfe-0551b61faff3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb41a06e-ccda-4a7f-ac1f-23e3195f385a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb41a06e-ccda-4a7f-ac1f-23e3195f385a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5a461ce3-344b-4039-b856-7f0ffbf9d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb41a06e-ccda-4a7f-ac1f-23e3195f385a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5a461ce3-344b-4039-b856-7f0ffbf9d9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5a461ce3-344b-4039-b856-7f0ffbf9d9fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5a461ce3-344b-4039-b856-7f0ffbf9d9fc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5a461ce3-344b-4039-b856-7f0ffbf9d9fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_af6181b1-d96c-4b05-b7cb-03a912cf4fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5a461ce3-344b-4039-b856-7f0ffbf9d9fc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_af6181b1-d96c-4b05-b7cb-03a912cf4fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_62c6b980-ddd8-4ab6-b878-5de047ca6e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_af6181b1-d96c-4b05-b7cb-03a912cf4fcc" xlink:to="loc_us-gaap_SubsequentEventMember_62c6b980-ddd8-4ab6-b878-5de047ca6e5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#CREDITAGREEMENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" xlink:type="extended" id="ica5794bfc22c46ca8ff826312fb41297_CREDITAGREEMENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2a054e47-ff79-4e67-854d-a1d27cb5db9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2a054e47-ff79-4e67-854d-a1d27cb5db9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_496db30b-8cfd-4399-8875-1a31ec297ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_496db30b-8cfd-4399-8875-1a31ec297ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_84f7eee9-cb01-4c43-b57c-d83839ce36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_84f7eee9-cb01-4c43-b57c-d83839ce36d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorPercent_3afafce0-4a90-40cb-9cf8-22f125b3ba4f" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentInterestRateFloorPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentInterestRateFloorPercent_3afafce0-4a90-40cb-9cf8-22f125b3ba4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent_5dbe3f54-7b06-4e7a-80a6-c77b960a7c0b" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent_5dbe3f54-7b06-4e7a-80a6-c77b960a7c0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_931c9055-f1ea-4d0f-be4c-02675789f52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_931c9055-f1ea-4d0f-be4c-02675789f52a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPeriodOfInterestOnly_d78a9815-8431-4f73-9440-f0a8a5e74b82" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPeriodOfInterestOnly"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentPeriodOfInterestOnly_d78a9815-8431-4f73-9440-f0a8a5e74b82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExtensionPeriod_fe051156-1c90-44cc-a17c-0d3a878ba6ae" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentExtensionPeriod_fe051156-1c90-44cc-a17c-0d3a878ba6ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPayments_e0921d7e-2779-45c0-9178-f54358bf3ee6" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentNumberOfMonthlyPayments_e0921d7e-2779-45c0-9178-f54358bf3ee6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_b6c126b2-bf15-425b-a994-6d0c661a5c90" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_b6c126b2-bf15-425b-a994-6d0c661a5c90" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentFeePercent_bd5e166a-5241-4552-9f01-3461cf0cae1d" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentPrepaymentFeePercent_bd5e166a-5241-4552-9f01-3461cf0cae1d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExitFee_37f5217f-ff7d-4ee8-96db-9e9ea10a6cef" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentExitFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentExitFee_37f5217f-ff7d-4ee8-96db-9e9ea10a6cef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_7a2e0005-c42d-4605-9172-ea531ae7c5b5" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_7a2e0005-c42d-4605-9172-ea531ae7c5b5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings_649322bb-3c21-4fed-93e7-340b865cadc2" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings_649322bb-3c21-4fed-93e7-340b865cadc2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentAnnualFeePercent_0183be5e-5a23-4d1d-ba8d-8227ea4d4868" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentAnnualFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentAnnualFeePercent_0183be5e-5a23-4d1d-ba8d-8227ea4d4868" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationFees_5b993377-9e41-4171-b0b1-a95e99504a66" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentTerminationFees_5b993377-9e41-4171-b0b1-a95e99504a66" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_5c373cdb-0873-4e91-b027-ccba72617ce4" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_5c373cdb-0873-4e91-b027-ccba72617ce4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a11d3a7d-4272-4614-82ab-a197b0e99f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a11d3a7d-4272-4614-82ab-a197b0e99f4b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_9b649de4-9bf7-4f57-adf5-2eb14f5e9539" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_9b649de4-9bf7-4f57-adf5-2eb14f5e9539" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_ca8745fc-917b-482d-ba74-44c576e81124" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_ca8745fc-917b-482d-ba74-44c576e81124" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_52dec2bc-f9b4-4e68-952f-ae21a2cbb202" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_52dec2bc-f9b4-4e68-952f-ae21a2cbb202" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_cd357439-1785-4c22-9726-b6a477d61034" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_cd357439-1785-4c22-9726-b6a477d61034" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentDefaultApplicableInterestRate_6746a44a-7375-4e3e-8c3e-9232e1a1392a" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentDefaultApplicableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentDefaultApplicableInterestRate_6746a44a-7375-4e3e-8c3e-9232e1a1392a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8b994a6f-c250-4ac2-9227-00507b0c5563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8b994a6f-c250-4ac2-9227-00507b0c5563" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f6558e16-6a78-4184-88d5-14eef35a7c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f6558e16-6a78-4184-88d5-14eef35a7c6f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd7cd940-73e7-4d1b-9555-3a3aace2e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd7cd940-73e7-4d1b-9555-3a3aace2e3ca" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_df24b030-3922-4d32-bb41-b875892bab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_df24b030-3922-4d32-bb41-b875892bab7c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8eeeb68f-4603-4179-bb9b-d53feb1d2ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_8eeeb68f-4603-4179-bb9b-d53feb1d2ad6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f7e0c5fa-0ddb-49b8-bc72-0aea6c77bfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f7e0c5fa-0ddb-49b8-bc72-0aea6c77bfb9" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_22f5922f-ff0b-4391-ace5-59fc0a2a2a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_22f5922f-ff0b-4391-ace5-59fc0a2a2a8e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_de4a97de-c801-49a5-81fb-96a041277721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_de4a97de-c801-49a5-81fb-96a041277721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_de4a97de-c801-49a5-81fb-96a041277721_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_de4a97de-c801-49a5-81fb-96a041277721" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_de4a97de-c801-49a5-81fb-96a041277721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5e888acf-e884-4c6a-a185-08b9a8a5428d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_de4a97de-c801-49a5-81fb-96a041277721" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5e888acf-e884-4c6a-a185-08b9a8a5428d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9e5f1fdb-bf0e-4a57-b477-aa579a815f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5e888acf-e884-4c6a-a185-08b9a8a5428d" xlink:to="loc_us-gaap_LineOfCreditMember_9e5f1fdb-bf0e-4a57-b477-aa579a815f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_DebtInstrumentAxis_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c2f4b14d-f27a-4612-b268-9b12d5d53e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c2f4b14d-f27a-4612-b268-9b12d5d53e5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember_f050e923-f5e9-4880-b172-8415e99d7d73" xlink:href="apyx-20230331.xsd#apyx_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2f4b14d-f27a-4612-b268-9b12d5d53e5f" xlink:to="loc_apyx_CreditAgreementMember_f050e923-f5e9-4880-b172-8415e99d7d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a4296dd1-8021-45af-9b9f-f32870c2d45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_CreditFacilityAxis_a4296dd1-8021-45af-9b9f-f32870c2d45a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a4296dd1-8021-45af-9b9f-f32870c2d45a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a4296dd1-8021-45af-9b9f-f32870c2d45a" xlink:to="loc_us-gaap_CreditFacilityDomain_a4296dd1-8021-45af-9b9f-f32870c2d45a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ae89c264-b539-4c90-b84f-3caf936e9e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a4296dd1-8021-45af-9b9f-f32870c2d45a" xlink:to="loc_us-gaap_CreditFacilityDomain_ae89c264-b539-4c90-b84f-3caf936e9e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ed9fe727-b255-4e73-aade-b454088723b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ae89c264-b539-4c90-b84f-3caf936e9e45" xlink:to="loc_us-gaap_SecuredDebtMember_ed9fe727-b255-4e73-aade-b454088723b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_439dcb96-3d6e-4864-837c-05db049a1a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ae89c264-b539-4c90-b84f-3caf936e9e45" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_439dcb96-3d6e-4864-837c-05db049a1a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis_18bfe92d-1799-4d84-a172-c180e98707ba" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_apyx_DebtInstrumentCovenantsAxis_18bfe92d-1799-4d84-a172-c180e98707ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_18bfe92d-1799-4d84-a172-c180e98707ba_default" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_18bfe92d-1799-4d84-a172-c180e98707ba" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_18bfe92d-1799-4d84-a172-c180e98707ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_18bfe92d-1799-4d84-a172-c180e98707ba" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember_dea24929-6cb5-44e4-9144-9bd47eb65060" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheOneMember_dea24929-6cb5-44e4-9144-9bd47eb65060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_07c2346c-9cf9-4d34-b5cc-97b8cad0e812" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_07c2346c-9cf9-4d34-b5cc-97b8cad0e812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_ee3922e0-a182-42ed-a674-90a4942c3a1d" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_ee3922e0-a182-42ed-a674-90a4942c3a1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_09879e17-eb9f-4f1d-8c18-658ed27ee66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_VariableRateAxis_09879e17-eb9f-4f1d-8c18-658ed27ee66d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_09879e17-eb9f-4f1d-8c18-658ed27ee66d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_09879e17-eb9f-4f1d-8c18-658ed27ee66d" xlink:to="loc_us-gaap_VariableRateDomain_09879e17-eb9f-4f1d-8c18-658ed27ee66d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a573f83c-7413-4ef9-ba5c-1a8476188fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_09879e17-eb9f-4f1d-8c18-658ed27ee66d" xlink:to="loc_us-gaap_VariableRateDomain_a573f83c-7413-4ef9-ba5c-1a8476188fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_2c3d785a-5c4c-4523-b040-ab743831350b" xlink:href="apyx-20230331.xsd#apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a573f83c-7413-4ef9-ba5c-1a8476188fe2" xlink:to="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_2c3d785a-5c4c-4523-b040-ab743831350b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_dc0320f7-3971-40a1-bb02-fa1745a79fae" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_dc0320f7-3971-40a1-bb02-fa1745a79fae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_dc0320f7-3971-40a1-bb02-fa1745a79fae_default" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_dc0320f7-3971-40a1-bb02-fa1745a79fae" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_dc0320f7-3971-40a1-bb02-fa1745a79fae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_dc0320f7-3971-40a1-bb02-fa1745a79fae" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember_dba5cf2f-cc5c-4b69-962d-500e99060d08" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember_dba5cf2f-cc5c-4b69-962d-500e99060d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember_ced49d7c-e8cf-458c-90ad-8513ef6577ba" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember_ced49d7c-e8cf-458c-90ad-8513ef6577ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember_107c0b09-191e-483f-b933-ce74756f5ca0" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember_107c0b09-191e-483f-b933-ce74756f5ca0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodAxis_93aa7615-1318-4709-a1ca-82338a9ea1d3" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodAxis_93aa7615-1318-4709-a1ca-82338a9ea1d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodDomain_93aa7615-1318-4709-a1ca-82338a9ea1d3_default" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodAxis_93aa7615-1318-4709-a1ca-82338a9ea1d3" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodDomain_93aa7615-1318-4709-a1ca-82338a9ea1d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodAxis_93aa7615-1318-4709-a1ca-82338a9ea1d3" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodOneMember_0460ebae-95fb-4938-9621-cf06edf15dcb" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodOneMember_0460ebae-95fb-4938-9621-cf06edf15dcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodTwoMember_58d8fcfc-b4aa-4ded-9059-64f03c93dead" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodTwoMember_58d8fcfc-b4aa-4ded-9059-64f03c93dead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodThreeMember_3bb1e958-2457-4603-bc75-971b231d55f9" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodThreeMember_3bb1e958-2457-4603-bc75-971b231d55f9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#CREDITAGREEMENTScheduleOfLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" xlink:type="extended" id="ib982b79e46e248bf86c5b4a7062f6ec4_CREDITAGREEMENTScheduleOfLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_cde18963-edcb-40f7-b6f0-48448dc586b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_cde18963-edcb-40f7-b6f0-48448dc586b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_f676261f-4864-4947-8d85-092975e1db63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_f676261f-4864-4947-8d85-092975e1db63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_996449ed-2064-4ec4-89af-9db80450ef2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_996449ed-2064-4ec4-89af-9db80450ef2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_33e52282-ea32-4500-b95f-6c9231e5cffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_LongTermDebt_33e52282-ea32-4500-b95f-6c9231e5cffb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c938a2b2-647d-4b9f-a8c4-c6947f6099db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c938a2b2-647d-4b9f-a8c4-c6947f6099db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c938a2b2-647d-4b9f-a8c4-c6947f6099db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c938a2b2-647d-4b9f-a8c4-c6947f6099db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c938a2b2-647d-4b9f-a8c4-c6947f6099db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3e86ab2a-25d6-46ee-8ca3-6b13b27f4910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c938a2b2-647d-4b9f-a8c4-c6947f6099db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3e86ab2a-25d6-46ee-8ca3-6b13b27f4910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_85b43142-30ed-46e2-81eb-1da1624f145e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3e86ab2a-25d6-46ee-8ca3-6b13b27f4910" xlink:to="loc_us-gaap_LineOfCreditMember_85b43142-30ed-46e2-81eb-1da1624f145e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bc7a72f3-fc67-4484-9b6e-2569cf3c2889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:to="loc_us-gaap_DebtInstrumentAxis_bc7a72f3-fc67-4484-9b6e-2569cf3c2889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc7a72f3-fc67-4484-9b6e-2569cf3c2889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc7a72f3-fc67-4484-9b6e-2569cf3c2889" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc7a72f3-fc67-4484-9b6e-2569cf3c2889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74fe1990-0392-4ad9-9749-0994bbc5b44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc7a72f3-fc67-4484-9b6e-2569cf3c2889" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74fe1990-0392-4ad9-9749-0994bbc5b44e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e8322b98-8da9-4c8e-9721-71487865bf73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74fe1990-0392-4ad9-9749-0994bbc5b44e" xlink:to="loc_us-gaap_LineOfCreditMember_e8322b98-8da9-4c8e-9721-71487865bf73" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="extended" id="iead77991bbb34cb38a4adb0714eb6cb3_INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18175314-0aae-4a7c-bbfb-dd9f49900e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18175314-0aae-4a7c-bbfb-dd9f49900e2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_ddc567fa-9fc1-4f65-b775-d25f60e30903" xlink:href="apyx-20230331.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_ddc567fa-9fc1-4f65-b775-d25f60e30903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_67fd513a-a584-4b1c-b5f5-b495367a5be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_67fd513a-a584-4b1c-b5f5-b495367a5be1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_35530245-3fa1-4da2-9fd2-c01ac632e539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:to="loc_us-gaap_MinorityInterestTable_35530245-3fa1-4da2-9fd2-c01ac632e539" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_76afa4da-0ab6-43b3-9004-6c94cfb2bafa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_35530245-3fa1-4da2-9fd2-c01ac632e539" xlink:to="loc_srt_OwnershipAxis_76afa4da-0ab6-43b3-9004-6c94cfb2bafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_76afa4da-0ab6-43b3-9004-6c94cfb2bafa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_76afa4da-0ab6-43b3-9004-6c94cfb2bafa" xlink:to="loc_srt_OwnershipDomain_76afa4da-0ab6-43b3-9004-6c94cfb2bafa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_95316349-0955-43c9-a776-2aa5b087508d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_76afa4da-0ab6-43b3-9004-6c94cfb2bafa" xlink:to="loc_srt_OwnershipDomain_95316349-0955-43c9-a776-2aa5b087508d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_2af3aec7-7e2a-41eb-b4a9-1613585d5bc6" xlink:href="apyx-20230331.xsd#apyx_ChineseSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_95316349-0955-43c9-a776-2aa5b087508d" xlink:to="loc_apyx_ChineseSupplierMember_2af3aec7-7e2a-41eb-b4a9-1613585d5bc6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" xlink:type="extended" id="i38bbbbecdb994e8c90a70ef4fbd11679_INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_cb07c817-22f2-40da-b584-514c34c46fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_cb07c817-22f2-40da-b584-514c34c46fb2" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_448db4a1-f139-4b34-9f8c-9ec2744649c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:to="loc_us-gaap_MinorityInterest_448db4a1-f139-4b34-9f8c-9ec2744649c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d365c366-d0fe-4c85-90b6-c46000e21a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d365c366-d0fe-4c85-90b6-c46000e21a52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5c242f18-46d3-4828-b6d9-6b2aa00c69f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_827d67b0-6452-41ca-9714-6cd15f90d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_cb07c817-22f2-40da-b584-514c34c46fb2" xlink:to="loc_us-gaap_MinorityInterestTable_827d67b0-6452-41ca-9714-6cd15f90d0aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dd86d4b5-5630-4702-a83c-4ee02e581768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_827d67b0-6452-41ca-9714-6cd15f90d0aa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dd86d4b5-5630-4702-a83c-4ee02e581768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_dd86d4b5-5630-4702-a83c-4ee02e581768_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dd86d4b5-5630-4702-a83c-4ee02e581768" xlink:to="loc_us-gaap_RelatedPartyDomain_dd86d4b5-5630-4702-a83c-4ee02e581768_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_134f6d70-b249-4ebc-ae69-7449734a1f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dd86d4b5-5630-4702-a83c-4ee02e581768" xlink:to="loc_us-gaap_RelatedPartyDomain_134f6d70-b249-4ebc-ae69-7449734a1f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_54491b96-1746-432a-a5c4-966ae2c3b8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_134f6d70-b249-4ebc-ae69-7449734a1f0d" xlink:to="loc_us-gaap_CorporateJointVentureMember_54491b96-1746-432a-a5c4-966ae2c3b8e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="i033bc6338ae64899a7191c78781a3276_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_9c29cca8-19b5-4c72-aaa4-f26aecf2ecd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_9c29cca8-19b5-4c72-aaa4-f26aecf2ecd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c435c945-d60a-482d-84fd-03fffe369291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9c29cca8-19b5-4c72-aaa4-f26aecf2ecd5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c435c945-d60a-482d-84fd-03fffe369291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6e334445-8b39-488e-9a6f-f790a1ef93fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9c29cca8-19b5-4c72-aaa4-f26aecf2ecd5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6e334445-8b39-488e-9a6f-f790a1ef93fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_b1311538-ce06-4853-bdac-9b38a77a3fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_b1311538-ce06-4853-bdac-9b38a77a3fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05fae923-c9d0-4769-b31c-875bf85343e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b1311538-ce06-4853-bdac-9b38a77a3fdb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05fae923-c9d0-4769-b31c-875bf85343e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a536dd46-4d64-45d0-b435-79bc043a416b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b1311538-ce06-4853-bdac-9b38a77a3fdb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a536dd46-4d64-45d0-b435-79bc043a416b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_b773f025-938c-4779-98ce-205fb326e719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_b773f025-938c-4779-98ce-205fb326e719" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7869f7dc-7114-454f-9e9b-520c3ad74893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b773f025-938c-4779-98ce-205fb326e719" xlink:to="loc_us-gaap_EarningsPerShareBasic_7869f7dc-7114-454f-9e9b-520c3ad74893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2bb7399c-dddd-45e6-99e0-43307ec7a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b773f025-938c-4779-98ce-205fb326e719" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2bb7399c-dddd-45e6-99e0-43307ec7a38b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_e9cd05fb-0aed-40d0-9725-b9e80aaa602b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_e9cd05fb-0aed-40d0-9725-b9e80aaa602b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea401c8c-5a2a-4492-9914-864e34488301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e9cd05fb-0aed-40d0-9725-b9e80aaa602b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea401c8c-5a2a-4492-9914-864e34488301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32708c0f-04fc-4790-8e7b-3ebd7cbc5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32708c0f-04fc-4790-8e7b-3ebd7cbc5cae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_749d5253-9aa3-4e91-96cb-d7bc331886e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32708c0f-04fc-4790-8e7b-3ebd7cbc5cae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_749d5253-9aa3-4e91-96cb-d7bc331886e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_749d5253-9aa3-4e91-96cb-d7bc331886e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_749d5253-9aa3-4e91-96cb-d7bc331886e4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_749d5253-9aa3-4e91-96cb-d7bc331886e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3164c947-760f-4e57-8587-8ecac1ea2003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_749d5253-9aa3-4e91-96cb-d7bc331886e4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3164c947-760f-4e57-8587-8ecac1ea2003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f13f7f2c-3b0b-4da7-91e6-e56daf2fd54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3164c947-760f-4e57-8587-8ecac1ea2003" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f13f7f2c-3b0b-4da7-91e6-e56daf2fd54b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_887d4b91-28dd-405a-a698-8b9a6e559abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3164c947-760f-4e57-8587-8ecac1ea2003" xlink:to="loc_us-gaap_WarrantMember_887d4b91-28dd-405a-a698-8b9a6e559abc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="ie748bc5b50e442439cc7839fb39ac248_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_af298908-5e2a-48b9-8b61-cc87188a163d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_af298908-5e2a-48b9-8b61-cc87188a163d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_6b4a35a5-bda0-4664-a41c-99ca7e2baf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_6b4a35a5-bda0-4664-a41c-99ca7e2baf4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_8425294c-efda-4aa5-bbc3-21c59a4fb231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_8425294c-efda-4aa5-bbc3-21c59a4fb231" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_eb7ecc81-09f8-4754-8fa3-ac33f4e7df27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_eb7ecc81-09f8-4754-8fa3-ac33f4e7df27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b9c0b470-9f1e-4c06-9a15-27e80fab5df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_PurchaseObligation_b9c0b470-9f1e-4c06-9a15-27e80fab5df5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c64bd604-c439-40db-8452-63a0f4edc614" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:to="loc_srt_RangeAxis_c64bd604-c439-40db-8452-63a0f4edc614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c64bd604-c439-40db-8452-63a0f4edc614_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c64bd604-c439-40db-8452-63a0f4edc614" xlink:to="loc_srt_RangeMember_c64bd604-c439-40db-8452-63a0f4edc614_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bdd5b34a-df2e-4915-bff4-4b95d2a7667b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c64bd604-c439-40db-8452-63a0f4edc614" xlink:to="loc_srt_RangeMember_bdd5b34a-df2e-4915-bff4-4b95d2a7667b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_895ddd77-8ff3-4df8-b5f0-dc8eceee6c39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bdd5b34a-df2e-4915-bff4-4b95d2a7667b" xlink:to="loc_srt_MinimumMember_895ddd77-8ff3-4df8-b5f0-dc8eceee6c39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0aeaba9e-c16c-48fe-a838-7907b9ed18f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bdd5b34a-df2e-4915-bff4-4b95d2a7667b" xlink:to="loc_srt_MaximumMember_0aeaba9e-c16c-48fe-a838-7907b9ed18f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c69ae03e-e461-4428-9db3-c565d7e1d5da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:to="loc_srt_LitigationCaseAxis_c69ae03e-e461-4428-9db3-c565d7e1d5da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c69ae03e-e461-4428-9db3-c565d7e1d5da_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c69ae03e-e461-4428-9db3-c565d7e1d5da" xlink:to="loc_srt_LitigationCaseTypeDomain_c69ae03e-e461-4428-9db3-c565d7e1d5da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_74aca4f4-15d1-4d95-a3eb-92c3a1e3eae7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c69ae03e-e461-4428-9db3-c565d7e1d5da" xlink:to="loc_srt_LitigationCaseTypeDomain_74aca4f4-15d1-4d95-a3eb-92c3a1e3eae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember_1ddebe5c-efc0-4341-9b83-802dd4a798de" xlink:href="apyx-20230331.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_74aca4f4-15d1-4d95-a3eb-92c3a1e3eae7" xlink:to="loc_apyx_SuitAgainstGoodwinAndSimbMember_1ddebe5c-efc0-4341-9b83-802dd4a798de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitsFiledIn2022Member_0e7b058c-a126-42eb-9738-d908c8e30914" xlink:href="apyx-20230331.xsd#apyx_SuitsFiledIn2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_74aca4f4-15d1-4d95-a3eb-92c3a1e3eae7" xlink:to="loc_apyx_SuitsFiledIn2022Member_0e7b058c-a126-42eb-9738-d908c8e30914" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i4cc6a6d27c304b5b8507e041cd74b858_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f7a8fb2f-2ca6-4e7e-ab0c-43409161af58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f7a8fb2f-2ca6-4e7e-ab0c-43409161af58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3a7f6130-053e-4b4b-b647-7f0914c972f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3a7f6130-053e-4b4b-b647-7f0914c972f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_eb5c29b5-aaf6-4ecc-aea2-ba0a0f15bbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:to="loc_us-gaap_DueFromRelatedParties_eb5c29b5-aaf6-4ecc-aea2-ba0a0f15bbb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42f1888c-388b-492b-b6fd-5a4a3e3d988c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42f1888c-388b-492b-b6fd-5a4a3e3d988c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b8eea84b-921a-45c1-a52f-426caabc3d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42f1888c-388b-492b-b6fd-5a4a3e3d988c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b8eea84b-921a-45c1-a52f-426caabc3d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b8eea84b-921a-45c1-a52f-426caabc3d49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b8eea84b-921a-45c1-a52f-426caabc3d49" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b8eea84b-921a-45c1-a52f-426caabc3d49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_18a5ef91-22eb-4d97-922d-1749715eec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b8eea84b-921a-45c1-a52f-426caabc3d49" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_18a5ef91-22eb-4d97-922d-1749715eec77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_d3468bd3-beef-4cee-96f5-ad299db9a3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_18a5ef91-22eb-4d97-922d-1749715eec77" xlink:to="loc_us-gaap_CoVenturerMember_d3468bd3-beef-4cee-96f5-ad299db9a3b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended" id="id323def9c3c04f7ea598227bca73b6dc_GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_136263d2-e6bf-4d40-bdce-50d0eb376ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_136263d2-e6bf-4d40-bdce-50d0eb376ca1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_faf7d3a2-2687-4bbd-a865-d868a27b3f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_OperatingIncomeLoss_faf7d3a2-2687-4bbd-a865-d868a27b3f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_3838576c-dc01-438e-acae-0aafc76ec46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_InterestIncomeOperating_3838576c-dc01-438e-acae-0aafc76ec46d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5c625324-14a2-4026-9e0c-8c391fd68fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_InterestExpense_5c625324-14a2-4026-9e0c-8c391fd68fc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_88721ec3-6545-44a4-8707-cf475e48c086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_88721ec3-6545-44a4-8707-cf475e48c086" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5134c1ef-b5f8-4ec5-b8c5-973c34338b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5134c1ef-b5f8-4ec5-b8c5-973c34338b42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:to="loc_srt_ConsolidationItemsAxis_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400" xlink:to="loc_srt_ConsolidationItemsDomain_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_314f0328-76aa-4e8b-8061-d7d0af9269b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400" xlink:to="loc_srt_ConsolidationItemsDomain_314f0328-76aa-4e8b-8061-d7d0af9269b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_33e9c7d8-b3b7-40b5-8a73-f2f0b3d99755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_314f0328-76aa-4e8b-8061-d7d0af9269b2" xlink:to="loc_us-gaap_OperatingSegmentsMember_33e9c7d8-b3b7-40b5-8a73-f2f0b3d99755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2a19f504-cec6-4dcb-b646-2719caadb33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_314f0328-76aa-4e8b-8061-d7d0af9269b2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2a19f504-cec6-4dcb-b646-2719caadb33b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0657a28b-fc9c-4ccf-a724-f82645ded872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0657a28b-fc9c-4ccf-a724-f82645ded872" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0657a28b-fc9c-4ccf-a724-f82645ded872_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0657a28b-fc9c-4ccf-a724-f82645ded872" xlink:to="loc_us-gaap_SegmentDomain_0657a28b-fc9c-4ccf-a724-f82645ded872_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_322bf8b8-05ab-4a2c-8615-e0b76f6b3549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0657a28b-fc9c-4ccf-a724-f82645ded872" xlink:to="loc_us-gaap_SegmentDomain_322bf8b8-05ab-4a2c-8615-e0b76f6b3549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_06ac1a48-08b2-41f5-807a-226d90afda4d" xlink:href="apyx-20230331.xsd#apyx_AdvancedEnergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_322bf8b8-05ab-4a2c-8615-e0b76f6b3549" xlink:to="loc_apyx_AdvancedEnergyMember_06ac1a48-08b2-41f5-807a-226d90afda4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_5183a42e-ac96-4044-8112-22e7ec6e0296" xlink:href="apyx-20230331.xsd#apyx_OEMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_322bf8b8-05ab-4a2c-8615-e0b76f6b3549" xlink:to="loc_apyx_OEMMember_5183a42e-ac96-4044-8112-22e7ec6e0296" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended" id="ibfcc0abc6a11486998eddfd73be4db7c_GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_eefc0704-fe14-45e9-8028-0442721b48ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5a806fa-cc0c-492f-a4fb-04cf6e8bc909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_eefc0704-fe14-45e9-8028-0442721b48ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5a806fa-cc0c-492f-a4fb-04cf6e8bc909" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b98c2b47-bd23-4a18-9818-55218bb03ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_eefc0704-fe14-45e9-8028-0442721b48ad" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b98c2b47-bd23-4a18-9818-55218bb03ffe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_daf329d1-402a-460d-ba0b-ea20eacb181e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b98c2b47-bd23-4a18-9818-55218bb03ffe" xlink:to="loc_srt_StatementGeographicalAxis_daf329d1-402a-460d-ba0b-ea20eacb181e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_daf329d1-402a-460d-ba0b-ea20eacb181e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_daf329d1-402a-460d-ba0b-ea20eacb181e" xlink:to="loc_srt_SegmentGeographicalDomain_daf329d1-402a-460d-ba0b-ea20eacb181e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_42f115f5-416c-4463-9f25-760a7ea806ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_daf329d1-402a-460d-ba0b-ea20eacb181e" xlink:to="loc_srt_SegmentGeographicalDomain_42f115f5-416c-4463-9f25-760a7ea806ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7466c942-4010-423b-a60a-6d838f8b6c2c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_42f115f5-416c-4463-9f25-760a7ea806ae" xlink:to="loc_country_US_7466c942-4010-423b-a60a-6d838f8b6c2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_fe4a6db4-ea17-4243-8aec-6be269dec111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_42f115f5-416c-4463-9f25-760a7ea806ae" xlink:to="loc_us-gaap_NonUsMember_fe4a6db4-ea17-4243-8aec-6be269dec111" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>apyx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:28fd0711-76c0-4c99-9948-92d9f912ad78,g:c54375b6-2eb5-4e7e-b289-a9d1feaf728d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a47e79e5-dc47-4fa5-bac2-9fc73bb865f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_3f1752e8-617c-4d1c-9f2c-0b809c1ce34c_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e1471a4b-72cb-4955-8f61-793bd2604e57_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_2cd79d5d-9bc6-4115-9814-5aba07b566bb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_27c7b098-804a-465e-9e31-2ee2abab779a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_a68bb38a-12cb-491b-8d2f-f0a3096e1b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_37ea1223-8d1f-4785-b700-c359cc77a0e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_7eb4c12b-27d8-4669-af54-7916ebc67014_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_97d0aef3-97b3-454d-b016-6db4c1a0ac01_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_a07c8cb9-bd45-4b42-83c4-f6eb4571a439_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_db25a336-e484-4fbc-a706-5bb8bc660485_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_cbcd8237-868d-4e41-ad23-01c1a1f2cd84_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember_22f9a1bd-6aaa-4f01-bee0-c506573be4bf_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period One</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period One [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_99b4bc24-bd7c-46ef-a5b1-acc8e0a9ac3b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2a561f42-1087-4d7e-8ed4-d6f9e39d24a7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_aba695ae-f024-4640-99af-9e566407c34c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_559b81c2-7bde-4496-a78d-da295393ced6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheOneMember_1caad0ea-3e29-41b5-894b-c999d537c4c2_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche One</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheOneMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche One [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheOneMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:to="lab_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7b92b16a-d45f-4575-a428-5629813c8fe3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_622188eb-52e8-48b6-953d-f84583a2b143_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_9c4ca4ca-a15b-4b7c-b9c5-bc13046b4a70_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:href="apyx-20230331.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9fdac52a-0b54-414e-beeb-39cb9acc7b22_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_680f980a-1f49-4f1f-9b38-bcf4545b446b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_41bff48b-7446-4e1b-9560-ab482b4357b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ad69a3fc-241c-4b9b-b460-2d795f8fe73d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bcdf413c-d7b8-4ce4-9b8c-162bb988d107_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackManagementFeeOnRentPayment_f01714ed-b3c5-419b-b56a-1d9100544ddf_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, management fee on rent payment</link:label>
    <link:label id="lab_apyx_SaleLeasebackManagementFeeOnRentPayment_label_en-US" xlink:label="lab_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Management Fee On Rent Payment</link:label>
    <link:label id="lab_apyx_SaleLeasebackManagementFeeOnRentPayment_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Management Fee On Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackManagementFeeOnRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:to="lab_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a689c0ed-f8f2-441c-8c34-df568a7f1453_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OEMMember_bac897be-93c1-4b5d-bb4d-a24cb0833231_terseLabel_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM</link:label>
    <link:label id="lab_apyx_OEMMember_label_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember" xlink:href="apyx-20230331.xsd#apyx_OEMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OEMMember" xlink:to="lab_apyx_OEMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings_dd22c3aa-0a30-4447-ba8b-5d6d09f038f3_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lockbox account, funds to be applied to borrowings</link:label>
    <link:label id="lab_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings_label_en-US" xlink:label="lab_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings</link:label>
    <link:label id="lab_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" xlink:to="lab_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_61a5f72a-ae6b-4265-8aba-5af819c26345_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_652d504b-5263-4148-b9dc-630e553e55b1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LongTermDebtMaturityAfterYearFour_3e172cdd-0e89-4d2b-938f-b4df303bd480_terseLabel_en-US" xlink:label="lab_apyx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_apyx_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_apyx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_apyx_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_apyx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LongTermDebtMaturityAfterYearFour" xlink:href="apyx-20230331.xsd#apyx_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LongTermDebtMaturityAfterYearFour" xlink:to="lab_apyx_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_5a81b636-359a-46b2-a421-e414ded81bbe_terseLabel_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_label_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_documentation_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:href="apyx-20230331.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:to="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0858b4c2-abab-4d8d-a4bb-189928394c5f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c862c1a-dc6e-4e8e-a369-f2c73abbd564_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e93a60e2-7286-4948-b7f7-401038c403f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ea07c041-a1e1-46bc-9779-1d8b2b1ea1e6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_031e369f-c750-4838-a271-e5148c0643be_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_d771b94f-e38d-48ad-8e82-998c2b450a24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_b80b9227-b04f-4e80-b218-430423831a1f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_1c37532b-eaa8-46ad-9dd6-361378a5b711_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_bcd58b43-3638-4ecf-8026-39b968e84eee_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_17d29146-72d3-4849-927d-0c4b9482be69_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b6e2d2e9-22e7-4f36-83e0-af2fefb9535b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_94baab3b-d16c-4d4c-ad48-5b0f2de19389_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantsAxis_a95e1dfd-792c-4aa3-b391-c52e59d92881_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantsAxis_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantsAxis_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis" xlink:to="lab_apyx_DebtInstrumentCovenantsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_cf851426-7491-42cf-8859-82d18c0127c9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ec92ffb1-3a4a-4a7d-bc15-8dd2a5d36074_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_eab38a61-5f0c-484b-9720-8631f7444328_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8ac00858-306a-4754-8e0b-1c2cfa2009d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_6e559543-8f3f-420c-b2e8-f203d7e73c5e_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing base, minimum balance</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:to="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6a596478-cc16-461a-96ec-34ec7f90803f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9af79461-9234-4e92-bdca-4848c5b016e7_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in cash operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5ad7e8cf-c22a-4c9d-8847-14cb3bd2bbfd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_fbdef38d-ab29-4999-a447-7e59ee311c95_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_5e4345a1-0e55-491b-99bb-679c94f8f605_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposition of Core business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4df4f4b5-0e4d-4622-a5e8-3dfa6e7adc01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_56398068-41fa-4e05-8cf7-6b9b2f2c5e71_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_994e2a97-120f-43fa-8a92-0eb50e3a1273_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_48378429-9100-453e-8916-5482855c6c98_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45476c66-92d7-45a0-aa34-859cf2689d84_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackTermOfLease_ecdddb84-5b79-4fea-8139-7f9ed470306b_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackTermOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, term of lease</link:label>
    <link:label id="lab_apyx_SaleLeasebackTermOfLease_label_en-US" xlink:label="lab_apyx_SaleLeasebackTermOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Term Of Lease</link:label>
    <link:label id="lab_apyx_SaleLeasebackTermOfLease_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackTermOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Term Of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackTermOfLease" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackTermOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackTermOfLease" xlink:to="lab_apyx_SaleLeasebackTermOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_156ced92-ae39-46a2-8536-296e7e408f75_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_02ff80f8-db54-45aa-990f-1f0227370575_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f3cfe58a-67bc-4bc9-8bdf-e270b17222c9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_29e92e9c-9128-46aa-b494-89f0584b4eec_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1dfb7d0a-96cf-4c5a-8dc0-2f5c33f0da98_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c215d086-b114-4352-9062-e6b6de57449f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_57b71490-6ada-4ef0-b240-d021c1296177_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3d3a9ee8-9ba4-4e71-a5d9-d8d62c16425c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_1c3ec5ba-1abf-4c53-beda-158e5108c5ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_321ed6b3-d06f-448a-9466-dd34f55f93c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CREDIT AGREEMENT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3cefb8b3-4aab-4b7d-952f-d8f78f6858fe_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentAnnualFeePercent_53660ad4-ae37-451e-8edd-43a134cdd9f0_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentAnnualFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fee</link:label>
    <link:label id="lab_apyx_DebtInstrumentAnnualFeePercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentAnnualFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Fee, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentAnnualFeePercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentAnnualFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Fee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentAnnualFeePercent" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentAnnualFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentAnnualFeePercent" xlink:to="lab_apyx_DebtInstrumentAnnualFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e7e9d943-e1e5-4c15-8ab8-20b656063460_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember_dd8b8178-855c-4300-8e95-bbba20bb7ebc_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Three</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Three [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AtTheMarketFacilityMember_d260a305-3f67-497e-8ad5-8ec553bd0dfb_terseLabel_en-US" xlink:label="lab_apyx_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Facility</link:label>
    <link:label id="lab_apyx_AtTheMarketFacilityMember_label_en-US" xlink:label="lab_apyx_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Facility [Member]</link:label>
    <link:label id="lab_apyx_AtTheMarketFacilityMember_documentation_en-US" xlink:label="lab_apyx_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AtTheMarketFacilityMember" xlink:href="apyx-20230331.xsd#apyx_AtTheMarketFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AtTheMarketFacilityMember" xlink:to="lab_apyx_AtTheMarketFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2858c5bf-6d16-4bd2-b048-d9c88a0e8103_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_e4bf31c5-dee7-47c5-9660-bbc40589bad3_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_346d7dac-4668-41b0-afec-2d14d8f2c2d3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6fc513d3-2c8a-4b82-9b5f-f8cfb804d6df_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_13c716cf-a5b3-428a-b05a-362c51d408a4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_9e1789e9-cc7a-45a1-9361-ca52e5c0acc8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_PropertyPlantAndEquipmentInService_581e9935-89da-49ef-b104-e38975b80e8c_totalLabel_en-US" xlink:label="lab_apyx_PropertyPlantAndEquipmentInService" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment in service</link:label>
    <link:label id="lab_apyx_PropertyPlantAndEquipmentInService_label_en-US" xlink:label="lab_apyx_PropertyPlantAndEquipmentInService" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, In Service</link:label>
    <link:label id="lab_apyx_PropertyPlantAndEquipmentInService_documentation_en-US" xlink:label="lab_apyx_PropertyPlantAndEquipmentInService" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, In Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PropertyPlantAndEquipmentInService" xlink:href="apyx-20230331.xsd#apyx_PropertyPlantAndEquipmentInService"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_PropertyPlantAndEquipmentInService" xlink:to="lab_apyx_PropertyPlantAndEquipmentInService" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a8f77f5a-040b-4770-89ac-01b2b454ceb5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentDefaultApplicableInterestRate_82d44fdc-89ff-4139-bd80-0d4d1c3c768c_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default, applicable interest rate</link:label>
    <link:label id="lab_apyx_DebtInstrumentDefaultApplicableInterestRate_label_en-US" xlink:label="lab_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default, Applicable Interest Rate</link:label>
    <link:label id="lab_apyx_DebtInstrumentDefaultApplicableInterestRate_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default, Applicable Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentDefaultApplicableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:to="lab_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3ae121f7-c814-4a3b-82d1-74508559c29f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_35287357-0ea7-4ccf-b218-dfc3f60ec015_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_5ee01fe1-792b-4221-afc5-9d59ba12fd33_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales tax payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2d29b23-6245-4a40-b1fd-9b1f15ac38dd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodDomain_33280feb-ca06-433c-b573-fcf9bc004171_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodDomain_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodDomain_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_07996a20-9cd4-415f-91a6-a0c8a98a532d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_20f34090-3076-457d-a125-70ea2682d74c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_c803bdb4-0c61-4203-a146-8e9fd04209fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_08eca065-fd6a-4cd7-8b55-20d81af86c32_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f272848b-ddd0-41c9-8ff7-5b3915e82129_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_697afa62-8c0f-485a-acee-bd180c8c49dc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_0ac2fc3b-a023-4f4f-b3ce-536572281adf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheThreeMember_2a4e3cff-2a36-48a3-9e5d-433722c3581b_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Three</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheThreeMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Three [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheThreeMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:to="lab_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77cca94a-d78f-4b7d-a921-07af76a213e1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3849154b-bf1e-480b-be28-330e7c21c334_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d83c5d6f-d3f8-4a83-9ab1-13beb0fbd411_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_1271fb2f-e19d-491c-a934-f7d878c22f9c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b50df0bd-eb28-47f9-b66e-9e0fb7641e5f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discounts</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c964a1ae-bdd3-48c2-8241-a9fd976f3478_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_6a40a504-48c2-4849-8f3e-6e9092309974_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTEREST IN JOINT VENTURE INVESTMENT</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_64883f23-834f-4983-a149-2a6f7a88ca7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of option fair value assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_fa64a88f-e28f-482b-b34f-e52635f3ea41_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_32306bd6-4af6-47f0-ad3c-78894f4f5443_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CreditAgreementMember_170ddf22-0e6a-416a-8c9f-2622808d9ab4_terseLabel_en-US" xlink:label="lab_apyx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_apyx_CreditAgreementMember_label_en-US" xlink:label="lab_apyx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_apyx_CreditAgreementMember_documentation_en-US" xlink:label="lab_apyx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember" xlink:href="apyx-20230331.xsd#apyx_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CreditAgreementMember" xlink:to="lab_apyx_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SecuritiesRegisteredNewIssues_17d6e801-30c2-4b73-89d5-d12e422cdda2_terseLabel_en-US" xlink:label="lab_apyx_SecuritiesRegisteredNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities registered, new issues</link:label>
    <link:label id="lab_apyx_SecuritiesRegisteredNewIssues_label_en-US" xlink:label="lab_apyx_SecuritiesRegisteredNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Registered, New Issues</link:label>
    <link:label id="lab_apyx_SecuritiesRegisteredNewIssues_documentation_en-US" xlink:label="lab_apyx_SecuritiesRegisteredNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Registered, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SecuritiesRegisteredNewIssues" xlink:href="apyx-20230331.xsd#apyx_SecuritiesRegisteredNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SecuritiesRegisteredNewIssues" xlink:to="lab_apyx_SecuritiesRegisteredNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_181bc071-acf5-4a54-a99e-00ba24c8eb78_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_db426dbe-9939-484d-904b-cfbeffef4727_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_d656775e-bba1-4a61-9e37-6f6dabfa21de_terseLabel_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_label_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_documentation_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability" xlink:href="apyx-20230331.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_UncertainTaxPositionsLiability" xlink:to="lab_apyx_UncertainTaxPositionsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_d4a4bcf2-4c8b-41c0-8c6f-f25c507e72ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_894d5367-3542-427b-8d46-c7fd6f4d56ce_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_7f3d32b8-68cd-48fb-9af5-5f13aeaf320e_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing base, minimum balance</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:to="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_d47f5f6a-a017-4c73-9e87-e62ce4302d64_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentPayment_8cb4df1c-ab60-4f80-94c3-18029dfe0f3e_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback. annual rent payment</link:label>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentPayment_label_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback. Annual Rent Payment</link:label>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentPayment_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback. Annual Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentPayment" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackAnnualRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackAnnualRentPayment" xlink:to="lab_apyx_SaleLeasebackAnnualRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9b35f397-14b9-4315-a3ee-015c85f88713_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_bd1b39d4-88e0-409a-a0e5-c068d10df6e8_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on net settlement of stock options (in shares)</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options, Shares</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares" xlink:href="apyx-20230331.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsShares" xlink:to="lab_apyx_StockSwapToAcquireOptionsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0df90121-3cf8-4f31-99cd-57ec312b2645_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_8fdd5891-9f6f-4295-8c2a-6ce16fb06d1a_terseLabel_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses and current liabilities</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:href="apyx-20230331.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:to="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackNetCashProceeds_d24618db-171e-41ee-a40c-3175d56fd38a_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackNetCashProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, net cash proceeds</link:label>
    <link:label id="lab_apyx_SaleLeasebackNetCashProceeds_label_en-US" xlink:label="lab_apyx_SaleLeasebackNetCashProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Net Cash Proceeds</link:label>
    <link:label id="lab_apyx_SaleLeasebackNetCashProceeds_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackNetCashProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Net Cash Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackNetCashProceeds" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackNetCashProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackNetCashProceeds" xlink:to="lab_apyx_SaleLeasebackNetCashProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bd83dff3-4232-4350-8047-5e35861f4f80_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84f21303-47da-4f3d-a80a-af72623d5791_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e71098c8-d63b-461f-83f5-719d475376a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5ea97c8-a9b3-4ca2-bfbc-b9adbe8672a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_999fbcad-50ec-4ed7-8a5d-f3da05629f6d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_8f1167cb-062b-41e6-a567-d6c7c2f4c672_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_2c4ef2d7-9fbf-4b9f-a6b6-22f75fdb06db_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_7913b102-b052-4843-9eeb-6f8c7f108778_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b25f6934-0332-4358-9bca-69e2460077c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_26559558-81fc-44fe-a733-57d49c646c65_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_159b5589-ffb5-469d-bfd2-09f35c5c58b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b268a97d-73fe-449e-b40b-52b426f19ecc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb938a59-9ba9-4e06-8b48-01aafee3ff1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_82ba105c-bad0-4529-b3f9-9e2fcab7679a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e471073a-a2ca-4c9e-b502-8fbb5f1b6ffb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c9fee72-6376-4ccb-b6c6-9ff49e6e704a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_98d632bf-5b06-44d3-be4a-f8232731eddb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50952093-3b3f-4c10-ade4-a842cf9c4dc1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_f75a809c-6d84-4626-bf81-4c9a1f74e84b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product liability claim insurance deductibles</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodAxis_3a37d698-ad53-451f-bc2d-7b47ffa1b8fe_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodAxis_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodAxis_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodAxis" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodAxis" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_35bde75c-2e01-4665-ae21-8f0a380951fa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3031004f-8ae7-474e-923d-9844eb0b5329_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_291a1a4b-a4d3-411f-bde9-998ef44713ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_334bf1aa-2183-45b1-aa91-1c603c5774e3_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AdvancedEnergyMember_99a123d7-8a3b-4d6d-9258-46dcb8884dff_terseLabel_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_label_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_documentation_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember" xlink:href="apyx-20230331.xsd#apyx_AdvancedEnergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdvancedEnergyMember" xlink:to="lab_apyx_AdvancedEnergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6057aff6-04ca-4e57-a9d4-1fc89ad5d12c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bafc5622-f565-4840-ad30-e39425bf922c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_6ff5c1dc-1a63-4497-9dce-aa0cbe43523b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_132f505b-c4a1-45e4-bbb5-354dc44eafa3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_5703bdef-3542-49f9-a6ec-3c00afc800d0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent_65f43fc3-eb62-4e06-b704-dfa7799b5a11_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit equal to annual rent</link:label>
    <link:label id="lab_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent_label_en-US" xlink:label="lab_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Security Deposit Equal To Annual Rent</link:label>
    <link:label id="lab_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Security Deposit Equal To Annual Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackSecurityDepositEqualToAnnualRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent" xlink:to="lab_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_575cbc51-4f07-4b94-a8d7-14b79228c814_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackPurchaseAgreement_84a1ac95-d392-47bb-a5f8-9f929abc1569_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase agreement</link:label>
    <link:label id="lab_apyx_SaleLeasebackPurchaseAgreement_label_en-US" xlink:label="lab_apyx_SaleLeasebackPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Purchase Agreement</link:label>
    <link:label id="lab_apyx_SaleLeasebackPurchaseAgreement_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackPurchaseAgreement" xlink:to="lab_apyx_SaleLeasebackPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_9f6e1b61-c73a-4c80-becb-b50e8988bd89_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate &amp; Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_8edbd1e1-f90e-4c25-9a26-d209b0190085_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve month net revenue target, year one</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:to="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_822a666b-363e-4615-adc5-61e2ebf869e3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_59e050dc-1ed3-48ef-8a48-ba2fe9babd6a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_14850f44-0f8b-4798-8d2a-3c575fdd9c70_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1565eb2d-06d5-45c3-bd71-bf5d10644916_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_ef45f9f6-7688-4a2b-91a6-4593e3c22ea8_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0304be74-8e3a-4c52-a61b-fc5634f6c33f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edd7cff9-78dc-40f1-bdfe-51b002020ab7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_e7ad792f-154a-49f6-9fb3-07a0ea0fe915_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve month net revenue target, year two</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:to="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_869caacb-8d03-4fc1-b759-db253b0217e8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_058440d6-ee3f-43a9-a89e-830911a7e4a3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_91b326fd-5da8-41b7-aa80-e05bbf89678f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_a233e1d1-b148-47c7-a126-def1ad76fd0b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5b04b2ae-5f21-4144-9397-8e261d0c44d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78727181-a177-48d0-84d4-53f48f3ea1b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0a045221-b1c9-48e7-a8e3-3fb931adbea2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_bbc3ae10-3e51-451b-b4a0-da3e4938e695_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a4e0439b-d461-4a08-9438-c4386700e3e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_619d1d28-f3ac-41e2-9077-738438981e08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bf3a37d8-f2f4-4d1b-8d83-02068159fc6e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ChineseSupplierMember_7825885f-8c29-4059-af72-f64c3bcc1609_terseLabel_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_label_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier [Member]</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_documentation_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember" xlink:href="apyx-20230331.xsd#apyx_ChineseSupplierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ChineseSupplierMember" xlink:to="lab_apyx_ChineseSupplierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_MoldsMember_c3003909-9c90-44b5-9afd-84b38632ba0f_terseLabel_en-US" xlink:label="lab_apyx_MoldsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molds</link:label>
    <link:label id="lab_apyx_MoldsMember_label_en-US" xlink:label="lab_apyx_MoldsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molds [Member]</link:label>
    <link:label id="lab_apyx_MoldsMember_documentation_en-US" xlink:label="lab_apyx_MoldsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MoldsMember" xlink:href="apyx-20230331.xsd#apyx_MoldsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_MoldsMember" xlink:to="lab_apyx_MoldsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_65374476-a6ea-432d-bb50-f2c24f80111f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_16032fea-f72b-4181-a650-1ac73a532abf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_49f28637-4ff2-4b92-b2de-bc774421f5b6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_065a4d08-4a5a-4619-b8c4-026110d19f16_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net of allowance of $359 and $668</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bd945ce1-8170-465d-9d1b-de96a173cf14_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_2b27d8db-758f-4a41-81fc-43f7c2977e2c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_629df4c0-b1a3-434b-9be4-cb7fda6578c6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8204f8bd-881c-4743-910b-61bc33f6ec34_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9aaee21a-d13f-4ed7-8e7a-8c8ddf582dcc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ab61e35f-7d8a-4c62-a6f5-7a277c0cab8b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_e345915c-1c17-4420-977f-d8aea53a9eb9_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_8d12af81-a15d-4aaa-9284-14a78cdc7b76_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d89c9f6c-b6f9-43a9-a7e2-a5b55741de77_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c4329dbc-b8b0-4afd-967c-9a2462d8b586_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_afeb0878-1c9f-4f6f-846a-a9f0cf130c34_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_559c87d6-d262-4c8c-b251-74c74b045fa6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1cd67456-4514-49f9-b82d-f36d3059d4b2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesAndWages_57546c85-d979-4b34-b496-8d51b89127af_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and related costs</link:label>
    <link:label id="lab_us-gaap_SalariesAndWages_label_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages" xlink:to="lab_us-gaap_SalariesAndWages" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6af9af8b-0c81-4389-a8f8-e7a7cd7d6b19_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9253c24a-8ab7-41e1-a379-b50fd7f79b33_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5a6ec2a6-4388-4a52-9821-237e228e4d24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock options and stock awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8182ab21-3bcd-4f93-bf49-f0b80b29b876_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6e067e60-9907-4e07-aabb-5f23cd8b485d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e69eb4f1-c0b0-4870-8de1-8ac8a380bf06_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d52a8c9a-cb4e-4766-b5cd-0e882cf3342a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f5b58ae3-a556-42c6-8112-585e1d276634_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodOneMember_51827ea2-538b-4b1b-9aaf-a0445e654033_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period One</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodOneMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period One [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodOneMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ddab84c4-089c-4e36-8f46-0f3639e9a2eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheTwoMember_1f86eee3-79e6-4b3f-b82a-e2050159eba1_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Two</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheTwoMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Two [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheTwoMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:to="lab_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a7623a30-0569-42ea-8e28-052c3e0ce5b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_80b29c47-2711-4041-bdd9-bba29f682022_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1557299d-9c5a-4a37-8cf3-10d13c9e5d6b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_1f911e58-f1b7-40a1-8e6c-e6125845f674_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPayments_61565810-4204-41ce-8807-573e4e52a9b5_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly payments</link:label>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPayments_label_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments</link:label>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPayments_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:to="lab_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90eeecc9-0d38-40a5-8073-f3701a344acd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3c49fd3b-035a-48c8-9704-27fabd501fa3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6a80161a-aac8-4e87-b95a-3eb82ef72aaa_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4a3549fb-4667-4acc-a87a-479933d94fd5_netLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7c5db47a-c224-45e9-933f-5a26069ee366_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantsDomain_c95d0598-379d-4155-b8f5-71ada40de761_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantsDomain_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantsDomain_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain" xlink:to="lab_apyx_DebtInstrumentCovenantsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_911acdb8-4a6f-40ae-a7f5-817518209017_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_97f68c84-e21b-4e11-bb65-7944f3b9ee33_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1c1735f4-8d51-44a0-97c0-d667c829a5b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_38c0b851-e249-4e88-a0c8-899888832260_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_47499545-0ceb-4e92-b101-777b0de6d681_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_5569a50f-7580-4ac0-8323-199c86010a8b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_0dbb795f-3101-4269-89ad-529f8b9b7d7a_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve month net revenue target, year three</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:to="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_599bb7f1-9bc8-4647-9754-be5b5ab26954_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5290b1f-46ea-4885-aba5-45cac83025fe_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_23f11ae1-4470-4d5b-860a-4650feb0c91f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4e99219d-8346-41ca-91a2-e2b6b70cde67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_aa3bfe0a-ebb9-428b-bb54-cfd6f0842216_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TotalRevenuePercent_97975b58-68b9-4c39-b21d-53a8fdd1870e_terseLabel_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International sales, percent of total revenue</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_label_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_documentation_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent" xlink:href="apyx-20230331.xsd#apyx_TotalRevenuePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TotalRevenuePercent" xlink:to="lab_apyx_TotalRevenuePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5935122a-aa10-49d9-b700-f0454d330597_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodTwoMember_2844870e-abbb-4faf-a335-759b1be5c92a_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Two</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodTwoMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Two [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodTwoMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_b556e451-6529-488c-b42e-2c2cce54743b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_8a4aea6d-9723-4139-a4c1-d795f3f1d265_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_80abff80-41d9-4787-9a1e-9aee9b4916f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_97461a11-8a31-464a-bebd-6eed10d1e20f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_5c277f9f-0020-46ab-b92c-7ca550e686c3_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents balance</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash And Cash Equivalents Balance</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash And Cash Equivalents Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:to="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b7af9014-84dc-439f-8c54-12d3923b0f6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_544a8463-1b69-4c96-9aaf-877b596c07c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_de218f1d-74cd-4608-b42d-e6782f0117dd_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_df56af24-56bf-4b89-814a-643c0a7c8399_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f3d2131b-f3f4-4fb1-a73e-3ae1368689cc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8f91226-2933-4b84-bcf9-7363453ede1a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed2ae186-b7f4-41bd-8a35-74c4671c4869_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_63f5c0c9-6f96-443e-9022-d9acb70e9ecd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonuses</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bb431a0b-137e-461e-95bd-c5051ad271d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e561cb2f-a7ed-4d4f-8835-4b882f4ae4b3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Apyx</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5cb1b175-7875-436d-b6a5-d972481de153_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_131bc65a-0ee0-4c0c-91be-861701cbf90b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d072c174-d297-4906-9a44-caf7c2088df9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fbb2020c-2c7c-4f5d-826a-0015061ce9ea_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_91d32d6f-dae7-4fef-90f1-5b0d20dd5d35_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2c0bba45-811c-4e27-8090-32f3e624cc0b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_7f657d44-c0d8-41f8-9f87-fec665741219_terseLabel_en-US" xlink:label="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Term Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Term Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Term Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:href="apyx-20230331.xsd#apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:to="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_64afc385-553f-4fec-9b1d-29774c75527b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodAxis_6efe2187-4caa-41cf-b502-08f31f0cf15d_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodAxis_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodAxis_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_bb03c2fe-ce6b-40a1-876d-9c2fe03901aa_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorPercent_dc26c25f-32d8-4af2-9ca1-e55e2b2a3099_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate floor</link:label>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorPercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate Floor, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorPercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate Floor, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorPercent" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentInterestRateFloorPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentInterestRateFloorPercent" xlink:to="lab_apyx_DebtInstrumentInterestRateFloorPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_634a9020-b9ce-4b87-8042-471613e26584_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f2a40d4-4dd2-4816-9542-c1034e7e8788_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_ad41d7a3-337d-433f-bbba-74c70465d32e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d3ea1a03-fdc0-4f7f-975e-c4fdea7021cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loan, principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_4dd3bc59-6c34-4b0a-8f46-b390ef505bd2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New claims filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_d9f0330a-b55f-42d1-9094-cd7e95bcf7b2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f14be87d-97e0-4b5e-8f8a-e0900c9b7b1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reporting information by segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9aa4ed2d-f125-470c-8f09-d3bbe9d1723f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0b8aeb7f-7544-40a4-92d3-f9d4a116e1f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ComputerEquipmentAndSoftwareMember_8abb5ee9-baf9-479e-ae12-f6f132fae10f_terseLabel_en-US" xlink:label="lab_apyx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_apyx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_apyx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_apyx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_apyx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentAndSoftwareMember" xlink:href="apyx-20230331.xsd#apyx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_apyx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f94a9135-99a4-4362-9dc4-410fccb91a22_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases from related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_14c37690-4eda-4a8f-af73-98518e94ffd7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_1d6168c4-b61a-4954-bfb5-74b595f76717_negatedTerseLabel_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of finance lease liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_label_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities" xlink:href="apyx-20230331.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RepaymentofFinanceLeaseLiabilities" xlink:to="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1a7e6b4-caf5-4234-82b0-9661a3e91274_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_df9fde8d-55d9-4046-be3c-d5e0f3e28350_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_449ae382-3ca5-4610-afb4-89c8686e371b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54b23de5-2eb6-4f66-bffd-205e98b2835c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7260be81-ebd7-417b-a900-3973561d5f19_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f94fc448-c6b4-4811-a949-4807fa08fab8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent_ca4d45e0-a328-42fa-b777-4d27f4bfff5e_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate floor spread</link:label>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate Floor Spread Adjustment, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate Floor Spread Adjustment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" xlink:to="lab_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_76773bcd-8e01-4dbc-b64a-72462a0d44a0_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, provision for obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_label_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_documentation_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory" xlink:href="apyx-20230331.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForObsolescenceInventory" xlink:to="lab_apyx_ProvisionForObsolescenceInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_50924c5c-54b6-434e-8202-03793e32f323_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5e28e6d6-ce7e-4fcd-8e6d-77a2078e671a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_69594d2a-c602-4a73-9bfe-5e31a659a4bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercises for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_15c669bb-edcb-42bc-a9d7-0808064cd982_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ae89d35e-b85d-4171-adee-0c7beff06ae1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other loss, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_59a5be56-3779-4446-8cd9-89589c7fdbc3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_12f7b0a9-806a-40ee-9c10-4396e58c3e85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_8ab30cad-2549-4fac-a93c-e48623162548_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentExitFee_bbff5f91-c0cc-4cac-8dd7-8758a4a4e410_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee</link:label>
    <link:label id="lab_apyx_DebtInstrumentExitFee_label_en-US" xlink:label="lab_apyx_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:label id="lab_apyx_DebtInstrumentExitFee_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExitFee" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentExitFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentExitFee" xlink:to="lab_apyx_DebtInstrumentExitFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1bdda057-e824-40d0-9562-63e1c336170f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5086b1ae-e244-4c44-9730-cebd8290418e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodDomain_83b9bc1d-7864-4b68-a7fa-0d7853ad0a53_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodDomain_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodDomain_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodDomain" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_bbfc2074-a530-4390-ab4a-08fa9ab5721f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue by geographic area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_997c4ca4-2591-4259-88b5-3b887d1ef971_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_b09b3eb0-0429-4833-93a8-d5d060165c56_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e54db93f-9b35-4205-a6f3-3b6b4392f332_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentFeePercent_a6cca483-d105-4e50-a623-e96d37c1375f_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentFeePercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentFeePercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentFeePercent" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentFeePercent" xlink:to="lab_apyx_DebtInstrumentPrepaymentFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_73331d4d-62d9-4b87-989c-155033c148d7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_ac1c0af0-d36b-4e48-b6d4-cdb111c43675_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_53af14b1-6332-427f-b260-32e6bbeec4e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_385068d4-c651-49c4-82d4-bb13faf18d07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e1d2714d-8bb2-4e1e-b4ad-026ea235aa5d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c25b5aab-01dc-4397-b60b-6828da8cb339_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_07657d8d-8bf6-4d6f-81cd-391c67b6bef3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3188691c-82ca-4b24-b1b1-e77bec5531f9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a331a217-c34a-437a-a3c2-b5f9a0f19c60_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e7606755-c204-48d4-923d-8aa40e42427f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_5fecccb3-4538-454b-b28a-a5c7878a8524_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationFees_930b15e6-20c8-45e7-9683-fd4e4c523eaf_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination fees</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationFees_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Fees</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationFees_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationFees" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationFees" xlink:to="lab_apyx_DebtInstrumentTerminationFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_086a2fbb-0109-4e6d-af94-058f557a8948_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5da67f3f-15b7-46e8-8da2-6ee34f8a1a64_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercises for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_04c4a740-ba5a-48a5-a0be-dfffff5e0b9c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_ebcd44d2-fa10-4661-b28e-23dcd6b6fd67_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEOGRAPHIC AND SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0c1896db-0f40-454b-a665-bc4adcb2e3ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_fdedfaf7-bd38-46ac-91c4-2aa81f44eba4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6e7a84da-2576-4fb8-8cb8-515f7864c1a8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d426a07a-b149-492d-92f2-66b52e43cf84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d2701ba7-536d-4852-9f9c-b369748caf47_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_17f0bb88-2b84-425b-8912-2b5449e42837_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8dfbe906-b029-4e10-806f-72c8f7cbf756_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_eccf2bf3-b448-40d0-99b1-4ea50d90962a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net of provision for obsolescence of $428 and $457</link:label>
    <link:label id="lab_us-gaap_InventoryNet_a1951aa7-f3ce-445f-a0cf-cb1fd693d4a7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5e7b06f2-0baf-4616-87ef-cc1c44852174_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_7caa3bbf-74c4-44cc-9052-8ce2f14ed3e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount, including accretion of exit fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_fae7d6dd-c5fd-45e7-89f6-80caeb7f36dd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_62fa4de0-ad78-42a1-9328-720327a10847_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ef58519d-e32e-4bca-bef8-409229989289_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6a96c887-4f51-4e92-9268-30c4d556e95f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_745f4e5b-29bb-45ce-b261-ad3af8db3b4c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8a1a00d1-8571-40b2-902a-21d3070e9f59_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_12fbde75-2bfb-4d0d-8963-8380d84c6dee_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs accrued</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPeriodOfInterestOnly_b2d28ab1-3ccb-461a-b952-c97f9f39650e_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of interest only</link:label>
    <link:label id="lab_apyx_DebtInstrumentPeriodOfInterestOnly_label_en-US" xlink:label="lab_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest Only</link:label>
    <link:label id="lab_apyx_DebtInstrumentPeriodOfInterestOnly_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest Only</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPeriodOfInterestOnly"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:to="lab_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6eb1bfeb-fc2d-4e7d-b80d-e33c63f19dd0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f71658db-0c91-4f1b-9c86-f26649fcc8fc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_32d33fa5-1ea5-43cd-8d26-aa5c8226de0d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5037411b-7648-40fe-b019-7985d8537449_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6833bee7-cc9f-4848-aa2f-be01f4ddf60d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_09ff0448-64d2-4b47-9c1a-fbd51b05c285_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_4c7af9d0-aa77-4de0-8f9b-901cc188cb72_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_093230fc-60d0-4678-9eb8-9e7fac37ce8c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c2f3e4e9-31c6-4aa2-8de6-0d03f0b8705d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_32a643af-37a5-4b45-b091-14d1a2e1fbb1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cb58cd2d-6c85-412a-8956-866db1bebd6f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7435acc-f5a0-4552-8976-be293202f9c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_2f998690-fb59-45e0-bc84-5b8a8a89c1fe_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_1ac69270-1b3a-4aae-aeee-bbc198500b65_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_4ff3393d-6e16-47ed-97ea-0dde0c1ee0f3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a31bcb7b-6e26-4462-b2e4-13d7f8fb6e69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_50445b8c-60bd-4614-9c8d-726be63e3dfe_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability" xlink:href="apyx-20230331.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollLiability" xlink:to="lab_apyx_JointAndSeveralPayrollLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ace3c7fd-f776-45a2-acf6-47fcd99b04d7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SuitsFiledIn2022Member_01c159c8-913d-4ce0-b615-1401aff18306_terseLabel_en-US" xlink:label="lab_apyx_SuitsFiledIn2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suits Filed in 2022</link:label>
    <link:label id="lab_apyx_SuitsFiledIn2022Member_label_en-US" xlink:label="lab_apyx_SuitsFiledIn2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suits Filed in 2022 [Member]</link:label>
    <link:label id="lab_apyx_SuitsFiledIn2022Member_documentation_en-US" xlink:label="lab_apyx_SuitsFiledIn2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suits Filed in 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitsFiledIn2022Member" xlink:href="apyx-20230331.xsd#apyx_SuitsFiledIn2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SuitsFiledIn2022Member" xlink:to="lab_apyx_SuitsFiledIn2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_5b9aba5a-4ab8-4ed1-bda4-39d1cedec508_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c73d7416-d706-4e34-b4c9-188cc4aa619a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_068714da-2fd2-4ff2-863c-eda724c0f614_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_abaea37f-e976-4ec4-9c92-26da67948be7_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_d2a514d2-1956-438f-8437-4d5d7404c380_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments excluded from diluted loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_5dbc5d21-bf21-43e8-8420-84e9f93500c9_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ceeef7d4-5aaf-409e-b3d2-f39fa14ccc75_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_306a8584-4d6c-4aac-96cf-f8a940aae905_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ca9df23e-4ed3-4be3-b571-f3d5893b16cd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5c3f0c86-ec40-4e75-8495-80e477543910_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7088f995-0456-4e55-8645-e081c21aeb63_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_180592be-a79f-4f0a-8c6b-ad4cbb396eea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4662264f-8b0f-4bc2-8246-1a0da5b2fd1e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_805d0b80-32d9-4010-adb0-7e5ef3fb0181_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CoVenturerMember_ba05794e-2888-4394-ac2d-38c7261fb0dc_terseLabel_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer</link:label>
    <link:label id="lab_us-gaap_CoVenturerMember_label_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CoVenturerMember" xlink:to="lab_us-gaap_CoVenturerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_140be015-d4ef-4325-ade8-c86ba6e49e28_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f7a08089-0ef4-48d0-9f75-415ec3ddb0fa_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0fcad225-af96-4810-9b44-42e99b39cc43_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_13e69ab0-9205-4632-8b5b-f7371666c4a7_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of China Joint Venture</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:href="apyx-20230331.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:to="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_179d4238-cf9f-4dcf-9eb6-e0600df4bbad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_073c335d-563d-4630-a112-0379ab8c6acd_terseLabel_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit Against Goodwin And Simb</link:label>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_label_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit Against Goodwin And Simb [Member]</link:label>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_documentation_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit Against Goodwin And Simb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember" xlink:href="apyx-20230331.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SuitAgainstGoodwinAndSimbMember" xlink:to="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_41cd10c2-32e6-40d2-92a7-32a83e318499_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required capital contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:href="apyx-20230331.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:to="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5b69b114-26e5-4df8-bbfd-4d5baeaca44f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentIncrease_8466391f-cfde-496a-ab4b-ab96627f2e22_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, annual rent increase</link:label>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentIncrease_label_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Annual Rent Increase</link:label>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentIncrease_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Annual Rent Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentIncrease" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackAnnualRentIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackAnnualRentIncrease" xlink:to="lab_apyx_SaleLeasebackAnnualRentIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1c1564b7-c0cc-4d02-a253-972df1151b33_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodThreeMember_d4e25f04-c9ef-4a8e-9a25-944c34c06560_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Three</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodThreeMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Three [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodThreeMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_07fee177-cc04-481e-8542-f0c0ac374f6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackRenewalTerm_181cefa8-95d8-43b4-9b51-6eb646b71bad_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, renewal term</link:label>
    <link:label id="lab_apyx_SaleLeasebackRenewalTerm_label_en-US" xlink:label="lab_apyx_SaleLeasebackRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Renewal Term</link:label>
    <link:label id="lab_apyx_SaleLeasebackRenewalTerm_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackRenewalTerm" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackRenewalTerm" xlink:to="lab_apyx_SaleLeasebackRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_c5769fc2-8e6f-4ba0-adb5-b1f17f74d3f9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_21c04515-7624-4f47-93b9-81aef8cd692f_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: provision for obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_cb1e4f5c-8480-47f4-9a19-f15352e7fded_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ab7e221a-1353-4849-877c-fa786f213c60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_655877d8-c004-4d4c-b164-0715a8122841_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_56f82f99-60ab-40b1-b398-9d2e59fe1422_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_99d045ac-fed3-41a2-8186-3d62b3f65022_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_f59baa58-6131-4761-948c-c3577ed3c028_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f63766f0-e25e-4f03-91cf-a7a74b4bf0a0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_8195258f-25df-4d32-8965-cd88b10eb0da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_72cbfd8f-5ef5-4750-a369-bd77eb3667b2_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swaps equity instruments received (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:href="apyx-20230331.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ShelfRegistrationMember_2aa2a820-8b8a-4a80-935c-205d6ef35d81_terseLabel_en-US" xlink:label="lab_apyx_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration</link:label>
    <link:label id="lab_apyx_ShelfRegistrationMember_label_en-US" xlink:label="lab_apyx_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration [Member]</link:label>
    <link:label id="lab_apyx_ShelfRegistrationMember_documentation_en-US" xlink:label="lab_apyx_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShelfRegistrationMember" xlink:href="apyx-20230331.xsd#apyx_ShelfRegistrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ShelfRegistrationMember" xlink:to="lab_apyx_ShelfRegistrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_d970e357-93c1-4189-ab74-c1076d25a8df_terseLabel_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_812a7fd7-dbdf-4ec0-b037-7c130fefde04_totalLabel_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="apyx-20230331.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_576d141f-5809-4fbb-a067-e09a504661a8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8afa1971-93ed-441f-a2ef-1aae8577bcc3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2ab675ce-d27f-47e9-868e-9c3a2de54685_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_23bb2fc8-8023-4ae0-9d97-f5abe8ab941d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_e11042af-8c51-401b-99fe-674a8e3af97e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees and legal related contingent liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a496c759-954e-49e4-9166-c7e30265364b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1a599869-be3a-4500-adce-88a18cc39ba1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_e8ba23a0-ba53-45ae-83d2-e5af4d031b19_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0e201964-f5b0-4b04-aafd-0f13ced2f718_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5e0f1d92-8199-4160-8d2e-29423f342c71_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640651-cd5c-43e2-b47c-927f5fe44dcc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_85675bc7-73f9-405b-b675-652bc0dd0575_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b725b8b7-8f04-48a5-b7e0-6d15eb3124dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_ac7b0220-5191-4707-87f2-99e1836a7d86_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_414c512d-ee8e-440a-80dc-1671b6a19d62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_9d76d17e-a4a4-4b46-83f7-35a7139117a9_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly payments, extension</link:label>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_label_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments, Extension</link:label>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments, Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:to="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_610c59ec-a785-46d8-beb9-dfc7e3b44724_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_label_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_documentation_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence" xlink:href="apyx-20230331.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForInventoryObsolescence" xlink:to="lab_apyx_ProvisionForInventoryObsolescence" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7e6207b4-ff99-4a3f-9136-58aef8676fb9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0d8936a8-f1a5-4290-aae9-cb0dde3ec20e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentExtensionPeriod_9134eef3-70ca-4dc3-9138-dbca7aa13555_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_apyx_DebtInstrumentExtensionPeriod_label_en-US" xlink:label="lab_apyx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Extension Period</link:label>
    <link:label id="lab_apyx_DebtInstrumentExtensionPeriod_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExtensionPeriod" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentExtensionPeriod" xlink:to="lab_apyx_DebtInstrumentExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember_f5ae43d7-dc16-429e-898a-c03546231663_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Two</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Two [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1fd16596-4edb-459b-9d93-9c702e57085d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>apyx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:28fd0711-76c0-4c99-9948-92d9f912ad78,g:c54375b6-2eb5-4e7e-b289-a9d1feaf728d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_34dc66bc-d1a9-4bc5-92d1-3d104bc2bdf1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_DocumentType_34dc66bc-d1a9-4bc5-92d1-3d104bc2bdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_117d4e3c-3808-4f4b-96ac-e0454c405944" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_DocumentQuarterlyReport_117d4e3c-3808-4f4b-96ac-e0454c405944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fecc0ed0-e1ad-4c68-b82c-3ac253cdc746" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_DocumentPeriodEndDate_fecc0ed0-e1ad-4c68-b82c-3ac253cdc746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a8e05e02-9dea-4972-b18e-ebe01aa7c1cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_DocumentTransitionReport_a8e05e02-9dea-4972-b18e-ebe01aa7c1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f066cf9a-d996-4a09-b250-fd877ceb70c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityFileNumber_f066cf9a-d996-4a09-b250-fd877ceb70c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3503fbf5-7b8a-4b5b-a359-d7522b483d6e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityRegistrantName_3503fbf5-7b8a-4b5b-a359-d7522b483d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f8f0aa28-1db0-4713-8ef7-1b77b23aa7bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f8f0aa28-1db0-4713-8ef7-1b77b23aa7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f113766d-1298-4366-bdeb-d4401ad8a200" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityTaxIdentificationNumber_f113766d-1298-4366-bdeb-d4401ad8a200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_231831a5-6b34-4806-a5db-83f3597b8c96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityAddressAddressLine1_231831a5-6b34-4806-a5db-83f3597b8c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5ac2684b-1d0f-4492-aeab-d4161ebcb859" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityAddressCityOrTown_5ac2684b-1d0f-4492-aeab-d4161ebcb859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0f75a15f-c5e6-43b3-83d9-e4b4dbdadc7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityAddressStateOrProvince_0f75a15f-c5e6-43b3-83d9-e4b4dbdadc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0c3573d3-b2cb-4e91-b50e-da5e019d77ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityAddressPostalZipCode_0c3573d3-b2cb-4e91-b50e-da5e019d77ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d29f1431-dbc1-421f-85f9-575ed952c145" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_CityAreaCode_d29f1431-dbc1-421f-85f9-575ed952c145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d07eb00e-c425-4dc8-96a0-511d79cf39c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_LocalPhoneNumber_d07eb00e-c425-4dc8-96a0-511d79cf39c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bb22c7c5-59fb-4f31-9959-26f79983da02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_Security12bTitle_bb22c7c5-59fb-4f31-9959-26f79983da02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5c8d0664-83e5-4146-a65b-851878e7b165" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_TradingSymbol_5c8d0664-83e5-4146-a65b-851878e7b165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2d90ff11-4e03-480e-bc73-904f48b9ec0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_SecurityExchangeName_2d90ff11-4e03-480e-bc73-904f48b9ec0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6c14bdcb-bee0-4667-8f78-5cfd8b735fa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityCurrentReportingStatus_6c14bdcb-bee0-4667-8f78-5cfd8b735fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3a31533b-5751-4498-8183-0b7e207eace0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityInteractiveDataCurrent_3a31533b-5751-4498-8183-0b7e207eace0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f5884722-7c09-4377-8676-29d23a23e048" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityFilerCategory_f5884722-7c09-4377-8676-29d23a23e048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_657ef55c-7a67-4a41-99f2-b5aa10702aae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntitySmallBusiness_657ef55c-7a67-4a41-99f2-b5aa10702aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fde26fc9-66b2-46cd-88cb-ff3249d97df8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityEmergingGrowthCompany_fde26fc9-66b2-46cd-88cb-ff3249d97df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7e73f895-8b19-4f9b-80fd-f43be99057b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityShellCompany_7e73f895-8b19-4f9b-80fd-f43be99057b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_75fd09a6-1a94-4ae4-9ceb-5d8eb630f82d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_75fd09a6-1a94-4ae4-9ceb-5d8eb630f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d4f059d7-fddb-47f3-850f-1d402fdbf73e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_EntityCentralIndexKey_d4f059d7-fddb-47f3-850f-1d402fdbf73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_836a74a0-b345-4bb0-abeb-5f9396775352" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_AmendmentFlag_836a74a0-b345-4bb0-abeb-5f9396775352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_65b5504e-900e-438e-8afd-69851c487869" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_CurrentFiscalYearEndDate_65b5504e-900e-438e-8afd-69851c487869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_947cc58b-e17b-498e-b746-0993871614f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_947cc58b-e17b-498e-b746-0993871614f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a553e5f8-3876-4b0d-a0c9-32fd9925b574" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_936002bc-5cfb-408a-a384-d4761a363ed2" xlink:to="loc_dei_DocumentFiscalYearFocus_a553e5f8-3876-4b0d-a0c9-32fd9925b574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8032d8a8-b6e8-4033-8d43-06f06f15616c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2ee4236c-36ed-4593-966c-0be955fcbf84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8032d8a8-b6e8-4033-8d43-06f06f15616c" xlink:to="loc_us-gaap_AssetsAbstract_2ee4236c-36ed-4593-966c-0be955fcbf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ee4236c-36ed-4593-966c-0be955fcbf84" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab01f451-3416-4ccc-871b-08db0e28ec44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab01f451-3416-4ccc-871b-08db0e28ec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39b8e6ba-e299-4c46-8b22-03c9508b3ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39b8e6ba-e299-4c46-8b22-03c9508b3ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_b46a818b-7aeb-48f3-b3c2-b75ca7824ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:to="loc_us-gaap_IncomeTaxesReceivable_b46a818b-7aeb-48f3-b3c2-b75ca7824ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_16a92826-39f5-42b8-b972-f49bbcdfe2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_16a92826-39f5-42b8-b972-f49bbcdfe2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a6210d06-3d88-4320-906d-5121230de24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:to="loc_us-gaap_InventoryNet_a6210d06-3d88-4320-906d-5121230de24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_5c905188-e99e-4de9-aa5f-3c15d7c26e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_5c905188-e99e-4de9-aa5f-3c15d7c26e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42d49f16-3f8c-4201-8bee-2f2658a2a7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42d49f16-3f8c-4201-8bee-2f2658a2a7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9da1b1b5-496a-4b89-aa0a-530e28906680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d49d8dd4-5f4d-4b64-a22a-ad0868d5ca38" xlink:to="loc_us-gaap_AssetsCurrent_9da1b1b5-496a-4b89-aa0a-530e28906680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e31bfba7-4fe3-424e-a118-477da29fa810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ee4236c-36ed-4593-966c-0be955fcbf84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e31bfba7-4fe3-424e-a118-477da29fa810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_80918e0e-ec62-4083-80b7-1d619e64516b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ee4236c-36ed-4593-966c-0be955fcbf84" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_80918e0e-ec62-4083-80b7-1d619e64516b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_e02096ec-5073-41d8-a467-7f0c3f7adce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ee4236c-36ed-4593-966c-0be955fcbf84" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_e02096ec-5073-41d8-a467-7f0c3f7adce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_eb29c4f8-516f-42a0-a310-620650bdf996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ee4236c-36ed-4593-966c-0be955fcbf84" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_eb29c4f8-516f-42a0-a310-620650bdf996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6b45bddd-9747-484f-9442-d8053df095d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ee4236c-36ed-4593-966c-0be955fcbf84" xlink:to="loc_us-gaap_Assets_6b45bddd-9747-484f-9442-d8053df095d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8032d8a8-b6e8-4033-8d43-06f06f15616c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_92a3bb1d-9933-4429-ae94-ba62ae199e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_92a3bb1d-9933-4429-ae94-ba62ae199e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_afefd2c4-119f-4e7e-86d3-6fb316784f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92a3bb1d-9933-4429-ae94-ba62ae199e5c" xlink:to="loc_us-gaap_AccountsPayableCurrent_afefd2c4-119f-4e7e-86d3-6fb316784f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_6608d898-004d-4997-91ff-8fb119235c58" xlink:href="apyx-20230331.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92a3bb1d-9933-4429-ae94-ba62ae199e5c" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_6608d898-004d-4997-91ff-8fb119235c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_274a5b7e-aee8-4f2f-9e51-70ae305c6488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92a3bb1d-9933-4429-ae94-ba62ae199e5c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_274a5b7e-aee8-4f2f-9e51-70ae305c6488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5defa646-2749-4998-8eb6-6b891528d17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92a3bb1d-9933-4429-ae94-ba62ae199e5c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5defa646-2749-4998-8eb6-6b891528d17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8ca8ace6-a3da-4829-ad0a-c69e636a0224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92a3bb1d-9933-4429-ae94-ba62ae199e5c" xlink:to="loc_us-gaap_LongTermDebtCurrent_8ca8ace6-a3da-4829-ad0a-c69e636a0224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6b705d6e-b315-4731-a523-d050d07c565a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92a3bb1d-9933-4429-ae94-ba62ae199e5c" xlink:to="loc_us-gaap_LiabilitiesCurrent_6b705d6e-b315-4731-a523-d050d07c565a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4f52aeb-0e66-43db-adfb-bb1ef16dfdab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4f52aeb-0e66-43db-adfb-bb1ef16dfdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_69e960a3-f4f7-4402-817d-f35218c35043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_69e960a3-f4f7-4402-817d-f35218c35043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f839eb75-bbe8-4862-9467-4ebd3727096e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f839eb75-bbe8-4862-9467-4ebd3727096e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fe53c8d8-ad04-4856-b1c4-0b0080657988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fe53c8d8-ad04-4856-b1c4-0b0080657988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4c244bca-b9d5-47bc-a8a2-f8620462284e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:to="loc_us-gaap_Liabilities_4c244bca-b9d5-47bc-a8a2-f8620462284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3296edf0-0784-40ca-a4b8-9df8383e24ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:to="loc_us-gaap_PreferredStockValue_3296edf0-0784-40ca-a4b8-9df8383e24ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3ec371b6-144d-420b-9e9f-9e31f5b86e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:to="loc_us-gaap_CommonStockValue_3ec371b6-144d-420b-9e9f-9e31f5b86e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_84c005a9-00c0-44d3-ae2e-c977d885b26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:to="loc_us-gaap_AdditionalPaidInCapital_84c005a9-00c0-44d3-ae2e-c977d885b26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1646789-f63e-4db9-974c-565f68bad676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1646789-f63e-4db9-974c-565f68bad676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f05e0c6-2bf6-46c0-9a92-100c13e8e47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:to="loc_us-gaap_StockholdersEquity_2f05e0c6-2bf6-46c0-9a92-100c13e8e47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_906c6ac8-a78c-4e67-8224-884d8c8563e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:to="loc_us-gaap_MinorityInterest_906c6ac8-a78c-4e67-8224-884d8c8563e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63dd9750-9447-4a54-9727-bca549adc5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7d5f95f6-db13-4df4-a5ad-6f0b2efe9f79" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63dd9750-9447-4a54-9727-bca549adc5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4f80333d-571d-40da-882c-e5d9b97a2881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0209342-5c65-4997-9837-baee189121f0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4f80333d-571d-40da-882c-e5d9b97a2881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3726fa24-1512-40bb-b1c2-f155d39a18af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3726fa24-1512-40bb-b1c2-f155d39a18af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory_5c4f77ac-6db9-466b-b36c-c84fad2b6f50" xlink:href="apyx-20230331.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_apyx_ProvisionForObsolescenceInventory_5c4f77ac-6db9-466b-b36c-c84fad2b6f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8d20a879-ec86-44fd-bcca-100437d45af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8d20a879-ec86-44fd-bcca-100437d45af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d7ce9d6a-de0f-47a3-acb7-645b1d950bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d7ce9d6a-de0f-47a3-acb7-645b1d950bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_368575f5-f647-4d2f-9805-bc30c0e0d443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_368575f5-f647-4d2f-9805-bc30c0e0d443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8299093f-bc3b-460f-9ac9-7d29ad09ae63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8299093f-bc3b-460f-9ac9-7d29ad09ae63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d6c7596b-e323-4795-8d64-d2dab2edb05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d6c7596b-e323-4795-8d64-d2dab2edb05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0766cf4a-2869-4700-90b9-fe21d98d9b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0766cf4a-2869-4700-90b9-fe21d98d9b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bd6c8b94-6b35-4d48-908c-2016f12f8590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bd6c8b94-6b35-4d48-908c-2016f12f8590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ca19655c-e188-4285-9957-c8f7ad20f845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_CommonStockSharesIssued_ca19655c-e188-4285-9957-c8f7ad20f845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b7bb63c-5f99-4c50-b520-12c0b476f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_344df04d-a6be-42e8-bebe-ffe6fce037da" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b7bb63c-5f99-4c50-b520-12c0b476f6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31256ee0-1c0f-4ac3-b8ab-19b7e396bea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31256ee0-1c0f-4ac3-b8ab-19b7e396bea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_45674b50-2e2a-45c0-926c-189eb43774e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_45674b50-2e2a-45c0-926c-189eb43774e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_43a92d72-312b-4c7f-8a04-e722383983a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_GrossProfit_43a92d72-312b-4c7f-8a04-e722383983a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_fd196c4a-4dcd-445b-b768-b53565150ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_fd196c4a-4dcd-445b-b768-b53565150ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_87ae9f3f-3e8f-4d1d-86f2-b6d96b502662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fd196c4a-4dcd-445b-b768-b53565150ab7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_87ae9f3f-3e8f-4d1d-86f2-b6d96b502662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_67fe82bc-bb44-4379-93c1-6c9191b3fbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fd196c4a-4dcd-445b-b768-b53565150ab7" xlink:to="loc_us-gaap_ProfessionalFees_67fe82bc-bb44-4379-93c1-6c9191b3fbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_307889da-98bd-48b0-bf82-727d86805719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fd196c4a-4dcd-445b-b768-b53565150ab7" xlink:to="loc_us-gaap_SalariesAndWages_307889da-98bd-48b0-bf82-727d86805719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_46082fe2-11d6-459f-948b-6f5869401c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fd196c4a-4dcd-445b-b768-b53565150ab7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_46082fe2-11d6-459f-948b-6f5869401c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d7b551d8-db41-42c0-940a-6356125e866f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fd196c4a-4dcd-445b-b768-b53565150ab7" xlink:to="loc_us-gaap_OperatingExpenses_d7b551d8-db41-42c0-940a-6356125e866f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b4e5cc73-9486-4376-9586-4e22f6629064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_OperatingIncomeLoss_b4e5cc73-9486-4376-9586-4e22f6629064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_7d7b6128-7d2c-4198-9bc8-56ec89b2cf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_InterestIncomeOperating_7d7b6128-7d2c-4198-9bc8-56ec89b2cf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b48bbaef-f83c-4d4d-b6db-71ad2d4cd025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_InterestExpense_b48bbaef-f83c-4d4d-b6db-71ad2d4cd025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_17cdfa12-abbe-4d95-a159-a2dc5acde740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_17cdfa12-abbe-4d95-a159-a2dc5acde740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_edcc3065-b7d9-46c9-84b2-eace21b4e128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_edcc3065-b7d9-46c9-84b2-eace21b4e128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a5d6945-3410-4140-86ab-0ea9e88d9a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a5d6945-3410-4140-86ab-0ea9e88d9a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_047c6abb-2ea0-4f83-b57a-45f202edc301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_047c6abb-2ea0-4f83-b57a-45f202edc301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d67261c5-65ba-414e-8ff8-d02b8490b856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_ProfitLoss_d67261c5-65ba-414e-8ff8-d02b8490b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2c9b45b5-902f-4277-8c88-d56d33b8322a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2c9b45b5-902f-4277-8c88-d56d33b8322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74a1b295-14ad-47e9-8fdd-600a0b0c4ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_NetIncomeLoss_74a1b295-14ad-47e9-8fdd-600a0b0c4ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_75b964a9-0693-49d2-b139-ec558225decf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0ca1462c-8206-4b0f-8636-9e7d4075a6a1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_75b964a9-0693-49d2-b139-ec558225decf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7641a221-2e64-4d64-aef5-0c9fb0a9e737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75b964a9-0693-49d2-b139-ec558225decf" xlink:to="loc_us-gaap_EarningsPerShareBasic_7641a221-2e64-4d64-aef5-0c9fb0a9e737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5c511f32-0829-43a0-9fb3-f7a8e0a387a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75b964a9-0693-49d2-b139-ec558225decf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5c511f32-0829-43a0-9fb3-f7a8e0a387a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dd4f1891-0553-43f8-aa80-5a8db64c3133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7ac59082-0cd7-4fcc-8981-f814e5ee665e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dd4f1891-0553-43f8-aa80-5a8db64c3133" xlink:to="loc_us-gaap_StatementTable_7ac59082-0cd7-4fcc-8981-f814e5ee665e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fd2d0342-7373-4b20-8b76-5fee7ee0ec21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7ac59082-0cd7-4fcc-8981-f814e5ee665e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fd2d0342-7373-4b20-8b76-5fee7ee0ec21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd2d0342-7373-4b20-8b76-5fee7ee0ec21" xlink:to="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f740e96f-d6da-4943-b5d4-de1acca6107b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:to="loc_us-gaap_CommonStockMember_f740e96f-d6da-4943-b5d4-de1acca6107b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e6560ea1-bd77-45bf-a626-3de8473993c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e6560ea1-bd77-45bf-a626-3de8473993c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3f35d29e-5a7c-4315-b13b-12e6b9f37d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:to="loc_us-gaap_RetainedEarningsMember_3f35d29e-5a7c-4315-b13b-12e6b9f37d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_74bd599f-5c01-4d43-929d-4744bd828f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3288c0e-196b-494f-a24d-867284d00487" xlink:to="loc_us-gaap_NoncontrollingInterestMember_74bd599f-5c01-4d43-929d-4744bd828f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_832e668f-f821-4482-96ed-01c0ce7ba6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7ac59082-0cd7-4fcc-8981-f814e5ee665e" xlink:to="loc_us-gaap_StatementLineItems_832e668f-f821-4482-96ed-01c0ce7ba6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_832e668f-f821-4482-96ed-01c0ce7ba6bd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8bb84d60-bea0-4640-ba40-67d4cdda0953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_SharesIssued_8bb84d60-bea0-4640-ba40-67d4cdda0953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd2c4ec6-3b1a-4731-aa1f-190013687df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd2c4ec6-3b1a-4731-aa1f-190013687df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3ae512f7-58e8-46bb-9f51-8188f136db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3ae512f7-58e8-46bb-9f51-8188f136db6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0972cda2-e8b0-452b-97a0-5a059d765f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0972cda2-e8b0-452b-97a0-5a059d765f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ac58914-4322-406d-b036-c1ffa40388a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ac58914-4322-406d-b036-c1ffa40388a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_0ac74ad9-7894-4779-b35f-cac02499ea81" xlink:href="apyx-20230331.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_0ac74ad9-7894-4779-b35f-cac02499ea81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c03abddb-6c43-4ba2-ba45-c65cb6fc930b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c03abddb-6c43-4ba2-ba45-c65cb6fc930b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_93c531b3-8bbb-4b0c-8a31-7529f45e0d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_ProfitLoss_93c531b3-8bbb-4b0c-8a31-7529f45e0d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_059c1833-9aef-47de-97b0-3f8b357c4bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_SharesIssued_059c1833-9aef-47de-97b0-3f8b357c4bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af583317-3813-4072-b302-eb1d27654fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a55a79-e215-47d7-a56d-300aa422021e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af583317-3813-4072-b302-eb1d27654fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2309ab3f-9c1a-44eb-a75a-55d2e0ed4c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2309ab3f-9c1a-44eb-a75a-55d2e0ed4c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7e0f0aaa-ce08-42dd-b312-19cd63a3d25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2309ab3f-9c1a-44eb-a75a-55d2e0ed4c1f" xlink:to="loc_us-gaap_ProfitLoss_7e0f0aaa-ce08-42dd-b312-19cd63a3d25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2309ab3f-9c1a-44eb-a75a-55d2e0ed4c1f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ba57d587-49f0-47d3-ad55-b5c6792d6001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ba57d587-49f0-47d3-ad55-b5c6792d6001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_28256ba2-3ec2-49a2-9002-dd4f08f4a533" xlink:href="apyx-20230331.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_28256ba2-3ec2-49a2-9002-dd4f08f4a533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_158ea543-271f-491f-b038-de38a6a340e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_158ea543-271f-491f-b038-de38a6a340e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5a341f32-d2c7-4230-adad-02fb7028a560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:to="loc_us-gaap_ShareBasedCompensation_5a341f32-d2c7-4230-adad-02fb7028a560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_87139923-67c7-4711-b46c-aed552901d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_87139923-67c7-4711-b46c-aed552901d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_2d717de8-84a0-415a-b370-7678d3402f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_2d717de8-84a0-415a-b370-7678d3402f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6afd194-14cb-4443-abe0-42dc22d5935d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa9aa1c2-c87b-4ac6-8ce1-b39c45aaa31c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6afd194-14cb-4443-abe0-42dc22d5935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8ef47e91-a1dd-48ca-8605-339de8565ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6afd194-14cb-4443-abe0-42dc22d5935d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8ef47e91-a1dd-48ca-8605-339de8565ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ce8c017c-2fc4-47aa-996f-06fb17dd2c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6afd194-14cb-4443-abe0-42dc22d5935d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ce8c017c-2fc4-47aa-996f-06fb17dd2c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_11e11e90-a8e3-4733-8c61-d5a462943a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6afd194-14cb-4443-abe0-42dc22d5935d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_11e11e90-a8e3-4733-8c61-d5a462943a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_068e82ae-fda2-46b6-8ca0-0fefa006be07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6afd194-14cb-4443-abe0-42dc22d5935d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_068e82ae-fda2-46b6-8ca0-0fefa006be07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a795cb03-74e6-4f25-83b2-a8290dea1eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6afd194-14cb-4443-abe0-42dc22d5935d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a795cb03-74e6-4f25-83b2-a8290dea1eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_978e4a82-9e81-4c6f-9068-25add173bb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6afd194-14cb-4443-abe0-42dc22d5935d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_978e4a82-9e81-4c6f-9068-25add173bb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2f20083-32c9-4c11-87ed-d14d74a78dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2309ab3f-9c1a-44eb-a75a-55d2e0ed4c1f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2f20083-32c9-4c11-87ed-d14d74a78dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f2940439-4404-4547-bb2e-3f53d03c10fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f2940439-4404-4547-bb2e-3f53d03c10fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7e30f1d-5155-48f5-829c-030db135c2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f2940439-4404-4547-bb2e-3f53d03c10fe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7e30f1d-5155-48f5-829c-030db135c2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8fce733-8082-4ba7-ba1e-999d6f921628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f2940439-4404-4547-bb2e-3f53d03c10fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8fce733-8082-4ba7-ba1e-999d6f921628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07ac6a37-6b5f-4fb0-aedb-6b6bb4a90cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07ac6a37-6b5f-4fb0-aedb-6b6bb4a90cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_f7a85bce-9e67-42a8-9e3a-2a2b0757af15" xlink:href="apyx-20230331.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07ac6a37-6b5f-4fb0-aedb-6b6bb4a90cb8" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_f7a85bce-9e67-42a8-9e3a-2a2b0757af15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_86d09d30-5248-4fac-b12b-ffea6fa2e643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07ac6a37-6b5f-4fb0-aedb-6b6bb4a90cb8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_86d09d30-5248-4fac-b12b-ffea6fa2e643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1a51c115-add4-44a0-bc03-23df300dcdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07ac6a37-6b5f-4fb0-aedb-6b6bb4a90cb8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1a51c115-add4-44a0-bc03-23df300dcdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_cfc07b74-bf4d-4760-bfb4-989af8f5aee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07ac6a37-6b5f-4fb0-aedb-6b6bb4a90cb8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_cfc07b74-bf4d-4760-bfb4-989af8f5aee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_2947295e-7ac6-4111-94f0-7f4327760cc1" xlink:href="apyx-20230331.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07ac6a37-6b5f-4fb0-aedb-6b6bb4a90cb8" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_2947295e-7ac6-4111-94f0-7f4327760cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c80982b0-4459-49e5-8e93-7337bd490090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07ac6a37-6b5f-4fb0-aedb-6b6bb4a90cb8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c80982b0-4459-49e5-8e93-7337bd490090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_621a1bca-6a2e-4ae7-87ba-cde4a6575a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_621a1bca-6a2e-4ae7-87ba-cde4a6575a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_96a68dcb-8264-4619-bc06-a30011dc2c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_96a68dcb-8264-4619-bc06-a30011dc2c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1f119d3-f0b5-49a1-aa7f-8384675f55d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1f119d3-f0b5-49a1-aa7f-8384675f55d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_358bcea5-0172-4d32-bfd2-e0e88945cada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_358bcea5-0172-4d32-bfd2-e0e88945cada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5527b982-2f4b-493a-8e51-e6f7fbd5184a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b9f92af6-965b-4b46-b1b9-488000860481" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5527b982-2f4b-493a-8e51-e6f7fbd5184a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3769280f-b669-4446-b071-bfe336d32c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5527b982-2f4b-493a-8e51-e6f7fbd5184a" xlink:to="loc_us-gaap_InterestPaidNet_3769280f-b669-4446-b071-bfe336d32c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_bd9664d4-a726-4fe4-b779-78cc5b8c42e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5527b982-2f4b-493a-8e51-e6f7fbd5184a" xlink:to="loc_us-gaap_IncomeTaxesPaid_bd9664d4-a726-4fe4-b779-78cc5b8c42e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="apyx-20230331.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7ac591c-ddf4-4663-87a9-086fd815620e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_aaec066b-e753-42b3-919a-6509919142da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7ac591c-ddf4-4663-87a9-086fd815620e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_aaec066b-e753-42b3-919a-6509919142da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20230331.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_59acc254-2992-471a-a7b5-82c791b205da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_9c429082-ea9c-458f-82d1-3194481549b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_59acc254-2992-471a-a7b5-82c791b205da" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_9c429082-ea9c-458f-82d1-3194481549b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20230331.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fd6c1fc6-7ac2-47be-b8de-9596ed50fc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_fd0f8a40-b850-4fb1-90be-96bac3fc442e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fd6c1fc6-7ac2-47be-b8de-9596ed50fc97" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_fd0f8a40-b850-4fb1-90be-96bac3fc442e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="apyx-20230331.xsd#ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dedec333-8cef-4466-8366-f13bc157ae17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cbca2d40-e265-4efc-b819-6b9781436428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dedec333-8cef-4466-8366-f13bc157ae17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cbca2d40-e265-4efc-b819-6b9781436428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20230331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_171265de-0ce1-4206-b857-4519a5fa09fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_605c0d5e-f9ac-4315-91f4-e158523a5b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_171265de-0ce1-4206-b857-4519a5fa09fe" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_605c0d5e-f9ac-4315-91f4-e158523a5b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CREDITAGREEMENT" xlink:type="simple" xlink:href="apyx-20230331.xsd#CREDITAGREEMENT"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CREDITAGREEMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_183fdf7e-cfac-4185-9f59-c5d963e06943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_eeffd743-8bab-48aa-bf2d-bd89a9ac4c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_183fdf7e-cfac-4185-9f59-c5d963e06943" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_eeffd743-8bab-48aa-bf2d-bd89a9ac4c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="simple" xlink:href="apyx-20230331.xsd#INTERESTINJOINTVENTUREINVESTMENT"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_9e5fc612-09d9-4d9c-8455-37b03ff62d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_28bfb5a9-498b-4940-8a2f-48ef6523f537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_9e5fc612-09d9-4d9c-8455-37b03ff62d75" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_28bfb5a9-498b-4940-8a2f-48ef6523f537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20230331.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6141b457-ddd9-40c9-9299-dfa6b6056e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8d50b8e1-5c1e-4973-a9d7-8adc07b200c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6141b457-ddd9-40c9-9299-dfa6b6056e53" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8d50b8e1-5c1e-4973-a9d7-8adc07b200c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="apyx-20230331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631174d7-4621-4c9f-9e21-17c0771dfd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_12aafaf7-2ee1-44cd-852a-6e95306fc5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631174d7-4621-4c9f-9e21-17c0771dfd5e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_12aafaf7-2ee1-44cd-852a-6e95306fc5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20230331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f6897fed-dede-4fa5-8de7-a054f37b98a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e18d9b40-1637-4b0f-ab28-b134d4addc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6897fed-dede-4fa5-8de7-a054f37b98a9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e18d9b40-1637-4b0f-ab28-b134d4addc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20230331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7f657034-538c-479b-bb4d-af7890b52540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7762bd17-25be-4c7d-b3b9-d451b6d9607e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7f657034-538c-479b-bb4d-af7890b52540" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7762bd17-25be-4c7d-b3b9-d451b6d9607e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20230331.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_28754341-1224-4487-b8bd-51ac3a17f7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d364b38e-58b3-48b0-b065-1110c5323134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_28754341-1224-4487-b8bd-51ac3a17f7b0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d364b38e-58b3-48b0-b065-1110c5323134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20230331.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c29b031a-291c-4077-b2b7-d861adcc29a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_31a4e59a-4b09-4d72-9181-ce9ae226e5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c29b031a-291c-4077-b2b7-d861adcc29a9" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_31a4e59a-4b09-4d72-9181-ce9ae226e5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="simple" xlink:href="apyx-20230331.xsd#BASISOFPRESENTATIONPolicies"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35147616-de3f-42d7-bfac-b66bb6ea6970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5d2e471d-0cdb-44f6-b74c-536b6456943b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35147616-de3f-42d7-bfac-b66bb6ea6970" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5d2e471d-0cdb-44f6-b74c-536b6456943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_4881c5ab-25de-45d6-a52b-bdf7f1dfcc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35147616-de3f-42d7-bfac-b66bb6ea6970" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_4881c5ab-25de-45d6-a52b-bdf7f1dfcc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9ef62a85-f6a7-45e3-a2ee-0f560d677a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35147616-de3f-42d7-bfac-b66bb6ea6970" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9ef62a85-f6a7-45e3-a2ee-0f560d677a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20230331.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_18635cb3-3152-4a95-8bd8-578f02e221b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2fd4777d-d134-4c46-88b7-de9a3ecb92a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_18635cb3-3152-4a95-8bd8-578f02e221b9" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2fd4777d-d134-4c46-88b7-de9a3ecb92a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="apyx-20230331.xsd#ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2dc9395a-232d-450e-9dda-93daa80fd326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d1af9e75-d3f8-4e59-bd7b-55b00702cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2dc9395a-232d-450e-9dda-93daa80fd326" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d1af9e75-d3f8-4e59-bd7b-55b00702cbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20230331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_05f892dd-45f0-4e28-b901-380ac2a255e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_a0e81e2a-a906-4875-bed1-ce9cb20b62b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_05f892dd-45f0-4e28-b901-380ac2a255e3" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_a0e81e2a-a906-4875-bed1-ce9cb20b62b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DebtTables" xlink:type="simple" xlink:href="apyx-20230331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f988a8b9-1e14-45cb-b984-61bddd4fa694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_41c8e035-70d7-4397-a95a-5d3719346a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f988a8b9-1e14-45cb-b984-61bddd4fa694" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_41c8e035-70d7-4397-a95a-5d3719346a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_efc72fd5-aac8-42c1-ba1a-29e2dd71b852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f988a8b9-1e14-45cb-b984-61bddd4fa694" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_efc72fd5-aac8-42c1-ba1a-29e2dd71b852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="simple" xlink:href="apyx-20230331.xsd#INTERESTINJOINTVENTUREINVESTMENTTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_d3768b7f-6845-4f2d-bd88-eb3653c74e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock_23f89f38-939b-4281-ae3b-76dc67b0240e" xlink:href="apyx-20230331.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_d3768b7f-6845-4f2d-bd88-eb3653c74e3c" xlink:to="loc_apyx_NoncontrollingInterestTableTextBlock_23f89f38-939b-4281-ae3b-76dc67b0240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20230331.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f9a4a190-be0c-4363-86c3-80f5d21ccd40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ff031711-dba4-4dc6-92e7-6189bf65c0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f9a4a190-be0c-4363-86c3-80f5d21ccd40" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ff031711-dba4-4dc6-92e7-6189bf65c0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="apyx-20230331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc87198e-ec73-4af6-a92f-939a96c954db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_010dfada-d7bf-4845-836f-6600826237f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc87198e-ec73-4af6-a92f-939a96c954db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_010dfada-d7bf-4845-836f-6600826237f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1c4e3f23-36c2-4db2-8c35-12c3891a8c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc87198e-ec73-4af6-a92f-939a96c954db" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1c4e3f23-36c2-4db2-8c35-12c3891a8c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20230331.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1973cdb5-e8e1-488f-85b3-0adfc34fed9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5c63314f-33af-4f06-a57b-e36b9a19df67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1973cdb5-e8e1-488f-85b3-0adfc34fed9e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5c63314f-33af-4f06-a57b-e36b9a19df67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_3887dd60-bc72-4ec5-a4f5-ea7dcd821e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1973cdb5-e8e1-488f-85b3-0adfc34fed9e" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_3887dd60-bc72-4ec5-a4f5-ea7dcd821e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#BASISOFPRESENTATIONDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10324dc0-3cca-45be-8230-ea05dadd1961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10324dc0-3cca-45be-8230-ea05dadd1961" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7f131701-c767-4e1c-b637-647c2dbe038b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7f131701-c767-4e1c-b637-647c2dbe038b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20ff6947-1525-4565-bddd-d45c7a60418c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7f131701-c767-4e1c-b637-647c2dbe038b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20ff6947-1525-4565-bddd-d45c7a60418c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AtTheMarketFacilityMember_fa619541-c227-451e-b1ad-1d20c7bff902" xlink:href="apyx-20230331.xsd#apyx_AtTheMarketFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20ff6947-1525-4565-bddd-d45c7a60418c" xlink:to="loc_apyx_AtTheMarketFacilityMember_fa619541-c227-451e-b1ad-1d20c7bff902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShelfRegistrationMember_44f7ddf4-8cc1-4347-807a-dc120434afeb" xlink:href="apyx-20230331.xsd#apyx_ShelfRegistrationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20ff6947-1525-4565-bddd-d45c7a60418c" xlink:to="loc_apyx_ShelfRegistrationMember_44f7ddf4-8cc1-4347-807a-dc120434afeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_54549fb3-5050-45ea-938d-45139ae8f1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_DebtInstrumentAxis_54549fb3-5050-45ea-938d-45139ae8f1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c3a792cb-9c42-41cd-8a32-a20359dfafba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_54549fb3-5050-45ea-938d-45139ae8f1af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c3a792cb-9c42-41cd-8a32-a20359dfafba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember_f1264cf0-2066-4449-9483-e6ffcb82af2e" xlink:href="apyx-20230331.xsd#apyx_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c3a792cb-9c42-41cd-8a32-a20359dfafba" xlink:to="loc_apyx_CreditAgreementMember_f1264cf0-2066-4449-9483-e6ffcb82af2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1ce8074e-7c1d-4c69-863c-e9c80f2644db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1ce8074e-7c1d-4c69-863c-e9c80f2644db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d4136d91-8257-405a-987c-761ed3114fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1ce8074e-7c1d-4c69-863c-e9c80f2644db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d4136d91-8257-405a-987c-761ed3114fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c4d72914-8d62-43f0-8d23-f3fcaae60e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d4136d91-8257-405a-987c-761ed3114fb6" xlink:to="loc_us-gaap_LineOfCreditMember_c4d72914-8d62-43f0-8d23-f3fcaae60e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_da4f1e8a-211d-4004-b721-4239bdcb85b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_CreditFacilityAxis_da4f1e8a-211d-4004-b721-4239bdcb85b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_80085029-6bfa-4124-bd30-044286082382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_da4f1e8a-211d-4004-b721-4239bdcb85b4" xlink:to="loc_us-gaap_CreditFacilityDomain_80085029-6bfa-4124-bd30-044286082382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_92e18f9b-e565-49f8-b657-658ec73acee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_80085029-6bfa-4124-bd30-044286082382" xlink:to="loc_us-gaap_SecuredDebtMember_92e18f9b-e565-49f8-b657-658ec73acee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f16e5aba-dabf-4b8d-a30e-55feda341b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_80085029-6bfa-4124-bd30-044286082382" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f16e5aba-dabf-4b8d-a30e-55feda341b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis_6b32d165-6634-427b-bb8a-bb77eff31c82" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_apyx_DebtInstrumentCovenantsAxis_6b32d165-6634-427b-bb8a-bb77eff31c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_6b32d165-6634-427b-bb8a-bb77eff31c82" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember_832db15f-92cb-496c-8704-356a056cd688" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheOneMember_832db15f-92cb-496c-8704-356a056cd688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_9ebf9c00-aaa4-4fce-aee5-7be024bde965" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_9ebf9c00-aaa4-4fce-aee5-7be024bde965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_642a8cf1-2705-4989-9ad1-05f543e3af50" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_8469f8e0-7965-4e64-a7ad-25b2fce4005f" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_642a8cf1-2705-4989-9ad1-05f543e3af50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89ed48a0-e4b5-402c-a40b-0f5095caa56a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_16dd525b-d850-492c-a781-e0c061d12b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_16dd525b-d850-492c-a781-e0c061d12b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_53bbdc14-0951-4c02-8aae-98d29dd9f94d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_OperatingIncomeLoss_53bbdc14-0951-4c02-8aae-98d29dd9f94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ef17787-9f01-4cdb-b344-61925be2435b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ef17787-9f01-4cdb-b344-61925be2435b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a2cbe0c-9b22-428b-ad84-f803c229e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a2cbe0c-9b22-428b-ad84-f803c229e9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_51c9289f-a14f-48d8-a615-b1c11c5515a6" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_51c9289f-a14f-48d8-a615-b1c11c5515a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SecuritiesRegisteredNewIssues_202f7745-00eb-4184-ad67-a0369aab12e6" xlink:href="apyx-20230331.xsd#apyx_SecuritiesRegisteredNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_apyx_SecuritiesRegisteredNewIssues_202f7745-00eb-4184-ad67-a0369aab12e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_aab227ff-209a-4506-a31d-51dff4fef711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_aab227ff-209a-4506-a31d-51dff4fef711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_45f3535b-226a-4f0b-a504-9c3ac93bb29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_45f3535b-226a-4f0b-a504-9c3ac93bb29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_123ee860-20f0-4c45-ba9a-f6b1be7dcb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_123ee860-20f0-4c45-ba9a-f6b1be7dcb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement_28bd102b-7ab5-4983-ba6b-0696344898fc" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_apyx_SaleLeasebackPurchaseAgreement_28bd102b-7ab5-4983-ba6b-0696344898fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_3e97fee5-eea9-48f3-9d90-59532d13815d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b3b1fb7-affe-496b-8779-fe9fff922a0b" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_3e97fee5-eea9-48f3-9d90-59532d13815d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#INVENTORIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_78105d14-f9c3-4068-8dc5-43fe968ada4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_3d14078e-ebad-4d1e-b123-5982a2e408d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78105d14-f9c3-4068-8dc5-43fe968ada4b" xlink:to="loc_us-gaap_InventoryRawMaterials_3d14078e-ebad-4d1e-b123-5982a2e408d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_95f028a0-ea8b-4670-aae9-b07be2b76a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78105d14-f9c3-4068-8dc5-43fe968ada4b" xlink:to="loc_us-gaap_InventoryWorkInProcess_95f028a0-ea8b-4670-aae9-b07be2b76a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_68cbffc3-fcbb-4335-a18c-821756e9c86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78105d14-f9c3-4068-8dc5-43fe968ada4b" xlink:to="loc_us-gaap_InventoryFinishedGoods_68cbffc3-fcbb-4335-a18c-821756e9c86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_02b1a7dc-1b0e-49f2-986a-84cc5526ba89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78105d14-f9c3-4068-8dc5-43fe968ada4b" xlink:to="loc_us-gaap_InventoryGross_02b1a7dc-1b0e-49f2-986a-84cc5526ba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_c464c4d6-c585-4ab3-a003-8e0c4d1ced53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78105d14-f9c3-4068-8dc5-43fe968ada4b" xlink:to="loc_us-gaap_InventoryValuationReserves_c464c4d6-c585-4ab3-a003-8e0c4d1ced53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_59204116-0781-4c27-94f7-8d19895e794d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_78105d14-f9c3-4068-8dc5-43fe968ada4b" xlink:to="loc_us-gaap_InventoryNet_59204116-0781-4c27-94f7-8d19895e794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_12742996-caf4-4bac-87fa-629634a2be29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59aac55d-ee1e-4494-b435-0a5431deb1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_12742996-caf4-4bac-87fa-629634a2be29" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59aac55d-ee1e-4494-b435-0a5431deb1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59aac55d-ee1e-4494-b435-0a5431deb1a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edef9e0b-0737-47a3-8b4b-34f80ad0b2c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_56e54cc1-73fe-41ae-a092-e7e9715ed71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_LandMember_56e54cc1-73fe-41ae-a092-e7e9715ed71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_61cf66b8-9ef0-4089-bd68-6d6b29bacdb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_61cf66b8-9ef0-4089-bd68-6d6b29bacdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_dd796264-3021-4eff-bc4c-3031e0943886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_dd796264-3021-4eff-bc4c-3031e0943886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_197260a2-c573-431a-b728-278bfebe50c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_197260a2-c573-431a-b728-278bfebe50c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentAndSoftwareMember_82a436ba-15ec-400e-9d73-1b19d186e48d" xlink:href="apyx-20230331.xsd#apyx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_apyx_ComputerEquipmentAndSoftwareMember_82a436ba-15ec-400e-9d73-1b19d186e48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e695c995-07a2-426e-959f-f0179ccbed87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e695c995-07a2-426e-959f-f0179ccbed87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MoldsMember_39128efb-61b4-443b-8c46-6c4cf346253e" xlink:href="apyx-20230331.xsd#apyx_MoldsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cecf26b7-ff1f-4595-aa0e-72fa67c3abf3" xlink:to="loc_apyx_MoldsMember_39128efb-61b4-443b-8c46-6c4cf346253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59aac55d-ee1e-4494-b435-0a5431deb1a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4659e9a3-e265-4841-a413-215ff6625770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4659e9a3-e265-4841-a413-215ff6625770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_25c37d95-3ad1-40ca-8d7f-3bd9be52325d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_25c37d95-3ad1-40ca-8d7f-3bd9be52325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PropertyPlantAndEquipmentInService_b4e70567-2a37-4067-9dbd-77e417abf019" xlink:href="apyx-20230331.xsd#apyx_PropertyPlantAndEquipmentInService"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_apyx_PropertyPlantAndEquipmentInService_b4e70567-2a37-4067-9dbd-77e417abf019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_d507491a-f55a-4a03-b485-324cbcb3b9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_ConstructionInProgressGross_d507491a-f55a-4a03-b485-324cbcb3b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_51d2126c-536f-45dc-93dc-52e4aeb5baad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_51d2126c-536f-45dc-93dc-52e4aeb5baad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_e46697b4-03ea-4bba-87a0-11c2fbbb45e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d98cf8d8-2c24-4411-a686-139f32c3243a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_e46697b4-03ea-4bba-87a0-11c2fbbb45e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c78f78db-575d-48ff-b064-3f1606b2bb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb41a06e-ccda-4a7f-ac1f-23e3195f385a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c78f78db-575d-48ff-b064-3f1606b2bb1d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb41a06e-ccda-4a7f-ac1f-23e3195f385a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5a461ce3-344b-4039-b856-7f0ffbf9d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb41a06e-ccda-4a7f-ac1f-23e3195f385a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5a461ce3-344b-4039-b856-7f0ffbf9d9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_af6181b1-d96c-4b05-b7cb-03a912cf4fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5a461ce3-344b-4039-b856-7f0ffbf9d9fc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_af6181b1-d96c-4b05-b7cb-03a912cf4fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_62c6b980-ddd8-4ab6-b878-5de047ca6e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_af6181b1-d96c-4b05-b7cb-03a912cf4fcc" xlink:to="loc_us-gaap_SubsequentEventMember_62c6b980-ddd8-4ab6-b878-5de047ca6e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb41a06e-ccda-4a7f-ac1f-23e3195f385a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement_05e0958d-2235-4f9e-9134-690a69f37dd9" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackPurchaseAgreement_05e0958d-2235-4f9e-9134-690a69f37dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackTermOfLease_6eeb365f-cd24-4e36-8fc1-3e6f558cb9db" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackTermOfLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackTermOfLease_6eeb365f-cd24-4e36-8fc1-3e6f558cb9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackRenewalTerm_16ad753f-5d2f-4010-be0e-5d34606668e7" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackRenewalTerm_16ad753f-5d2f-4010-be0e-5d34606668e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentPayment_027de48d-a9e7-453c-9030-57f3e6d7fabd" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackAnnualRentPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackAnnualRentPayment_027de48d-a9e7-453c-9030-57f3e6d7fabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentIncrease_14dbc90b-3494-4273-8092-d1826b71da44" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackAnnualRentIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackAnnualRentIncrease_14dbc90b-3494-4273-8092-d1826b71da44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackManagementFeeOnRentPayment_6e6d3c92-4036-4cef-b339-68df553514a5" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackManagementFeeOnRentPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackManagementFeeOnRentPayment_6e6d3c92-4036-4cef-b339-68df553514a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackNetCashProceeds_5189758c-9b82-4ac5-afc2-cc692a50ddf3" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackNetCashProceeds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackNetCashProceeds_5189758c-9b82-4ac5-afc2-cc692a50ddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent_1cc99dcb-b0ab-4f09-bbfe-0551b61faff3" xlink:href="apyx-20230331.xsd#apyx_SaleLeasebackSecurityDepositEqualToAnnualRent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_145a699a-d9cf-4707-b56c-13860aea3ce3" xlink:to="loc_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent_1cc99dcb-b0ab-4f09-bbfe-0551b61faff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_cef52de5-a9f7-4723-a199-d249a85a744e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_us-gaap_AccruedSalariesCurrent_cef52de5-a9f7-4723-a199-d249a85a744e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_c9661054-a436-428b-a2f2-56d3a655b814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_us-gaap_AccruedBonusesCurrent_c9661054-a436-428b-a2f2-56d3a655b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_c14e8d2a-846d-4a3f-a6b5-5e3505e9dfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_c14e8d2a-846d-4a3f-a6b5-5e3505e9dfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_7aee110e-519f-4f08-9548-3d57f13db417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_7aee110e-519f-4f08-9548-3d57f13db417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_eb1dccb9-992b-4075-a0af-354303b972c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_eb1dccb9-992b-4075-a0af-354303b972c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5b6a82d7-d43f-4dad-a9b2-8b91d6c263ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5b6a82d7-d43f-4dad-a9b2-8b91d6c263ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68ff782c-e9e3-4329-9807-cb6696f03d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68ff782c-e9e3-4329-9807-cb6696f03d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_21cbbf0b-79c6-4f91-a4d5-b126a621bae8" xlink:href="apyx-20230331.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_21cbbf0b-79c6-4f91-a4d5-b126a621bae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_2257932b-a03d-419f-ae9d-e4d8c7e98149" xlink:href="apyx-20230331.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_apyx_UncertainTaxPositionsLiability_2257932b-a03d-419f-ae9d-e4d8c7e98149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_c3fa994a-13d2-48f2-858d-aa334b12bc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_c3fa994a-13d2-48f2-858d-aa334b12bc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_81338ddf-be41-474c-b7e5-ce3a7efec906" xlink:href="apyx-20230331.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_81338ddf-be41-474c-b7e5-ce3a7efec906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_19a54b2d-8223-4cce-8eda-b3fcaec56dae" xlink:href="apyx-20230331.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb8e91c4-4521-494e-8636-7fca3c66f6dc" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_19a54b2d-8223-4cce-8eda-b3fcaec56dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#CREDITAGREEMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_04464eb6-4215-4e13-af6d-a2173131ee04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_04464eb6-4215-4e13-af6d-a2173131ee04" xlink:to="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_de4a97de-c801-49a5-81fb-96a041277721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_de4a97de-c801-49a5-81fb-96a041277721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5e888acf-e884-4c6a-a185-08b9a8a5428d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_de4a97de-c801-49a5-81fb-96a041277721" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5e888acf-e884-4c6a-a185-08b9a8a5428d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9e5f1fdb-bf0e-4a57-b477-aa579a815f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5e888acf-e884-4c6a-a185-08b9a8a5428d" xlink:to="loc_us-gaap_LineOfCreditMember_9e5f1fdb-bf0e-4a57-b477-aa579a815f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_DebtInstrumentAxis_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c2f4b14d-f27a-4612-b268-9b12d5d53e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_345c9bdc-472a-4c2e-8ed8-6b8cec1c797c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c2f4b14d-f27a-4612-b268-9b12d5d53e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember_f050e923-f5e9-4880-b172-8415e99d7d73" xlink:href="apyx-20230331.xsd#apyx_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2f4b14d-f27a-4612-b268-9b12d5d53e5f" xlink:to="loc_apyx_CreditAgreementMember_f050e923-f5e9-4880-b172-8415e99d7d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a4296dd1-8021-45af-9b9f-f32870c2d45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_CreditFacilityAxis_a4296dd1-8021-45af-9b9f-f32870c2d45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ae89c264-b539-4c90-b84f-3caf936e9e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a4296dd1-8021-45af-9b9f-f32870c2d45a" xlink:to="loc_us-gaap_CreditFacilityDomain_ae89c264-b539-4c90-b84f-3caf936e9e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ed9fe727-b255-4e73-aade-b454088723b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ae89c264-b539-4c90-b84f-3caf936e9e45" xlink:to="loc_us-gaap_SecuredDebtMember_ed9fe727-b255-4e73-aade-b454088723b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_439dcb96-3d6e-4864-837c-05db049a1a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ae89c264-b539-4c90-b84f-3caf936e9e45" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_439dcb96-3d6e-4864-837c-05db049a1a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis_18bfe92d-1799-4d84-a172-c180e98707ba" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_apyx_DebtInstrumentCovenantsAxis_18bfe92d-1799-4d84-a172-c180e98707ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_18bfe92d-1799-4d84-a172-c180e98707ba" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember_dea24929-6cb5-44e4-9144-9bd47eb65060" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheOneMember_dea24929-6cb5-44e4-9144-9bd47eb65060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_07c2346c-9cf9-4d34-b5cc-97b8cad0e812" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_07c2346c-9cf9-4d34-b5cc-97b8cad0e812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_ee3922e0-a182-42ed-a674-90a4942c3a1d" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_faf81028-a16a-4555-81a6-c0da902ca4ea" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_ee3922e0-a182-42ed-a674-90a4942c3a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_09879e17-eb9f-4f1d-8c18-658ed27ee66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_VariableRateAxis_09879e17-eb9f-4f1d-8c18-658ed27ee66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a573f83c-7413-4ef9-ba5c-1a8476188fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_09879e17-eb9f-4f1d-8c18-658ed27ee66d" xlink:to="loc_us-gaap_VariableRateDomain_a573f83c-7413-4ef9-ba5c-1a8476188fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_2c3d785a-5c4c-4523-b040-ab743831350b" xlink:href="apyx-20230331.xsd#apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a573f83c-7413-4ef9-ba5c-1a8476188fe2" xlink:to="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_2c3d785a-5c4c-4523-b040-ab743831350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_dc0320f7-3971-40a1-bb02-fa1745a79fae" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_dc0320f7-3971-40a1-bb02-fa1745a79fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_dc0320f7-3971-40a1-bb02-fa1745a79fae" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember_dba5cf2f-cc5c-4b69-962d-500e99060d08" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember_dba5cf2f-cc5c-4b69-962d-500e99060d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember_ced49d7c-e8cf-458c-90ad-8513ef6577ba" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember_ced49d7c-e8cf-458c-90ad-8513ef6577ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember_107c0b09-191e-483f-b933-ce74756f5ca0" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentPeriodTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_b9a95ef6-6f71-4c27-8f32-9372778d62ee" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember_107c0b09-191e-483f-b933-ce74756f5ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodAxis_93aa7615-1318-4709-a1ca-82338a9ea1d3" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodAxis_93aa7615-1318-4709-a1ca-82338a9ea1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodAxis_93aa7615-1318-4709-a1ca-82338a9ea1d3" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodOneMember_0460ebae-95fb-4938-9621-cf06edf15dcb" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodOneMember_0460ebae-95fb-4938-9621-cf06edf15dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodTwoMember_58d8fcfc-b4aa-4ded-9059-64f03c93dead" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodTwoMember_58d8fcfc-b4aa-4ded-9059-64f03c93dead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodThreeMember_3bb1e958-2457-4603-bc75-971b231d55f9" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_fefada4e-d51f-48d8-ab36-34d860cebb63" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodThreeMember_3bb1e958-2457-4603-bc75-971b231d55f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6c609fb-bbd5-405a-bb3b-5fb50f0ca875" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2a054e47-ff79-4e67-854d-a1d27cb5db9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2a054e47-ff79-4e67-854d-a1d27cb5db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_496db30b-8cfd-4399-8875-1a31ec297ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_496db30b-8cfd-4399-8875-1a31ec297ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_84f7eee9-cb01-4c43-b57c-d83839ce36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_84f7eee9-cb01-4c43-b57c-d83839ce36d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorPercent_3afafce0-4a90-40cb-9cf8-22f125b3ba4f" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentInterestRateFloorPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentInterestRateFloorPercent_3afafce0-4a90-40cb-9cf8-22f125b3ba4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent_5dbe3f54-7b06-4e7a-80a6-c77b960a7c0b" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent_5dbe3f54-7b06-4e7a-80a6-c77b960a7c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_931c9055-f1ea-4d0f-be4c-02675789f52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_931c9055-f1ea-4d0f-be4c-02675789f52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPeriodOfInterestOnly_d78a9815-8431-4f73-9440-f0a8a5e74b82" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPeriodOfInterestOnly"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentPeriodOfInterestOnly_d78a9815-8431-4f73-9440-f0a8a5e74b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExtensionPeriod_fe051156-1c90-44cc-a17c-0d3a878ba6ae" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentExtensionPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentExtensionPeriod_fe051156-1c90-44cc-a17c-0d3a878ba6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPayments_e0921d7e-2779-45c0-9178-f54358bf3ee6" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentNumberOfMonthlyPayments_e0921d7e-2779-45c0-9178-f54358bf3ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_b6c126b2-bf15-425b-a994-6d0c661a5c90" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_b6c126b2-bf15-425b-a994-6d0c661a5c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentFeePercent_bd5e166a-5241-4552-9f01-3461cf0cae1d" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentPrepaymentFeePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentPrepaymentFeePercent_bd5e166a-5241-4552-9f01-3461cf0cae1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExitFee_37f5217f-ff7d-4ee8-96db-9e9ea10a6cef" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentExitFee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentExitFee_37f5217f-ff7d-4ee8-96db-9e9ea10a6cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_7a2e0005-c42d-4605-9172-ea531ae7c5b5" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_7a2e0005-c42d-4605-9172-ea531ae7c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings_649322bb-3c21-4fed-93e7-340b865cadc2" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings_649322bb-3c21-4fed-93e7-340b865cadc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentAnnualFeePercent_0183be5e-5a23-4d1d-ba8d-8227ea4d4868" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentAnnualFeePercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentAnnualFeePercent_0183be5e-5a23-4d1d-ba8d-8227ea4d4868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationFees_5b993377-9e41-4171-b0b1-a95e99504a66" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentTerminationFees"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentTerminationFees_5b993377-9e41-4171-b0b1-a95e99504a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_5c373cdb-0873-4e91-b027-ccba72617ce4" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_5c373cdb-0873-4e91-b027-ccba72617ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a11d3a7d-4272-4614-82ab-a197b0e99f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a11d3a7d-4272-4614-82ab-a197b0e99f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_9b649de4-9bf7-4f57-adf5-2eb14f5e9539" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_9b649de4-9bf7-4f57-adf5-2eb14f5e9539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_ca8745fc-917b-482d-ba74-44c576e81124" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_ca8745fc-917b-482d-ba74-44c576e81124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_52dec2bc-f9b4-4e68-952f-ae21a2cbb202" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_52dec2bc-f9b4-4e68-952f-ae21a2cbb202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_cd357439-1785-4c22-9726-b6a477d61034" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_cd357439-1785-4c22-9726-b6a477d61034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentDefaultApplicableInterestRate_6746a44a-7375-4e3e-8c3e-9232e1a1392a" xlink:href="apyx-20230331.xsd#apyx_DebtInstrumentDefaultApplicableInterestRate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_apyx_DebtInstrumentDefaultApplicableInterestRate_6746a44a-7375-4e3e-8c3e-9232e1a1392a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8b994a6f-c250-4ac2-9227-00507b0c5563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8b994a6f-c250-4ac2-9227-00507b0c5563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f6558e16-6a78-4184-88d5-14eef35a7c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f6558e16-6a78-4184-88d5-14eef35a7c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd7cd940-73e7-4d1b-9555-3a3aace2e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd7cd940-73e7-4d1b-9555-3a3aace2e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_df24b030-3922-4d32-bb41-b875892bab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_df24b030-3922-4d32-bb41-b875892bab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8eeeb68f-4603-4179-bb9b-d53feb1d2ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_8eeeb68f-4603-4179-bb9b-d53feb1d2ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f7e0c5fa-0ddb-49b8-bc72-0aea6c77bfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f7e0c5fa-0ddb-49b8-bc72-0aea6c77bfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_22f5922f-ff0b-4391-ace5-59fc0a2a2a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5da55fe9-55aa-4784-bc24-7a66c0b3e614" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_22f5922f-ff0b-4391-ace5-59fc0a2a2a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#CREDITAGREEMENTScheduleOfLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cedbb5ae-7c35-4ba6-ad26-2571c3597729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cedbb5ae-7c35-4ba6-ad26-2571c3597729" xlink:to="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c938a2b2-647d-4b9f-a8c4-c6947f6099db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c938a2b2-647d-4b9f-a8c4-c6947f6099db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3e86ab2a-25d6-46ee-8ca3-6b13b27f4910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c938a2b2-647d-4b9f-a8c4-c6947f6099db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3e86ab2a-25d6-46ee-8ca3-6b13b27f4910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_85b43142-30ed-46e2-81eb-1da1624f145e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3e86ab2a-25d6-46ee-8ca3-6b13b27f4910" xlink:to="loc_us-gaap_LineOfCreditMember_85b43142-30ed-46e2-81eb-1da1624f145e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bc7a72f3-fc67-4484-9b6e-2569cf3c2889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:to="loc_us-gaap_DebtInstrumentAxis_bc7a72f3-fc67-4484-9b6e-2569cf3c2889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74fe1990-0392-4ad9-9749-0994bbc5b44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc7a72f3-fc67-4484-9b6e-2569cf3c2889" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74fe1990-0392-4ad9-9749-0994bbc5b44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e8322b98-8da9-4c8e-9721-71487865bf73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74fe1990-0392-4ad9-9749-0994bbc5b44e" xlink:to="loc_us-gaap_LineOfCreditMember_e8322b98-8da9-4c8e-9721-71487865bf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc39c3e7-8be5-4beb-8932-69c61331b51e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_cde18963-edcb-40f7-b6f0-48448dc586b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_cde18963-edcb-40f7-b6f0-48448dc586b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_f676261f-4864-4947-8d85-092975e1db63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_f676261f-4864-4947-8d85-092975e1db63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_996449ed-2064-4ec4-89af-9db80450ef2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_996449ed-2064-4ec4-89af-9db80450ef2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_33e52282-ea32-4500-b95f-6c9231e5cffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d962b385-f87a-4f68-93df-82958721cc83" xlink:to="loc_us-gaap_LongTermDebt_33e52282-ea32-4500-b95f-6c9231e5cffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_69b0fd3d-b45b-4eb9-af9e-cb2e07a20eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_02bf0b7b-092c-4ede-bc31-f27f3bc2f58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_69b0fd3d-b45b-4eb9-af9e-cb2e07a20eb8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_02bf0b7b-092c-4ede-bc31-f27f3bc2f58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_910cf975-2cb3-4c75-8ec4-773e63a6047b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_69b0fd3d-b45b-4eb9-af9e-cb2e07a20eb8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_910cf975-2cb3-4c75-8ec4-773e63a6047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_19f38412-d667-4150-a596-fc3ac5a0aa45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_69b0fd3d-b45b-4eb9-af9e-cb2e07a20eb8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_19f38412-d667-4150-a596-fc3ac5a0aa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c162100f-540b-40c9-808b-64d67b6ad865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_69b0fd3d-b45b-4eb9-af9e-cb2e07a20eb8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c162100f-540b-40c9-808b-64d67b6ad865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0fd65374-59f8-48d1-b752-de369605d853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_69b0fd3d-b45b-4eb9-af9e-cb2e07a20eb8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0fd65374-59f8-48d1-b752-de369605d853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LongTermDebtMaturityAfterYearFour_e13c5fb5-4f08-471c-8e8a-02d234f47db2" xlink:href="apyx-20230331.xsd#apyx_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_69b0fd3d-b45b-4eb9-af9e-cb2e07a20eb8" xlink:to="loc_apyx_LongTermDebtMaturityAfterYearFour_e13c5fb5-4f08-471c-8e8a-02d234f47db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_bf5fce7c-9bbd-493b-b307-78dbfa9b8ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_69b0fd3d-b45b-4eb9-af9e-cb2e07a20eb8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_bf5fce7c-9bbd-493b-b307-78dbfa9b8ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_6490fafd-2913-4c51-af3a-57f449a90985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_35530245-3fa1-4da2-9fd2-c01ac632e539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_6490fafd-2913-4c51-af3a-57f449a90985" xlink:to="loc_us-gaap_MinorityInterestTable_35530245-3fa1-4da2-9fd2-c01ac632e539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_76afa4da-0ab6-43b3-9004-6c94cfb2bafa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_35530245-3fa1-4da2-9fd2-c01ac632e539" xlink:to="loc_srt_OwnershipAxis_76afa4da-0ab6-43b3-9004-6c94cfb2bafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_95316349-0955-43c9-a776-2aa5b087508d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_76afa4da-0ab6-43b3-9004-6c94cfb2bafa" xlink:to="loc_srt_OwnershipDomain_95316349-0955-43c9-a776-2aa5b087508d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_2af3aec7-7e2a-41eb-b4a9-1613585d5bc6" xlink:href="apyx-20230331.xsd#apyx_ChineseSupplierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_95316349-0955-43c9-a776-2aa5b087508d" xlink:to="loc_apyx_ChineseSupplierMember_2af3aec7-7e2a-41eb-b4a9-1613585d5bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_35530245-3fa1-4da2-9fd2-c01ac632e539" xlink:to="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18175314-0aae-4a7c-bbfb-dd9f49900e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_18175314-0aae-4a7c-bbfb-dd9f49900e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_ddc567fa-9fc1-4f65-b775-d25f60e30903" xlink:href="apyx-20230331.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_ddc567fa-9fc1-4f65-b775-d25f60e30903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_67fd513a-a584-4b1c-b5f5-b495367a5be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_90e972e3-e304-4995-9e61-4fe202f65114" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_67fd513a-a584-4b1c-b5f5-b495367a5be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_10d8beb6-c585-4ddb-bbcf-556127d68e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_827d67b0-6452-41ca-9714-6cd15f90d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_10d8beb6-c585-4ddb-bbcf-556127d68e69" xlink:to="loc_us-gaap_MinorityInterestTable_827d67b0-6452-41ca-9714-6cd15f90d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dd86d4b5-5630-4702-a83c-4ee02e581768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_827d67b0-6452-41ca-9714-6cd15f90d0aa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dd86d4b5-5630-4702-a83c-4ee02e581768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_134f6d70-b249-4ebc-ae69-7449734a1f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dd86d4b5-5630-4702-a83c-4ee02e581768" xlink:to="loc_us-gaap_RelatedPartyDomain_134f6d70-b249-4ebc-ae69-7449734a1f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_54491b96-1746-432a-a5c4-966ae2c3b8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_134f6d70-b249-4ebc-ae69-7449734a1f0d" xlink:to="loc_us-gaap_CorporateJointVentureMember_54491b96-1746-432a-a5c4-966ae2c3b8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_cb07c817-22f2-40da-b584-514c34c46fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_827d67b0-6452-41ca-9714-6cd15f90d0aa" xlink:to="loc_us-gaap_MinorityInterestLineItems_cb07c817-22f2-40da-b584-514c34c46fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cb07c817-22f2-40da-b584-514c34c46fb2" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_448db4a1-f139-4b34-9f8c-9ec2744649c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:to="loc_us-gaap_MinorityInterest_448db4a1-f139-4b34-9f8c-9ec2744649c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d365c366-d0fe-4c85-90b6-c46000e21a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d365c366-d0fe-4c85-90b6-c46000e21a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5c242f18-46d3-4828-b6d9-6b2aa00c69f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_a987eeb2-8d37-4815-936e-f1722826036c" xlink:to="loc_us-gaap_MinorityInterest_5c242f18-46d3-4828-b6d9-6b2aa00c69f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cb42d99c-d46e-422e-8be0-e2a4bfdd7436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32708c0f-04fc-4790-8e7b-3ebd7cbc5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cb42d99c-d46e-422e-8be0-e2a4bfdd7436" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32708c0f-04fc-4790-8e7b-3ebd7cbc5cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_749d5253-9aa3-4e91-96cb-d7bc331886e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32708c0f-04fc-4790-8e7b-3ebd7cbc5cae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_749d5253-9aa3-4e91-96cb-d7bc331886e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3164c947-760f-4e57-8587-8ecac1ea2003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_749d5253-9aa3-4e91-96cb-d7bc331886e4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3164c947-760f-4e57-8587-8ecac1ea2003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f13f7f2c-3b0b-4da7-91e6-e56daf2fd54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3164c947-760f-4e57-8587-8ecac1ea2003" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f13f7f2c-3b0b-4da7-91e6-e56daf2fd54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_887d4b91-28dd-405a-a698-8b9a6e559abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3164c947-760f-4e57-8587-8ecac1ea2003" xlink:to="loc_us-gaap_WarrantMember_887d4b91-28dd-405a-a698-8b9a6e559abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32708c0f-04fc-4790-8e7b-3ebd7cbc5cae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_9c29cca8-19b5-4c72-aaa4-f26aecf2ecd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_9c29cca8-19b5-4c72-aaa4-f26aecf2ecd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c435c945-d60a-482d-84fd-03fffe369291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9c29cca8-19b5-4c72-aaa4-f26aecf2ecd5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c435c945-d60a-482d-84fd-03fffe369291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6e334445-8b39-488e-9a6f-f790a1ef93fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9c29cca8-19b5-4c72-aaa4-f26aecf2ecd5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6e334445-8b39-488e-9a6f-f790a1ef93fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_b1311538-ce06-4853-bdac-9b38a77a3fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_b1311538-ce06-4853-bdac-9b38a77a3fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05fae923-c9d0-4769-b31c-875bf85343e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b1311538-ce06-4853-bdac-9b38a77a3fdb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05fae923-c9d0-4769-b31c-875bf85343e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a536dd46-4d64-45d0-b435-79bc043a416b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b1311538-ce06-4853-bdac-9b38a77a3fdb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a536dd46-4d64-45d0-b435-79bc043a416b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_b773f025-938c-4779-98ce-205fb326e719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_b773f025-938c-4779-98ce-205fb326e719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7869f7dc-7114-454f-9e9b-520c3ad74893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b773f025-938c-4779-98ce-205fb326e719" xlink:to="loc_us-gaap_EarningsPerShareBasic_7869f7dc-7114-454f-9e9b-520c3ad74893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2bb7399c-dddd-45e6-99e0-43307ec7a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b773f025-938c-4779-98ce-205fb326e719" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2bb7399c-dddd-45e6-99e0-43307ec7a38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_e9cd05fb-0aed-40d0-9725-b9e80aaa602b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ea3cb95-25a6-4889-984b-d2811924a5ed" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_e9cd05fb-0aed-40d0-9725-b9e80aaa602b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea401c8c-5a2a-4492-9914-864e34488301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e9cd05fb-0aed-40d0-9725-b9e80aaa602b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea401c8c-5a2a-4492-9914-864e34488301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e81ea833-c6a9-40d0-93c4-76cf9c7809d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_81faf084-cc16-49a9-b4c1-c15f2da05ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e81ea833-c6a9-40d0-93c4-76cf9c7809d7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_81faf084-cc16-49a9-b4c1-c15f2da05ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_564f5d86-a475-4b3a-8347-fe6380bdc771" xlink:href="apyx-20230331.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e81ea833-c6a9-40d0-93c4-76cf9c7809d7" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_564f5d86-a475-4b3a-8347-fe6380bdc771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_1b982cbb-d221-4318-aab7-cb8c18083760" xlink:href="apyx-20230331.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e81ea833-c6a9-40d0-93c4-76cf9c7809d7" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_1b982cbb-d221-4318-aab7-cb8c18083760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e34d21f2-ea76-41ac-83e0-5b3f81eec1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_87357557-8fe7-4a93-bcc8-9b929c22cf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e34d21f2-ea76-41ac-83e0-5b3f81eec1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_87357557-8fe7-4a93-bcc8-9b929c22cf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_32c4599b-456c-4f0c-9366-1f1a3331cead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_87357557-8fe7-4a93-bcc8-9b929c22cf5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_32c4599b-456c-4f0c-9366-1f1a3331cead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7c084842-f4db-4586-8066-5dcf7990d5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_87357557-8fe7-4a93-bcc8-9b929c22cf5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7c084842-f4db-4586-8066-5dcf7990d5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60904720-b6a9-4d72-83c5-7b2606a76bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_87357557-8fe7-4a93-bcc8-9b929c22cf5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60904720-b6a9-4d72-83c5-7b2606a76bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1318e6fb-ddba-41ac-ae08-1558d722b5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_87357557-8fe7-4a93-bcc8-9b929c22cf5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1318e6fb-ddba-41ac-ae08-1558d722b5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3788992-a718-4d00-97f0-af753b8a32fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_87357557-8fe7-4a93-bcc8-9b929c22cf5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3788992-a718-4d00-97f0-af753b8a32fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c84a68b1-678b-4bc4-a76f-7984b002f459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e34d21f2-ea76-41ac-83e0-5b3f81eec1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c84a68b1-678b-4bc4-a76f-7984b002f459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ffbfd033-1835-4971-a4f7-01af788aa3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c84a68b1-678b-4bc4-a76f-7984b002f459" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ffbfd033-1835-4971-a4f7-01af788aa3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f08aeebd-b7cd-47ef-ab41-9a3c1277828d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c84a68b1-678b-4bc4-a76f-7984b002f459" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f08aeebd-b7cd-47ef-ab41-9a3c1277828d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20a04cb-b63d-4d43-9464-51daa6308e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c84a68b1-678b-4bc4-a76f-7984b002f459" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20a04cb-b63d-4d43-9464-51daa6308e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_7d8ad19c-0074-4a88-b6de-88c784219ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c84a68b1-678b-4bc4-a76f-7984b002f459" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_7d8ad19c-0074-4a88-b6de-88c784219ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bf447e9b-4e46-4bf8-b053-cd480818b836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c84a68b1-678b-4bc4-a76f-7984b002f459" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bf447e9b-4e46-4bf8-b053-cd480818b836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62095acf-01c1-4448-8a13-d35c8f9c437a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7c8cabbc-c80e-47a7-8ea4-5ee2e4808c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62095acf-01c1-4448-8a13-d35c8f9c437a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7c8cabbc-c80e-47a7-8ea4-5ee2e4808c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1ca7e7cc-3598-4823-9bd6-876941f06749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62095acf-01c1-4448-8a13-d35c8f9c437a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1ca7e7cc-3598-4823-9bd6-876941f06749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f1138c11-d897-4c1b-89c1-f6a25c04c698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62095acf-01c1-4448-8a13-d35c8f9c437a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f1138c11-d897-4c1b-89c1-f6a25c04c698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f345cf6e-43e4-461d-8371-eed3e3c3bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62095acf-01c1-4448-8a13-d35c8f9c437a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f345cf6e-43e4-461d-8371-eed3e3c3bcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_59a42f22-4488-472c-8a8c-d028f764d7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62095acf-01c1-4448-8a13-d35c8f9c437a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_59a42f22-4488-472c-8a8c-d028f764d7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91b187a2-421a-465d-b167-40fd7e6eca86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_41f0517a-443d-413e-a935-d04e6584e9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91b187a2-421a-465d-b167-40fd7e6eca86" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_41f0517a-443d-413e-a935-d04e6584e9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8d309904-5ddd-4fc6-837c-dc1fdb55b726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91b187a2-421a-465d-b167-40fd7e6eca86" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8d309904-5ddd-4fc6-837c-dc1fdb55b726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_12484b1c-bfcd-4be0-bb08-75680b93f727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91b187a2-421a-465d-b167-40fd7e6eca86" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_12484b1c-bfcd-4be0-bb08-75680b93f727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_622198bb-a99b-4a1d-a83e-33a7f82b902f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_622198bb-a99b-4a1d-a83e-33a7f82b902f" xlink:to="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c64bd604-c439-40db-8452-63a0f4edc614" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:to="loc_srt_RangeAxis_c64bd604-c439-40db-8452-63a0f4edc614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bdd5b34a-df2e-4915-bff4-4b95d2a7667b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c64bd604-c439-40db-8452-63a0f4edc614" xlink:to="loc_srt_RangeMember_bdd5b34a-df2e-4915-bff4-4b95d2a7667b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_895ddd77-8ff3-4df8-b5f0-dc8eceee6c39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bdd5b34a-df2e-4915-bff4-4b95d2a7667b" xlink:to="loc_srt_MinimumMember_895ddd77-8ff3-4df8-b5f0-dc8eceee6c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0aeaba9e-c16c-48fe-a838-7907b9ed18f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bdd5b34a-df2e-4915-bff4-4b95d2a7667b" xlink:to="loc_srt_MaximumMember_0aeaba9e-c16c-48fe-a838-7907b9ed18f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c69ae03e-e461-4428-9db3-c565d7e1d5da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:to="loc_srt_LitigationCaseAxis_c69ae03e-e461-4428-9db3-c565d7e1d5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_74aca4f4-15d1-4d95-a3eb-92c3a1e3eae7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c69ae03e-e461-4428-9db3-c565d7e1d5da" xlink:to="loc_srt_LitigationCaseTypeDomain_74aca4f4-15d1-4d95-a3eb-92c3a1e3eae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember_1ddebe5c-efc0-4341-9b83-802dd4a798de" xlink:href="apyx-20230331.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_74aca4f4-15d1-4d95-a3eb-92c3a1e3eae7" xlink:to="loc_apyx_SuitAgainstGoodwinAndSimbMember_1ddebe5c-efc0-4341-9b83-802dd4a798de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitsFiledIn2022Member_0e7b058c-a126-42eb-9738-d908c8e30914" xlink:href="apyx-20230331.xsd#apyx_SuitsFiledIn2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_74aca4f4-15d1-4d95-a3eb-92c3a1e3eae7" xlink:to="loc_apyx_SuitsFiledIn2022Member_0e7b058c-a126-42eb-9738-d908c8e30914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8e383ee5-5b82-454a-a415-00188bff4c41" xlink:to="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_af298908-5e2a-48b9-8b61-cc87188a163d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_af298908-5e2a-48b9-8b61-cc87188a163d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_6b4a35a5-bda0-4664-a41c-99ca7e2baf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_6b4a35a5-bda0-4664-a41c-99ca7e2baf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_8425294c-efda-4aa5-bbc3-21c59a4fb231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_8425294c-efda-4aa5-bbc3-21c59a4fb231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_eb7ecc81-09f8-4754-8fa3-ac33f4e7df27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_eb7ecc81-09f8-4754-8fa3-ac33f4e7df27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b9c0b470-9f1e-4c06-9a15-27e80fab5df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_62d91c99-1dce-48ba-a8db-8a4a5cea2f84" xlink:to="loc_us-gaap_PurchaseObligation_b9c0b470-9f1e-4c06-9a15-27e80fab5df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_34846bcf-306f-493f-9e27-ed94da6129eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42f1888c-388b-492b-b6fd-5a4a3e3d988c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_34846bcf-306f-493f-9e27-ed94da6129eb" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42f1888c-388b-492b-b6fd-5a4a3e3d988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b8eea84b-921a-45c1-a52f-426caabc3d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42f1888c-388b-492b-b6fd-5a4a3e3d988c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b8eea84b-921a-45c1-a52f-426caabc3d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_18a5ef91-22eb-4d97-922d-1749715eec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b8eea84b-921a-45c1-a52f-426caabc3d49" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_18a5ef91-22eb-4d97-922d-1749715eec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_d3468bd3-beef-4cee-96f5-ad299db9a3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_18a5ef91-22eb-4d97-922d-1749715eec77" xlink:to="loc_us-gaap_CoVenturerMember_d3468bd3-beef-4cee-96f5-ad299db9a3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_42f1888c-388b-492b-b6fd-5a4a3e3d988c" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f7a8fb2f-2ca6-4e7e-ab0c-43409161af58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f7a8fb2f-2ca6-4e7e-ab0c-43409161af58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3a7f6130-053e-4b4b-b647-7f0914c972f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3a7f6130-053e-4b4b-b647-7f0914c972f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_eb5c29b5-aaf6-4ecc-aea2-ba0a0f15bbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f7f84b3c-2169-4690-afd6-d3205bf8bcb9" xlink:to="loc_us-gaap_DueFromRelatedParties_eb5c29b5-aaf6-4ecc-aea2-ba0a0f15bbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5ef42ebe-e509-4d28-8748-f306a5a87540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_fc277141-5ec5-4908-80b2-fcf6d1667ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5ef42ebe-e509-4d28-8748-f306a5a87540" xlink:to="loc_us-gaap_NumberOfReportableSegments_fc277141-5ec5-4908-80b2-fcf6d1667ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_53f2134d-3086-4680-a837-ca2b97ec5759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5ef42ebe-e509-4d28-8748-f306a5a87540" xlink:to="loc_us-gaap_NumberOfOperatingSegments_53f2134d-3086-4680-a837-ca2b97ec5759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent_8cd8183b-3320-42dd-87e3-db946c37e95c" xlink:href="apyx-20230331.xsd#apyx_TotalRevenuePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5ef42ebe-e509-4d28-8748-f306a5a87540" xlink:to="loc_apyx_TotalRevenuePercent_8cd8183b-3320-42dd-87e3-db946c37e95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6b3392bd-1930-4f3b-820e-05b2bd8cf2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6b3392bd-1930-4f3b-820e-05b2bd8cf2dc" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:to="loc_srt_ConsolidationItemsAxis_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_314f0328-76aa-4e8b-8061-d7d0af9269b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c1df7b71-3a7a-40c1-a8c8-69f0fabb4400" xlink:to="loc_srt_ConsolidationItemsDomain_314f0328-76aa-4e8b-8061-d7d0af9269b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_33e9c7d8-b3b7-40b5-8a73-f2f0b3d99755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_314f0328-76aa-4e8b-8061-d7d0af9269b2" xlink:to="loc_us-gaap_OperatingSegmentsMember_33e9c7d8-b3b7-40b5-8a73-f2f0b3d99755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2a19f504-cec6-4dcb-b646-2719caadb33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_314f0328-76aa-4e8b-8061-d7d0af9269b2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2a19f504-cec6-4dcb-b646-2719caadb33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0657a28b-fc9c-4ccf-a724-f82645ded872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0657a28b-fc9c-4ccf-a724-f82645ded872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_322bf8b8-05ab-4a2c-8615-e0b76f6b3549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0657a28b-fc9c-4ccf-a724-f82645ded872" xlink:to="loc_us-gaap_SegmentDomain_322bf8b8-05ab-4a2c-8615-e0b76f6b3549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_06ac1a48-08b2-41f5-807a-226d90afda4d" xlink:href="apyx-20230331.xsd#apyx_AdvancedEnergyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_322bf8b8-05ab-4a2c-8615-e0b76f6b3549" xlink:to="loc_apyx_AdvancedEnergyMember_06ac1a48-08b2-41f5-807a-226d90afda4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_5183a42e-ac96-4044-8112-22e7ec6e0296" xlink:href="apyx-20230331.xsd#apyx_OEMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_322bf8b8-05ab-4a2c-8615-e0b76f6b3549" xlink:to="loc_apyx_OEMMember_5183a42e-ac96-4044-8112-22e7ec6e0296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e3fea41-604d-4d1c-8e74-9bffe87eaf9d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_136263d2-e6bf-4d40-bdce-50d0eb376ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_136263d2-e6bf-4d40-bdce-50d0eb376ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_faf7d3a2-2687-4bbd-a865-d868a27b3f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_OperatingIncomeLoss_faf7d3a2-2687-4bbd-a865-d868a27b3f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_3838576c-dc01-438e-acae-0aafc76ec46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_InterestIncomeOperating_3838576c-dc01-438e-acae-0aafc76ec46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5c625324-14a2-4026-9e0c-8c391fd68fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_InterestExpense_5c625324-14a2-4026-9e0c-8c391fd68fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_88721ec3-6545-44a4-8707-cf475e48c086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_88721ec3-6545-44a4-8707-cf475e48c086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5134c1ef-b5f8-4ec5-b8c5-973c34338b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_770577fc-174f-4ef0-8539-681999ed6f8a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5134c1ef-b5f8-4ec5-b8c5-973c34338b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20230331.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b0ee1351-1cf9-4440-8f83-ccbae1c3e54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b98c2b47-bd23-4a18-9818-55218bb03ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b0ee1351-1cf9-4440-8f83-ccbae1c3e54b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b98c2b47-bd23-4a18-9818-55218bb03ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_daf329d1-402a-460d-ba0b-ea20eacb181e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b98c2b47-bd23-4a18-9818-55218bb03ffe" xlink:to="loc_srt_StatementGeographicalAxis_daf329d1-402a-460d-ba0b-ea20eacb181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_42f115f5-416c-4463-9f25-760a7ea806ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_daf329d1-402a-460d-ba0b-ea20eacb181e" xlink:to="loc_srt_SegmentGeographicalDomain_42f115f5-416c-4463-9f25-760a7ea806ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7466c942-4010-423b-a60a-6d838f8b6c2c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_42f115f5-416c-4463-9f25-760a7ea806ae" xlink:to="loc_country_US_7466c942-4010-423b-a60a-6d838f8b6c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_fe4a6db4-ea17-4243-8aec-6be269dec111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_42f115f5-416c-4463-9f25-760a7ea806ae" xlink:to="loc_us-gaap_NonUsMember_fe4a6db4-ea17-4243-8aec-6be269dec111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_eefc0704-fe14-45e9-8028-0442721b48ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b98c2b47-bd23-4a18-9818-55218bb03ffe" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_eefc0704-fe14-45e9-8028-0442721b48ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5a806fa-cc0c-492f-a4fb-04cf6e8bc909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_eefc0704-fe14-45e9-8028-0442721b48ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5a806fa-cc0c-492f-a4fb-04cf6e8bc909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>apyx-20230331_g1.jpg
<TEXT>
begin 644 apyx-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *0 _(# 2(  A$! Q$!_\0
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MG[CPEF'UO ^PD_>IZ?+I_E\AE%%%?&'VX5]*?LA^.-LFI^%+F3 ;_3;3<>_
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MVX9RCZ]6^LUE^[A^+[?+=_<?#<49S]0H?5J+_>3_  7?U>R^;->BBBOV<_$
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MK\\/$WA^Y\*^(-1TB['^D64[0L<8#8/##V(P1[&OR+B_ ^RQ$<7%:3T?JO\
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MR/R+C3'^TK0P47I'5^KV^Y?F%%%%?HI^:!1110 4444 %%%% !1110 4444
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M^G*+BY Z&9Q\H/\ NH?_ !\^E?3GB;Q!;>%?#^H:O>'%M9PM,PZ%L#A1[DX
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M\[****_FD_J **** /H[]C7_ )"7BG_KC;_^A25]15\N_L:_\A+Q3_UQM_\
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M6C7I.THO^OO.7%86GC*$\/65XR5OZ]#]+E99%5E(96&00<@BG5X+^R[\5/\
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MYJZ:L_F:4ZDJ,XU(.S3NO5'YJ7=K-8W4UM<1F*XA=HY(VZJP."#]"*BKV/\
M:B\$_P#"-?$(ZI#'ML]83SP0, 3# D'U/RM_P.O'*_G3'866"Q,\//>+_P"&
M?S1_2V!Q<<=A:>)AM)7^?5?)Z!1117"=QT'@#Q9+X'\9:3K<63]DF#2*/XHS
M\KK^*DC\:_0JUNHKZUAN('$D,J"1'7HRD9!'U%?FK7V=^R_XV_X2;X>)ILTF
MZ]T=_LQR>3"<F,_@,K_P"OT7@_'<E6>#D]):KU6_WK\C\UXTP/M*,,;%:QT?
MH]ON?YG;_%'QDO@/P)JVL[@)XHMEN#SF9OE3COR03[ U^?DDC2R,[L7=CEF8
MY))[FOHG]KSQI]JU33/"]O)F.U7[9= 'CS&!$:GW"Y/_  ,5\Z5YW%6.^LXW
MV,7[M/3Y]?T7R/3X1P/U7 ^WDO>J:_);?J_F%%%%?%GVX5VGP>\%GQY\0M)T
MQTWV8D^T77&0(4Y8'Z\+]6%<77U?^R/X*_L[P[?^)9X\3:@_V>W)'(A0_,1]
M7R/^ "O=R3 _7\="DU[JU?HO\]OF>!GN/_L_ 5*J?O/1>K_RW^1] =.!P*6B
MBOZ /YV"BBB@ HHHH **** "BBB@ HHHH **** "BBO)_P!H;XI_\*^\*&SL
M9MNN:DIC@VGYH8^CR^Q'0>YSV-<F+Q5/!T)8BJ](_P!6^9V8/"5<=7AAZ*]Z
M3_I_(\5_::^*G_"6^(1X>TZ;=I.ER$2LI^6>XZ$_1>5'N6/I7B-'6BOY[QV,
MJ8_$2Q%7=_@NB^1_1N!P5++\/##4MH_B^K^84445PG>%=Y\&?AK+\3/&4%DZ
MNNEV^)KZ9>,1@\*#_>8\#\3VKB+6UFOKJ&WMXVFGF<1QQH,LS$X  ]2:^\/@
MW\-8?AEX.@L6"MJ=QB:^F7^*0C[H/]U1P/Q/>OJ.'\J_M+%7FOW<-7Y]E\_R
M/E>(LV_LO"6IO]Y/2/EW?R_,M_$3X<Z?X\\$S^'S'';!$!LG5<+;R*,(0!V[
M$#L37P5JVE7>AZE=:??0M;WEM(T4L3=58'!K]):^;_VJOA;]JMU\9:=#F:$+
M%J"(/O)T67\.%/MM]#7V_%.4_6*/URBO>AOYQ_X'Y7/A.$\X>&K_ %*L_=F]
M/*7_  ?SL?+]%%%?D!^RA1110!]D?LU_%3_A-/#7]B:A-NUG2T"AF/S3P=%?
MW*\*?^ GO7M%?G5X+\77W@;Q+8ZUI[[;BV?)0G"R(>&1O8C(_6OO[PGXGL?&
M7AZQUC3I/,M;J,.OJIZ%3[@Y!^E?M/#.;?7L/]7JO]Y#\5T?RV?R[GX?Q3E'
MU#$?6*2_=S_!]5\]U\^QKT445]H?#A1110 4444 %%%% !1110 4444 %%%%
M !1110 5SWC[Q;#X'\'ZIK<^#]EA)C1CC?(>$7\6(%=#7R_^UYXY\VZT[PI;
M2?+$!>784_Q'(C4_0;FQ_M*:\;-\<LOP4Z_79>KV_P SV\FP#S+'4Z'V=WZ+
M?_+YGSK>WDVHWD]W<R--<3R-+)(QR69CDD_4DU#117\^-MN[/Z,225D%%%%(
M9I>&]!N?%&OZ?I%FN;F\G6%.,@9."Q]@,D^PK]#M!T2V\-Z)8Z79KMMK.%8(
MP>N%&,GW/4_6OF;]D7P/]LUC4/%-Q'^[LP;6U)'!D8?.P]PI _X&:^J:_8.$
M<![#"O%36L]O1?YO]#\8XQS#ZQBHX2#]VGO_ (G_ )*WXA1117WI^?!1110
MUF"*68@*!DD]!7XE?M6_&)OCC\<?$/B**4R:3')]@TL9.!:Q$A&&>F\[I,=C
M(:_27]OCXR_\*F^ FI6EI/Y6N>)2=)M-K89(V7]_(._$>5R.C2(:_'ZOJ\EP
M]E*O+T7ZG@9E6NU27JPHHHKZ@\,**** "OV(_80^,O\ PMWX":7'>3^;KGAX
MC2;W<V6=44>3(<\G='M!)ZLCU^.]?3?_  3Y^,P^%GQVM=*O9_*T3Q0JZ9<;
MCA4GSFW<_P# R4]A*3VKR<SP_M\.[;QU._!5O95E?9Z'Z\4445\$?6!1110
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MC"/#3?O4_P GM]SO^!^+<89?]7Q:Q4%[M3?_ !+?[U9_>7****^Z/@ HHHH
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M/X/HG_H6?05X'7XYQ1FWUNO]4I/W(;^<O^!M]Y^U<*91]3H?6ZR]^:T\H_\
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M*^8/J0KW#]F/XJ?\(KX@_P"$<U&;;I.IR#R6<\0W!P ?8-PI]]OO7A]'2N_
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M,_9.#<O]CAI8R:UGHO1?YO\ )!1117Y^?H@5);V\EW<100HTLTC!$11DLQ.
M!^-1U[%^R_X&_P"$H^("ZG/'NL=&47!R.#,<B(?@06_X *[<%A9XW$PP\-Y/
M_AW\EJ<..Q<,#AJF)GM%7_R7S>A]3_#;P='X#\$Z5HJ!?-@B!G=?XY6^9S_W
MT3CV KIZ**_HNE2C1IQI05E%67R/YJK59UZDJM1W<G=_,****U,@HHHH ^+/
MVQOV1?BC^TE\2+34M*UKPW9>&M,M%MK"TO[NY67<WS32,JP,H9FPO#'*QIT.
M17@W_#K+XK_]#!X-_P# V[_^1:_4RBO5I9EB*,%3A:R\C@G@J523G*]V?EG_
M ,.LOBO_ -#!X-_\#;O_ .1:/^'67Q7_ .A@\&_^!MW_ /(M?J916O\ :^*[
MK[B/[/H=F?EG_P .LOBO_P!#!X-_\#;O_P"1:/\ AUE\5_\ H8/!O_@;=_\
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M:<8'EN2=H]E;<O\ P&OO.O$?VJO W_"0>"8M;MTW7FCN6; Y:!\!_P CM;V
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MWK#[DW#!6!"0GYG<WN"M>WU7L;&#3;*WL[:,16]O&L44:]%50 !^ %6*_HK
M82.!PT,/'[*_'J_FS^:\PQDL?BJF)G]I_AT7R04445WGGA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !5>^L8-2LKBSN8Q+;W$;12QMT96
M!!'X@U8HI-)JS&FXNZ/SM\>>%)_!'B_5=$GR3:3%$<_QQGE&_%2#^-8-?3G[
M7G@?S(--\5VZ?-'_ *%=D?W228V/T.X?BM?,=?SWF^!>7XV=#INO1[?Y']'9
M/CUF6!IXCKL_5;_Y_,****\<]D<CM&ZNC%74Y#*<$&OOWX2^-E^('@/2]6+
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M/#1J_"M?=EOUZ=SY>HKZA_X8UL_^AIG_ / )?_BZ/^&-;/\ Z&F?_P  E_\
MBZ\[_5C-?^?7_DT?\ST_]:LH_P"?O_DLO\CY>KZI_93^&,^CV=QXLU& Q37D
M?DV*.,,(<Y:3'^T0,>P)Z$5T_@O]F'PCX5NH[N[$VNW2'*_;<>2I]?+ P?\
M@1(KU_IP.!7UV1<-5,'66*Q;5ULEKKW?Z?>?&Y_Q/3QE!X3!IV>[>FG9?K?T
ML+1117Z*?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/XN\-6WC#PSJ6BW?\ J+R%HBV,E#U5A[A@"/I7Y^^*O"^H>#=>
MN](U2 P7=NVUA_"P[,I[J1R#7Z-5R_CCX;>'_B)9I;ZW8K.T8(BN$.R:+/\
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MX'Z]CX1DO=C[S^7^;LCYKB+'_P!GY?.47[TO=7J_\E=GME%%%?O1_/@4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHK[H^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?GK\3_^2E>+?^PO=_\ HYZY
MFNF^)_\ R4KQ;_V%[O\ ]'/7,U_->*_WBIZO\S^GL+_N]/\ PK\D%%%%<QU'
MH7[/W_)8O#7_ %VD_P#13U]W5\(_L_?\EB\-?]=I/_13U]W5^P<&_P"XU/\
M&_R1^,\;?[_3_P "_-A1117WI^>A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\-_M)?\EJ\1?\ ;M_Z315]R5\-_M)?\EJ\1?\
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MBBOK#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[QJ7(N "Q"C)  SV%<O_ ,/3?BO_ -"_X-_\ KO_ .2:^>?VBO\ DX+XG?\
M8SZI_P"E<M>?5]_3P.&<(MP6Q\E/%5U)I2/V,_8R_:@G_:4\$ZK/K%M96'B?
M2;D1W=MIZ.D+1."89%#LQ&=KJ06/*$\9 KZ'K\7?V-/C5_PI'XZ:-J5W.T6@
MZD?[,U09^40R$;9#_N.$?/7 8=Z_:*OE<RPJPU;W5[KV/=P5=UJ7O;H****\
MH] **** "H;JZAL;:6XN)4AMX4,DDDC!510,DD]@!4U?*W_!1+XU'X9_!*3P
M_87!AUOQ6S6$>PX9+4 &X;\598_^VI]*WHTG7J1IQZF56HJ4'-]#YR\8?\%2
M?'D/BK5X_#F@^&)- 2ZD2PDOK6Y:=X Q",Y6=1N(P2 HQG%9/_#TWXK_ /0O
M^#?_  "N_P#Y)KXXHK[M9?A4K<B/E7BZ][\Q^U7[(_QHUOX]_!VV\6>(+73[
M/49+R>W,6FQND6U& !P[N<\\\U[37RQ_P38_Y-AL?^PI=_\ H0KZGKX?%14*
M\XQ6B;/I\/)RI1E+>P4445RG0?GA\>O^"A_Q'^%OQB\5^$])T7PO<:=I-XUO
M!+>6ERTS* #EBMPH)Y[ 5P7_  ]-^*__ $+_ (-_\ KO_P"2:\:_;&_Y.<^(
MO_84;_T%:\=K[VC@<-*E%N"O9'RE3%5E.24NI]C_ /#TWXK_ /0O^#?_  "N
M_P#Y)H_X>F_%?_H7_!O_ (!7?_R37QQ16WU#"_\ /M&7UNO_ #L^Q_\ AZ;\
M5_\ H7_!O_@%=_\ R31_P]-^*_\ T+_@W_P"N_\ Y)KXXHH^H87_ )]H/K=?
M^=GV/_P]-^*__0O^#?\ P"N__DFC_AZ;\5_^A?\ !O\ X!7?_P DU\<44?4,
M+_S[0?6Z_P#.S['_ .'IOQ7_ .A?\&_^ 5W_ /)-?J!I-T]_I=G<R!1)-"DC
M!> "5!./SK^?BOZ O#O_ "+^E_\ 7K%_Z *^?S;#TJ"A[.-KW_0]?+ZU2JY<
M[OL:-%%%?.'LGYX?'K_@H?\ $?X6_&+Q7X3TG1?"]QIVDWC6\$MY:7+3,H .
M6*W"@GGL!7!?\/3?BO\ ]"_X-_\  *[_ /DFO&OVQO\ DYSXB_\ 84;_ -!6
MO':^]HX'#2I1;@KV1\I4Q593DE+J?8__  ]-^*__ $+_ (-_\ KO_P"2:/\
MAZ;\5_\ H7_!O_@%=_\ R37QQ16WU#"_\^T9?6Z_\[/L?_AZ;\5_^A?\&_\
M@%=__)-3V?\ P50^)L<V;OPSX3GC_NPV]U&?S,[?RKXQHH_L_"_\^T'UNO\
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MB5%,L3'WRC(/^NAKLS/#JM0<K:QU_P SGP-9TJJ71Z'ZVT445\&?5A7YZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?A;^T5_R<%\3O\ L9]4_P#2N6O/J]!_:*_Y."^)
MW_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZA0K%&#*2K Y!'45[S\1/@BMK^RK\*OB
MAID&%NC>Z7J^Q?XQ?7)@F/U4&,D_W8QWKP:G3J1JIN/1M?<*<'!I/R?WG[4_
MLA_&@?'+X':)K5S/Y^N6:_V=JN?O&XC !<_[ZE'^KD=J]JK\G?\ @G+\;/\
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MN<8RQ4$U=K.\._\ (OZ7_P!>L7_H K1K\Y>Y]DM@HHHI#/Q._;&_Y.<^(O\
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M_>:GJSZS"_P8>@4445Q'2?B=^V-_R<Y\1?\ L*-_Z"M>.U[%^V-_R<Y\1?\
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M97/B?(_?BQM%L;&WMD8LD,:QJS=2 ,<_E5BBBORT^Z"OSU_X*T_\TJ_[BO\
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M_!AZ+\CXJM_$EZL_6S_@FQ_R;#8_]A2[_P#0A7U/7RQ_P38_Y-AL?^PI=_\
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M*7D89X!VJ0,]R.O2OT>4HTH-O1(^,BG.5ENSSNBOTZ_X=4_#[_H;O$WYV_\
M\:H_X=4_#[_H;O$WYV__ ,:KRO[6PO=_<>A_9]?M^)^8M%?IU_PZI^'W_0W>
M)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU1_:V%[O[@_L^OV_$_,6BOTZ_X=4_#[
M_H;O$WYV_P#\:KX]_;"_9M@_9K^(&G:5IM[=:GHFI6(NK:ZO OF;PQ62,[0
M2"%/ Z.*Z*&84,1/V=-ZF-7"5:,>>:T/!@2I!!P?:OW"_9C^*0^,7P-\*>)I
M)?-OYK46]^<\_:HOW<I/IN92P]F%?A]7W_\ \$K_ (I^3J'BOX>7<V%G5=9L
M$8X&]=L<X'J2/)('HC&N3-Z/M*'.MXG1E]7DJ\KV9^BE%%%?$'TY\D?\%.O^
M3;[7_L/6O_HN:ORCK]7/^"G7_)M]K_V'K7_T7-7Y1U]OD_\ NWS9\OF/\?Y'
MNG[#O_)U7P^_Z^IO_2:6OV?K\8/V'?\ DZKX??\ 7U-_Z32U^S]>1G7\>/I^
MK/1RS^%+U_1!1117SYZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?A;^T5_R<%\3O\ L9]4_P#2N6O/
MJ]!_:*_Y."^)W_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZG[&_P#!/_\ Y-&\!_\
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M,E9:16W^9]/A,*L/&[^)A1117E'>%?GK_P %:?\ FE7_ '%?_;.OT*K\]?\
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MOP-:I.LHRDVC[9HHHKXT^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6*W\[^]A[&G_ "K[CQO_ (8[^"W_ $3K1O\ OVW_ ,51_P ,=_!;_HG6C?\
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M?C-XLC\-^%=9N+[5I(7G6*2PFA&Q!ECN90.]>T5^2/\ P39_Y.>L?^P7=_\
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MUYHHHKQ3TPHHHH XWXT?\D=\=_\ 8!O_ /TG>OP>K]X?C1_R1WQW_P!@&_\
M_2=Z_!ZOK<D^"?JCY_-/BB?L;_P3_P#^31O ?_;_ /\ I?<U]#5\\_\ !/\
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MPG5]E9IGVS1117DGH!17Y'_&#]N[XHWWQ0\42>$_&5QIOAI;^6/3K>&W@91
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MW8[_ '>7]=3Y(_8Y_P"3G/AU_P!A1?\ T%J_;&OQ._8Y_P"3G/AU_P!A1?\
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MY;:?BSBI<F)Q#G5>G]61[5I_["OP.L=)-A_P@MO<(R@--<7=PTS>^_S,J?\
M=P*^-?VT/V%[7X-Z$_C?P-+<S^&(Y%2_TVY?S)+'<0JR*_5HRQ"D'YE)!R03
MM^T/^&XO@;_T4"S_ / 6Y_\ C5<O\4/VN/@5XY^&_BGP])XZL;@:IIEQ:",V
MMP,L\;*N#Y?!R00>Q&:\+#U<=2J*4E)KK=,]2M3PM2#2<4^FQ^:7[.OQFO\
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M*G_DL7BW_L G_P!*(J^8_CK\3I/C)\7/%'C)HF@35+LO!"_WD@11'"K>XC1
M<=P:^G/^"5/_ "6+Q;_V 3_Z415]MB(.GE[@]U%?H?+T9*IC.9;-L_3VO*/V
MI/A;_P +A^!/BSPY%%YNH-:F[L /O?:8CYD8'IN*[#[.:]7HKXFG-TY*<=T?
M42BIQ<7LS^>^&:6SN(Y8G:&:)@Z.IPRL#D$>A!K]6?CG^TE%>_L)Q^,[6X5-
M4\5Z=%I2>6P&VZE!CNE7'0H$N,8_NCI7P=^V5\+?^%2_M#>*-,AB$.F7TO\
M:M@ ,#R9R6VCV5_,3_@%>>ZA\2-9U+X;Z-X(GGW:+I6H7.HP)WWS+&I!]EV,
M1[RO[8^\JT(8U4JJV3O\OZL?*4ZLL*ZE-]=/F97A'PS?>-/%.D:!IL?FZAJE
MW%96Z>LDCA5S[9-?O%X'\(V7@'P;HGAO35VV.DV<5G#Q@E40+N/N<9/N37YB
M_P#!,_X6?\)E\;+KQ5=0^9I_A:T,J,1D?:I@T<0Q[()F]BJU^J]>%G-;FJ*D
MOL_FSU,MI<L'4?4****^=/9"BBB@#\@/^"B?_)U?B7_KULO_ $FCKL_^"67_
M "<%X@_[%>X_]*[2N,_X*)_\G5^)?^O6R_\ 2:.NS_X)9?\ )P7B#_L5[C_T
MKM*^WJ?\BW_MU'R\?]]^;/U,HHHKX@^H"BBB@ K\PO\ @JM_R6+PE_V 1_Z4
M2U^GM?F+_P %5H77XN^$)2I$;:'M#8X)%Q(2/U'YU[&4_P"]+T9YN8?P'\CB
M_P#@FS_R<]8_]@N[_P#017ZW5^1G_!-VXBA_:@TM)'5'FTZ\2,$_>;R]V!^"
MD_A7ZYUIG'^\KT7ZD9;_  ?F>)_MH6KW7[+OQ#2-S&PT\2;E]%E1B/Q (_&O
MQ8K]ZOBEX1_X3_X:^*O#0(5]7TNYL49NBM)$RJWX$@_A7X,W=I-8W4UM<1-#
M<0NT<D;C#*P.""/4$5Z>227LYP\_Z_(X\SC[\9>1]+:3_P $Z_C%K6EV>H6U
MEI!MKN%)XMVHJ#L90PR,>A%6_P#AVS\:?^?'1O\ P9+_ (5]W?L1_&2P^+GP
M&T"-;A&UO0;>/2M2M=PWHT:[8Y"/1T56SC&=X_A-?0%<-7-,52J2IR2T\O\
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MGZ5^.=FL+7<"W+,EN742,G4+GDCWQFNG)J,.259K6]C#,JLN94UMN>P_"?\
M8_\ BI\9M)35_#_AMH]'D_U>H:C,EM%+[IN.YQVW*",]Z] _X=L_&G_GQT;_
M ,&2_P"%?K!HEI8:?HUA:Z7'%%ID-O'':I!_JUB"@(%]MH&/:KU<<\YKN3Y4
MDCICEM*WO-MGX??'']FOQI^SS_8O_"806</]L>?]E^R7(FSY7E[\X''^M3]:
M[']@'_D[GP'_ -O_ /Z07->R_P#!5CQ9:ZAXZ\#>'H;A9;G2[&XNIXE(/E>>
M\84'T)$&<'M@]^?&OV ?^3N? ?\ V_\ _I!<U[JJSK8"52INXR_4\ITXTL6H
M0V37Z'[(5\"_\%8O^1?^''_7U??^@0U]]5\#?\%8E;_A'/AR^T[!=WH+8X!*
M0X'Z'\J^6RW_ 'N'S_)GO8[_ '>7]=3Y'_8Y_P"3G/AU_P!A1?\ T%J_;&OQ
M*_9!N(K7]IKX<O*ZQH=6C0%CQN8%5'XD@?C7[:UWYU_&CZ?J<F5_PY>OZ!7P
M+_P5B_Y%_P"''_7U??\ H$-??5? O_!6+_D7_AQ_U]7W_H$-<&6?[W#Y_DSK
MQW^[R_KJ?)'['/\ R<Y\.O\ L*+_ .@M7[8U^)W['/\ R<Y\.O\ L*+_ .@M
M7[8UWYU_&CZ?J<N6?PI>OZ'YZ_\ !6G_ )I5_P!Q7_VSKYJ_8=_Y.J^'W_7U
M-_Z32U]*_P#!6G_FE7_<5_\ ;.OFK]AW_DZKX??]?4W_ *32UZ>%_P"19\I?
MJ<.(_P!]^:_0_9^BBBOBCZ8_&_\ ;^_Y.Y\>?]N'_I!;5[M_P2=_Y&#XC_\
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M^\T_5?F<V)_@S]&?D%7]"=?SV5_0G7NYY_R[^?Z'EY7]OY?J%?C1^W)\*_\
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ML1/$=TO^#^AX$J[J48T>W](_2_\ X)?_  L/AOX6ZUXVNX=EUXBNO(MF8?\
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M:XN/ %K'(3G;:7MU;)_WS%*J_I7:_#O]GOX;_"BX%UX4\'Z9I-X 5%X(S+<
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M/4_$;G6+C<,$(X A7Z>4J-]7-?2=06=G#I]G!:VT206\"+%%%&,*B@8"@=@
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MO4KGQ#K=S=ZE>:A.YEU&Z+.9I %+#<>I 9.!T!7H,5[=^P#_ ,G<^ _^W_\
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M=P=_D>-_9M5.RDK'Y$7?PC\3Z=\+8?B#>Z=)9>&KG48],M)[@%&NI'CED+1
MCYD41$%NF2 ,X;"?!?\ Y+%X$_[#UC_Z4)7Z&_\ !4[4;6S^"'A/25VQS3>(
M(YX8U  \N*VG5L#T!E3\Z_/WX!Z?)JWQS^'EG'G=-XAT]<@9VC[0F3CV&3^%
M>CA\0\3AY59*VYQUJ*HUE33OL?NQ1117Y^?7!1110!QOQH_Y([X[_P"P#?\
M_I.]?@]7[^^*O#\/BSPOK&AW$DD-OJ=G-92218WJLB%"5R,9 :OCS_AU3\/O
M^AN\3?G;_P#QJOH,LQE'"QDJCW/(QV'J5W%P6Q\'^#_VE/B?X!\.VF@^'?&F
MIZ3H]IO\BSMW4)'O=G;&1W9F/XUL?\-C?&C_ **+K/\ W\7_ .)K[8_X=4_#
M[_H;O$WYV_\ \:H_X=4_#[_H;O$WYV__ ,:KTWC\ W=K_P E.%83%I63_$^)
M_P#AL;XT?]%%UG_OXO\ \31_PV-\:/\ HHNL_P#?Q?\ XFOMC_AU3\/O^AN\
M3?G;_P#QJC_AU3\/O^AN\3?G;_\ QJCZ]E_\J_\  1_5<9W_ !.H_P""=?Q0
M\5_%3X7^)=0\6ZY=:[>V^L&"*:Z8%DC\B-MHP!QDD_C6W_P42_Y-5\2_]?5E
M_P"E,==[^SK^SKHO[-OA?4M#T/4K_4[>^O/MKR:ALWJVQ4P-B@8PH_.MOXX?
M!_3?CK\.K_P?J][=:?8WDD4CW%EM\T&.0.,;@1R5':OGI5J2QBJQ^&Z9ZZIS
M^K>SE\5C\*J_H3KXF_X=4_#[_H;O$WYV_P#\:K[9KKS3%TL5R>R>U_T.? X>
MI0YN=;V_4*YWXA>"['XC>!=>\+ZD,V6K64MG(V 2F]2 X]U.&'N!7145X:;B
MTT>HTFK,_G\\2>'[WPGXAU/1-2B\C4--NI+.YB/\$D;E&'Y@U]0?\$V_A7_P
MG7QX/B*ZA\S3?"ML;PDC*FYDS'"I_#S''O$*^N_B]_P3T\"_%[XB:QXONM:U
MG2+S5'66>VL#"(?,"*I8!HR<MMW'GDDFO3OV=?V</#O[-OAK4M(T"ZO-1;4+
MO[5/>7^PRMA JI\B@;5PQ''5VKZK$YI3J89QA\37_#G@4<!.%92E\*_I'K5%
M%%?*'T!\/_\ !0S]E+4/B);Q?$?PC9O>ZW86_DZKI\*EI+JW7)66,#[SH,@K
MU9<8Y7!_-O0=>U/PKK5KJNCW]SI6J6;^9!=VLC1RQ-TR&'([C\<5_0)7@WQ?
M_8G^%7QDO9M1U'1)-%UJ9BTNIZ'(+:61CU+K@QNQ/)9D+'UKZ' YFJ,/8UE=
M'CXK NI+VE)V9\)^&O\ @IA\8O#]C';W?_"/^('1=OVC4[!A(?<^3)&,_AWK
MA_BK^VW\6?BYI<VE:EKZ:5I$Z[)K'181;)*,8(=\F0J>ZEMI]*^J[_\ X)0>
M'Y+@M9?$'4K>#LEQI\<K#D_Q!U'3':NA\)_\$M?AWI5Q'-KOB'7=>V8)@C:.
MUB?CD-A6;'T8'WKN6*RV#YXQU]#E]AC9+ED]/4^(/V3[3XF3?&'2I_A;'(VM
MPL!<2.#]C6W)&\71Z>40.1U) V_,%K]J[?S?L\7V@H9]H\PQ@A=V.<9YQFN?
M\ _#?PO\+=!31O">AV>A:<IR8K6/!=L8W.QRSMC^)B3QUKI:\+'8Q8RHI*-D
MOO\ F>KA<.\/"S=[GYX_\%./$?Q/66RTG[!)9_"]A&_VRQ9G6[N.NVY.!LVG
M[J'Y3][)/"?%7PU^,/C/X/ZLVH>#_$-YH=P^/-2%@T4V.GF1,"CX_P!H&OW:
MU#3;35[&>RO[6&]LYU*2V]Q&)(Y%/4,I&"/8U\S_ ! _X)S_  >\;7<MW96.
MH>$[F0EF&B7(6$MZ^5(KJH]DVBO1P>8T*=+V-:&GWW]3BQ.#JSJ>UIRU/D72
M?^"GWQ>TZU$5Q8^%]5D'_+:[L)E<_P#?J9%_3M7'?$[]O7XN_%#2+K2I]6M-
M TVZ0QSV^AVY@,B$$%3(S-( 0<$!AD=<U],7G_!)_0GF)M?B%J,,6/NS:;'(
MWYB1?Y5L^&_^"5O@2QF1]<\6Z]JRKSY=JD-JK'/?*N<=.A!]ZZUB<L@^>,5?
MT.?V..DN5O3U/S@\&^#-;^('B2RT#P[IEQJ^KWC[(;6V3<Q]2>RJ!R6.  "2
M0*_:S]F_X,P? 7X0Z+X229+J]A5KB^ND&%FN9#ND(_V1PHSSM49YK2^%?P-\
M#?!73WM/!WAVUT@R*%FN@#)<3X_ORL2S#/.,X'8"N\KRL?F#Q=H05HK\3T,)
M@UA_>D[L****\8](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH @N[J#3[6:YN9H[:VA1I)9I6"
MI&H&69F/   ))/3%?"7C;_@I]IVB_&**RT315UGX?6NZWNKU<K=73Y'[Z#)"
MA%QPK??!)RN1C[4\>>!](^)7@_5?#.O0/<Z3J4/DW$<<C1L5R""&4Y!! /X<
MYK\Q/CA_P3C\?^ ;^>\\%H?&WA\L6C6$JE]"OH\1P'[#,>2>NU:]C+J>%J-K
M$/7IV^_N>;C)5XI.BM#[V\'_ +8?P;\:6,=S:_$#1]/++EH-8N!8R(>X(FV\
MCV)'H37&_&;]OKX8?#70KLZ'K=MXS\0;"+6QTE_-A+XX,DX^14!ZX);T%?E/
MK'PS\8>'Y'35?"FN::Z?>6\TZ:(KSCD,HK0\+_!/X@^-+F*#1/!6O:DTF"'A
MT^7RP#T)<KM4<CDD#FO764X6+YY3T]5^9Y[S"O)<JCJ87C'Q;J?CSQ5JWB+6
M9_M.J:G<O=7$G0%V.2 .P'0#L !7Z@_\$V_@W<_#WX/7?B?4[=K?4O%DT=S$
MD@PPLXP1 2.VXO(X]59#7E?[-/\ P39O;?5K/Q%\6# MO RRQ>&;>02F5NH%
MQ(/EVCNB$[N[ 9!_0R.-(8UCC54C4!551@ #H /2N7,\=3G#ZO1=UU[>AO@<
M+.,O;5-Q]?/OQ8_;B^&?P:\9:MX5U^35GUO31&9K>SLMX/F1)*H5BP!^5UZD
M<U]!5^5W[;'P!^)'C;]ISQEK6@>"-<UC2;K[%Y-[9V3R12;;*!&VL!@X96!]
MP:\S 4:5>JXUG96].J.[%U:E*"E35W<\@_:J_:(NOVD/B6VN_99-.T6SA%II
MEC(P+QQ EB[XXWLQ)..@"C)VY/TG_P $L?A2;S7O$_Q#O+<F&RC&DZ?(R\&5
M\/,P]U01KQVE85Y7\*O^"=OQ6\=:M"-?TY/!>B[OWUYJ,B/,5[B.%&+%O][:
M/>OU'^&/PVT/X1^!]+\*>';<V^EZ?'L3><R2L22\CGNS,22??@ 8%>SC\51I
M4/JU!WZ:=$>9A,/5J5?;55_PYU5%%%?*'T 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<91P]#ZMAW=[>B_S'AL/4K5?;5EYG6T445\D?0A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545939690768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APYX MEDICAL CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2644611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5115 Ulmerton Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Clearwater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APYX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,597,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000719135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938153360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 16,255<span></span>
</td>
<td class="nump">$ 10,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net of allowance of $359 and $668</a></td>
<td class="nump">9,966<span></span>
</td>
<td class="nump">10,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">7,752<span></span>
</td>
<td class="nump">7,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of provision for obsolescence of $428 and $457</a></td>
<td class="nump">10,946<span></span>
</td>
<td class="nump">11,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">4,569<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,779<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">52,684<span></span>
</td>
<td class="nump">42,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,109<span></span>
</td>
<td class="nump">6,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">646<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,239<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">56,784<span></span>
</td>
<td class="nump">51,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">2,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,626<span></span>
</td>
<td class="nump">8,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Term loan, net</a></td>
<td class="nump">8,778<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,526<span></span>
</td>
<td class="nump">11,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">20,570<span></span>
</td>
<td class="nump">13,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">75,235<span></span>
</td>
<td class="nump">73,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(39,218)<span></span>
</td>
<td class="num">(35,735)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">36,052<span></span>
</td>
<td class="nump">37,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">36,214<span></span>
</td>
<td class="nump">37,793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 56,784<span></span>
</td>
<td class="nump">$ 51,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982154&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545939606064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 359<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProvisionForObsolescenceInventory', window );">Inventories, provision for obsolescence</a></td>
<td class="nump">428<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">$ 3,387<span></span>
</td>
<td class="nump">$ 5,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,597,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,597,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForObsolescenceInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Obsolescence, Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForObsolescenceInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545939717840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 12,142<span></span>
</td>
<td class="nump">$ 12,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">4,569<span></span>
</td>
<td class="nump">4,274<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">7,573<span></span>
</td>
<td class="nump">8,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Other costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">1,740<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related costs</a></td>
<td class="nump">5,068<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,255<span></span>
</td>
<td class="nump">5,465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total other costs and expenses</a></td>
<td class="nump">13,184<span></span>
</td>
<td class="nump">14,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,611)<span></span>
</td>
<td class="num">(5,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other loss, net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other loss, net</a></td>
<td class="num">(188)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(5,799)<span></span>
</td>
<td class="num">(5,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(2,267)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(3,532)<span></span>
</td>
<td class="num">(5,968)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders</a></td>
<td class="num">$ (3,483)<span></span>
</td>
<td class="num">$ (5,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938198304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 54,009<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 66,221<span></span>
</td>
<td class="num">$ (12,551)<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,968)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,945)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">49,843<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">68,023<span></span>
</td>
<td class="num">(18,496)<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">37,793<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">73,282<span></span>
</td>
<td class="num">(35,735)<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Proceeds received from issuance of warrants</a></td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(3,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,483)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 36,214<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 75,235<span></span>
</td>
<td class="num">$ (39,218)<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545936954768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,532)<span></span>
</td>
<td class="num">$ (5,968)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProvisionForInventoryObsolescence', window );">Provision for inventory obsolescence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="num">(371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(776)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,435)<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,881)<span></span>
</td>
<td class="num">(4,518)<span></span>
</td>
<td class="num">$ (20,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,289<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,754)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_RepaymentofFinanceLeaseLiabilities', window );">Repayment of finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,112<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,063<span></span>
</td>
<td class="num">(4,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">$ 10,192<span></span>
</td>
<td class="nump">10,192<span></span>
</td>
<td class="nump">30,870<span></span>
</td>
<td class="nump">30,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,255<span></span>
</td>
<td class="nump">26,234<span></span>
</td>
<td class="nump">$ 10,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForInventoryObsolescence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Inventory Obsolescence</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForInventoryObsolescence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_RepaymentofFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of Finance Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_RepaymentofFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938891632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company&#8221;, &#8220;Apyx&#8221;, &#8220;it&#8221; and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its plan to accelerate and fully fund the development of its advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, the Company sold its Core business in 2018 for gross proceeds of $97&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Medical Device Safety Communication (&#8220;Safety Communication&#8221;). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as &#8220;tightening&#8221;). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#174; Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion&#174; device system for certain dermal resurfacing procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion&#174; APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers  about the clearance for the Renuvion&#174; APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Financial Accounting Standards Board&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#8217;s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term.  During the year ended December 31, 2022, the Company incurred an operating loss of $23.6&#160;million and used $20.3&#160;million of cash in operations. During the three months ended March 31, 2023, the Company incurred an operating loss of $5.6&#160;million and used $1.9&#160;million of cash in operations. As of March 31, 2023, the Company had cash and cash equivalents of $16.3&#160;million, of which the Company must maintain $10.0&#160;million under its Credit Agreement. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100&#160;million. The shelf registration included an embedded ATM facility for up to $40&#160;million. To date, the Company has not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25&#160;million, comprised of (i) an initial tranche of $10&#160;million, (ii) a second tranche of $5&#160;million, and (iii) a third tranche of $10&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10&#160;million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement, see Note 6.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, the Company&#8217;s Board of Directors approved a plan to sell and leaseback the Company&#8217;s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of the Company&#8217;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement, see Note 4.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company&#8217;s tax refunds were approved for approximately $0.2&#160;million more than the amount recorded in the Company&#8217;s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company&#8217;s U.S. headcount by 14%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations and its debt covenants for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938808256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938167040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545939904480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT</a></td>
<td class="text">ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,295&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company&#8217;s unencumbered real property. On February 27, 2023, the Company&#8217;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of the Company&#8217;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $7,650,000. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the requirements of ASC Topic 360,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Property, Plant, and Equipment, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Company has determined that the real property to be sold meets the requirements to be presented as held for sale. Accordingly, the Company has presented the associated assets as held for sale in the accompanying unaudited condensed consolidated balance sheet and the table above at March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the &#8220;Lease&#8221;) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (10) years commencing from the closing (the &#8220;Initial Term&#8221;), and a renewal term of five (5) years, exercisable at the Company&#8217;s option. The annual fixed rent will be $619,500 for the first year of the Initial Term, and will be subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.</span></div>On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit equal to one years rent, taxes, first months rent, expenses, and fees. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital to its operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943839280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations on the liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943120768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CREDIT AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CREDIT AGREEMENT</a></td>
<td class="text">CREDIT AGREEMENTOn February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;), by and among the Company (as borrower) and Apyx China Holding Corp., the Company&#8217;s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively &#8220;MidCap&#8221;).<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement provides for an up to $35&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25&#160;million, comprised of (i) an initial tranche of $10&#160;million, (ii) a second tranche of $5&#160;million, and (iii) a third tranche of $10&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10&#160;million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the Credit Agreement. The Credit Agreement matures on February 1, 2028.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Term Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The initial tranche of $10&#160;million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company&#8217;s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each term loan bears interest at a floating rate reset monthly based on an adjusted  one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.1% at March 31, 2023). Interest is payable monthly in arrears on the first day of each month.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The first twenty-four (24) months of the term loans constitute an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity on February 1, 2028. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment fees, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee is being accreted over the life of the Credit Agreement utilizing the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the Credit Agreement contains a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet at March 31, 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Revolving Facility</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. Borrowings are limited to the lesser of the Company&#8217;s borrowing base and the revolving commitment of $10,000,000. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the revolving facility, the Company is required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account will be swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings will be promptly returned to the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Loans made under the revolving facility bear interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (8.8% at March 31, 2023). The Company is obligated to pay a fee equal to 0.5%  per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee. Terminations and reductions of the commitments are subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10&#160;million under the revolving facility. If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, the Company has drawn no amounts on the revolving facility. As of March 31, 2023, the Company had approximately $5,700,000 available to be drawn on the revolving facility. As the Credit Agreement contains a subjective acceleration clause and the Company is required to maintain a lockbox, any amounts drawn on the revolving facility will be presented as a current liability in the consolidated financial statements. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Collateral</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Covenants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49&#160;million, $60&#160;million and $70&#160;million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $10&#160;million in cash and cash equivalents during the duration of the Credit Agreement&#8217;s term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023, the Company was in compliance with the financial covenants contained within the Credit Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Events of Default</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement also contains customary Events of Default</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the Credit Agreement. The bifurcated derivative is de minimis to the Company's unaudited condensed consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Issuance of Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company&#8217;s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering  warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Debt Issuance Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with entering into the Credit Agreement, the Company incurred debt issuance costs of approximately $1.8&#160;million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan will be amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and will be amortized over the life of the term loans starting at the issuance date. If these loans are not issued, the Company will recognize </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the deferred costs at the point that the Company's rights to borrow on the term loans expires. The costs allocated to the revolving facility will be recognized on a straight-line basis over the term of the Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Included in interest expense for the three months ended March 31, 2023 are $17,000 and $37,000, respectively, of amortization of the debt issuance costs and amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three months ended March 31, 2023 are $12,000 and $1,000, respectively, of amortization of the debt issuance costs and amortization of the debt discount on the revolving facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s term loan, net consists of the following at March 31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.864%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount, including accretion of exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, principal repayments on the term loan are as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:86.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140546019160128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">INTEREST IN JOINT VENTURE INVESTMENT</a></td>
<td class="text">INTEREST IN JOINT VENTURE INVESTMENT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier (&#8220;China JV&#8221;) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943150224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,483)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,945)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140546029336144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $1,367,000 in stock-based compensation expense for the three months ended March 31, 2023, as compared with $1,650,000 for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended March 31, 2022, we received 22,654 options as payment in the exercise of 19,013 options. There were no such exercises for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (&#8220;2023 Grants&#8221;) utilizing a Black Scholes model.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"/><td style="width:71.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140546019270848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES Income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March&#160;31, 2023 and 2022, respectively. For the three months ended March&#160;31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company&#8217;s liability for uncertain tax positions, including accrued interest and penalties of approximately $2.1&#160;million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on the net operating loss (&#8220;NOL&#8221;) and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140546102633904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company recorded an estimated loss of $250,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed with the U.S. Securities and Exchange Commission on the Company&#8217;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#8220;Hattaway Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#8220;Goodwin&#8221;), the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, and Tara Semb (&#8220;Semb&#8221;), the Company&#8217;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#8217;s Advanced Energy products and the impact such usage would have on the Company&#8217;s business, operations and prospects. The Hattaway Complaint seeks an unspecified amount of damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Hattaway Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff&#8217;s allegations could be subject to separate </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the &#8220;Stein Suit&#8221;) against individual members of the Company&#8217;s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the &#8220;Pritchard Case&#8221;).  The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing.  The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously.  The outcome of the action is not within the Company&#8217;s control and may not be known for a prolonged period of time.  In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company&#8217;s financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the Company had purchase commitments totaling approximately $4.0&#160;million, substantially all of which is expected to be purchased within the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938869808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China JV is also a supplier to the Company. For the three months ended March&#160;31, 2023 and 2022, the Company made purchases from this supplier of approximately $44,000 and $124,000, respectively. At March&#160;31, 2023 and December&#160;31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $2,000 and $8,000, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938764464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC AND SEGMENT INFORMATION</a></td>
<td class="text">GEOGRAPHIC AND SEGMENT INFORMATION <div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 26.9% of total revenues for the three months ended March 31, 2023,  as compared with approximately 39.6% of total revenues for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"><tr><td style="width:1.0%"/><td style="width:63.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943903376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share based compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938908784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943127792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,295&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545944641872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545939899104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s term loan, net consists of the following at March 31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.864%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount, including accretion of exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, principal repayments on the term loan are as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:86.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938869808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_NoncontrollingInterestTableTextBlock', window );">Schedule of China Joint Venture</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545939557664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings (loss) per share</a></td>
<td class="text">The following table provides the computation of basic and diluted loss per share.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,483)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,945)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938839344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options and stock awards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of option fair value assumptions</a></td>
<td class="text">The Company calculated the grant date fair value of options granted in 2023 (&#8220;2023 Grants&#8221;) utilizing a Black Scholes model.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"/><td style="width:71.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943182384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of reporting information by segment</a></td>
<td class="text">Summarized financial information with respect to reportable segments is as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of revenue by geographic area</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"><tr><td style="width:1.0%"/><td style="width:63.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545934271520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2023</div></th>
<th class="th"><div>Jan. 09, 2023</div></th>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from the disposition of Core business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,611<span></span>
</td>
<td class="nump">$ 5,871<span></span>
</td>
<td class="nump">$ 23,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in cash operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">4,518<span></span>
</td>
<td class="nump">20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance', window );">Cash and cash equivalents balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackPurchaseAgreement', window );">Purchase agreement</a></td>
<td class="nump">$ 7,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apyx_AtTheMarketFacilityMember', window );">At-The-Market Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SecuritiesRegisteredNewIssues', window );">Securities registered, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apyx_ShelfRegistrationMember', window );">Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SecuritiesRegisteredNewIssues', window );">Securities registered, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash And Cash Equivalents Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SecuritiesRegisteredNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Registered, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SecuritiesRegisteredNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apyx_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apyx_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apyx_ShelfRegistrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apyx_ShelfRegistrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545939516736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 4,388<span></span>
</td>
<td class="nump">$ 4,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">4,655<span></span>
</td>
<td class="nump">5,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross inventories</a></td>
<td class="nump">11,374<span></span>
</td>
<td class="nump">12,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: provision for obsolescence</a></td>
<td class="num">(428)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 10,946<span></span>
</td>
<td class="nump">$ 11,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545937897936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 4,956<span></span>
</td>
<td class="nump">$ 11,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,387)<span></span>
</td>
<td class="num">(5,041)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_PropertyPlantAndEquipmentInService', window );">Property and equipment in service</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">6,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,109<span></span>
</td>
<td class="nump">6,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">4,569<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">4,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">2,472<span></span>
</td>
<td class="nump">2,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MoldsMember', window );">Molds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 847<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_PropertyPlantAndEquipmentInService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, In Service</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_PropertyPlantAndEquipmentInService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982154&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545939639856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 08, 2023</div></th>
<th class="th"><div>Mar. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackPurchaseAgreement', window );">Purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackTermOfLease', window );">Sale leaseback, term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackRenewalTerm', window );">Sale leaseback, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackAnnualRentPayment', window );">Sale leaseback. annual rent payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackAnnualRentIncrease', window );">Sale leaseback, annual rent increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackManagementFeeOnRentPayment', window );">Sale leaseback, management fee on rent payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackTermOfLease', window );">Sale leaseback, term of lease</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackNetCashProceeds', window );">Sale leaseback, net cash proceeds</a></td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent', window );">Security deposit equal to annual rent</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackAnnualRentIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Annual Rent Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackAnnualRentIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackAnnualRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback. Annual Rent Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackAnnualRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackManagementFeeOnRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Management Fee On Rent Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackManagementFeeOnRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackNetCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Net Cash Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackNetCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackSecurityDepositEqualToAnnualRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Security Deposit Equal To Annual Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackSecurityDepositEqualToAnnualRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackTermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Term Of Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackTermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545937002864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 848<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued commissions</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Accrued product warranties</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Accrued product liability claim insurance deductibles</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees and legal related contingent liabilities</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liabilities</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_UncertainTaxPositionsLiability', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax payable</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accrued expenses and current liabilities</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,626<span></span>
</td>
<td class="nump">$ 8,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Accrued Expenses And Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_UncertainTaxPositionsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Positions Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_UncertainTaxPositionsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126907644&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545933873648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CREDIT AGREEMENT - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($) </div>
<div>monthlyPayment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne', window );">Twelve month net revenue target, year one</a></td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo', window );">Twelve month net revenue target, year two</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree', window );">Twelve month net revenue target, year three</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance', window );">Cash and cash equivalents balance</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentDefaultApplicableInterestRate', window );">Default, applicable interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentInterestRateFloorPercent', window );">Interest rate floor</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent', window );">Interest rate floor spread</a></td>
<td class="nump">7.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentPeriodOfInterestOnly', window );">Period of interest only</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentExtensionPeriod', window );">Extension period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentNumberOfMonthlyPayments', window );">Number of monthly payments | monthlyPayment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension', window );">Number of monthly payments, extension | monthlyPayment</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentExitFee', window );">Exit fee</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Secured Debt | Adjusted Term Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentInterestRateFloorPercent', window );">Interest rate floor</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent', window );">Interest rate floor spread</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentAnnualFeePercent', window );">Annual fee</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount', window );">Borrowing base, minimum balance</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings', window );">Lockbox account, funds to be applied to borrowings</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentTerminationFees', window );">Termination fees</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent', window );">Borrowing base, minimum balance</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentTerminationFees', window );">Termination fees</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentTerminationFees', window );">Termination fees</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Agreement | Revolving Credit Facility | Adjusted Term Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentAnnualFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Fee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentAnnualFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash And Cash Equivalents Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentDefaultApplicableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default, Applicable Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentDefaultApplicableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentInterestRateFloorPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate Floor, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentInterestRateFloorPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate Floor Spread Adjustment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentNumberOfMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentNumberOfMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Payments, Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPeriodOfInterestOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest Only</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPeriodOfInterestOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPrepaymentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPrepaymentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Termination Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545933920224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount, including accretion of exit fee</a></td>
<td class="num">(737)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan, net</a></td>
<td class="nump">8,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943639504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">2,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">3,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">3,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan, net</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943687760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_NoncontrollingInterestRequiredCapitalContribution', window );">Required capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apyx_ChineseSupplierMember', window );">Chinese Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestRequiredCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Required Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestRequiredCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apyx_ChineseSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apyx_ChineseSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545936981328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">$ 211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545934302832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Earnings Per Share Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to stockholders, basic</a></td>
<td class="num">$ (3,483)<span></span>
</td>
<td class="num">$ (5,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to stockholders, diluted</a></td>
<td class="num">$ (3,483)<span></span>
</td>
<td class="num">$ (5,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">34,598<span></span>
</td>
<td class="nump">34,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">34,598<span></span>
</td>
<td class="nump">34,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments (in shares)</a></td>
<td class="nump">7,783<span></span>
</td>
<td class="nump">6,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments (in shares)</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545938238256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">$ 1,367<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived', window );">Stock swaps equity instruments received (in shares)</a></td>
<td class="nump">22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps (in shares)</a></td>
<td class="nump">19,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545934757808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Summary of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares) | shares</a></td>
<td class="nump">6,520,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,408,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(146,164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares) | shares</a></td>
<td class="nump">7,783,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in dollars per shares) | $ / shares</a></td>
<td class="nump">8.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943692608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545934754016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (2,267)<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">39.10%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545933753072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Costs accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember', window );">Suit Against Goodwin And Simb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Costs accrued</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member', window );">Suits Filed in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Costs accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">New claims filed | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | lease</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Suit Against Goodwin And Simb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Suits Filed in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Suit Against Goodwin And Simb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Suits Filed in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545943615632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Co-venturer - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases from related party</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545937108832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_TotalRevenuePercent', window );">International sales, percent of total revenue</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">39.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_TotalRevenuePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Revenue, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_TotalRevenuePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545933356544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 12,142<span></span>
</td>
<td class="nump">$ 12,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(5,611)<span></span>
</td>
<td class="num">(5,871)<span></span>
</td>
<td class="num">$ (23,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(2,267)<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Advanced Energy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">9,690<span></span>
</td>
<td class="nump">10,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(1,326)<span></span>
</td>
<td class="num">(1,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | OEM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">2,452<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate &amp; Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(5,136)<span></span>
</td>
<td class="num">(4,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">$ (2,267)<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140545933928896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 12,142<span></span>
</td>
<td class="nump">$ 12,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">8,871<span></span>
</td>
<td class="nump">7,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 3,271<span></span>
</td>
<td class="nump">$ 4,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>apyx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apyx="http://apyxmedical.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apyx-20230331.xsd" xlink:type="simple"/>
    <context id="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i45bd55a6ca54408a973dca3478244f79_I20230510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="icea0a6dbf6c34a688351e2f5840efa13_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd413f451a2b4d84baf891bc120bef43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i700d97178d1c46b7bec5f0372efea304_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9633d667b894c12a7a3c33ec5e248c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcf286c1d1ac4c6a9c53a9c75c20d4fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbc8cd3754b8424cbe8a8f678d790982_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i19af6f40a56e4da7be4be449774e9c38_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9497de4ef599443782493d1d3dbc6609_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie6931ca2b85e4446925ba4947ddbe1f2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4434306a747741429a540f6a76d96647_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia9fa3089458f42aaa023258bbce7b89b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie7f3a4fe886c472bb7f4d921600ce418_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2a8e01e3706a4c1a911c23a654ab59de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i791bf538170f41c58addc94c2a446640_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i87f633cacdd140aa9bab43f887b78a2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i11e1edafd25048a898c12ed311d1309e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f2ed1527d7c4ddf9a25ba44fc615c47_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8fe44f8091664b47a7bff608e2b30703_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7d048bc9f0341638ec692b0b8f93ca7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3301b75ad88b4456ac3325aa744427ee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0bdfda32745048c198232e04864a2e0c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if1c5d633167d49f083a557d93bdab57d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i302145e8cbf54af2abc2a3fd7137c26e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i188f6d41df7e4eb08c173022c9d1302e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic1d14b67a6cb40a08208352f01687ae9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4329db9485b349278676f47f9db880a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibbf0f4361aaa413daa96a1cde208b376_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9396d3bd36c8431da99d9d9421e5af7b_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i3932728fc7a04ebaa43fed7736e1c40c_D20221122-20221122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apyx:ShelfRegistrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="i842683acc0a34f84893c61d6455c84bd_D20221122-20221122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apyx:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="i9f7ad3b30f9045f4a940c5dd6e62909f_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i22587808ca5d48bab5471ce1b3d5871d_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="ic4a9c2aec01046399022caa446b9ec13_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i0e46158015eb4aec901c105c23099f18_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i9789c9d226394206be51a46193f836c3_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="ia32fcb27739a44c999f32b3a61c449f6_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="i26213cf5bc234af691fd6ad429fc40cf_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="ib02d47ac09b44377974655e36339723e_D20230109-20230109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <context id="i6a3f2eb674df41a2ae74e07a8d73a59c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i444e3d03e8b34aea95597bd9077be349_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79d67f218c964b66aa874fbba351e483_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i28d4a532478246d4bf4d795e035840ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e80aa911f544e7a99cf80274b923c6a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i41c447b579b144bf96d49d5e10b32eee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52498e454d8e4e4a9cc70ff49ba56436_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i67f1d0dccbc94a32bfdc2e93912d45e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56b3a3086a39456d82fe6d3a37c11a9b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0311da46d2f74bb18fbfe7861fcd1a6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb80eb1f91e44c0eaf61e0cd23a39e01_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i66c7b33ceee847c4b00c7492e4b509f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5534ca1fb36e45c69f14c9ee7219b0e5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:MoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i94ef5925e82e463ca7c4bf42717d5767_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:MoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if55075181de3450781da931211bae736_D20230508-20230508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="i099455fbc1dc4ad496d841a9e2cbc539_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i5d5ece174ab94a1db32622d52c60a23c_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="if473b8c0c1e64a71aaa04d5e033d18a5_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i326c0815b32647328b23564b770a38b5_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i8a9fbd2dc730476f8a383e982377fba4_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="id84b5b8ace5c47e0ab7d98a27c878c5a_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="ia8727fd78b5f49719ede74e72b308e36_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i6475488d296841caa68cd47c85e020e8_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i959de39370604cf7aad3380d9347c61e_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="if7f997a25acb43b78c977a49616ca9cb_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i5d5b6ac44ade4700b26334526cfe5f12_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i52b5c4f206324a52b8b01adbfe778760_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idb361a5c665a4bcbb5b44abe46d8fc2b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6338653760b44614b5950f6458c874e5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4271a8fb9da64a4789ce96b320c25e39_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if3f9fa1ecfdb48119493afdf30b2022a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6aa4190bc3674f469e5b158e6869197c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9eb98c8ff23e49bc88f698fa56afd8ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b4980f0f2ab4be298429e6c68c4337c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i994301f8b554452584f2e4a03b35f7ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie30ce932627140d1a2b179341ef78232_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ce5d204aa7344c59e93d632a33eef74_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i857f1353ae2c4ec3bc1c0d6d91f7e28c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib96384db7fff41dbb63293f4abff78af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idd237ef53a384e9e80d9d797d4712603_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3163fe51e869499585757dba371b5390_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i968a4cfb77a54232afc8b80ea39ad52b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie59716d0f60c45d9aded6f41b3e4a29f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4c3ed228146b4231874ddd7a84ecf89c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b520559f24c441e931060ece6becb9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1fa5e6669544a54afa2eccf6e04c7a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i429b0f131ab543fbb23ba8b453c39589_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2994bfe0e594059a28c66ab8010af39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc25d1761ff44d87a5e3cce964599c64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i03f055d56d024c43ab76ceb69016f0cc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i42273566c1174b14a4e8392f80ba2427_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5d07b00814b44846ae29c9126733b0ab_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia7e994b58a5f469cb23af8692f7bf53f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iead2dc3eba5e47188eea66a730ec7ba2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iabe7f3502b4347be9913b0ff042c7661_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8478849b5317485ba002f297876ef34b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ef61e5dd37545a3ad7e31b677f88c1d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5569b815eaea4f9d9cdfcb8f7e5f0209_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6176a8f8df744f2b97ab2568640c4a9d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic12b47ef6b0e48508323229d60109300_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="monthlypayment">
        <measure>apyx:monthlyPayment</measure>
    </unit>
    <unit id="lease">
        <measure>apyx:lease</measure>
    </unit>
    <unit id="segment">
        <measure>apyx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN18xLTEtMS0xLTI3ODUy_400a54fe-4da9-4a46-83fc-2e6835158cdd">0000719135</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN18yLTEtMS0xLTI3ODUy_a04ed26e-72bb-4779-94a2-a0c84fd09e2d">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN18zLTEtMS0xLTI3ODUy_8fc8e637-ebf3-47b9-95a1-1026c9d66197">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN180LTEtMS0xLTI3ODUy_f1c0b744-ab9c-4298-99e8-1e586045cf64">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80L2ZyYWc6NDZmNDg5NWQ1ODQ0NDQwZTlhNWY5M2I5ZmZiYTg0MjIvdGFibGU6NTBkZjNkMzQ1NzVlNGNhNWI5YmE2MjBkZjRkNTZiMzcvdGFibGVyYW5nZTo1MGRmM2QzNDU3NWU0Y2E1YjliYTYyMGRmNGQ1NmIzN181LTEtMS0xLTI3ODUy_49117a52-0375-4794-a0a2-b74808a9809a">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentType
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ1_97f719d9-8fcb-40e9-874f-bffd5aaeea8e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6ZDYwYzFkOGQyNDAzNDY4NWJmNTNmNjY4ODExODBjYmYvdGFibGVyYW5nZTpkNjBjMWQ4ZDI0MDM0Njg1YmY1M2Y2Njg4MTE4MGNiZl8wLTItMS0xLTI3ODUy_f9860a47-3022-4a38-b7be-2a0e8e375315">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6ZDYwYzFkOGQyNDAzNDY4NWJmNTNmNjY4ODExODBjYmYvdGFibGVyYW5nZTpkNjBjMWQ4ZDI0MDM0Njg1YmY1M2Y2Njg4MTE4MGNiZl8xLTQtMS0xLTI3ODUy_2b345f4b-d684-49ab-9d55-cad6f3d7321d">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6ZDYwYzFkOGQyNDAzNDY4NWJmNTNmNjY4ODExODBjYmYvdGFibGVyYW5nZTpkNjBjMWQ4ZDI0MDM0Njg1YmY1M2Y2Njg4MTE4MGNiZl81LTItMS0xLTI3ODUy_c7761172-599a-4c8d-b76b-078cb19af5a7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6ZDYwYzFkOGQyNDAzNDY4NWJmNTNmNjY4ODExODBjYmYvdGFibGVyYW5nZTpkNjBjMWQ4ZDI0MDM0Njg1YmY1M2Y2Njg4MTE4MGNiZl83LTQtMS0xLTI3ODUy_1ffe6cc7-a783-4b38-8f67-810e960919e2">0-12183</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NDcxZTg2Yjc3MmQxNDBkOTk1ZGZiMTA0MGZjNzE1NzEvdGFibGVyYW5nZTo0NzFlODZiNzcyZDE0MGQ5OTVkZmIxMDQwZmM3MTU3MV8xLTAtMS0xLTI3ODUy_188efc5f-19f2-4d87-87a2-8a3b1fbe274a">APYX MEDICAL CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NDIzMzVjZDY5MjgyNDVlNDg5OGM0ZjRjNzE4YmM4OGIvdGFibGVyYW5nZTo0MjMzNWNkNjkyODI0NWU0ODk4YzRmNGM3MThiYzg4Yl8wLTAtMS0xLTI3ODUy_d66174c5-217a-40a7-bb5a-208431e52eff">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NDIzMzVjZDY5MjgyNDVlNDg5OGM0ZjRjNzE4YmM4OGIvdGFibGVyYW5nZTo0MjMzNWNkNjkyODI0NWU0ODk4YzRmNGM3MThiYzg4Yl8wLTItMS0xLTI3ODUy_bee6e10d-0387-44c4-814e-685196f4e452">11-2644611</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ2_570509d1-01df-4671-8a0f-37a32400757e">5115 Ulmerton Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTUy_375d0697-6687-42fa-ba44-564a9f969a44">Clearwater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTUz_9dd8f5c2-c004-4095-beaf-3ddbcbfe01a7">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ3_8bf03cea-d573-4a74-9f76-3425efcbafdf">33760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ4_7aeb0e60-a576-41c9-a916-7a0e0c53325e">727</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQ5_715189b8-297a-4687-8623-99043b821da4">384-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6YzNiNTc4MzMwYTNmNDBiOGExYTMwNjk5ZjkzMTMyNGIvdGFibGVyYW5nZTpjM2I1NzgzMzBhM2Y0MGI4YTFhMzA2OTlmOTMxMzI0Yl8xLTAtMS0xLTI3ODUy_5a9a48aa-c738-4a63-bda6-3ab268a5060e">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6YzNiNTc4MzMwYTNmNDBiOGExYTMwNjk5ZjkzMTMyNGIvdGFibGVyYW5nZTpjM2I1NzgzMzBhM2Y0MGI4YTFhMzA2OTlmOTMxMzI0Yl8xLTEtMS0xLTI3ODUy_11682321-17bd-48a8-9755-e7765d7c4136">APYX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6YzNiNTc4MzMwYTNmNDBiOGExYTMwNjk5ZjkzMTMyNGIvdGFibGVyYW5nZTpjM2I1NzgzMzBhM2Y0MGI4YTFhMzA2OTlmOTMxMzI0Yl8xLTItMS0xLTI3ODUy_da6c84c4-75b4-4d79-aad5-66562610c6b3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTUw_ce13948c-2293-4930-942f-299fb7686141">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTUx_cf664d52-441c-45d3-9ffa-519e010737b9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NTI5MDJkNzZjZWRlNGM0ZDk2NjY5NGI4NTllZTJlZWQvdGFibGVyYW5nZTo1MjkwMmQ3NmNlZGU0YzRkOTY2Njk0Yjg1OWVlMmVlZF8xLTAtMS0xLTI3ODUy_4bd575f0-5d57-499c-8ba4-6dcf0438d9ee">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NTI5MDJkNzZjZWRlNGM0ZDk2NjY5NGI4NTllZTJlZWQvdGFibGVyYW5nZTo1MjkwMmQ3NmNlZGU0YzRkOTY2Njk0Yjg1OWVlMmVlZF8xLTQtMS0xLTI3ODUy_525c9051-70be-4ac9-8e46-103f96baf2de">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGFibGU6NTI5MDJkNzZjZWRlNGM0ZDk2NjY5NGI4NTllZTJlZWQvdGFibGVyYW5nZTo1MjkwMmQ3NmNlZGU0YzRkOTY2Njk0Yjg1OWVlMmVlZF8yLTQtMS0xLTI3ODUy_4f6b2590-e286-42e7-99d3-767a0bca1953">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8xNTQz_f9970786-1d73-4fad-a24b-a59dc9454a27">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i45bd55a6ca54408a973dca3478244f79_I20230510"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xL2ZyYWc6ZTNkNGYwMDI2NjkyNDA4ZTk3MDNlY2FiOTgzNDYxMTUvdGV4dHJlZ2lvbjplM2Q0ZjAwMjY2OTI0MDhlOTcwM2VjYWI5ODM0NjExNV8yNzQ4Nzc5MDcxMDIy_84f23e2b-bcf8-4445-8fca-9d8e7cf37a5a"
      unitRef="shares">34597822</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMy0xLTEtMS0yNzg1Mg_5da3d28e-93e6-4e49-b453-e5007acffd31"
      unitRef="usd">16255000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMy0zLTEtMS0yNzg1Mg_e909998d-37a7-4963-a1e2-55235ffcda9e"
      unitRef="usd">10192000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNC0wLTEtMS0yNzg1Mi90ZXh0cmVnaW9uOjc5Y2Y1YTAyOTE4MTQ0OWRiNGIyNjc1YjlkZDM4MDM5XzU0_02cdd8c6-f03a-42fe-892c-b7397ff7b9d0"
      unitRef="usd">359000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNC0wLTEtMS0yNzg1Mi90ZXh0cmVnaW9uOjc5Y2Y1YTAyOTE4MTQ0OWRiNGIyNjc1YjlkZDM4MDM5XzYx_27f54d05-265a-4587-a80c-f7b5aa91f312"
      unitRef="usd">668000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNC0xLTEtMS0yNzg1Mg_988054b9-a757-4f52-ae5e-affc2974d5e6"
      unitRef="usd">9966000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNC0zLTEtMS0yNzg1Mg_6a7b58da-8017-40fa-953f-11f9f10dc0e2"
      unitRef="usd">10602000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNS0xLTEtMS0yNzg1Mg_e9ee9afe-3255-4fc8-a6f3-c3c835969be1"
      unitRef="usd">7752000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNS0zLTEtMS0yNzg1Mg_e82d42be-5630-4948-9ed7-6cd9dd9bdea0"
      unitRef="usd">7545000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNi0xLTEtMS0yNzg1Mg_2158a497-94e3-4aef-83c1-aa3ddc7f8019"
      unitRef="usd">417000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNi0zLTEtMS0yNzg1Mg_0e5efda5-2fa3-426f-beba-e06d33db4aa8"
      unitRef="usd">99000</us-gaap:OtherReceivablesNetCurrent>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNy0wLTEtMS0yNzg1Mi90ZXh0cmVnaW9uOjlmMzk4YzJmMWE3NzQxNTNhMWVkY2UxMDczNWY2ZDg5XzU0_e57a1197-26da-4f1a-a54b-280d5673de59"
      unitRef="usd">428000</apyx:ProvisionForObsolescenceInventory>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNy0wLTEtMS0yNzg1Mi90ZXh0cmVnaW9uOjlmMzk4YzJmMWE3NzQxNTNhMWVkY2UxMDczNWY2ZDg5XzYx_8aec5397-ecce-4d8f-9087-d4b5abce2cc4"
      unitRef="usd">457000</apyx:ProvisionForObsolescenceInventory>
    <us-gaap:InventoryNet
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNy0xLTEtMS0yNzg1Mg_f53e83e7-c12c-4830-8864-75a91eab0f2e"
      unitRef="usd">10946000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfNy0zLTEtMS0yNzg1Mg_1997e1e5-0acf-4883-a586-63d54e344129"
      unitRef="usd">11797000</us-gaap:InventoryNet>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOS0xLTEtMS0yODM2Nw_23744043-79dc-40fe-83c9-d6b67f1c8de2"
      unitRef="usd">4569000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOS0zLTEtMS0yODM2Nw_b23084a2-3910-4ea7-a790-91a0e131dd33"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOC0xLTEtMS0yNzg1Mg_abf99352-4d8e-45d6-aae9-50ce328ee43d"
      unitRef="usd">2779000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOC0zLTEtMS0yNzg1Mg_97d5a67b-644e-4f6b-b720-a87bcdddb790"
      unitRef="usd">2737000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOS0xLTEtMS0yNzg1Mg_3a18f716-5002-492c-b6e2-35ad363c48ac"
      unitRef="usd">52684000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfOS0zLTEtMS0yNzg1Mg_09a13594-fcd0-4472-882b-6ec0a3646e9e"
      unitRef="usd">42972000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTAtMS0xLTEtMjc4NTI_0d345193-37e5-4678-b0b6-bed2c3fcf717"
      unitRef="usd">2109000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTAtMy0xLTEtMjc4NTI_f27874bb-4424-48c6-be38-321271687c31"
      unitRef="usd">6761000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTEtMS0xLTEtMjc4NTI_656c8907-41ee-4eb6-a0e2-4770dcaa225b"
      unitRef="usd">646000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTEtMy0xLTEtMjc4NTI_b65fd126-34fc-412f-8e1f-83d9b5512f62"
      unitRef="usd">710000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTItMS0xLTEtMjc4NTI_b1d52d39-6f95-4c12-a858-e6c9df4620cd"
      unitRef="usd">106000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTItMy0xLTEtMjc4NTI_2c5c3cee-5605-48fe-9b22-baffe8be9a42"
      unitRef="usd">115000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTQtMS0xLTEtMjc4NTI_907b414b-b6f9-47bc-841d-ae0a579986d2"
      unitRef="usd">1239000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTQtMy0xLTEtMjc4NTI_e642c8e6-41ef-41eb-946c-d63e82ff1cfb"
      unitRef="usd">1217000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTUtMS0xLTEtMjc4NTI_4b9eb2cb-7852-49bf-a345-12035be367e4"
      unitRef="usd">56784000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMTUtMy0xLTEtMjc4NTI_40884312-d85c-4229-a129-c271935caefb"
      unitRef="usd">51775000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjEtMS0xLTEtMjc4NTI_75da868f-6427-48e0-aed0-cb4743c447f6"
      unitRef="usd">1905000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjEtMy0xLTEtMjc4NTI_b4f8d663-3d8f-4440-97ca-26345322f58c"
      unitRef="usd">2669000</us-gaap:AccountsPayableCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjItMS0xLTEtMjc4NTI_abb3d8bf-84aa-471f-aa3c-996292ffe08f"
      unitRef="usd">7626000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjItMy0xLTEtMjc4NTI_174849c3-1e95-4084-ab4e-ba4d6275d458"
      unitRef="usd">8928000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjMtMS0xLTEtMjc4NTI_57d6da1f-3391-4bf9-be64-c5ccbed4721c"
      unitRef="usd">184000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjMtMy0xLTEtMjc4NTI_9a6e475e-f8ed-47b4-937a-0569f3c358bf"
      unitRef="usd">216000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjQtMS0xLTEtMjc4NTI_3b501793-e849-4e72-812c-6b53e6bc859e"
      unitRef="usd">33000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjQtMy0xLTEtMjc4NTI_2eeec5c7-3bf8-463a-87a6-6dd0adeab83d"
      unitRef="usd">37000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjUtMS0xLTEtMjc4NTI_40f92877-fe55-4e92-a44d-dcb0f49cc412"
      unitRef="usd">8778000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjUtMy0xLTEtMjc4NTI_6acc2b30-8ba5-4d39-b309-8d7f7f4c4170"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjYtMS0xLTEtMjc4NTI_50ac7fee-ffe5-433e-b0d8-8fdcf48db8c4"
      unitRef="usd">18526000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjYtMy0xLTEtMjc4NTI_952604de-19f2-44c2-b734-0376dd38a141"
      unitRef="usd">11850000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjctMS0xLTEtMjc4NTI_e07bb3f0-09f6-4516-a6b8-35c5cc81b17d"
      unitRef="usd">448000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjctMy0xLTEtMjc4NTI_44723e23-a9ef-4660-95e4-7ce449383501"
      unitRef="usd">470000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjgtMS0xLTEtMjc4NTI_258569c2-775d-4341-a910-7061b82a3eae"
      unitRef="usd">68000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjgtMy0xLTEtMjc4NTI_09413ea9-25fc-42ed-99bf-70c13a380157"
      unitRef="usd">73000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjktMS0xLTEtMjc4NTI_6f1d4b7d-b42f-44c0-8c33-4afff456264e"
      unitRef="usd">1343000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMjktMy0xLTEtMjc4NTI_e8159c43-0e84-4448-b875-4e79f4cb99a3"
      unitRef="usd">1408000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzAtMS0xLTEtMjc4NTI_fb38f39c-2825-4ed7-9c1d-e5f8be98e73c"
      unitRef="usd">185000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzAtMy0xLTEtMjc4NTI_2c9fdf57-781e-4762-b0dd-ea77e7b63aff"
      unitRef="usd">181000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzEtMS0xLTEtMjc4NTI_0229fe77-38d7-434d-bd82-aa71811c4126"
      unitRef="usd">20570000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzEtMy0xLTEtMjc4NTI_c566555b-3a00-45bd-85db-1ebbeb4a378d"
      unitRef="usd">13982000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV8yMQ_3b723a1a-c367-4760-b1f0-27ef38548e6c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV8yMQ_d3c71c07-8b22-4bf4-945a-f22004895183"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV8zNQ_183bcfab-c8ea-4e80-b6ad-ae7866c20d94"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV8zNQ_c94bb00a-003c-411a-b517-bc227462f783"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV81Nw_2e1899cc-bd17-4abf-9b50-2b11a33d31c6"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV81Nw_85d9c793-564f-46d2-8dfe-dc08eed9cced"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV81Nw_a4f274eb-4ac5-41f8-99c9-1fe411028dd8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjgxMDQvdGV4dHJlZ2lvbjo5MjNlMzYyNTVlZWI0YWM3YjA1OWJmMDBhNmI0ODQ3ZV81Nw_ccf4e7ef-a0c5-4513-8d98-60a5f4339c35"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzUtMS0xLTEtMjk1NTE_b26437ea-e9ea-4650-b701-3b6253d0004f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzUtMy0xLTEtMjk1NTM_76f350d4-c186-4552-b830-978694d18dc0"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl8xOA_642585e2-12fe-48d7-8312-67a6ab2b2ea7"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl8xOA_98617d48-b20c-492e-9cdc-e07ce82fda68"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl8zMg_aaffd130-8a8f-4495-b49b-85b3e77c0b9a"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl8zMg_d2ac7c8b-d434-4a8f-858a-39b7fd56e47b"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl81NA_5e27ac52-0250-434d-9131-491de344286c"
      unitRef="shares">34597822</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMC0xLTEtMjc4NTIvdGV4dHJlZ2lvbjo4NTk0ZTkyNTA3MmY0MDgyOTk0MjYzNzRjYTZjMjdhZl81NA_d61029e1-4d50-4b26-9aaf-9b8a87b923da"
      unitRef="shares">34597822</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMS0xLTEtMjc4NTI_cb1c8e24-e28d-41dd-ad9e-28a221c5f89a"
      unitRef="usd">35000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzMtMy0xLTEtMjc4NTI_3eaacb42-20c3-4690-b0fe-0154ebecab0a"
      unitRef="usd">35000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzQtMS0xLTEtMjc4NTI_26026e45-d660-4692-a99b-4d43b8874746"
      unitRef="usd">75235000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzQtMy0xLTEtMjc4NTI_c4dc9e48-04d0-4897-92a0-7e163c156e09"
      unitRef="usd">73282000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzUtMS0xLTEtMjc4NTI_a74a421f-c435-4b08-959f-2bba2b478104"
      unitRef="usd">-39218000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzUtMy0xLTEtMjc4NTI_923c12a8-f158-4fe2-8af8-6baa7ba8f371"
      unitRef="usd">-35735000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzYtMS0xLTEtMjc4NTI_d10a89f0-8aee-4c5d-9d36-c9bd856cff70"
      unitRef="usd">36052000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzYtMy0xLTEtMjc4NTI_e29f6968-c8f0-4eb6-99b4-ab3d9bd06d29"
      unitRef="usd">37582000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzctMS0xLTEtMjc4NTI_22a49511-e0bd-4893-8064-ae89424392e8"
      unitRef="usd">162000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzctMy0xLTEtMjc4NTI_236a3c91-c343-401a-ac3e-a032abc751c8"
      unitRef="usd">211000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzgtMS0xLTEtMjc4NTI_ca1b5580-5558-4b1d-bece-66ef89c48953"
      unitRef="usd">36214000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzgtMy0xLTEtMjc4NTI_049b3b50-4fed-42bf-bf00-4d9ec1f0228a"
      unitRef="usd">37793000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzktMS0xLTEtMjc4NTI_2a098edf-0a63-48da-8a1f-b3dfe6f07545"
      unitRef="usd">56784000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xNi9mcmFnOjU2MjE1ZmE3NjgwZDQ4MjhhZjE4NzY3OWM2ZGNlY2RkL3RhYmxlOjI5YWIyZTE2YTUyNzQ5Mjg5ZDdjNmJhYTI5OTA5YjIyL3RhYmxlcmFuZ2U6MjlhYjJlMTZhNTI3NDkyODlkN2M2YmFhMjk5MDliMjJfMzktMy0xLTEtMjc4NTI_d1913908-b0c5-4fb7-84dc-1ce6de5d12f6"
      unitRef="usd">51775000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMi0xLTEtMS0yNzg1Mg_47d477cb-736d-4452-90c5-691766d76371"
      unitRef="usd">12142000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMi0zLTEtMS0yNzg1Mg_db20eef5-50ca-4645-8344-8919e783c961"
      unitRef="usd">12493000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMy0xLTEtMS0yNzg1Mg_4ba73c09-dd08-4d18-bed1-5eeb1d345e5e"
      unitRef="usd">4569000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMy0zLTEtMS0yNzg1Mg_1cc02982-4508-4503-86d9-baa96a1a90cf"
      unitRef="usd">4274000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNC0xLTEtMS0yNzg1Mg_30e7b242-85ec-4cb1-b2b3-edf00e75d8a6"
      unitRef="usd">7573000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNC0zLTEtMS0yNzg1Mg_ae8356dc-8d05-4178-bfd5-0316ef05f16d"
      unitRef="usd">8219000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNi0xLTEtMS0yNzg1Mg_3721da6a-8bd6-434c-a67b-4b98f34c1c6c"
      unitRef="usd">1121000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNi0zLTEtMS0yNzg1Mg_f649cec1-ae39-4ceb-a7b5-1035d12984b6"
      unitRef="usd">1158000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNy0xLTEtMS0yNzg1Mg_19eece4f-a392-495f-9d8c-76cd9a7aadf0"
      unitRef="usd">1740000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfNy0zLTEtMS0yNzg1Mg_80fa33e0-4069-4603-8fb3-d8a412ec5412"
      unitRef="usd">2286000</us-gaap:ProfessionalFees>
    <us-gaap:SalariesAndWages
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfOC0xLTEtMS0yNzg1Mg_7bc4e2ed-af27-49a7-957a-7d2ab3ccc2a5"
      unitRef="usd">5068000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfOC0zLTEtMS0yNzg1Mg_7a18870f-01e6-4eaa-b98c-831221bd784f"
      unitRef="usd">5181000</us-gaap:SalariesAndWages>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfOS0xLTEtMS0yNzg1Mg_67dea5ba-67cc-44cc-9c87-07c2bea3c09f"
      unitRef="usd">5255000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfOS0zLTEtMS0yNzg1Mg_eb6c9993-0319-4016-bfce-9731b05f3d59"
      unitRef="usd">5465000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTAtMS0xLTEtMjc4NTI_e19da63d-be57-4a9d-b8bf-72c78a5c5010"
      unitRef="usd">13184000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTAtMy0xLTEtMjc4NTI_98f1cac1-4d7d-477e-9980-938b4d969395"
      unitRef="usd">14090000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTEtMS0xLTEtMjc4NTI_93985a87-9f7f-4afb-b555-f1284eb0249e"
      unitRef="usd">-5611000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTEtMy0xLTEtMjc4NTI_83df6372-59f3-4b56-9294-3a9cdf4deb9d"
      unitRef="usd">-5871000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTItMS0xLTEtMjc4NTI_abbab44d-85ce-44e1-941e-855b75cddbe9"
      unitRef="usd">51000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTItMy0xLTEtMjc4NTI_38ea9ced-f882-4bbb-bb34-0ff186e8a958"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTMtMS0xLTEtMjc4NTI_03c153f0-8054-4168-a4ae-cc4ad2dbbf48"
      unitRef="usd">234000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTMtMy0xLTEtMjc4NTI_2fc67e03-55e6-4e74-ad7a-07239000c599"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTQtMS0xLTEtMjc4NTI_892d8189-9240-4eee-b4ac-854e0cbb1e54"
      unitRef="usd">-5000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTQtMy0xLTEtMjc4NTI_58fd4126-8692-41d2-b996-9c41188b5c2e"
      unitRef="usd">-21000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTUtMS0xLTEtMjc4NTI_8d55164e-d4ca-4a8c-b30f-7e7c440bf61c"
      unitRef="usd">-188000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTUtMy0xLTEtMjc4NTI_8fcbde53-eef1-421a-bc74-a06f5429acc5"
      unitRef="usd">-27000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTYtMS0xLTEtMjc4NTI_964c9071-92de-40ba-8c0f-2be876d570c1"
      unitRef="usd">-5799000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTYtMy0xLTEtMjc4NTI_9049c4bd-5bbd-4295-aef1-efb102bdfa88"
      unitRef="usd">-5898000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTctMS0xLTEtMjc4NTI_835b2e11-ba5f-43ef-be89-884c059cf452"
      unitRef="usd">-2267000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTctMy0xLTEtMjc4NTI_576ee45e-7d74-4442-b209-f327e04ea8c5"
      unitRef="usd">70000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTgtMS0xLTEtMjc4NTI_5b187a7b-264e-480a-9b52-72b2f5b101d8"
      unitRef="usd">-3532000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTgtMy0xLTEtMjc4NTI_33489982-cac7-4b6b-bee9-7337c0d47286"
      unitRef="usd">-5968000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTktMS0xLTEtMjc4NTI_392e02f0-dc3f-4db6-88ad-fcbe5481a0ae"
      unitRef="usd">-49000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMTktMy0xLTEtMjc4NTI_9439347c-0b35-4849-894f-5f5aadb07a89"
      unitRef="usd">-23000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjAtMS0xLTEtMjc4NTI_72510674-5004-4069-8be6-595197bb4250"
      unitRef="usd">-3483000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjAtMy0xLTEtMjc4NTI_f79e3914-8fc1-4900-9b81-794d32f67d07"
      unitRef="usd">-5945000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjQtMS0xLTEtMjc4NTI_9e581336-963e-45cc-86ce-26b764e13000"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjQtMS0xLTEtMjc4NTI_e5b30bc6-d305-412d-a66e-1ccf42f58ff7"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjQtMy0xLTEtMjc4NTI_a33078ff-e486-40b0-a870-2c0a989f5c96"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xOS9mcmFnOjI3NGZhZmUwMDZhOTQ3MmNhOTlkZGE3YjU0NTM3Mjc3L3RhYmxlOmFiY2Q4YzIzNzRkMDQ4MTdiOWMxZGE3YzFkYzNjMDM5L3RhYmxlcmFuZ2U6YWJjZDhjMjM3NGQwNDgxN2I5YzFkYTdjMWRjM2MwMzlfMjQtMy0xLTEtMjc4NTI_ca3d06c3-9312-48f1-abe2-fb31d35ae86b"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesIssued
      contextRef="i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy0xLTEtMS0yNzg1Mg_6f90889a-ca1c-4cb6-9dab-fc32afd52d94"
      unitRef="shares">34410000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy0zLTEtMS0yNzg1Mg_9b8b0685-51f0-4bea-b93d-95c947e07a8f"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd413f451a2b4d84baf891bc120bef43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy01LTEtMS0yNzg1Mg_16bdcd55-09c4-46af-929a-20dc8117fe51"
      unitRef="usd">66221000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i700d97178d1c46b7bec5f0372efea304_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy03LTEtMS0yNzg1Mg_367a277b-d03e-4a5b-8349-d133cf00b753"
      unitRef="usd">-12551000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9633d667b894c12a7a3c33ec5e248c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy05LTEtMS0yNzg1Mg_75978fb9-6bef-41c4-ae24-aacd352858d9"
      unitRef="usd">305000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcf286c1d1ac4c6a9c53a9c75c20d4fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMy0xMS0xLTEtMjc4NTI_88e91095-0e1c-41df-a5e0-f70df3cd6a85"
      unitRef="usd">54009000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idbc8cd3754b8424cbe8a8f678d790982_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNS0xLTEtMS0yNzg1Mg_43f17d23-1919-4c29-bbc2-1dc9c2ab08b9"
      unitRef="shares">24000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i19af6f40a56e4da7be4be449774e9c38_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNS01LTEtMS0yNzg1Mg_bf362841-2fa1-41c3-9c30-92fdbe6e32ba"
      unitRef="usd">152000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNS0xMS0xLTEtMjc4NTI_00ee20be-fce2-428f-ab3a-d137566d81c0"
      unitRef="usd">152000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i19af6f40a56e4da7be4be449774e9c38_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNi01LTEtMS0yNzg1Mg_e480912e-225e-45a5-9595-54c85dc37e18"
      unitRef="usd">1650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNi0xMS0xLTEtMjc4NTI_c34299a8-fd97-4d63-b9a1-c00f045e9410"
      unitRef="usd">1650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="idbc8cd3754b8424cbe8a8f678d790982_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfNy0xLTEtMS0yNzg1Mg_39c76f10-9a17-4a04-b8d1-9ebfad8b540a"
      unitRef="shares">19000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i9497de4ef599443782493d1d3dbc6609_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfOS03LTEtMS0yNzg1Mg_adfec92b-3de5-46c5-8b00-cb590d8b5c79"
      unitRef="usd">-5945000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie6931ca2b85e4446925ba4947ddbe1f2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfOS05LTEtMS0yNzg1Mg_cde4e9c7-a8a1-4ffc-8943-585af4af644c"
      unitRef="usd">-23000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfOS0xMS0xLTEtMjc4NTI_bfe029df-40f9-4bcd-b785-404c4cabbc12"
      unitRef="usd">-5968000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i4434306a747741429a540f6a76d96647_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtMS0xLTEtMjc4NTI_20d73901-706d-4207-823d-b1b2d4b12a8a"
      unitRef="shares">34453000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4434306a747741429a540f6a76d96647_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtMy0xLTEtMjc4NTI_339e8ba4-db91-45e3-b8c3-271a2ef1b372"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9fa3089458f42aaa023258bbce7b89b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtNS0xLTEtMjc4NTI_3d01cfa3-5b24-4f00-b657-4c2fc0f4196f"
      unitRef="usd">68023000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7f3a4fe886c472bb7f4d921600ce418_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtNy0xLTEtMjc4NTI_39099b02-ec9c-4586-a040-b81cacf9c8e3"
      unitRef="usd">-18496000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a8e01e3706a4c1a911c23a654ab59de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtOS0xLTEtMjc4NTI_e6fd0a92-6df9-46f1-bf61-eb325ca383d7"
      unitRef="usd">282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i791bf538170f41c58addc94c2a446640_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTAtMTEtMS0xLTI3ODUy_5b48e356-5269-40c5-8bad-61c8f0d35b69"
      unitRef="usd">49843000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i87f633cacdd140aa9bab43f887b78a2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItMS0xLTEtMjc4NTI_9b335511-35c7-49f4-92e5-8aebf70c812d"
      unitRef="shares">34598000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87f633cacdd140aa9bab43f887b78a2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItMy0xLTEtMjc4NTI_b8415fe8-210b-4f52-875e-74092ca5b093"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11e1edafd25048a898c12ed311d1309e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItNS0xLTEtMjc4NTI_091ab952-2282-4f32-87ec-f9316e5350aa"
      unitRef="usd">73282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f2ed1527d7c4ddf9a25ba44fc615c47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItNy0xLTEtMjc4NTI_455941fe-c8bf-47e9-b9b1-ae9108dc970f"
      unitRef="usd">-35735000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fe44f8091664b47a7bff608e2b30703_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItOS0xLTEtMjc4NTI_a4d9a90a-9e25-47a9-8965-2cf71dcec863"
      unitRef="usd">211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTItMTEtMS0xLTI3ODUy_af9ef9c2-1b1c-40a5-a395-41c63d63f022"
      unitRef="usd">37793000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib7d048bc9f0341638ec692b0b8f93ca7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTUtNS0xLTEtMjc4NTI_cc103ebf-caeb-4dd2-ad56-ae6584e3dab6"
      unitRef="usd">1367000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTUtMTEtMS0xLTI3ODUy_8d8ad942-7c06-4312-b94f-f6510fcbd00a"
      unitRef="usd">1367000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ib7d048bc9f0341638ec692b0b8f93ca7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTctNS0xLTEtMjc4NTI_ed416aa9-9444-48a1-bfc7-2dd80195ba4b"
      unitRef="usd">586000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTctMTEtMS0xLTI3ODUy_842bb8be-6e17-4a04-9e96-7fd65681b170"
      unitRef="usd">586000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ProfitLoss
      contextRef="i3301b75ad88b4456ac3325aa744427ee_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTgtNy0xLTEtMjc4NTI_ce3e317c-2744-4d87-8d51-895108d216f9"
      unitRef="usd">-3483000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0bdfda32745048c198232e04864a2e0c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTgtOS0xLTEtMjc4NTI_97a01174-4788-402f-a9a8-b5fe7c96d2cd"
      unitRef="usd">-49000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTgtMTEtMS0xLTI3ODUy_7064fdc6-64d6-463f-b623-a94a00abf1ee"
      unitRef="usd">-3532000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="if1c5d633167d49f083a557d93bdab57d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktMS0xLTEtMjc4NTI_d3c891f0-6ce2-4bfe-bf83-c03c461833ff"
      unitRef="shares">34598000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1c5d633167d49f083a557d93bdab57d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktMy0xLTEtMjc4NTI_a59f6a15-fa06-41b0-b672-3ec106a58717"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i302145e8cbf54af2abc2a3fd7137c26e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktNS0xLTEtMjc4NTI_f576d0e5-94f9-48a1-8d50-1695bd0bc84b"
      unitRef="usd">75235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i188f6d41df7e4eb08c173022c9d1302e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktNy0xLTEtMjc4NTI_d89e4218-b416-42cf-b874-98d2d3400dbf"
      unitRef="usd">-39218000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1d14b67a6cb40a08208352f01687ae9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktOS0xLTEtMjc4NTI_b6f11ff5-3e13-4478-986d-041e3f9b5d7c"
      unitRef="usd">162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yMi9mcmFnOmQzNDNmY2FlYzExMzQ0YzZiYmJmY2UzNjBlNGI4ZTYwL3RhYmxlOjQ3OGY2MGMwYmVjZTQ3YWI4MDAwZGY3ZmE4NDUxNWZlL3RhYmxlcmFuZ2U6NDc4ZjYwYzBiZWNlNDdhYjgwMDBkZjdmYTg0NTE1ZmVfMTktMTEtMS0xLTI3ODUy_ad102ef2-31ec-4b51-aa79-7a192ed6a9ae"
      unitRef="usd">36214000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMy0xLTEtMS0yNzg1Mg_4b73681d-2abe-4a2a-9b47-83e1596e0206"
      unitRef="usd">-3532000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMy0zLTEtMS0yNzg1Mg_0cbd694e-f127-40fa-8171-46c7aaef587e"
      unitRef="usd">-5968000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfNS0xLTEtMS0yNzg1Mg_4a6933dc-6eb1-424b-a91d-b95cb30bafb1"
      unitRef="usd">203000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfNS0zLTEtMS0yNzg1Mg_1c8d9f5d-906a-42d2-ac2d-4aaba163bf76"
      unitRef="usd">225000</us-gaap:DepreciationDepletionAndAmortization>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfNi0xLTEtMS0yNzg1Mg_743af969-4528-49b9-a360-edf9f1adfe30"
      unitRef="usd">0</apyx:ProvisionForInventoryObsolescence>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfNi0zLTEtMS0yNzg1Mg_bd3db15e-9da9-4ad6-9baa-7f7c7157e935"
      unitRef="usd">85000</apyx:ProvisionForInventoryObsolescence>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfOC0xLTEtMS0yNzg1Mg_f07c97da-bd34-4baf-9e95-b5d102b622fa"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfOC0zLTEtMS0yNzg1Mg_64fcde23-0ecb-4ad7-bc0a-1b68a05c525c"
      unitRef="usd">-26000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfOS0xLTEtMS0yNzg1Mg_2f5aa4ed-938b-4d83-9b44-23844eb2ef57"
      unitRef="usd">1367000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfOS0zLTEtMS0yNzg1Mg_cc48a936-e6d7-4760-abce-92536ed80b5f"
      unitRef="usd">1650000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTAtMS0xLTEtMjc4NTI_562eeaf6-b851-4052-9810-a7d92900464d"
      unitRef="usd">-142000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTAtMy0xLTEtMjc4NTI_c6aebc0c-7ca0-4cc2-aa7a-076d3a3f63bf"
      unitRef="usd">140000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTEtMS0xLTEtMjc4NTI_c9c02a2a-9a37-4cb7-b159-d869d6475eb7"
      unitRef="usd">67000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTEtMy0xLTEtMjc4NTI_4e47cf14-a2b9-4574-b547-8638ff2e9718"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTMtMS0xLTEtMjc4NTI_b717ad92-065d-4a60-b041-c963e42dbadf"
      unitRef="usd">-837000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTMtMy0xLTEtMjc4NTI_7a406807-a645-4d99-b59b-7e756a708c9e"
      unitRef="usd">-475000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTQtMS0xLTEtMjc4NTI_64af65ad-90d4-4c66-bead-fd3af27d3793"
      unitRef="usd">-858000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTQtMy0xLTEtMjc4NTI_8acb7d89-2023-4f18-90f0-7a6d50411950"
      unitRef="usd">-649000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTUtMS0xLTEtMjc4NTI_c3a5fd39-e461-4879-a702-840d6d366fa6"
      unitRef="usd">207000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTUtMy0xLTEtMjc4NTI_8f69da3f-c676-435f-9b39-37a4d3e1c243"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTYtMS0xLTEtMjc4NTI_22bf96d9-682a-49d0-89a1-f384bff30c4a"
      unitRef="usd">-879000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTYtMy0xLTEtMjc4NTI_a79b69f6-d7c8-445a-9b2c-202b83965cfc"
      unitRef="usd">371000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTctMS0xLTEtMjc4NTI_0b9ca07e-0af3-4277-b24c-dc74a6f56860"
      unitRef="usd">-776000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTctMy0xLTEtMjc4NTI_7aa21959-6538-4bbc-9088-9eda28301689"
      unitRef="usd">-51000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTgtMS0xLTEtMjc4NTI_165ca53b-e7c2-41ab-a0da-47e3034b87b1"
      unitRef="usd">-1435000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTgtMy0xLTEtMjc4NTI_4c1ead7e-fe41-4cec-a66e-ef8aa4f3d242"
      unitRef="usd">-1378000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTktMS0xLTEtMjc4NTI_8044ac7a-3f8f-44f9-af4c-5c41c979aeb3"
      unitRef="usd">-1881000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMTktMy0xLTEtMjc4NTI_b4c20489-20e6-4fc1-9020-20b084c7ed52"
      unitRef="usd">-4518000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjEtMS0xLTEtMjc4NTI_8002e8e9-2d75-4678-a4d3-3f58f9086c80"
      unitRef="usd">110000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjEtMy0xLTEtMjc4NTI_005d9545-04a4-47ae-87b9-5b0e3a88f77b"
      unitRef="usd">279000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjQtMS0xLTEtMjc4NTI_45e2b2a6-9a04-48c8-8b90-42d5c1f7f754"
      unitRef="usd">-110000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjQtMy0xLTEtMjc4NTI_55e50844-dabb-4ec4-9f91-efb29506c246"
      unitRef="usd">-279000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjYtMS0xLTEtMjc4NTI_83b4b8d1-0e82-488f-b976-bbfbaba3fe24"
      unitRef="usd">0</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjYtMy0xLTEtMjc4NTI_eb0e1c64-ddbd-4e85-a04b-3dae31add61b"
      unitRef="usd">152000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjctMS0xLTEtMjc4NTI_2388f146-48a1-4305-8ff4-116c7db1bb6e"
      unitRef="usd">9289000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjctMy0xLTEtMjc4NTI_f2cf1284-3e20-443a-a5b1-4f52546edec1"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjgtMS0xLTEtMjgxNjY_544a7ffe-944e-4832-8000-a449b70f9048"
      unitRef="usd">1754000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjgtMy0xLTEtMjgxNjY_3558e762-d21e-4422-9aed-8a00d78bd78b"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjktMS0xLTEtMzA2Njk_70d7129e-d487-4dc7-b85e-d3c5c0f13bd1"
      unitRef="usd">586000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjktMy0xLTEtMzA2NzY_6e84a038-7af1-4fd3-99ec-279b0fe0885d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjgtMS0xLTEtMjc4NTI_0b9ff6f9-09e9-49f0-b0a7-f0634ecf36b3"
      unitRef="usd">9000</apyx:RepaymentofFinanceLeaseLiabilities>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMjgtMy0xLTEtMjc4NTI_d610a6e2-3c84-49bc-903e-2b3e19914141"
      unitRef="usd">54000</apyx:RepaymentofFinanceLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzAtMS0xLTEtMjc4NTI_27dbc242-cdad-450c-9af4-f1adb5f92ce0"
      unitRef="usd">8112000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzAtMy0xLTEtMjc4NTI_f6d7a417-ec38-406b-b131-9287fcc891b3"
      unitRef="usd">98000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzEtMS0xLTEtMjc4NTI_ba0ab695-3b5e-44cd-bbe6-70b1a6f0154a"
      unitRef="usd">-58000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzEtMy0xLTEtMjc4NTI_8e47ef5b-8cee-4581-be99-d9cd9ece5763"
      unitRef="usd">63000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzItMS0xLTEtMjc4NTI_ffc1ac84-250d-4d80-816b-32cfa70317d2"
      unitRef="usd">6063000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzItMy0xLTEtMjc4NTI_3fae79f2-b3c6-475e-b180-82e8f9c97b4c"
      unitRef="usd">-4636000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzMtMS0xLTEtMjc4NTI_e8770eb5-f634-40c7-8b69-50070927b0ad"
      unitRef="usd">10192000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifcf286c1d1ac4c6a9c53a9c75c20d4fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzMtMy0xLTEtMjc4NTI_3a884525-8d20-4f3b-a2f5-30505b1f3214"
      unitRef="usd">30870000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzQtMS0xLTEtMjc4NTI_ddb52913-9de7-49cb-a308-2489845be091"
      unitRef="usd">16255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i791bf538170f41c58addc94c2a446640_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzQtMy0xLTEtMjc4NTI_0dc108df-9369-4932-9660-6b154c5f632b"
      unitRef="usd">26234000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzctMS0xLTEtMjc4NTI_548c23e4-f600-4f61-bbd8-7fcc76298ebe"
      unitRef="usd">1000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzctMy0xLTEtMjc4NTI_e1a0561f-ab7c-4ed2-8c5f-fe18347bec1c"
      unitRef="usd">8000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzgtMS0xLTEtMjc4NTI_f6e3c0e9-c819-4047-84e6-ffa65d3ff5a9"
      unitRef="usd">125000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8yNS9mcmFnOjU2MDhlZGY5NmZkOTRjMWM4MzBjNjBiMjg4NDVmYmU1L3RhYmxlOjRlYmI2NDJiNDI2NTQzNGM4ZGQ3YmUwMzhkNWRhMTUyL3RhYmxlcmFuZ2U6NGViYjY0MmI0MjY1NDM0YzhkZDdiZTAzOGQ1ZGExNTJfMzgtMy0xLTEtMjc4NTI_6ae1c1c4-4115-4b5d-85e1-28c50ef01543"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMzA2Nw_0919c1d8-1589-4ae9-a278-0385158af5ef">BASIS OF PRESENTATION&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apyx Medical Corporation (&#x201c;Company&#x201d;, &#x201c;Apyx&#x201d;, &#x201c;it&#x201d; and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an advanced energy technology company with a passion for elevating people&#x2019;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#xae; in the cosmetic surgery market and J-Plasma&#xae; in the hospital surgical market. Renuvion&#xae; and J-Plasma&#xae; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of its plan to accelerate and fully fund the development of its advanced energy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;business, with a focus in the cosmetic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;surgery market, the Company sold its Core business in 2018 for gross proceeds of $97&#160;million.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 14, 2022, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) posted a Medical Device Safety Communication (&#x201c;Safety Communication&#x201d;). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as &#x201c;tightening&#x201d;). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#xae; Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion&#xae; device system for certain dermal resurfacing procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#xae; APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion&#xae; APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#xae; APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion&#xae; APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers  about the clearance for the Renuvion&#xae; APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Management believes that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the requirements of the Financial Accounting Standards Board&#x2019;s Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#x2019;s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term.  During the year ended December 31, 2022, the Company incurred an operating loss of $23.6&#160;million and used $20.3&#160;million of cash in operations. During the three months ended March 31, 2023, the Company incurred an operating loss of $5.6&#160;million and used $1.9&#160;million of cash in operations. As of March 31, 2023, the Company had cash and cash equivalents of $16.3&#160;million, of which the Company must maintain $10.0&#160;million under its Credit Agreement. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100&#160;million. The shelf registration included an embedded ATM facility for up to $40&#160;million. To date, the Company has not utilized this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#x201c;Credit Agreement&#x201d;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement provides for an up to $35&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25&#160;million, comprised of (i) an initial tranche of $10&#160;million, (ii) a second tranche of $5&#160;million, and (iii) a third tranche of $10&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10&#160;million, subject to a borrowing base equal to certain percentages of the Company&#x2019;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a more in depth description of the terms of the Credit Agreement, see Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, 2023, the Company&#x2019;s Board of Directors approved a plan to sell and leaseback the Company&#x2019;s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#x201c;Purchase Agreement&#x201d;) with VK Acquisitions VI, LLC (the &#x201c;Purchaser&#x201d;), for the sale of the Company&#x2019;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#x201c;Property&#x201d;) for a purchase price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For a more in depth description of the terms of the Purchase Agreement, see Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company&#x2019;s tax refunds were approved for approximately $0.2&#160;million more than the amount recorded in the Company&#x2019;s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company&#x2019;s U.S. headcount by 14%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations and its debt covenants for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i4329db9485b349278676f47f9db880a6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODIwNjg3_9c89341b-648d-4f98-afd0-375396f5d35f"
      unitRef="usd">97000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibbf0f4361aaa413daa96a1cde208b376_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMzI5ODUzNDkwNDM4Ng_30e4336f-148d-43c6-9c7d-53814776e870"
      unitRef="usd">-23600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibbf0f4361aaa413daa96a1cde208b376_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMzI5ODUzNDkwNDQwMQ_4cc929f1-a2b8-49a7-b745-5e6115844c51"
      unitRef="usd">-20300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2Mzk3_a8b17725-3694-4d78-b6fa-848a5615150e"
      unitRef="usd">-5600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2NDEw_aca96ec9-c88c-4712-93ee-1fc2fd907183"
      unitRef="usd">-1900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2NTA3_944cf7c1-ff66-4c86-8438-e34d9150c467"
      unitRef="usd">16300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance
      contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMjc0ODc3OTA5MTQ3NA_62618fac-0bef-4f5a-940e-8f725387e31e"
      unitRef="usd">10000000</apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance>
    <apyx:SecuritiesRegisteredNewIssues
      contextRef="i3932728fc7a04ebaa43fed7736e1c40c_D20221122-20221122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2OTg5_2e63c08c-dffc-493f-9ba6-565dcd0ae98a"
      unitRef="usd">100000000</apyx:SecuritiesRegisteredNewIssues>
    <apyx:SecuritiesRegisteredNewIssues
      contextRef="i3932728fc7a04ebaa43fed7736e1c40c_D20221122-20221122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI2OTg5_379f5d2b-b356-4e1b-9ac0-5ba6da25991d"
      unitRef="usd">100000000</apyx:SecuritiesRegisteredNewIssues>
    <apyx:SecuritiesRegisteredNewIssues
      contextRef="i842683acc0a34f84893c61d6455c84bd_D20221122-20221122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3MDYx_1828c93b-6edf-4bef-8288-ec768335292f"
      unitRef="usd">40000000</apyx:SecuritiesRegisteredNewIssues>
    <apyx:SecuritiesRegisteredNewIssues
      contextRef="i842683acc0a34f84893c61d6455c84bd_D20221122-20221122"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3MDYx_a9669397-6125-40f4-9adc-c02e1b83c2cc"
      unitRef="usd">40000000</apyx:SecuritiesRegisteredNewIssues>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9f7ad3b30f9045f4a940c5dd6e62909f_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3NDE5_531bedb5-ea39-4ef1-976b-eea2b3d5c4b9"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i22587808ca5d48bab5471ce1b3d5871d_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3NTc2_0a1841f3-f5d1-42f7-9761-43b0fc7eb589"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic4a9c2aec01046399022caa446b9ec13_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3NjIw_7c659f2c-6bca-4393-85eb-79b6baaf6d18"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0e46158015eb4aec901c105c23099f18_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3NjUw_90b0c99e-8caf-4eae-8a4b-0682b2bd6d89"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9789c9d226394206be51a46193f836c3_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3Njg0_4b188167-f308-4955-9de8-3e5b1ca64f87"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia32fcb27739a44c999f32b3a61c449f6_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI3Nzgx_04becdd9-a0fc-4d6c-bf56-f7a17d27a95b"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <apyx:SaleLeasebackPurchaseAgreement
      contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI4NTUw_bb27c763-430a-46da-878f-1462390d26a7"
      unitRef="usd">7650000</apyx:SaleLeasebackPurchaseAgreement>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i26213cf5bc234af691fd6ad429fc40cf_D20230101-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfMjc0ODc3OTA5MDU5Ng_a92f1248-ecac-4326-b665-4eb72ee92a01"
      unitRef="usd">200000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="ib02d47ac09b44377974655e36339723e_D20230109-20230109"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zMS9mcmFnOmI0YzQ4Mzk4YTk4ZTQzMzQ5YzZjY2U3OGJkZTVlNGNiL3RleHRyZWdpb246YjRjNDgzOThhOThlNDMzNDljNmNjZTc4YmRlNWU0Y2JfNTQ5NzU1ODI5Njgx_200fd990-60a1-4906-a0e7-58723257474b"
      unitRef="number">0.14</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNC9mcmFnOjY2OGZjYzRkOTk2MDRmMDE4MTNkOTU3N2Q0ZTc5ZDA3L3RleHRyZWdpb246NjY4ZmNjNGQ5OTYwNGYwMTgxM2Q5NTc3ZDRlNzlkMDdfMTU3MA_c48367c7-5214-4633-8327-0c330a72a5f3">RECENT ACCOUNTING PRONOUNCEMENTS &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNC9mcmFnOjY2OGZjYzRkOTk2MDRmMDE4MTNkOTU3N2Q0ZTc5ZDA3L3RleHRyZWdpb246NjY4ZmNjNGQ5OTYwNGYwMTgxM2Q5NTc3ZDRlNzlkMDdfMTU3Ng_8ba55403-7e45-459d-968d-7985d62658ad">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RleHRyZWdpb246M2Q5MDEwZDRlNzFkNGEzZTlhMTFkNzY4ODhlYWYyMzVfMzk0_0867486a-b90a-4aa6-8701-c248b92fbee9">INVENTORIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RleHRyZWdpb246M2Q5MDEwZDRlNzFkNGEzZTlhMTFkNzY4ODhlYWYyMzVfNDA3_0c62eb38-972c-4dd4-ac44-93093fdba07e">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RleHRyZWdpb246M2Q5MDEwZDRlNzFkNGEzZTlhMTFkNzY4ODhlYWYyMzVfNDAx_9f2c2cef-cb12-4ac9-9611-000caf3c4e6c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMS0xLTEtMS0yNzg1Mg_8841de79-b0b7-48a1-b55a-d191505f3880"
      unitRef="usd">4388000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMS0zLTEtMS0yNzg1Mg_4affcaf0-e6e7-48ab-b20a-645aeab8ebc5"
      unitRef="usd">4979000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMi0xLTEtMS0yNzg1Mg_eb466ff5-25a6-4a4d-9670-ef8478df276f"
      unitRef="usd">2331000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMi0zLTEtMS0yNzg1Mg_91899dc2-ec5e-4b71-830d-55803c7a9f1b"
      unitRef="usd">2160000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMy0xLTEtMS0yNzg1Mg_6e15ab01-6116-445a-ab2b-fc65a554481e"
      unitRef="usd">4655000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfMy0zLTEtMS0yNzg1Mg_13ccefd4-1889-41c4-a72a-e406b16ee1a0"
      unitRef="usd">5115000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNC0xLTEtMS0yNzg1Mg_ce229317-05d6-4a96-b95c-988ea54def5c"
      unitRef="usd">11374000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNC0zLTEtMS0yNzg1Mg_f33fd9d6-9f09-46d1-8a58-93c9205a08da"
      unitRef="usd">12254000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNS0xLTEtMS0yNzg1Mg_9e712a58-c02a-4567-b8db-ac12ff644b0c"
      unitRef="usd">428000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNS0zLTEtMS0yNzg1Mg_bf9a4f74-6a2c-4e45-a110-865591d3b471"
      unitRef="usd">457000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNi0xLTEtMS0yNzg1Mg_4344f53d-b520-4440-8474-09483632ee5d"
      unitRef="usd">10946000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80MC9mcmFnOjNkOTAxMGQ0ZTcxZDRhM2U5YTExZDc2ODg4ZWFmMjM1L3RhYmxlOjE0N2UwYTEzYWQ2MDQyYjNhY2RjOGMyMmU2YmU0MzBmL3RhYmxlcmFuZ2U6MTQ3ZTBhMTNhZDYwNDJiM2FjZGM4YzIyZTZiZTQzMGZfNi0zLTEtMS0yNzg1Mg_547a703a-198b-42e3-947f-5eaa5ee5da18"
      unitRef="usd">11797000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMTI4Nw_a96d1d82-8493-47a5-912e-d8273b64c668">ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;br/&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company&#x2019;s unencumbered real property. On February 27, 2023, the Company&#x2019;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#x201c;Purchase Agreement&#x201d;) with VK Acquisitions VI, LLC (the &#x201c;Purchaser&#x201d;), for the sale of the Company&#x2019;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#x201c;Property&#x201d;) for a purchase price of $7,650,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with the requirements of ASC Topic 360,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; Property, Plant, and Equipment, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the Company has determined that the real property to be sold meets the requirements to be presented as held for sale. Accordingly, the Company has presented the associated assets as held for sale in the accompanying unaudited condensed consolidated balance sheet and the table above at March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the &#x201c;Lease&#x201d;) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (10) years commencing from the closing (the &#x201c;Initial Term&#x201d;), and a renewal term of five (5) years, exercisable at the Company&#x2019;s option. The annual fixed rent will be $619,500 for the first year of the Initial Term, and will be subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.&lt;/span&gt;&lt;/div&gt;On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit equal to one years rent, taxes, first months rent, expenses, and fees. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital to its operations.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMzI5ODUzNDg5MjM0NA_7c47c026-523b-45e2-b3b6-c093d644f9ca">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;br/&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6a3f2eb674df41a2ae74e07a8d73a59c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMS0xLTEtMS0yOTkwMw_2af1b2fa-ab38-4ae4-b1c9-a99e5ad3af2c"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i444e3d03e8b34aea95597bd9077be349_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMS0zLTEtMS0yOTkwNA_fba62408-ff1a-4439-ac8f-359fa4c12dbc"
      unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i79d67f218c964b66aa874fbba351e483_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMi0xLTEtMS0yOTkwMw_bf54a742-6b4b-4917-8215-ebb84731222d"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i28d4a532478246d4bf4d795e035840ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMi0zLTEtMS0yOTkwNA_f96e40b0-1cdf-4762-9d15-0050f4d74056"
      unitRef="usd">4426000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e80aa911f544e7a99cf80274b923c6a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMy0xLTEtMS0yOTkwMw_82133042-5f4b-4274-ade5-26b5cfefa1b6"
      unitRef="usd">2472000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i41c447b579b144bf96d49d5e10b32eee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMy0zLTEtMS0yOTkwNA_f88178a2-e784-4036-8257-3c3000a17dfd"
      unitRef="usd">2613000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i52498e454d8e4e4a9cc70ff49ba56436_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNC0xLTEtMS0yOTkwMw_bffa413e-92cd-4b12-aadc-e6fba446cf39"
      unitRef="usd">213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i67f1d0dccbc94a32bfdc2e93912d45e2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNC0zLTEtMS0yOTkwNA_a5424529-c2ff-49da-b0a4-4d6d3f8c2664"
      unitRef="usd">211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i56b3a3086a39456d82fe6d3a37c11a9b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNS0xLTEtMS0yOTkwMw_570cfb6d-1a0e-476d-9f3e-c2577971f78f"
      unitRef="usd">1230000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0311da46d2f74bb18fbfe7861fcd1a6b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNS0zLTEtMS0yOTkwNA_884236cf-cc22-4f78-a4c4-899f6438f6b2"
      unitRef="usd">1420000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieb80eb1f91e44c0eaf61e0cd23a39e01_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNi0xLTEtMS0yOTkwMw_4438ea9f-fda6-4730-81a8-34ae800730f6"
      unitRef="usd">178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i66c7b33ceee847c4b00c7492e4b509f0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNi0zLTEtMS0yOTkwNA_ea2def3d-0ccb-474d-9b70-36eef882ebb6"
      unitRef="usd">178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5534ca1fb36e45c69f14c9ee7219b0e5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNy0xLTEtMS0yOTkwMw_674f9972-51b3-4479-8b4d-1e8e4f8906a3"
      unitRef="usd">847000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i94ef5925e82e463ca7c4bf42717d5767_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfNy0zLTEtMS0yOTkwNA_7ae44436-1a85-495e-a5d5-43c9e8c5a8ca"
      unitRef="usd">847000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfOC0xLTEtMS0yOTkwMw_3acdfd3d-e9dc-4579-b3c5-7e099f3f21b0"
      unitRef="usd">4956000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfOC0zLTEtMS0yOTkwNA_ac95d17d-a228-4bf7-a678-1e2f8cc26fac"
      unitRef="usd">11295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfOS0xLTEtMS0yOTkwMw_72acc73b-510f-4472-84b0-fa7ce474b7f2"
      unitRef="usd">3387000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfOS0zLTEtMS0yOTkwNA_ad5a8515-09cf-4435-91cd-cf6276672f41"
      unitRef="usd">5041000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <apyx:PropertyPlantAndEquipmentInService
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTAtMS0xLTEtMjk5MDM_6809e47a-d473-4509-a40c-98278d09aabe"
      unitRef="usd">1569000</apyx:PropertyPlantAndEquipmentInService>
    <apyx:PropertyPlantAndEquipmentInService
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTAtMy0xLTEtMjk5MDQ_2c6d61fd-3bd4-4273-9d86-2884b055df0c"
      unitRef="usd">6254000</apyx:PropertyPlantAndEquipmentInService>
    <us-gaap:ConstructionInProgressGross
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTEtMS0xLTEtMjk5MDM_ede0f480-5cdf-4b7d-bca9-44768fbcd0b8"
      unitRef="usd">540000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTEtMy0xLTEtMjk5MDQ_797bffcf-58c6-4acc-b1d3-8a50d9149d7a"
      unitRef="usd">507000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTItMS0xLTEtMjk5MDM_c2a44098-7c17-40c2-b0a3-ea4687bc141f"
      unitRef="usd">2109000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTItMy0xLTEtMjk5MDQ_23f2ebce-fe8c-4e58-9c9d-cdde22156867"
      unitRef="usd">6761000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTQtMS0xLTEtMjk4OTU_d5c916c6-abe6-467c-ab38-75c5aee9d136"
      unitRef="usd">4569000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RhYmxlOjg0ZGQ0YzM5MmE5ZTRhZjhhMjhmOWFkZWYyYWM2N2ZmL3RhYmxlcmFuZ2U6ODRkZDRjMzkyYTllNGFmOGEyOGY5YWRlZjJhYzY3ZmZfMTQtMy0xLTEtMjk5MDE_ac885a5d-5b9f-4151-9849-d80243b6c775"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <apyx:SaleLeasebackPurchaseAgreement
      contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE3NDk0_d238407c-9d5f-4462-8af6-e99e7ec07f32"
      unitRef="usd">7650000</apyx:SaleLeasebackPurchaseAgreement>
    <apyx:SaleLeasebackTermOfLease
      contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4NTI2_293419ae-8e5a-4022-84a9-0f253b32c1e8">P10Y</apyx:SaleLeasebackTermOfLease>
    <apyx:SaleLeasebackRenewalTerm
      contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4NjE1_c28d1bdc-6eb8-4722-9176-e9ff0b66da17">P5Y</apyx:SaleLeasebackRenewalTerm>
    <apyx:SaleLeasebackAnnualRentPayment
      contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4Njk0_2274fd1e-0880-418b-95c3-39310259b57c"
      unitRef="usd">619500</apyx:SaleLeasebackAnnualRentPayment>
    <apyx:SaleLeasebackAnnualRentIncrease
      contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4NzYz_493d8e63-d590-41ac-979a-f08e33ebc5dc"
      unitRef="number">0.04</apyx:SaleLeasebackAnnualRentIncrease>
    <apyx:SaleLeasebackManagementFeeOnRentPayment
      contextRef="i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfNTQ5NzU1ODE4OTQ1_108d1866-51be-4ffd-a08c-7cbdba295a51"
      unitRef="number">0.03</apyx:SaleLeasebackManagementFeeOnRentPayment>
    <apyx:SaleLeasebackTermOfLease
      contextRef="if55075181de3450781da931211bae736_D20230508-20230508"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMjc0ODc3OTA3OTI3NQ_2bdcc53c-93d6-475a-a3ff-eb7b675f5188">P10Y</apyx:SaleLeasebackTermOfLease>
    <apyx:SaleLeasebackNetCashProceeds
      contextRef="if55075181de3450781da931211bae736_D20230508-20230508"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMjc0ODc3OTA4MDc5Mg_a3e4af63-51dc-4c2f-880e-da4a036a2de8"
      unitRef="usd">6600000</apyx:SaleLeasebackNetCashProceeds>
    <apyx:SaleLeasebackSecurityDepositEqualToAnnualRent
      contextRef="if55075181de3450781da931211bae736_D20230508-20230508"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8zNy9mcmFnOjg5ZjkwNDY2MmZhNjQ1ODY4Y2EyNzlmZjc1ZDg3NDU1L3RleHRyZWdpb246ODlmOTA0NjYyZmE2NDU4NjhjYTI3OWZmNzVkODc0NTVfMjc0ODc3OTA4MDgxNg_ad95761c-55c1-44e4-82e1-39692c500990">P1Y</apyx:SaleLeasebackSecurityDepositEqualToAnnualRent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RleHRyZWdpb246NzM2NDQ2MDQ2NWY3NGU4MWIzNWRlYTEyZDM3ZjJiYzNfMzE4_c5b7a2a8-88a1-49e0-bf4f-1ce5a64ec87f">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees and legal related contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations on the liability.</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RleHRyZWdpb246NzM2NDQ2MDQ2NWY3NGU4MWIzNWRlYTEyZDM3ZjJiYzNfMzIy_fc9b7f9b-c236-47d6-bf7e-d50589eaa4da">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees and legal related contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMS0xLTEtMS0yNzg1Mg_42cf0591-bd70-4f94-a0a8-ce4a3b74c65b"
      unitRef="usd">848000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMS0zLTEtMS0yNzg1Mg_155c1bef-9b0f-434a-97ce-aa8dafae705e"
      unitRef="usd">563000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMi0xLTEtMS0yNzg1Mg_38799e41-3702-4daa-b1e6-2a08c64e7084"
      unitRef="usd">570000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMi0zLTEtMS0yNzg1Mg_f956ea1d-fd73-45e0-bcda-c2ca77499904"
      unitRef="usd">0</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMy0xLTEtMS0yNzg1Mg_d05d2403-c5a8-405d-ba72-33c3d807a73c"
      unitRef="usd">790000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMy0zLTEtMS0yNzg1Mg_38219a41-200b-4390-8ba3-77f114312ec6"
      unitRef="usd">847000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNC0xLTEtMS0yNzg1Mg_9040acdd-9b9a-44d9-8b60-a3ceb39fece9"
      unitRef="usd">368000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNC0zLTEtMS0yNzg1Mg_e36d365f-4b37-4793-bbd6-b80c9ad94da8"
      unitRef="usd">391000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNS0xLTEtMS0yNzg1Mg_38cb699e-45fb-4761-8d81-c0249bfa7183"
      unitRef="usd">1794000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNS0zLTEtMS0yNzg1Mg_2d6d118f-95ef-491b-8b52-8892f8c00b3f"
      unitRef="usd">1825000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNi0xLTEtMS0yNzg1Mg_a0177d72-49d2-49fe-93ec-abc7bd04cc95"
      unitRef="usd">924000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNi0zLTEtMS0yNzg1Mg_9c68cbd3-9ee9-41e3-bc95-b6c4ee2157e4"
      unitRef="usd">901000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNy0xLTEtMS0yNzg1Mg_31909e1f-776d-46d0-b9eb-db80bfb896d3"
      unitRef="usd">1053000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfNy0zLTEtMS0yNzg1Mg_18ce188b-4401-45c2-92a0-770098a5044c"
      unitRef="usd">853000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfOC0xLTEtMS0yNzg1Mg_93ac79c1-dbe6-44ae-995e-d35e5112119b"
      unitRef="usd">345000</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfOC0zLTEtMS0yNzg1Mg_04bece26-d9a3-4c68-a63e-048f945c79e1"
      unitRef="usd">345000</apyx:JointAndSeveralPayrollLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfOS0xLTEtMS0yNzg1Mg_ed152f81-0657-4713-8eb2-b054c1af468e"
      unitRef="usd">0</apyx:UncertainTaxPositionsLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfOS0zLTEtMS0yNzg1Mg_f4dfb0e5-c335-4f77-95dc-8f333415250a"
      unitRef="usd">2079000</apyx:UncertainTaxPositionsLiability>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTAtMS0xLTEtMjc4NTI_fa176f86-02f0-40ea-af14-2a6a2b42723b"
      unitRef="usd">211000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTAtMy0xLTEtMjc4NTI_e54412ea-16ee-4a88-85fd-ce27eb8de8df"
      unitRef="usd">245000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTEtMS0xLTEtMjc4NTI_2dfa38e0-b9ed-41f3-b1b0-9514796dc0b8"
      unitRef="usd">723000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTEtMy0xLTEtMjc4NTI_47ab82de-764b-4466-84e4-1df28cba020b"
      unitRef="usd">879000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTItMS0xLTEtMjc4NTI_abb3d8bf-84aa-471f-aa3c-996292ffe08f"
      unitRef="usd">7626000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80My9mcmFnOjczNjQ0NjA0NjVmNzRlODFiMzVkZWExMmQzN2YyYmMzL3RhYmxlOmQyNDBjZDllZGNlYTQ1MTJiZjk5YjA2MDEyZmI0ZmMzL3RhYmxlcmFuZ2U6ZDI0MGNkOWVkY2VhNDUxMmJmOTliMDYwMTJmYjRmYzNfMTItMy0xLTEtMjc4NTI_2c041c70-291c-4dad-93d6-98d03be238b7"
      unitRef="usd">8928000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjQy_117f330e-e3e0-4787-9a35-435fa5b91aee">CREDIT AGREEMENTOn February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#x201c;Credit Agreement&#x201d;), by and among the Company (as borrower) and Apyx China Holding Corp., the Company&#x2019;s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively &#x201c;MidCap&#x201d;).&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Credit Agreement provides for an up to $35&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25&#160;million, comprised of (i) an initial tranche of $10&#160;million, (ii) a second tranche of $5&#160;million, and (iii) a third tranche of $10&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10&#160;million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the Credit Agreement. The Credit Agreement matures on February 1, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline"&gt;Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The initial tranche of $10&#160;million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company&#x2019;s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Each term loan bears interest at a floating rate reset monthly based on an adjusted  one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.1% at March 31, 2023). Interest is payable monthly in arrears on the first day of each month.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The first twenty-four (24) months of the term loans constitute an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity on February 1, 2028. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment fees, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee is being accreted over the life of the Credit Agreement utilizing the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As the Credit Agreement contains a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet at March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline"&gt;Revolving Facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. Borrowings are limited to the lesser of the Company&#x2019;s borrowing base and the revolving commitment of $10,000,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the revolving facility, the Company is required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account will be swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings will be promptly returned to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Loans made under the revolving facility bear interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (8.8% at March 31, 2023). The Company is obligated to pay a fee equal to 0.5%  per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee. Terminations and reductions of the commitments are subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10&#160;million under the revolving facility. If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2023, the Company has drawn no amounts on the revolving facility. As of March 31, 2023, the Company had approximately $5,700,000 available to be drawn on the revolving facility. As the Credit Agreement contains a subjective acceleration clause and the Company is required to maintain a lockbox, any amounts drawn on the revolving facility will be presented as a current liability in the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline"&gt;Collateral&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline"&gt;Covenants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49&#160;million, $60&#160;million and $70&#160;million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $10&#160;million in cash and cash equivalents during the duration of the Credit Agreement&#x2019;s term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March 31, 2023, the Company was in compliance with the financial covenants contained within the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline"&gt;Events of Default&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Credit Agreement also contains customary Events of Default&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the Credit Agreement. The bifurcated derivative is de minimis to the Company's unaudited condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline"&gt;Issuance of Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the Company&#x2019;s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering  warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with entering into the Credit Agreement, the Company incurred debt issuance costs of approximately $1.8&#160;million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan will be amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and will be amortized over the life of the term loans starting at the issuance date. If these loans are not issued, the Company will recognize &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the deferred costs at the point that the Company's rights to borrow on the term loans expires. The costs allocated to the revolving facility will be recognized on a straight-line basis over the term of the Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Included in interest expense for the three months ended March 31, 2023 are $17,000 and $37,000, respectively, of amortization of the debt issuance costs and amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three months ended March 31, 2023 are $12,000 and $1,000, respectively, of amortization of the debt issuance costs and amortization of the debt discount on the revolving facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s term loan, net consists of the following at March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount, including accretion of exit fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2023, principal repayments on the term loan are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9f7ad3b30f9045f4a940c5dd6e62909f_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzE5_e57b5d6c-9080-4169-a05f-932774c0f1d9"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i22587808ca5d48bab5471ce1b3d5871d_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMjkz_1e3fa01c-3da3-459a-9961-1c891ff581ee"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic4a9c2aec01046399022caa446b9ec13_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzA2_01d0340b-8c0a-4d46-8d26-da3658f551e2"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0e46158015eb4aec901c105c23099f18_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzU4_fd542869-59e7-47a9-93c9-1c10018a6aa4"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9789c9d226394206be51a46193f836c3_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTc0_137fb466-0f55-4519-a1c8-a61bef2bb5c2"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia32fcb27739a44c999f32b3a61c449f6_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzMy_0853be1f-7ca8-4b81-94fa-6eed125e1896"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic4a9c2aec01046399022caa446b9ec13_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzQ1_f74247bd-65ee-4602-bc97-36a7cdbcdbdb"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i099455fbc1dc4ad496d841a9e2cbc539_D20230217-20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzcw_a861a6a0-9442-4693-b6ba-a842a640161e"
      unitRef="number">0.001</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <apyx:DebtInstrumentInterestRateFloorPercent
      contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzc2_a92ba963-2e04-4beb-baaf-4d090dc64838"
      unitRef="number">0.025</apyx:DebtInstrumentInterestRateFloorPercent>
    <apyx:DebtInstrumentInterestRateFloorSpreadAdjustmentPercent
      contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTg3_d25dd8dc-485c-4f8e-9e03-9f5ccc597505"
      unitRef="number">0.0735</apyx:DebtInstrumentInterestRateFloorSpreadAdjustmentPercent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic4a9c2aec01046399022caa446b9ec13_I20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0Mjc4_a55a4da8-a5bf-4866-9a9f-912b47f86b05"
      unitRef="number">0.121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <apyx:DebtInstrumentPeriodOfInterestOnly
      contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjAy_7387f6a8-a9f7-4d78-8673-9b7f169d9c49">P24M</apyx:DebtInstrumentPeriodOfInterestOnly>
    <apyx:DebtInstrumentExtensionPeriod
      contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjE4_65eacc1e-5ff4-4b37-91bd-bb3744a573bd">P12M</apyx:DebtInstrumentExtensionPeriod>
    <apyx:DebtInstrumentNumberOfMonthlyPayments
      contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjA4_d76ccab0-09fe-44d3-8e30-df5b5631f956"
      unitRef="monthlypayment">36</apyx:DebtInstrumentNumberOfMonthlyPayments>
    <apyx:DebtInstrumentNumberOfMonthlyPaymentsExtension
      contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0MzIy_90b9efaa-4b3d-4bfc-a9d0-81ead5f9a1d7"
      unitRef="monthlypayment">24</apyx:DebtInstrumentNumberOfMonthlyPaymentsExtension>
    <apyx:DebtInstrumentPrepaymentFeePercent
      contextRef="i5d5ece174ab94a1db32622d52c60a23c_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzgy_0e07e3f2-57fe-499a-a05d-bb51ccc1af69"
      unitRef="number">0.03</apyx:DebtInstrumentPrepaymentFeePercent>
    <apyx:DebtInstrumentPrepaymentFeePercent
      contextRef="if473b8c0c1e64a71aaa04d5e033d18a5_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzg2_73a2207a-1286-405b-a441-66289943f979"
      unitRef="number">0.02</apyx:DebtInstrumentPrepaymentFeePercent>
    <apyx:DebtInstrumentPrepaymentFeePercent
      contextRef="i326c0815b32647328b23564b770a38b5_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzkw_62457637-9bb5-45b3-bd7b-597c1f946e83"
      unitRef="number">0.01</apyx:DebtInstrumentPrepaymentFeePercent>
    <apyx:DebtInstrumentExitFee
      contextRef="i90e7407b3f17460390b4a483fa3bf354_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxMzk0_8a689bd5-026b-4789-a2da-4051d3f0c413"
      unitRef="number">0.04</apyx:DebtInstrumentExitFee>
    <apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount
      contextRef="i8a9fbd2dc730476f8a383e982377fba4_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDE1_1bf64806-008f-44e3-ada3-9e2be21a7dac"
      unitRef="usd">10000000</apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount>
    <apyx:DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings
      contextRef="id84b5b8ace5c47e0ab7d98a27c878c5a_D20230217-20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTEwMTA0_6b8aa698-7718-46fd-9ea9-02750b4ee3f0">P5D</apyx:DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia8727fd78b5f49719ede74e72b308e36_D20230217-20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDMz_f20ebd73-1af4-4feb-992a-a685979ea7a4"
      unitRef="number">0.001</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <apyx:DebtInstrumentInterestRateFloorPercent
      contextRef="i6475488d296841caa68cd47c85e020e8_D20230217-20230217"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDM5_1410ba69-e7a6-4a89-b06c-89320e299bc3"
      unitRef="number">0.025</apyx:DebtInstrumentInterestRateFloorPercent>
    <apyx:DebtInstrumentInterestRateFloorSpreadAdjustmentPercent
      contextRef="i6475488d296841caa68cd47c85e020e8_D20230217-20230217"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTEwMTEw_44521f68-f97c-4d94-a6ae-42b9dd3ca4ec"
      unitRef="number">0.0400</apyx:DebtInstrumentInterestRateFloorSpreadAdjustmentPercent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8a9fbd2dc730476f8a383e982377fba4_I20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0Mjg2_53d32c14-2d13-4635-b08f-1cb5ed89ee51"
      unitRef="number">0.088</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <apyx:DebtInstrumentAnnualFeePercent
      contextRef="i6475488d296841caa68cd47c85e020e8_D20230217-20230217"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTMw_d28032e5-8501-437e-8eb1-4b936a54aa96"
      unitRef="number">0.005</apyx:DebtInstrumentAnnualFeePercent>
    <apyx:DebtInstrumentTerminationFees
      contextRef="id84b5b8ace5c47e0ab7d98a27c878c5a_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjI1_a4f2d366-011f-416e-a364-64a42d682920"
      unitRef="number">0.03</apyx:DebtInstrumentTerminationFees>
    <apyx:DebtInstrumentTerminationFees
      contextRef="i959de39370604cf7aad3380d9347c61e_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTY2_a43898a7-9b50-41be-8a6b-8b0d53beb8b2"
      unitRef="number">0.02</apyx:DebtInstrumentTerminationFees>
    <apyx:DebtInstrumentTerminationFees
      contextRef="if7f997a25acb43b78c977a49616ca9cb_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTcw_c251c7eb-8521-434a-b368-ce960067b3c7"
      unitRef="number">0.01</apyx:DebtInstrumentTerminationFees>
    <apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent
      contextRef="id84b5b8ace5c47e0ab7d98a27c878c5a_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDU4_55055cd2-fee6-43fb-ad6d-472be5dc3777"
      unitRef="number">0.30</apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent>
    <apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount
      contextRef="i8a9fbd2dc730476f8a383e982377fba4_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDQ1_83c6c303-9b88-4902-a6b5-2ee0c57a9535"
      unitRef="usd">10000000</apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="ia32fcb27739a44c999f32b3a61c449f6_I20230217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0Mjky_28f7ff2a-b50a-476a-be04-ddeda86abe53"
      unitRef="usd">5700000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne
      contextRef="i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTM2_54aa59b3-cebf-4514-a73b-ac92b5b05ce7"
      unitRef="usd">49000000</apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne>
    <apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo
      contextRef="i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDYz_13fc9f0c-7f40-416f-912a-9ff2717f6e19"
      unitRef="usd">60000000</apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo>
    <apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree
      contextRef="i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDc2_b07819a5-e0d3-49c5-9045-157f39559d83"
      unitRef="usd">70000000</apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree>
    <apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance
      contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNDg5_40849602-8637-44f9-94b7-32820fc37b90"
      unitRef="usd">10000000</apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance>
    <apyx:DebtInstrumentDefaultApplicableInterestRate
      contextRef="i5d5b6ac44ade4700b26334526cfe5f12_D20230217-20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTAy_8dbaaa2f-1124-4aa6-af38-87abe51b8c8f"
      unitRef="number">0.02</apyx:DebtInstrumentDefaultApplicableInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTA2_9886e561-3cd9-45f3-b12f-1c1ec56d0f0c"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTE1_cae81284-677c-40c0-a462-9355057540d5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNTIz_54fd2aab-561b-4ee7-8815-520ecda847ec"
      unitRef="usdPerShare">3.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8zMjk4NTM0OTIxNjQw_e94eec9d-b9db-4dcf-bd81-74d6a96df9f5">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i9396d3bd36c8431da99d9d9421e5af7b_I20230217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0MzA2_1bf07c62-0180-4837-b9cb-44789d7c6299"
      unitRef="usd">1800000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i52b5c4f206324a52b8b01adbfe778760_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI4NzA5_0e5e52b7-37d6-4b0e-9134-3c6bf28a7844"
      unitRef="usd">17000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i52b5c4f206324a52b8b01adbfe778760_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI4NzE4_6a844c9d-60b5-4c65-8ad0-c2652ff89657"
      unitRef="usd">37000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="idb361a5c665a4bcbb5b44abe46d8fc2b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI4NzI3_ec798470-837a-47ab-8279-362adadc4b4d"
      unitRef="usd">12000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="idb361a5c665a4bcbb5b44abe46d8fc2b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI4NzM4_576e1f45-fcb8-4237-938d-367802024552"
      unitRef="usd">1000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0MzAz_59295b91-fad1-4b63-a697-e25000917a44">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s term loan, net consists of the following at March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount, including accretion of exit fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6338653760b44614b5950f6458c874e5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ZTk4YWJjNTNjNjNjNDQzNzliOTMzNTQxN2U0YzNkOTEvdGFibGVyYW5nZTplOThhYmM1M2M2M2M0NDM3OWI5MzM1NDE3ZTRjM2Q5MV8xLTItMS0xLTMwNzE0_ff7830e2-a8ac-46e0-af0f-03b0e05de929"
      unitRef="usd">10000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ZTk4YWJjNTNjNjNjNDQzNzliOTMzNTQxN2U0YzNkOTEvdGFibGVyYW5nZTplOThhYmM1M2M2M2M0NDM3OWI5MzM1NDE3ZTRjM2Q5MV8yLTItMS0xLTMwNzE0_417b29a3-9e0e-4e28-9f2d-7f73c3da0a04"
      unitRef="usd">485000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ZTk4YWJjNTNjNjNjNDQzNzliOTMzNTQxN2U0YzNkOTEvdGFibGVyYW5nZTplOThhYmM1M2M2M2M0NDM3OWI5MzM1NDE3ZTRjM2Q5MV8zLTItMS0xLTMwNzE0_4c621e5a-a797-414a-9889-a654fbb3d956"
      unitRef="usd">737000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ZTk4YWJjNTNjNjNjNDQzNzliOTMzNTQxN2U0YzNkOTEvdGFibGVyYW5nZTplOThhYmM1M2M2M2M0NDM3OWI5MzM1NDE3ZTRjM2Q5MV80LTItMS0xLTMwNzE0_1cee06d4-3fbf-428b-a29a-229f75424ef6"
      unitRef="usd">8778000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGV4dHJlZ2lvbjo5ODIyZjhjZjNhZWM0Y2NkOWFjZmQ2ZWY1NjJiNDYwMl8yNzQ4Nzc5MTI0MzA0_b599af2b-54ac-49b6-b8f4-f22b0848400e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2023, principal repayments on the term loan are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV8xLTEtMS0xLTMwNzI5_fd257e22-44e0-4791-b323-1f7061d1fb9f"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV8yLTEtMS0xLTMwNzI5_7142ce9c-96fe-4629-9f7b-30203f394254"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV8zLTEtMS0xLTMwNzI5_b489bbfc-d172-4c3f-81c9-c3d351c42aeb"
      unitRef="usd">2778000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV80LTEtMS0xLTMwNzI5_d21e4ab5-b8da-409b-b7eb-aea15a158dc1"
      unitRef="usd">3333000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV81LTEtMS0xLTMwNzI5_f6ff1e0a-324a-4e2e-a5b3-644c50a456cf"
      unitRef="usd">3333000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <apyx:LongTermDebtMaturityAfterYearFour
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV82LTEtMS0xLTMwNzI5_10392987-502a-4ded-9bd9-77701965a917"
      unitRef="usd">556000</apyx:LongTermDebtMaturityAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF8xMDA0L2ZyYWc6OTgyMmY4Y2YzYWVjNGNjZDlhY2ZkNmVmNTYyYjQ2MDIvdGFibGU6ODBmNDRjZDBiM2ViNGRhNGFiZmVmNDIwZDI3NDMyMTEvdGFibGVyYW5nZTo4MGY0NGNkMGIzZWI0ZGE0YWJmZWY0MjBkMjc0MzIxMV83LTEtMS0xLTMwNzI5_e7997bd2-cfc2-4375-9c04-92de3015dd22"
      unitRef="usd">10000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfNjIx_1f3d67ac-4361-4711-bb77-b597a28370d2">INTEREST IN JOINT VENTURE INVESTMENT&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company executed a joint venture agreement with its Chinese supplier (&#x201c;China JV&#x201d;) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company&#x2019;s ownership investment in the China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i4271a8fb9da64a4789ce96b320c25e39_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfMTU2_e3c59f74-cf4d-43fe-aac9-cb4f3a18c6a6"
      unitRef="number">0.51</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <apyx:NoncontrollingInterestRequiredCapitalContribution
      contextRef="if3f9fa1ecfdb48119493afdf30b2022a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfMzY5_ac20b183-a613-4254-8091-22386b8ce08b"
      unitRef="usd">357000</apyx:NoncontrollingInterestRequiredCapitalContribution>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i6aa4190bc3674f469e5b158e6869197c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfMzI5ODUzNDg4NDQ2OQ_6c074e93-1c68-4f67-b54c-343994059baf"
      unitRef="usd">203000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i9eb98c8ff23e49bc88f698fa56afd8ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfMzI5ODUzNDg4NDQ3OQ_00a5c1b0-4c8f-4103-b0f3-11881b471399"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <apyx:NoncontrollingInterestTableTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RleHRyZWdpb246Y2NlNjhhYjA4ODU1NDE5OWFkMjcyOGY1MWI4NDE5OWJfNjIy_7c3e7825-b7f4-43cf-b54a-1ac9c4dd75e9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company&#x2019;s ownership investment in the China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</apyx:NoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="i8b4980f0f2ab4be298429e6c68c4337c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfMi0yLTEtMS0yNzg1Mg_614b3ba0-7a8d-4803-bf05-e4f3d4ae7ace"
      unitRef="usd">219000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i994301f8b554452584f2e4a03b35f7ac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfMi00LTEtMS0yNzg1Mg_536f2a19-8904-43ad-a7f7-28335af98464"
      unitRef="usd">317000</us-gaap:MinorityInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie30ce932627140d1a2b179341ef78232_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfNC0yLTEtMS0yNzg1Mg_190cb1a9-477b-4330-9979-f0dfb4002997"
      unitRef="usd">-51000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3ce5d204aa7344c59e93d632a33eef74_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfNC00LTEtMS0yNzg1Mg_80bd60bd-ce04-4f6a-8575-b5f04220c068"
      unitRef="usd">-23000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="i857f1353ae2c4ec3bc1c0d6d91f7e28c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfNS0yLTEtMS0yNzg1Mg_71ae5524-01b7-45d6-b443-87b947413657"
      unitRef="usd">168000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ib96384db7fff41dbb63293f4abff78af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80Ni9mcmFnOmNjZTY4YWIwODg1NTQxOTlhZDI3MjhmNTFiODQxOTliL3RhYmxlOmIzYThhYjQ1MDFkNTRiYjZhNmZjODJmZDk3NzIxYjU0L3RhYmxlcmFuZ2U6YjNhOGFiNDUwMWQ1NGJiNmE2ZmM4MmZkOTc3MjFiNTRfNS00LTEtMS0yNzg1Mg_04ccb972-e271-4f3f-bcb9-4785d7954d92"
      unitRef="usd">294000</us-gaap:MinorityInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RleHRyZWdpb246ZjY3YTRhZmM0ZDZlNGNlNTk0YjFiNzRiNzMwYmYwYTBfNTM0_d3099f62-e9bf-48d9-8d9d-25ff2730f231">EARNINGS (LOSS) PER SHARE &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share (&#x201c;basic EPS&#x201d;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#x201c;diluted EPS&#x201d;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RleHRyZWdpb246ZjY3YTRhZmM0ZDZlNGNlNTk0YjFiNzRiNzMwYmYwYTBfNTM4_394adbf3-dec0-4f25-8fda-0a692e6b6f0b">The following table provides the computation of basic and diluted loss per share.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMy0yLTEtMS0yNzg1Mg_572125aa-8124-4ac3-89a2-6c7e289a2ab9"
      unitRef="usd">-3483000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMy0yLTEtMS0yNzg1Mg_dc228632-f94f-4b73-bea6-49b738360845"
      unitRef="usd">-3483000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMy00LTEtMS0yNzg1Mg_09eb75f7-962e-4bc1-886c-9e427e6d2dec"
      unitRef="usd">-5945000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMy00LTEtMS0yNzg1Mg_883918a2-ffe5-47c7-92db-3427d638832c"
      unitRef="usd">-5945000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfNi0yLTEtMS0yNzg1Mg_72475432-9e5e-4dfc-aca9-4de3ee5a5180"
      unitRef="shares">34598000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfNi0yLTEtMS0yNzg1Mg_86228d8c-f815-466b-ab87-38d947f61401"
      unitRef="shares">34598000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfNi00LTEtMS0yNzg1Mg_4ea220da-529d-4abb-a65d-15ed0b148fc4"
      unitRef="shares">34429000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfNi00LTEtMS0yNzg1Mg_f886c8f1-6b7f-484b-bb77-c2bffb108d77"
      unitRef="shares">34429000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfOS0yLTEtMS0yNzg1Mg_c337521e-6346-447d-8890-e1f07a12b257"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfOS0yLTEtMS0yNzg1Mg_d4195e92-d9bf-49cb-a4ee-49151d13048e"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfOS00LTEtMS0yNzg1Mg_27a296f0-44da-4d65-9d0c-c80e404c151b"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfOS00LTEtMS0yNzg1Mg_9986b3e0-4585-4d69-84bd-832052dd07af"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idd237ef53a384e9e80d9d797d4712603_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMTMtMi0xLTEtMjc4NTI_a99f1e2e-bc5e-4d1f-ba43-ce6b4f1d8bbc"
      unitRef="shares">7783000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3163fe51e869499585757dba371b5390_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMTMtNC0xLTEtMjc4NTI_2213f821-dff8-45b0-95c5-d77bd4106fbd"
      unitRef="shares">6796000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i968a4cfb77a54232afc8b80ea39ad52b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMTQtMi0xLTEtMjk4ODg_d951411f-f2f5-4131-8d28-3e78a892e315"
      unitRef="shares">250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie59716d0f60c45d9aded6f41b3e4a29f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF80OS9mcmFnOmY2N2E0YWZjNGQ2ZTRjZTU5NGIxYjc0YjczMGJmMGEwL3RhYmxlOjcxZThhZDYyOGMzMjQyZjE5OTRmY2VkZWI4ZWZmYzllL3RhYmxlcmFuZ2U6NzFlOGFkNjI4YzMyNDJmMTk5NGZjZWRlYjhlZmZjOWVfMTQtNC0xLTEtMjk4ODk_7e22e700-9ac2-4f6b-a11d-55a0ebdbbc7b"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTUxMg_253306c0-ec3c-4359-973b-ebb250e76b38">STOCK-BASED COMPENSATION &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized approximately $1,367,000 in stock-based compensation expense for the three months ended March 31, 2023, as compared with $1,650,000 for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,520,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,783,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended March 31, 2022, we received 22,654 options as payment in the exercise of 19,013 options. There were no such exercises for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (&#x201c;2023 Grants&#x201d;) utilizing a Black Scholes model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTUxNA_ade53ef1-ca93-41f7-871b-589af35c4d6f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfNjUw_292020ec-3d76-4040-a496-6b35326e5f79"
      unitRef="usd">1367000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfNzE4_b00c0d9a-2ec7-4ba9-8c37-2a71223fa55f"
      unitRef="usd">1650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTUxOA_7342c07f-bd35-40a7-a522-3ae6508d44be">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,520,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,783,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNS0xLTEtMS0yNzg1Mg_7a70e3c7-d42b-4f32-8c45-b4edfba6c95e"
      unitRef="shares">6520444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNS0zLTEtMS0yNzg1Mg_a6c7a994-9df8-41cc-91cd-522a2cdf78b0"
      unitRef="usdPerShare">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNi0xLTEtMS0yNzg1Mg_8bd365ba-23ae-445d-b77a-8853dc7f96d9"
      unitRef="shares">1408865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNi0zLTEtMS0yNzg1Mg_a182348b-269b-4f7b-9dc9-7847563d956d"
      unitRef="usdPerShare">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNy0xLTEtMS0yNzg1Mg_1f887bc6-654a-4d11-bb4d-14e6ad4f6874"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfNy0zLTEtMS0yNzg1Mg_b6dda139-1fa1-4dee-8d10-7c85f944e842"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfOC0xLTEtMS0yNzg1Mg_74db3f76-12ef-4413-af44-0e3da501e38d"
      unitRef="shares">146164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfOC0zLTEtMS0yNzg1Mg_2368c203-b498-4033-b500-67f3562ff17e"
      unitRef="usdPerShare">8.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfOS0xLTEtMS0yNzg1Mg_2276cbe8-0c35-4e1f-b7cd-cb5999fd70cb"
      unitRef="shares">7783145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmYwZTcxMGZiYTZmYTQyNGNhN2IzOWE1YzE0OTNmZmEyL3RhYmxlcmFuZ2U6ZjBlNzEwZmJhNmZhNDI0Y2E3YjM5YTVjMTQ5M2ZmYTJfOS0zLTEtMS0yNzg1Mg_a873518f-32bf-428b-a711-bc264d635376"
      unitRef="usdPerShare">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTE4NA_21e98b8f-6fd5-48b7-9193-db3fbb1e3bbf"
      unitRef="shares">22654</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTIzMg_571894ba-ba89-4dc7-bd53-0bdfb6f7430e"
      unitRef="shares">19013</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RleHRyZWdpb246YjllOTEyNGIzMzdjNDI2OWI0MDExMTBmYjgwZWNlNTBfMTUyMQ_41e8d161-61e6-4fab-9e61-4e98493fcd7b">The Company calculated the grant date fair value of options granted in 2023 (&#x201c;2023 Grants&#x201d;) utilizing a Black Scholes model.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfMS0xLTEtMS0yNzg1Mg_2a535307-1356-4a33-a8ee-137ba6dd2386"
      unitRef="usdPerShare">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfMi0xLTEtMS0yNzg1Mg_3d09d32b-503c-43cf-9ffc-ad7c4f4065d8"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfMy0xLTEtMS0yNzg1Mg_c2ef20da-e4a0-4e4a-b246-822c1ee3c35c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfNC0xLTEtMS0yNzg1Mg_94ece69c-22a8-4b43-a886-8e8218c53d8f"
      unitRef="number">0.858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81Mi9mcmFnOmI5ZTkxMjRiMzM3YzQyNjliNDAxMTEwZmI4MGVjZTUwL3RhYmxlOmEzNTk4ZDZjYWMzZDRlMzlhYmU4ZWQyYzU0OTdjZGRmL3RhYmxlcmFuZ2U6YTM1OThkNmNhYzNkNGUzOWFiZThlZDJjNTQ5N2NkZGZfNS0xLTEtMS0yNzg1Mg_9aaa71a6-a0cd-4788-a685-c11cd6774ca2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfMTI3OQ_bad1d9a8-778a-442d-940d-32a8a4539e27">INCOME TAXES Income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March&#160;31, 2023 and 2022, respectively. For the three months ended March&#160;31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company&#x2019;s liability for uncertain tax positions, including accrued interest and penalties of approximately $2.1&#160;million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on the net operating loss (&#x201c;NOL&#x201d;) and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfNjY_cd555d65-0fd8-4b06-80f5-2177e62e741f"
      unitRef="usd">-2267000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfNzM_4f3bfbdb-b232-4846-84ca-6125b23926b9"
      unitRef="usd">70000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfMTA0_533923bb-47d6-42ad-a569-16a25f4f9118"
      unitRef="number">0.391</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfMTEx_95b8c9b9-d726-4cfd-b09e-63d2dfcc3940"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81NS9mcmFnOmIwNTBiOGM3MjNkMDRiYjZiNmJiMGY1MTQxN2FiNDJiL3RleHRyZWdpb246YjA1MGI4YzcyM2QwNGJiNmI2YmIwZjUxNDE3YWI0MmJfMzI5ODUzNDg4OTk5Ng_b4ab9fe9-fe4a-4f0d-919e-8fa2e6bc588d"
      unitRef="usd">2100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMzE3Mg_12f6808e-691e-49bc-99e3-31a34d10d708">COMMITMENTS AND CONTINGENCIES&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#x2019;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#x2019;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#x2019;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company recorded an estimated loss of $250,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed with the U.S. Securities and Exchange Commission on the Company&#x2019;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#x201c;Hattaway Complaint&#x201d;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#x201c;Goodwin&#x201d;), the Company&#x2019;s President and Chief Executive Officer and a member of the Company&#x2019;s Board of Directors, and Tara Semb (&#x201c;Semb&#x201d;), the Company&#x2019;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#x2019;s Advanced Energy products and the impact such usage would have on the Company&#x2019;s business, operations and prospects. The Hattaway Complaint seeks an unspecified amount of damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Hattaway Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff&#x2019;s allegations could be subject to separate &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the &#x201c;Stein Suit&#x201d;) against individual members of the Company&#x2019;s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the &#x201c;Pritchard Case&#x201d;).  The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing.  The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously.  The outcome of the action is not within the Company&#x2019;s control and may not be known for a prolonged period of time.  In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company&#x2019;s financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, the Company had purchase commitments totaling approximately $4.0&#160;million, substantially all of which is expected to be purchased within the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i4c3ed228146b4231874ddd7a84ecf89c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMjYwMw_02cd6945-6a1b-490d-b65c-758dfa744eaa"
      unitRef="usd">250000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i1b520559f24c441e931060ece6becb9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMjYwOQ_487fa2f0-be30-4ca1-8981-d791759e12d8"
      unitRef="usd">1000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMjY1OQ_0e1e2bfc-6001-4795-b308-b641fad09913"
      unitRef="usd">250000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ib1fa5e6669544a54afa2eccf6e04c7a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIxOTMz_df7c32a5-8d37-45d8-8408-96bc48df323b"
      unitRef="usd">475000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i429b0f131ab543fbb23ba8b453c39589_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIxOTQw_a204e7f6-a23c-45b8-a440-b42f9ff0b2aa"
      unitRef="usd">2500000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ib2994bfe0e594059a28c66ab8010af39_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIxOTkx_f698cd6f-3c1b-4069-91a0-6cc908d4b536"
      unitRef="usd">475000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="idc25d1761ff44d87a5e3cce964599c64_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyNDYy_0db17e9d-e207-4f50-b1b8-f34e5ecfc769"
      unitRef="lease">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="idc25d1761ff44d87a5e3cce964599c64_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyNjE3_f8a8d708-d171-421d-9698-7d18b18668ea"
      unitRef="lease">10</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i03f055d56d024c43ab76ceb69016f0cc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyODY1_9daad6b0-ecf3-4ad6-99e7-dd604c63d0d9"
      unitRef="usd">1450000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i42273566c1174b14a4e8392f80ba2427_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyODcy_26b4b3bf-74a4-4691-ab93-f1f1ac7c24c1"
      unitRef="usd">2400000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i5d07b00814b44846ae29c9126733b0ab_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfNTQ5NzU1ODIyOTIz_9562c7bb-7187-4012-909c-e2da83379a36"
      unitRef="usd">1450000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PurchaseObligation
      contextRef="icea0a6dbf6c34a688351e2f5840efa13_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF81OC9mcmFnOmZhYWY1MDcxZWQwZTQ0NTViZDA3ZTRlMGU5YzBjNThlL3RleHRyZWdpb246ZmFhZjUwNzFlZDBlNDQ1NWJkMDdlNGUwZTljMGM1OGVfMzA4MQ_402b9976-d46e-4d07-83a2-974278e72c07"
      unitRef="usd">4000000</us-gaap:PurchaseObligation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNzI2_9ffa9a52-5a0b-4171-87fa-6fb674772ded">RELATED PARTY TRANSACTIONS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several relatives of Nikolay Shilev, Apyx Bulgaria&#x2019;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#x2019;s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev&#x2019;s son, is a quality manager in the quality assurance department.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The partner in the Company's China JV is also a supplier to the Company. For the three months ended March&#160;31, 2023 and 2022, the Company made purchases from this supplier of approximately $44,000 and $124,000, respectively. At March&#160;31, 2023 and December&#160;31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $2,000 and $8,000, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="ia7e994b58a5f469cb23af8692f7bf53f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNjE4_102323cc-56b7-4741-87b1-a4dc029d3011"
      unitRef="usd">44000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="iead2dc3eba5e47188eea66a730ec7ba2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNjI1_c8d9d1a9-3b46-4ea5-a46c-24b8eddcc04f"
      unitRef="usd">124000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="iabe7f3502b4347be9913b0ff042c7661_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNzE2_68d2fdf1-a386-4f24-9fb3-5fdd90cf63e4"
      unitRef="usd">2000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueFromRelatedParties
      contextRef="i8478849b5317485ba002f297876ef34b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82MS9mcmFnOmEyNTdlNGFjMTE3NTRmMTg5MDg5ZWNlMDQxOGZlN2M1L3RleHRyZWdpb246YTI1N2U0YWMxMTc1NGYxODkwODllY2UwNDE4ZmU3YzVfNzIz_7f5df988-53b7-427f-be05-d873907ce3b6"
      unitRef="usd">8000</us-gaap:DueFromRelatedParties>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTYxMQ_e3dc2771-67f0-494c-8d72-6c4698ec33b9">GEOGRAPHIC AND SEGMENT INFORMATION &lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate &amp;amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International sales represented approximately 26.9% of total revenues for the three months ended March 31, 2023,  as compared with approximately 39.6% of total revenues for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfODYy_88af0a16-a31c-4ebd-9c02-69f6c5d9657a"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfODYy_c86b0e30-aec4-468e-a621-ed2496352a4a"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTYyMA_ffc54475-d23a-4a58-98c2-87ba7b77b825">Summarized financial information with respect to reportable segments is as follows:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMi0zLTEtMS0yNzg1Mg_c5a01ca5-c4a3-41be-bbbb-202297aa4ca3"
      unitRef="usd">9690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMi01LTEtMS0yNzg1Mg_6b56bf20-d74e-44cf-950d-e92183d0c425"
      unitRef="usd">2452000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMi03LTEtMS0yNzg1Mg_f9f6e8c0-408a-42b7-855f-7e45e63a1b68"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMi05LTEtMS0yNzg1Mg_1a1c238a-8627-44f9-9941-aa1c846cc9b8"
      unitRef="usd">12142000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTQtMy0xLTEtMjc4NTI_76c46548-eb49-4c3e-9adc-e389737dff1d"
      unitRef="usd">-1326000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTQtNS0xLTEtMjc4NTI_e7882d92-dcb9-46eb-b6f5-7f0fb15470c4"
      unitRef="usd">851000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTQtNy0xLTEtMjc4NTI_af63c46f-6de1-471a-b6ed-a2ae7bac02c8"
      unitRef="usd">-5136000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTQtOS0xLTEtMjc4NTI_1d31d349-1f50-4820-b7ef-f3722724352e"
      unitRef="usd">-5611000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTYtMy0xLTEtMjc4NTI_8bca8eb7-b7b5-4a6d-847c-949db05434bb"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTYtNS0xLTEtMjc4NTI_9c9a9a8e-e32c-4432-823e-9cae70063cf9"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTYtNy0xLTEtMjc4NTI_d30b76fd-50c9-4bd7-8a0e-df1a6bff62b3"
      unitRef="usd">51000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTYtOS0xLTEtMjc4NTI_d2f2414c-89a4-4d66-a09e-2293bcc3e721"
      unitRef="usd">51000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTctMy0xLTEtMjc4NTI_7958b89c-07b3-42ce-b0c1-f1697c2113dc"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTctNS0xLTEtMjc4NTI_7842da07-7abd-4dbc-bb08-f951fb5a05f5"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTctNy0xLTEtMjc4NTI_080edf8a-6e80-4ce2-90be-a7cc14e75c06"
      unitRef="usd">234000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTctOS0xLTEtMjc4NTI_31a3a69b-3f52-4e8f-afe2-fd01b1cc8aa3"
      unitRef="usd">234000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTgtMy0xLTEtMjc4NTI_95f8f7d2-3d1f-4b9b-ba6c-d09b06db5754"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTgtNS0xLTEtMjc4NTI_3f2783f5-fe70-4302-b37c-e7edd7e465fd"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTgtNy0xLTEtMjc4NTI_3a3f4782-9b12-4e48-8925-73d5a82ccfd7"
      unitRef="usd">-5000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMTgtOS0xLTEtMjc4NTI_2749b959-8b2a-42ef-b680-b50f65497b14"
      unitRef="usd">-5000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMjItMy0xLTEtMjc4NTI_d6d4d8a1-711d-43f6-bebb-da381e19b0f1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic4573fe195fc4ab0b8c07fcbf1887ae4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMjItNS0xLTEtMjc4NTI_77bc3513-6666-455e-ab7c-7b447d37e416"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i194afa727a3f499e86e1fa7092f71cc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMjItNy0xLTEtMjc4NTI_060a882e-03ce-4bb0-b62b-4c4c1a297fed"
      unitRef="usd">-2267000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmEyN2E1YmZmMmViYTQzZjhhZDM4YjEyZDE5ZjdjZjFjL3RhYmxlcmFuZ2U6YTI3YTViZmYyZWJhNDNmOGFkMzhiMTJkMTlmN2NmMWNfMjItOS0xLTEtMjc4NTI_1ebb1a2a-10a6-4139-a95e-a7a356742349"
      unitRef="usd">-2267000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMi0zLTEtMS0yNzg1Mg_7a34dbb5-16da-4e22-9b7d-c2024318833a"
      unitRef="usd">10814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMi01LTEtMS0yNzg1Mg_687137fa-f26d-4fd9-a3c2-5af5f09af48a"
      unitRef="usd">1679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMi03LTEtMS0yNzg1Mg_88f003e8-7b6e-4eca-9bc3-042c3476ce1a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMi05LTEtMS0yNzg1Mg_9b19104e-527d-489a-86eb-c67412243e6e"
      unitRef="usd">12493000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTQtMy0xLTEtMjc4NTI_b44b57a6-8610-4f2e-b0fe-1dcd4ef52567"
      unitRef="usd">-1339000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTQtNS0xLTEtMjc4NTI_0eb068f6-7dff-4cf9-9f8d-dce222e6be79"
      unitRef="usd">317000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTQtNy0xLTEtMjc4NTI_9df79c86-45ee-4d17-824f-728f89742405"
      unitRef="usd">-4849000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTQtOS0xLTEtMjc4NTI_d5d28630-9228-4fee-80d6-b85f4957c349"
      unitRef="usd">-5871000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTYtMy0xLTEtMjc4NTI_953cb192-5c16-448b-ad96-1bcb456bf76e"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTYtNS0xLTEtMjc4NTI_0b7a740f-5c10-4ee1-a7fa-fab5b7fa9bd0"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTYtNy0xLTEtMjc4NTI_1e212ae6-9924-4801-9274-43d5cedaf196"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTYtOS0xLTEtMjc4NTI_296b2bc5-09e3-4629-9e96-15864da88ef3"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTgtMy0xLTEtMjc4NTI_bda339cf-e56a-438e-8169-231f01123b86"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTgtNS0xLTEtMjc4NTI_a324eb4d-a2ed-4732-92b5-aa4aec8e4b5a"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTgtNy0xLTEtMjc4NTI_b534959b-5980-4725-a642-bc6dcc885361"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTgtOS0xLTEtMjc4NTI_c09f3186-d867-4b58-9742-38ba627058ad"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTktMy0xLTEtMjc4NTI_7b746a31-2a52-4344-b231-b1eebcc5cb1f"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTktNS0xLTEtMjc4NTI_4cd111f4-97d8-4b7e-9470-57cec26f695d"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTktNy0xLTEtMjc4NTI_8e71cd55-03ae-496d-bd15-46b8ce0d95db"
      unitRef="usd">-21000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMTktOS0xLTEtMjc4NTI_00cab033-8c4b-495a-b804-4fe14fb28d38"
      unitRef="usd">-21000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5816e0f0139e439babfd2c115d2384b8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMjMtMy0xLTEtMjc4NTI_f94a68df-0ae2-473f-83bf-5b927e506f41"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icd4175b8318e43f2ae8c0e79fe59fcff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMjMtNS0xLTEtMjc4NTI_f58370fb-00fe-4866-9839-4a15d0a8014d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2eb1e09647ca42a6a55605bad4a55957_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMjMtNy0xLTEtMjc4NTI_1c8373c7-aeb9-4d3f-a72a-a0e14017d91e"
      unitRef="usd">70000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOmM4MmMyMDM5YjY2NjQzMjk5YmIwZGVhZGM0ZDU4NTMxL3RhYmxlcmFuZ2U6YzgyYzIwMzliNjY2NDMyOTliYjBkZWFkYzRkNTg1MzFfMjMtOS0xLTEtMjc4NTI_26f69397-aa20-4474-ba1b-82b4119f8cd7"
      unitRef="usd">70000</us-gaap:IncomeTaxExpenseBenefit>
    <apyx:TotalRevenuePercent
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTQwMA_6a9c4bd1-4c51-4487-a163-b122d6f9c6de"
      unitRef="number">0.269</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTQ2NQ_0b965f77-06fc-4eba-b51c-ce958d21c42c"
      unitRef="number">0.396</apyx:TotalRevenuePercent>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RleHRyZWdpb246NjBlNDIzZGYzMzM4NDc0YTg0YTgyYmZjMmQzNGNjZWFfMTYxMg_b39d86e0-bb2d-415d-9ef7-93a482050c97">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ef61e5dd37545a3ad7e31b677f88c1d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfMy0xLTEtMS0yNzg1Mg_565563a0-5fff-4702-9580-9da0c8caff5d"
      unitRef="usd">8871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5569b815eaea4f9d9cdfcb8f7e5f0209_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfMy0zLTEtMS0yNzg1Mg_c8229cfe-eca9-42ba-8c99-262bf3a52d16"
      unitRef="usd">7548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6176a8f8df744f2b97ab2568640c4a9d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfNC0xLTEtMS0yNzg1Mg_3bb8f0b6-c723-4c1d-a77a-ec05db224cf5"
      unitRef="usd">3271000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic12b47ef6b0e48508323229d60109300_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfNC0zLTEtMS0yNzg1Mg_13739e98-b8bf-4aa9-8d2d-83a18b5bae31"
      unitRef="usd">4945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1859d1f280245f78801a6687dc86e14_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfNS0xLTEtMS0yNzg1Mg_01e3bf2f-6d3d-4e02-9cc8-ba2ca5dfe88d"
      unitRef="usd">12142000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2f77ffb41aa4ffc842fe94f69cf1446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxYmU1MmZlOGEzNDQ0ZGFiNzc1ODBkNDc4MmY1OWNkL3NlYzo4MWJlNTJmZThhMzQ0NGRhYjc3NTgwZDQ3ODJmNTljZF82NC9mcmFnOjYwZTQyM2RmMzMzODQ3NGE4NGE4MmJmYzJkMzRjY2VhL3RhYmxlOjFlNDhkZjFhODliZjQyODNhOWJlNDA0MTg4NzU5ZDkxL3RhYmxlcmFuZ2U6MWU0OGRmMWE4OWJmNDI4M2E5YmU0MDQxODg3NTlkOTFfNS0zLTEtMS0yNzg1Mg_a4116004-4ef9-4a29-8f3b-982d974d39f8"
      unitRef="usd">12493000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M7!/)./2,XT*;610,!K5C-W:S^Y95XX:"K"CTE,XK!48J[)&U;%)#0ZAIA.
M8W"';/R6C:PCBB9Z<8A@OVBWF451,E!1X [1V(UH X'MV=" W- X:[?MNVUF
MEGWW9.>-D7Y=IQ+28UX)584M5#OO)%+^\LT;L,V-9*OF)=*<2<G*YG))B9JI
MVD#]OF!,OM[H]U+M>\CI_U!+ P04    " #)>*M6 P;N*+0#  #'#   &
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M0MBKT?2<P0%QBXWGMQ-[%;'7G>8PS)*,0<E%L/7 >X1B*S:W-$(XX4+1'_E
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MK\Z,3IP9@L^T$!L.XB(EJ:7\PET^.%<^/G-^Y! 82(P'ENB%Y7OD5/P+%^]
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M%Q\:F>H]C,^8R5&$RUGY6DH.WTUDJ[/JU8;JBZ"[\MG]%16";LO##<$I82I
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MB@8-M+G5KB$[(2=RBUES;M2<'TOQO,@-TJV,H BO%))EH,;!<;% C00:H^3
MF@:BB'XP-5BAT9)O9O4@A ^&_<S]8'+[ 'XY0'8PZ]+B &7?YE\]#-,\+^F$
MK)5[*)VZQUI_,C)&:Q60DA@XJ#RR!@N:X@<Q+3&#VY-.Y9W -#%,[L7>W?6G
M,K*U-/FA#30C#,P@K:!.I9TD>-?BLZLI.L2V&OD3]/'KTI0[3&D^VXB5;4Z%
MS@J@Q^?<9VZ K,57' )LMY[:23:55'3&0NV9H]F[0VO#)/Y\3$E,_$-F&ZDE
MNO!;.N"AT%FZ]89/(+QX9,_]R0&5=9;GW#,):6TT%2';<-=-'K8,GZQ]?UQ-
MU+Y@0QFR[$^_P,Z([%,.&1@)AQLI,? !%,RZ*S9\K?>;S=#UE<[_)ZFCK4[D
M#& E?0"_E=.IYR'^%\;^="Q(I:?O:MW=8QQ4C^V!(XC,T<P3YSS&1]D8Y3!Q
M)WB)N_[9\!PEF@7[%5Y^LR[@=6A^;MIA6!J9T4'+]J2:3T6;("=<[32Z1+&'
M3!/;W*GC4L%*<Q2G40)L?T+155Q]#Y/F_FVAD"C=J1&DT4Y'M(?JK3!)O[(A
MI>#>/G[9&D-TS.NNYJ#JF<Z1Z/AH>GSXI#U 8D;YO.C1='QXW/U,0T@2<%BU
MQ UVZF4P" 9R"T'8DC*QO43PAW@ZW<G2Y/#YES@ZX_T/O9E&FKRSLQK5+8BT
M;=WR:/*DEWQ$O\A9V) (IW^Z<\--T*/)^'#<<2:!G4_Q(" "QUE[2-D>SPT"
MP%^:[W4JITD&PI@A5[JG"* <$JF>Z]JT;ZT)#M4E&8UB,Q\*^3X+);*]_)NF
MJ:BB!-5;#:[1]]'I*\F$]S6B+K)VX+S9]YC.PGZ@)S/:G_ 3^\)TNLL7YM;Q
MX4I<&C?G\51W&--)D!HM.3R2*JW7N6RA,W2*!%([;]=R2A=\--94M /H&&\<
MT.YZ>9J(L#\0_SE]/OMXI6CHR._F7EP(G@SI>;;?W9!%10^T1EU +F5&2VIS
M&C79.8WB@T.3SG!U0O)(W8C0/!I2_VJHH<27#N!JGVBTMU*VT-]5[#PTOK+Y
MN:[413+QY2_J8R"GVB<L+[#\0))ONZX#6K^,0B)"!C1&UWDL8)_V<-J@&!3D
MJ'\MA3DD$<S;0II[_)^N*FRQVK;:,1UHM(H_/NV\O%5F*NHCQR\:7)B2\ANC
M@Q3?\B@Y0'</@KGUCCOUWBQ?9N5^ZGAU8G)ZV@<OZI^#);?%\WU[0++(N:>C
M8^(R6QH)>>-^S[ZE=?0.7^8;JP:$N2ZRLA+@"OD]Y!+@[Q5Z4SP1Q7+XZ+VI
MOTB4_*J7=<@W@BB=57/ 01T9@DR)Z,X@A7B2V/=S*Q,R:MD7)MY71QAG%Y:*
M/2U]:4S3%2X Y7Y#?Q4@#D_'2 #L"3E'4X8[ITBZ9=6][4YNN."(S2?S?/!0
MU71^&K-@NQ.J+U*!%I"%?T)/I9Y\Q="YDY4;<;[)A0X^@TR1QG847@FS[169
M:)P<(E F,3.=?=I)C&8/9%>ZWK.&3;/V+MGF_:Z[Y^8/QZ#K!DMUNBYT0T7>
M[KC3K;LG\OSRW^HL0\J(*07_<CE2/_YXOI-&:+?VIV>;Y>6FY!VJ6Z&_YJ*;
M\P'9E#'$QI<V5BP_ZR<%=\52^QE=STK]C^BNY3]IOY,\E0,M#;B4Y/E'3T=/
M3L>C\7C<3:-W#MUIJ$)1Y%Y>9'XD51VWGG+IC_$S&<O=B^ZV%M]&VL 0%TV.
M!WTM[WV!TEGCVYSD+K<#-SGIJM@?="F><D?XE:13.[?MH0,]O?QP R%UT=XC
MX%&XU*^^":F1P+_/63>@.E:U_@SOH%M&<K,I75,Q*6OIW16?[*)B*#5=G6NR
M5>G+9TOWE:#U1^/#:9>C6$T@F\H3"9[P;RJA.EQMO^U\6-^]T8YCV U?4 =_
M=UJ-MN0>%I)<;01#=X*VJGZ$E96VG"LYF%9U9[%>R!W7!]M*-TH)]IA&FE'N
M$O;=P^:-(,8C*@646 W?_4N7%FC(B4JVX4-O#@BT+R-IZ9*B8VD"=>6-V&4P
MD*&ZZDX]F#<9WX+(C=-;UY+PW)1+UB!1:B\>#TO6JTWJVM'5_G4BF\N5J-TB
M#D]0M&P@'#ZVY6/@(N/+-2VFG_<^S:<$0GR7^?G24G^[:X8"\>2_OG" (F=_
M/?,T[ROO7!EK5[6G=G)>).<--"#$_Z+J>^7E[MB4:0+30X1V$CX9#C/'XZBV
MZY;K7#.:NL"DFM+XW]D:G46V%=VJW'V,TP_R^J[I+QK=??/0-_?<7:2>12[\
MY/]&62Z/^3)=F@CQ,9,.@2.[1*#DFXZN9G>3?3)#?TPQ/)A@N!3PK!E?.8#;
M$Z#3F=,0!3,6)YU_/"3[KOO^1X,_X4"J7O ?JE" !L/RUQS=K]W?PIS)GX#T
MR^4/:5#2+"SLY\P<6\>'3T_W5) _3I$OM:_X#T)FOJY]P1_)X4R@!7@^]TA,
MZ0N]H/L+H=?_!U!+ P04    " #)>*M6$3JJ;XH$  #X"0  &    'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;*56;4\;.1#^*Z.M5!4IY&4#E"L0*:2TI6HI
M(G#WX70?G-U)UJK7WMI>4O[]/;:7;4X"3KK[DMCKF6=FGGFQ3[?&?G<5LZ>?
MM=+N+*N\;]Z-1JZHN!9N:!K6.%D;6PN/K=V,7&-9E%&I5J-\/#X:U4+J;'8:
MOUW;V:EIO9*:KRVYMJZ%?3AG9;9GV21[_' C-Y4/'T:STT9L>,G^KKFVV(UZ
ME%+6K)TTFBROS[+YY-WY09"/ K]+WKJ=-85(5L9\#YO+\BP;!X=8<>$#@L#?
M/2]8J0 $-WYTF%EO,BCNKA_1/\38$<M*.%X8]8<L?766'6=4\EJTRM^8[2?N
MXCD,>(51+O[2-LF^/<BH:)TW=:<,#VJIT[_XV?&PHW \?D8A[Q3RZ'<R%+U\
M+[R8G5JS)1ND@186,=2H#>>D#DE9>HM3"3T_N[E87%S=TGRQ^'9W=7MY]9&N
M;[Y=8;VX^(J#Y>G(PTJ0'14=XGE"S)]!G-)7HWWEZ$*77/Y3?P3O>A?S1Q?/
M\Q<!OPH[I.ED0/DXG[Z -^U#GD:\Z3-X\Z(PK?92;VCIA2Z%+1W=-:7P3-C2
MHA)ZPR0U[4A>6ZD+V2BF/^<KYRVJZ:^GN$FF#YXV'3KLG6M$P6<96LBQO>=L
M]OK5Y&A\\D)@!WU@!R^A_Z=<_C]$NM3TN=6,U$R.!N0KI@]2"S E%#W)\[G!
M'[UY_>HXS\<G'^;+\[B<G.R1=*[E\FFU+CV/>O/E7:\63.]/IH,=RY<:&6HQ
M.KP+8I/\9&&YE)Z^&.?8T9M;T\B"IOG1WI!NX72;X(N8>1?CD'4CI T85)N2
M%6$ 8N4\K7L[ FC>Q:(IV'J,0#+0M:B=WH$!-H5JRQ /RJ9,-9;$+!<L[\5*
M,<0*=$THJPYU0!6K<M^;?8R>UDK_@&&S\N2X"#O)R:XR0D,V+"W_:"6JBF V
M"7A#K8-!TIB.\'\++O<5)F1PAG\VF(P<()SK8O25\!A 2@',8:Z%)@ADL+!*
M)H?-1LLX3\V:A,),!Q<<R5&1W$"H=!VC<,R1L7(#RI1ZZ%(\H"T^\WK-<21'
M9:%U&QA%'%)[MK*F!K\&N5\QU'5P6:QQ0N_!6KW"8G(89L+D-^!)7T4G'TB4
MIHG^0;V6'@$.0Y5>F?NDE!1BI:+X^J);WL63_<GXF4*B?7JVB ;PR2*1(9J4
MED]<;H+'G=#QY' O)>D+BQWEXX-\CRYZ(C#!<89P*EE4X6YA"Y,I [U0&87
M/CXCN:[OD4#CL@;/B/*&&V-C#RT,"EF':@A-A3*6KD!D#V#K7ZG-\]0>":/C
MMG,HE-2C;0+=GP42:!^HF],IDZ M]!&*.F1<&_22",F% ZA-_PMZB 1U31&
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MF]C<PH?JT22.2_=1[JVF4TXXN[AY__GJ_<</=S=7][/($J$S1_D6?-Z!DR?
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M>)&.FKZB^[I_VWUTC>8T9;AX ":$RGVH5O6>'HA?MB7AJ20*,A]7JC7H.[R
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MI^,>T_Y.ZU^LJMP]<JDLHG*/F>"IT'0 ^RNE;/M"!G;_6+C\/U!+ P04
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M%Y.U]D'[W=<)PQ'$;X6E,+JGUPV& HB[&2*>YLTO!$K)58!OH=BCF#Z_SL"
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MY)J%$A>D&@T.1P&8;I9U&Z=K/S_FVM$T\LN"QC\:%J#[A=9NO6$#FS\4TW\
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M\71\0/_9YTZY;)C!6R4>>6;S:3 *(,,MJX1=J?UG;/(9.+Q4">-_85_;)E$
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M^]-Q#TS]N*TG3I?^0;G2CIZG?IC1_P$T?(#VUUJ[=L(*NG\8YW\#4$L#!!0
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M6N@5F%]0U Y]CQE'SBT10(<WF&AVW+T]?"7.#?D@N,2#-BTA"^DTY1QN7:/
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M\<PH!DDC$M+&3\U5AC;D/)A#3>&KD"AB *"VW&<GM,/^ S\AN2WAKYJS66G
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MEP4]8JB= ^WG2MF-X1*TS^+T+U!+ P04    " #)>*M63&298+P"  #7!0
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MV0.TOY+2'"?V@N9-'O\$4$L#!!0    ( ,EXJU96'&*![0,  ,$)   9
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;*U6;6_C-@S^*T3NT"6 T<2R\]8F
M =(VU\N'OB#IM@_#/B@V$QMG2YZD-.U^_2C9\=I>FG;  -N2+/+A0XJ4--I)
M]4,GB :>\DSH<2,QICAKMW648,[UJ2Q0T,Q:JIP;&JI-6Q<*>>R4\JS-.IU>
M.^>I:$Q&[M^]FHSDUF2IP'L%>IOG7#U?8"9WXX;?V/]8I)O$V!_MR:C@&URB
M^;6X5S1JURAQFJ/0J12@<#UN3/VSBZZ5=P*_I;C3+_I@/5E)^<,.YO&XT;&$
M,,/(6 1.S2->8I99(*+Q5X79J$U:Q9?]/?HWYSOYLN(:+V7V>QJ;9-P8-"#&
M-=]F9B%WW['RQQ&,9*;=%W:E;-AM0+351N:5,C'(4U&V_*F*PPN%0><=!58I
M,,>[-.187G'#)R,E=Z"L-*'9CG/5:1.Y5-A%61I%LRGIF<GU[.YZ,;W_/K^$
MZ>T5+&?7-[/;!YC??KM;W$P?YG>WT'S@JPQU:]0V9-"JM:,*_*($9^^ !W C
MA4DTS$2,\6O]-A&MV;(]VPMV%/"&JU,(? ]8AP5'\(+:^\#A!>_@+7%#"69@
M@854)A4;^&.ZTD91KOQYR-T2+3R,9NOG3!<\PG&#"D2C>L3&Y.2+W^N<'^$:
MUES#8^B3)=5CO,T0Y)JJ8<\W%65AV@Q?/8,N'3K$_2CZ8>Y+5ZGIWQC#.A5<
M1"G/7EG<I28A,KJ@&@,C*UXV7?9,-*0:N(:US*C^]1D\) KQ55X K6J4U,L*
MS;D D\BMYB+6+9C&CV29Q&8"U>89[F8W<"D5&>(&X83GQ3G<F005/$A#_):<
MDA6^PM#K#3O4,B_L,FI/O@R8S\ZIYS//#QG,121SA&8F-9E9*YD#[77*>::A
MZ7L!Z[5@T/6AV?7\@/K4]GR_19H&R6M#L7 0>^A]2RKTU%+X1%NH_EFLR8*P
M57U+#RP5#P3MQ3_)=EONK4@;_@0K%+A.#X@RC_7ZK;K]*.+L_XJXW_$&?F@[
M7J\_?!OR<!A\(N3!L$6\^M ,O4$X="$?]#\1<@;L$P$?M-S[8;"9WRH_+\+]
M'FB_8Y\C!=ZM"[S['PK\$<46;4EO4&X4+Y(T D['[J'2/HI[N+07!PTHW-!*
M>.Z<BT':K,#J%$+UBW8^L\ZY3M*"RMV-_',*9%1N!Y5"*AYE&J%G^7Y4^V]2
MSVT +B?+I")Z5V1;&^N]B,LE%LX:)5X]]14&-DVH[7O=</!&+/ 8S87>,.Q6
M&5OO 75F'EJ_]HMCE?S?N,N#ADANA2E/V/IO?3^9EL?RO^+EY88*;I-2BF>X
M)M7.:9^63)47AG)@9.$.Z94T%&S73>B.A<H*T/Q:2K,?6 /UK6WR#U!+ P04
M    " #)>*M65CY&UBT)   B;P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6S5W5UOZC@:!_"O8K&CU8S44_+"6[LM4MO$B:/I.57;V;U8[44  ]$)
M,1.']AQI/OPZ(24$@@O5?RYZTT*:Y^>D/ \QL4FN7D7Z7<XYS\B/19S(Z]8\
MRY:7[;8<S_DBE.=BR1/UEZE(%V&FGJ:SMERF/)P408NX;1E&K[T(HZ0UO"J6
M/:3#*['*XBCA#RF1J\4B3'_>\EB\7K?,UMN"QV@VS_(%[>'5,ISQ)Y[]L7Q(
MU;/V1IE$"Y[(2"0DY=/KUHUY&=C=/*!8X]\1?Y5;CTF^*R,AON=/V.2Z9>1;
MQ&,^SG(B5+]>^!V/XUQ2V_%GB;8V;>:!VX_?=%KLO-J942CYG8C_$TVR^75K
MT"(3/@U7<?8H7GU>[E"Q@6,1R^(G>2W7-5IDO)*96)3!:@L64;+^'?XH_Q%;
M 6;G0(!5!EC'!MAE@'UL0*<,Z.P&= \$=,N [K$!O3*@=^PF]<N _FY [T#
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M_HP6B9&CJ%/[' -'8&!;CI# -(Z.5AP=@1S](;MO2<E_M_=&%T>=<N,&!E+
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MW01E'7 ]E=(\&/8N+U_BZ ]02P,$%     @ R7BK5G%WY0B& @  O@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULE951;YLP%(7_BL6JJ97:0DB
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M+CR?!_.%9$DV(2V95/-6=ANJ$1JX=E#[*\;D\T(_H!S*W3]02P,$%     @
MR7BK5A, Q)M5 P  Q L  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
MQ59=;^(X%/TK5]G1[HPT;;Z 0A<B%<IH6JEL!2W[L-H'DQAB-;$SM@/MOU_;
M"1D(:30S0MH78COW'I]S8U_.<,?XBX@QEO":)E2,K%C*[-JV11CC%(E+EF&J
MWJP93Y%44[ZQ1<8QBDQ2FMB>X_3L%!%J!4.S]LB#(<ME0BA^Y"#R-$7\;8P3
MMAM9KK5?F)--+/6"'0PSM,$++)^S1ZYF=H42D11301@%CM<CZ\:]GK@FP40L
M"=Z)@S%H*2O&7O3D+AI9CF:$$QQ*#8'48XLG.$DTDN+QK02UJCUUXN%XC_[%
MB%=B5DC@"4O^)I&,1U;?@@BO49[(.=M]Q:6@KL8+62+,+^S*6,>",!>2I66R
M8I 26CS1:UF(@P2%TYS@E0E>/:'S3H)?)OA&:,',R+I%$@5#SG; =;1"TP-3
M&Y.MU!"J/^-"<O66J#P9W,V>IO/IX@GN9G#_EYK!<CI[>IY/U<)2K3^H&5S
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M<D,PM-/: .ZO.%>'@7Y _M5C]!U02P,$%     @ R7BK5HLG/47+ @  >@<
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MZU?T3_8!.^OY$4T UDT MI;%1RG\BF[*SNMZJX'2"!3-=*E; .Q#)RX&;0I
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M[8VM^>Q#>P,)%A"B,6;B%<T8)AP7I^7GG0Q%MP)2_JO.]H+7J>=5F:3+,QQ
MWY"I@@-;@N%]_-!V6Y_K/#LFF7\DLBT_G<I/IXG=&^<LB&2.X&C.:"J35F%O
MINRM<[%@<S6;2I]+SW%ZYG+3F_V0MK43XS<NZC\E=RK)G4;)?@Y(T"VI,=2>
MU,Z>$FM':^-,[_T/CD2V98I;F>+^TY2]/^" +8U,[SU)QR3SW;T-.[^J=JSP
MQ=RH"RFPA:ZO' 4T)Z)(JM5H5<('NG+MC _;W5%1B?_2%/<"F3(7,>$H@;FD
M;%U<RHUE1:TM.H)FNOH\42%KF6Y&\GH"3 7([W-*Q;JC)J@N/-X?4$L#!!0
M   ( ,EXJU9M9UDFM@(  &<'   9    >&PO=V]R:W-H965T<R]S:&5E=#0V
M+GAM;*V546_:,!#'OXJ52=,F=20DD*X=1 )*6QZ@"+KM8=J#"0=$=>S,=J#[
M]CL[(:-5FE757L"^W/WO?I?XW#L(^:!V )H\IHRKOK/3.KMT717O(*6J)3+@
M^&0C9$HU;N7659D$NK9!*7-]SPO=E";<B7K6-I=13^2:)1SFDJ@\3:G\/00F
M#GVG[1P-BV2[T\;@1KV,;F$)^FLVE[AS*Y5UD@)7B>!$PJ;O#-J7H]#X6X=O
M"1S4R9H8DI40#V8S6?<=SQ0$#&)M%"C^[6$$C!DA+.-7J>E4*4W@Z?JH?FW9
MD65%%8P$^YZL]:[O?';(&C8T9WHA#K=0\G2-7BR8LK_D4/B&YPZ)<Z5%6@9C
M!6G"BW_Z6/;A) !UZ@/\,L!_'M!Y(2 H P(+6E1FL:ZHIE%/B@.1QAO5S,+V
MQD8C3<+-6UQJB4\3C-/1S?CN9C&8WTY&9#"[(LOQS70\NR>3V?7=8CJXG]S-
MR"<RHU)2TV[RX0HT39CZB%8%6WR=NN=JK,.HN7&9<UCD]%_(&9"IX'JGR)BO
M8?TTWL7Z*PC_"#'T&P6G5+9(T#XCON<'-?6,7A_N-Y035#T-K%[P@MZR: Q9
M0":D3OB6_!BLE);XR?ZLZU:AUJE7,\?X4F4TAKZ#YU2!W(,3O7_7#KTO=:C_
M2>P)>*<"[S2I1[,\78$D8H/GVZ#3%8/C9Z+JR NYKI4S\V8?8?_WISB-"=^(
MTZUPNJ_$P:%I#@"^R2::[C]I&O.]D2:L:,)&F@G7(#DUPY,RHB@#=4:0*S:?
M*C)JH=$N80\\ASJ\0K[MG?!Y+3^\>,98ZQ9<A)5;4;U[,K-2D%L[RA6)1<YU
M<?(K:W5;#.R0?&8?XBU2#/V_,L45A.=ZFW!%&&Q0TFN=8_ME,=:+C1:9G8PK
MH7'.VN4.;T*0Q@&?;X30QXU)4-VMT1]02P,$%     @ R7BK5B?$':FX!0
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MC3B".0 /&)(D[CUX\#Z*-^^I>/L+U_@W4$L#!!0    ( ,EXJU:7BKL<P
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M21P6^N)SN S3B!(+T@,@O0M"_N-9D#X Z5\$DA7Z<$]3"S( ((,+0HXB>0U
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M5K=ORFJS4L0<AG)[<&T*8;MC546Z+6N6LMR>OGN?OME_^A]02P,$%     @
MR7BK5I(LH):X 0  YQP  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<\W9.V["0!2%X:T@+X#A/B A@E1ITD9LP(+A(1ZV/!,%=A\$!1R4(@V:4UDS
MEJ__ZI,UGGS%79TWS2&M-VWJ'?>[0YI6ZYS;MQ#2?!WW=>HW;3R<[RR;;E_G
M\[);A;:>;^M5##H8C$)W/Z-ZG]S/[,U.;?S/Q&:YW,SC1S/_WL=#_F-P^&FZ
M;5K'F*O>K.Y6,4^K<-S=ME.X7*1_GESU/A?3JOM<2!5*!RD$:?D@@R K'^00
MY.6#AA T+!\T@J!1^: 7"'HI'_0*0:_E@\80-"X?) .4<4"0]( U@=:"7 N!
MUX)@"X'8@F0+@=F": N!VH)L"X';@G +@=R"= N!W8)X"X'>BGHK@=Z*>BN!
MWOKPL4V@MZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WH=Y&
MH+>AWD:@MZ'>1J"W/1R6$.AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H;:BW
M$>CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.T/A]T$>COJ[01Z.^KM!'H[ZNT$>COJ
M[<_4.^73+J9;SW6-[W\FU?G\;+R]_K*\;J*$PPO. ?YKOO\"4$L#!!0    (
M ,EXJU:,3^J/N@$  .X<   3    6T-O;G1E;G1?5'EP97-=+GAM;,W9R6["
M,!0%T%]!V2)B/)0. C9MMRV+_H";/$A$$ENVH?#W=<(@M:*HB$J]FT2)[7=?
M;.EL,G[;6O*]35TU?I(4(=@'QGQ64*U]:BPU<61N7*U#?'0+9G6VU MB8C@<
ML<PT@9HP"&V-9#I^HKE>5:'WO(FO?6F:2>*H\DGO<3>QS9HDVMJJS'2(XVS=
MY-]2!ON$-*[LYOBBM+X?)R3L9$([\G/ ?MWKFIPK<^K-M LONHZSV*9B/FPK
M\NGY$B=Z-/-YF5%NLE4=EZ3>.M*Y+XA"7:6[HOWSR2'N,.VN_.K\KLRYP#AS
MYHSU\<0<71YW.))V]<#&0N1">?X3CXFQ]-7?1^UIYY3_,CMN[X=QR^X\/.MN
MU^_QUS,^UK^P#P'2AP3I0X'T<0/2QPBDCUN0/NY ^K@'Z8,/41I!$96CD,I1
M3.4HJ'(453D*JQS%58X"*T>15:#(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J
M4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4616*K I%5H4BJT*15:'(
MJE!D52BR*A19U7_*^F[,\J__P+7WM-9E<\AGW6_.Z2=02P$"% ,4    " #)
M>*M6!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P
M+GAM;%!+ 0(4 Q0    ( ,EXJU:+VZ\@[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,EXJU:97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ R7BK5JIZ/SR\!0  K!X  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,EXJU;/J\_"F08
M ),<   8              " @?\-  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " #)>*M6 P;N*+0#  #'#   &               @('.
M%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ R7BK5I$5
M"B@@!0   10  !@              ("!N!@  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( ,EXJU8G_4X!F@4  (0A   8
M  " @0X>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #)
M>*M6#?W_=^P'  !L,@  &               @('>(P  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ R7BK5J%\]/"T$0  +30  !@
M         ("! "P  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( ,EXJU81.JIOB@0  /@)   8              " @>H]  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #)>*M6<R%-TDP#  #[!@
M&               @(&J0@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ R7BK5E-\5SL:!P  9!   !D              ("!+$8  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #)>*M6BCPZ$%P#
M  "5!P  &0              @(%]30  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( ,EXJU8S&'_.K1   !0R   9              "
M@1!1  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ R7BK
M5FFCP"_) P  7 @  !D              ("!]&$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " #)>*M6LMV/FZT#  !-"   &0
M        @('T90  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( ,EXJU9U;J!C704  &T,   9              " @=AI  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ R7BK5H E*AZR P  90@
M !D              ("!;&\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " #)>*M6SK&$THT,  !Q(P  &0              @(%5<P
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,EXJU9KMK3C
M6P,  (P'   9              " @1F   !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ R7BK5F/'(Y;X!0  LPX  !D
M ("!JX,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #)
M>*M6M@<=B$@&  !A#@  &0              @(':B0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,EXJU;FEMY]OP(  +X%   9
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M970R-2YX;6Q02P$"% ,4    " #)>*M6DK&80!T#  ">!@  &0
M    @(&SH   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M ,EXJU:H+O])@P,  )\'   9              " @0>D  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ R7BK5E8<8H'M P  P0D  !D
M             ("!P:<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " #)>*M65CY&UBT)   B;P  &0              @('EJP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,EXJU9&(+.<V (
M !0(   9              " @4FU  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ R7BK5L/%DJ;S!   A1L  !D              ("!
M6+@  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #)>*M6
MP9Q?[8$#  !@#@  &0              @(&"O0  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,EXJU:+UT<*UP,  *0,   9
M      " @3K!  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ R7BK5O*ZS*^4"@  1U\  !D              ("!2,4  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #)>*M6SX<WF[<"  "5!P
M&0              @($3T   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( ,EXJU9Q=^4(A@(  +X&   9              " @0'3  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ R7BK5D?UV=@8
M P  H L  !D              ("!OM4  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " #)>*M6$P#$FU4#  #$"P  &0
M@($-V0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,EX
MJU9U/=+8%P0   $1   9              " @9G<  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ R7BK5HLG/47+ @  >@<  !D
M         ("!Y^   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " #)>*M6"^[WIT8#  #M"@  &0              @('IXP  >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,EXJU:KJRO%P0(  -@&
M   9              " @6;G  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ R7BK5GA$.M&W @  - <  !D              ("!7NH
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #)>*M6(&^"
M/"T%  "G)P  &0              @(%,[0  >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( ,EXJU8Z$3,=T0(  /P(   9
M  " @;#R  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
MR7BK5FUG62:V @  9P<  !D              ("!N/4  'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " #)>*M6)\0=J;@%  !-)   &0
M            @(&E^   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( ,EXJU:AKPZ*_0(  ,0*   9              " @93^  !X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ R7BK5O 1N+4N P
M[A(   T              ( !R $! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #)>*M6EXJ[',     3 @  "P              @ $A!0$ 7W)E;',O+G)E
M;'-02P$"% ,4    " #)>*M6)7*.ICL$   W(   #P              @ $*
M!@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ R7BK5I(LH):X 0  YQP
M !H              ( !<@H! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ R7BK5HQ/ZH^Z 0  [AP  !,              ( !8@P!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #@ .  _#P  30X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>112</ContextCount>
  <ElementCount>256</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT</Role>
      <ShortName>ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - CREDIT AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CREDITAGREEMENT</Role>
      <ShortName>CREDIT AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables</Role>
      <ShortName>ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATIONDetails</Role>
      <ShortName>BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIESTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails</Role>
      <ShortName>ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - CREDIT AGREEMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails</Role>
      <ShortName>CREDIT AGREEMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails</Role>
      <ShortName>CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails</Role>
      <ShortName>CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INCOMETAXES</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="apyx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. apyx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedParties in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. apyx-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="apyx-20230331.htm">apyx-20230331.htm</File>
    <File>a2023q110-kexhibit311.htm</File>
    <File>a2023q110-kexhibit312.htm</File>
    <File>a2023q110-kexhibit322.htm</File>
    <File>a2023q110-qexhibit321.htm</File>
    <File>apyx-20230331.xsd</File>
    <File>apyx-20230331_cal.xml</File>
    <File>apyx-20230331_def.xml</File>
    <File>apyx-20230331_lab.xml</File>
    <File>apyx-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>apyx-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="449">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "apyx-20230331.htm": {
   "axisCustom": 3,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 449,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 112,
   "dts": {
    "calculationLink": {
     "local": [
      "apyx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apyx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "apyx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "apyx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apyx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "apyx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 395,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 43,
   "keyStandard": 213,
   "memberCustom": 20,
   "memberStandard": 23,
   "nsprefix": "apyx",
   "nsuri": "http://apyxmedical.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://apyxmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT",
     "shortName": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - CREDIT AGREEMENT",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://apyxmedical.com/role/CREDITAGREEMENT",
     "shortName": "CREDIT AGREEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://apyxmedical.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - BASIS OF PRESENTATION (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies",
     "shortName": "BASIS OF PRESENTATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://apyxmedical.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables",
     "shortName": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://apyxmedical.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i4329db9485b349278676f47f9db880a6_D20180101-20181231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - BASIS OF PRESENTATION (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
     "shortName": "BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i4329db9485b349278676f47f9db880a6_D20180101-20181231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - INVENTORIES (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://apyxmedical.com/role/INVENTORIESDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails",
     "shortName": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "apyx:SaleLeasebackPurchaseAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails",
     "shortName": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314",
      "decimals": null,
      "lang": "en-US",
      "name": "apyx:SaleLeasebackTermOfLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - CREDIT AGREEMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails",
     "shortName": "CREDIT AGREEMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails",
     "shortName": "CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails",
     "shortName": "CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "if3f9fa1ecfdb48119493afdf30b2022a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "if3f9fa1ecfdb48119493afdf30b2022a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:NoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i8b4980f0f2ab4be298429e6c68c4337c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Summary of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - INCOME TAXES (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://apyxmedical.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ia7e994b58a5f469cb23af8692f7bf53f_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ia7e994b58a5f469cb23af8692f7bf53f_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i8ef61e5dd37545a3ad7e31b677f88c1d_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - BASIS OF PRESENTATION",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://apyxmedical.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20230331.htm",
      "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities and Other Liabilities, Current",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Term Secured Overnight Financing Rate (SOFR)",
        "label": "Adjusted Term Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "Adjusted Term Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "localname": "AdjustedTermSecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AdvancedEnergyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Energy [Member]",
        "label": "Advanced Energy [Member]",
        "terseLabel": "Advanced Energy"
       }
      }
     },
     "localname": "AdvancedEnergyMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AtTheMarketFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Facility",
        "label": "At-The-Market Facility [Member]",
        "terseLabel": "At-The-Market Facility"
       }
      }
     },
     "localname": "AtTheMarketFacilityMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ChineseSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chinese Supplier",
        "label": "Chinese Supplier [Member]",
        "terseLabel": "Chinese Supplier"
       }
      }
     },
     "localname": "ChineseSupplierMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentAnnualFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Fee, Percent",
        "label": "Debt Instrument, Annual Fee, Percent",
        "terseLabel": "Annual fee"
       }
      }
     },
     "localname": "DebtInstrumentAnnualFeePercent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount",
        "label": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount",
        "terseLabel": "Borrowing base, minimum balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent",
        "label": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent",
        "terseLabel": "Borrowing base, minimum balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash And Cash Equivalents Balance",
        "label": "Debt Instrument, Covenant, Cash And Cash Equivalents Balance",
        "terseLabel": "Cash and cash equivalents balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashAndCashEquivalentsBalance",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Tranche One",
        "label": "Debt Instrument, Covenant, Tranche One [Member]",
        "terseLabel": "Debt Instrument, Covenant, Tranche One"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTrancheOneMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentCovenantTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Tranche Three",
        "label": "Debt Instrument, Covenant, Tranche Three [Member]",
        "terseLabel": "Debt Instrument, Covenant, Tranche Three"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTrancheThreeMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentCovenantTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Tranche Two",
        "label": "Debt Instrument, Covenant, Tranche Two [Member]",
        "terseLabel": "Debt Instrument, Covenant, Tranche Two"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTrancheTwoMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One",
        "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One",
        "terseLabel": "Twelve month net revenue target, year one"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three",
        "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three",
        "terseLabel": "Twelve month net revenue target, year three"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two",
        "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two",
        "terseLabel": "Twelve month net revenue target, year two"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenants",
        "label": "Debt Instrument, Covenants [Axis]",
        "terseLabel": "Debt Instrument, Covenants [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentCovenantsAxis",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_DebtInstrumentCovenantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenants [Domain]",
        "label": "Debt Instrument, Covenants [Domain]",
        "terseLabel": "Debt Instrument, Covenants [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentCovenantsDomain",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentDefaultApplicableInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Default, Applicable Interest Rate",
        "label": "Debt Instrument, Default, Applicable Interest Rate",
        "terseLabel": "Default, applicable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentDefaultApplicableInterestRate",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentExitFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Exit Fee",
        "label": "Debt Instrument, Exit Fee",
        "terseLabel": "Exit fee"
       }
      }
     },
     "localname": "DebtInstrumentExitFee",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Extension Period",
        "label": "Debt Instrument, Extension Period",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "DebtInstrumentExtensionPeriod",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_DebtInstrumentInterestRateFloorPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate Floor, Percent",
        "label": "Debt Instrument, Interest Rate Floor, Percent",
        "terseLabel": "Interest rate floor"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFloorPercent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate Floor Spread Adjustment, Percent",
        "label": "Debt Instrument, Interest Rate Floor Spread Adjustment, Percent",
        "terseLabel": "Interest rate floor spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFloorSpreadAdjustmentPercent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings",
        "label": "Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings",
        "terseLabel": "Lockbox account, funds to be applied to borrowings"
       }
      }
     },
     "localname": "DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_DebtInstrumentNumberOfMonthlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Monthly Payments",
        "label": "Debt Instrument, Number Of Monthly Payments",
        "terseLabel": "Number of monthly payments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfMonthlyPayments",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Monthly Payments, Extension",
        "label": "Debt Instrument, Number Of Monthly Payments, Extension",
        "terseLabel": "Number of monthly payments, extension"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfMonthlyPaymentsExtension",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "apyx_DebtInstrumentPeriodOfInterestOnly": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Period Of Interest Only",
        "label": "Debt Instrument, Period Of Interest Only",
        "terseLabel": "Period of interest only"
       }
      }
     },
     "localname": "DebtInstrumentPeriodOfInterestOnly",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_DebtInstrumentPrepaymentFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee, Percent",
        "label": "Debt Instrument, Prepayment Fee, Percent",
        "terseLabel": "Prepayment fee"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period",
        "label": "Debt Instrument, Prepayment Period [Axis]",
        "terseLabel": "Debt Instrument, Prepayment Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodAxis",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period [Domain]",
        "label": "Debt Instrument, Prepayment Period [Domain]",
        "terseLabel": "Debt Instrument, Prepayment Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodDomain",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period One",
        "label": "Debt Instrument, Prepayment Period One [Member]",
        "terseLabel": "Debt Instrument, Prepayment Period One"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodOneMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period Three",
        "label": "Debt Instrument, Prepayment Period Three [Member]",
        "terseLabel": "Debt Instrument, Prepayment Period Three"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodThreeMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period Two",
        "label": "Debt Instrument, Prepayment Period Two [Member]",
        "terseLabel": "Debt Instrument, Prepayment Period Two"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodTwoMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentTerminationFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Fees",
        "label": "Debt Instrument, Termination Fees",
        "terseLabel": "Termination fees"
       }
      }
     },
     "localname": "DebtInstrumentTerminationFees",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period",
        "label": "Debt Instrument, Termination Period [Axis]",
        "terseLabel": "Debt Instrument, Termination Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodAxis",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period [Domain]",
        "label": "Debt Instrument, Termination Period [Domain]",
        "terseLabel": "Debt Instrument, Termination Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodDomain",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period One",
        "label": "Debt Instrument, Termination Period One [Member]",
        "terseLabel": "Debt Instrument, Termination Period One"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodOneMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period Three",
        "label": "Debt Instrument, Termination Period Three [Member]",
        "terseLabel": "Debt Instrument, Termination Period Three"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodThreeMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period Two",
        "label": "Debt Instrument, Termination Period Two [Member]",
        "terseLabel": "Debt Instrument, Termination Period Two"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodTwoMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_JointAndSeveralPayrollLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 10.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint And Several Payroll Liability",
        "label": "Joint And Several Payroll Liability",
        "terseLabel": "Joint and several payroll liability"
       }
      }
     },
     "localname": "JointAndSeveralPayrollLiability",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, After Year Four",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_MoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molds",
        "label": "Molds [Member]",
        "terseLabel": "Molds"
       }
      }
     },
     "localname": "MoldsMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_NoncontrollingInterestRequiredCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Required Capital Contribution",
        "label": "Noncontrolling Interest, Required Capital Contribution",
        "terseLabel": "Required capital contribution"
       }
      }
     },
     "localname": "NoncontrollingInterestRequiredCapitalContribution",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of China Joint Venture"
       }
      }
     },
     "localname": "NoncontrollingInterestTableTextBlock",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_OEMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OEM [Member]",
        "terseLabel": "OEM"
       }
      }
     },
     "localname": "OEMMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Expenses And Liabilities, Current",
        "label": "Other Accrued Expenses And Liabilities, Current",
        "terseLabel": "Other accrued expenses and current liabilities"
       }
      }
     },
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "label": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_PropertyPlantAndEquipmentInService": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant And Equipment, In Service",
        "label": "Property, Plant And Equipment, In Service",
        "totalLabel": "Property and equipment in service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentInService",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForInventoryObsolescence": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Inventory Obsolescence",
        "label": "Provision For Inventory Obsolescence",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "ProvisionForInventoryObsolescence",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForObsolescenceInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Obsolescence, Inventory",
        "label": "Provision For Obsolescence, Inventory",
        "terseLabel": "Inventories, provision for obsolescence"
       }
      }
     },
     "localname": "ProvisionForObsolescenceInventory",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_RepaymentofFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of Finance Lease Liabilities",
        "label": "Repayment of Finance Lease Liabilities",
        "negatedTerseLabel": "Repayment of finance lease liabilities"
       }
      }
     },
     "localname": "RepaymentofFinanceLeaseLiabilities",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackAnnualRentIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Annual Rent Increase",
        "label": "Sale Leaseback, Annual Rent Increase",
        "terseLabel": "Sale leaseback, annual rent increase"
       }
      }
     },
     "localname": "SaleLeasebackAnnualRentIncrease",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_SaleLeasebackAnnualRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback. Annual Rent Payment",
        "label": "Sale Leaseback. Annual Rent Payment",
        "terseLabel": "Sale leaseback. annual rent payment"
       }
      }
     },
     "localname": "SaleLeasebackAnnualRentPayment",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackManagementFeeOnRentPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Management Fee On Rent Payment",
        "label": "Sale Leaseback, Management Fee On Rent Payment",
        "terseLabel": "Sale leaseback, management fee on rent payment"
       }
      }
     },
     "localname": "SaleLeasebackManagementFeeOnRentPayment",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_SaleLeasebackNetCashProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Net Cash Proceeds",
        "label": "Sale Leaseback, Net Cash Proceeds",
        "terseLabel": "Sale leaseback, net cash proceeds"
       }
      }
     },
     "localname": "SaleLeasebackNetCashProceeds",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Purchase Agreement",
        "label": "Sale Leaseback, Purchase Agreement",
        "terseLabel": "Purchase agreement"
       }
      }
     },
     "localname": "SaleLeasebackPurchaseAgreement",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails",
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Renewal Term",
        "label": "Sale Leaseback, Renewal Term",
        "terseLabel": "Sale leaseback, renewal term"
       }
      }
     },
     "localname": "SaleLeasebackRenewalTerm",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_SaleLeasebackSecurityDepositEqualToAnnualRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Security Deposit Equal To Annual Rent",
        "label": "Sale Leaseback, Security Deposit Equal To Annual Rent",
        "terseLabel": "Security deposit equal to annual rent"
       }
      }
     },
     "localname": "SaleLeasebackSecurityDepositEqualToAnnualRent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_SaleLeasebackTermOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Term Of Lease",
        "label": "Sale Leaseback, Term Of Lease",
        "terseLabel": "Sale leaseback, term of lease"
       }
      }
     },
     "localname": "SaleLeasebackTermOfLease",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_SecuritiesRegisteredNewIssues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Registered, New Issues",
        "label": "Securities Registered, New Issues",
        "terseLabel": "Securities registered, new issues"
       }
      }
     },
     "localname": "SecuritiesRegisteredNewIssues",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ShelfRegistrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration",
        "label": "Shelf Registration [Member]",
        "terseLabel": "Shelf Registration"
       }
      }
     },
     "localname": "ShelfRegistrationMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "terseLabel": "Stock swaps equity instruments received (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockSwapToAcquireOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock swap to acquire options shares.",
        "label": "Stock swap to acquire options, Shares",
        "terseLabel": "Shares issued on net settlement of stock options (in shares)"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsShares",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_SuitAgainstGoodwinAndSimbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suit Against Goodwin And Simb",
        "label": "Suit Against Goodwin And Simb [Member]",
        "terseLabel": "Suit Against Goodwin And Simb"
       }
      }
     },
     "localname": "SuitAgainstGoodwinAndSimbMember",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_SuitsFiledIn2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suits Filed in 2022",
        "label": "Suits Filed in 2022 [Member]",
        "terseLabel": "Suits Filed in 2022"
       }
      }
     },
     "localname": "SuitsFiledIn2022Member",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TotalRevenuePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Revenue, Percent",
        "label": "Total Revenue, Percent",
        "terseLabel": "International sales, percent of total revenue"
       }
      }
     },
     "localname": "TotalRevenuePercent",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_UncertainTaxPositionsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain Tax Positions Liability",
        "label": "Uncertain Tax Positions Liability",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositionsLiability",
     "nsuri": "http://apyxmedical.com/20230331",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r181",
      "r226",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r248",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r300",
      "r302",
      "r303",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r181",
      "r226",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r248",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r300",
      "r302",
      "r303",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r345",
      "r431",
      "r454",
      "r477",
      "r478",
      "r492",
      "r494",
      "r500",
      "r534",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r345",
      "r431",
      "r454",
      "r477",
      "r478",
      "r492",
      "r494",
      "r500",
      "r534",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r343",
      "r345",
      "r356",
      "r357",
      "r358",
      "r430",
      "r431",
      "r454",
      "r477",
      "r478",
      "r492",
      "r494",
      "r500",
      "r528",
      "r534",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r343",
      "r345",
      "r356",
      "r357",
      "r358",
      "r430",
      "r431",
      "r454",
      "r477",
      "r478",
      "r492",
      "r494",
      "r500",
      "r528",
      "r534",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r251",
      "r252",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r493",
      "r499",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r463",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r493",
      "r499",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, net of allowance of $359 and $668"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 8.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued product liability claim insurance deductibles"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 11.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees and legal related contingent liabilities"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r31",
      "r481"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "verboseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r31",
      "r481"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 9.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r73",
      "r156"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": {
       "order": 1.0,
       "parentTag": "apyx_PropertyPlantAndEquipmentInService",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization",
        "terseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r521",
      "r522",
      "r523",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r98",
      "r99",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r85",
      "r87",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Proceeds received from issuance of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r160",
      "r258",
      "r265",
      "r266",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r40",
      "r327",
      "r414",
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r327",
      "r414",
      "r490",
      "r491",
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discounts"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive instruments (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r118",
      "r131",
      "r158",
      "r178",
      "r234",
      "r240",
      "r246",
      "r261",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r388",
      "r392",
      "r401",
      "r498",
      "r532",
      "r533",
      "r543"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r151",
      "r163",
      "r178",
      "r261",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r388",
      "r392",
      "r401",
      "r498",
      "r532",
      "r533",
      "r543"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r71",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r59",
      "r154",
      "r479"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r53",
      "r59",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r110"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CoVenturerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.",
        "label": "Co-venturer [Member]",
        "terseLabel": "Co-venturer"
       }
      }
     },
     "localname": "CoVenturerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r284",
      "r285",
      "r464",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r521",
      "r522",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r338",
      "r339",
      "r342"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Short-term contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r338",
      "r339",
      "r342"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r66",
      "r239",
      "r240",
      "r241",
      "r242",
      "r248",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate &amp; Other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r45",
      "r433"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Other costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r177",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r321",
      "r328",
      "r329",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "CREDIT AGREEMENT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r119",
      "r120",
      "r130",
      "r181",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r415",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r120",
      "r130",
      "r332"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Term loan",
        "totalLabel": "Term loan, net"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r112",
      "r114",
      "r305",
      "r415",
      "r488",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Mortgage loan, principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r33",
      "r112",
      "r334",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34",
      "r181",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r415",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r88",
      "r89",
      "r90",
      "r91",
      "r111",
      "r112",
      "r114",
      "r129",
      "r181",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r415",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r111",
      "r114",
      "r535"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized debt discount, including accretion of exit fee"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r57",
      "r229"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r347",
      "r361",
      "r362",
      "r363",
      "r368",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r123",
      "r138",
      "r159",
      "r294",
      "r295",
      "r296",
      "r302",
      "r303",
      "r304",
      "r426",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "negatedTerseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r125",
      "r137",
      "r294",
      "r295",
      "r296",
      "r302",
      "r303",
      "r304",
      "r426",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r170",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r202",
      "r205",
      "r212",
      "r213",
      "r214",
      "r218",
      "r396",
      "r397",
      "r449",
      "r452",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r170",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r205",
      "r212",
      "r213",
      "r214",
      "r218",
      "r396",
      "r397",
      "r449",
      "r452",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r87",
      "r146",
      "r166",
      "r167",
      "r168",
      "r182",
      "r183",
      "r184",
      "r188",
      "r196",
      "r198",
      "r221",
      "r262",
      "r337",
      "r364",
      "r365",
      "r366",
      "r375",
      "r376",
      "r395",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r421",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r43",
      "r178",
      "r234",
      "r239",
      "r245",
      "r248",
      "r261",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r401",
      "r485",
      "r532"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r38",
      "r117",
      "r126",
      "r141",
      "r234",
      "r239",
      "r245",
      "r248",
      "r450",
      "r485"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r371",
      "r373",
      "r374",
      "r380",
      "r382",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r180",
      "r197",
      "r198",
      "r232",
      "r369",
      "r381",
      "r383",
      "r453"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "netLabel": "Income tax (benefit) expense",
        "terseLabel": "Income tax (benefit) expense",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r54",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r124",
      "r139",
      "r508"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income tax receivables",
        "terseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r113",
      "r128",
      "r169",
      "r228",
      "r413"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r172",
      "r175",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r509"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r512"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r162",
      "r480",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventories, net",
        "verboseLabel": "Inventories, net of provision for obsolescence of $428 and $457"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r161",
      "r220",
      "r269",
      "r270",
      "r271",
      "r432",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r511"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r69",
      "r512"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: provision for obsolescence"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r178",
      "r261",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r389",
      "r392",
      "r393",
      "r401",
      "r484",
      "r532",
      "r543",
      "r544"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r122",
      "r135",
      "r498",
      "r518",
      "r527",
      "r541"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r152",
      "r178",
      "r261",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r389",
      "r392",
      "r393",
      "r401",
      "r498",
      "r532",
      "r543",
      "r544"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r120",
      "r132",
      "r318",
      "r333",
      "r488",
      "r489"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Term loan, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Term loan, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r83",
      "r181",
      "r323"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r83",
      "r181",
      "r323"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r83",
      "r181",
      "r323"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r83",
      "r181",
      "r323"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r520"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r286",
      "r287",
      "r288",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r286",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Costs accrued"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r287",
      "r288",
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "New claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r37",
      "r121",
      "r134",
      "r178",
      "r261",
      "r292",
      "r295",
      "r296",
      "r297",
      "r303",
      "r304",
      "r401"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending interest in China JV",
        "periodStartLabel": "Beginning interest in China JV",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "INTEREST IN JOINT VENTURE INVESTMENT"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r37",
      "r44",
      "r102",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in cash operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r39",
      "r58",
      "r127",
      "r140",
      "r150",
      "r164",
      "r165",
      "r168",
      "r178",
      "r187",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r210",
      "r234",
      "r239",
      "r245",
      "r248",
      "r261",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r397",
      "r401",
      "r485",
      "r532"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r104",
      "r108",
      "r164",
      "r165",
      "r197",
      "r198",
      "r514"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to Apyx"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r202",
      "r203",
      "r211",
      "r214",
      "r234",
      "r239",
      "r245",
      "r248",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to stockholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to stockholders, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r148",
      "r185",
      "r186",
      "r189",
      "r190",
      "r199",
      "r200",
      "r201",
      "r259",
      "r260",
      "r263",
      "r264",
      "r377",
      "r378",
      "r379",
      "r394",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r416",
      "r417",
      "r420",
      "r422",
      "r434",
      "r435",
      "r436",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r93",
      "r103",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Contributions from non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r101",
      "r337",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total other costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r234",
      "r239",
      "r245",
      "r248",
      "r485"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTerseLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r11",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other loss, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other loss, net",
        "verboseLabel": "Other income (loss), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from the disposition of Core business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r31",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Accrued product warranties"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r150",
      "r164",
      "r165",
      "r173",
      "r178",
      "r187",
      "r197",
      "r198",
      "r234",
      "r239",
      "r245",
      "r248",
      "r261",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r301",
      "r303",
      "r304",
      "r387",
      "r390",
      "r391",
      "r397",
      "r401",
      "r450",
      "r485",
      "r496",
      "r497",
      "r514",
      "r532"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r72",
      "r155"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": {
       "order": 2.0,
       "parentTag": "apyx_PropertyPlantAndEquipmentInService",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails",
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r74",
      "r136",
      "r451",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r171",
      "r267"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r344",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r145",
      "r425",
      "r426",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchases from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r344",
      "r425",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r423",
      "r424",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r100",
      "r144",
      "r551"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r92",
      "r133",
      "r458",
      "r462",
      "r498"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r146",
      "r182",
      "r183",
      "r184",
      "r188",
      "r196",
      "r198",
      "r262",
      "r364",
      "r365",
      "r366",
      "r375",
      "r376",
      "r395",
      "r455",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r225",
      "r226",
      "r238",
      "r243",
      "r244",
      "r250",
      "r251",
      "r254",
      "r340",
      "r341",
      "r433"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Salaries and related costs"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Sales tax payable"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r34",
      "r88",
      "r89",
      "r90",
      "r91",
      "r111",
      "r112",
      "r114",
      "r129",
      "r488",
      "r490",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and diluted earnings (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r23",
      "r24",
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails",
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r42",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of revenue by geographic area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of reporting information by segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock options and stock awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of option fair value assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails",
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r486",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r234",
      "r237",
      "r242",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Strike price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r348",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r149",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r486",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r87",
      "r146",
      "r166",
      "r167",
      "r168",
      "r182",
      "r183",
      "r184",
      "r188",
      "r196",
      "r198",
      "r221",
      "r262",
      "r337",
      "r364",
      "r365",
      "r366",
      "r375",
      "r376",
      "r395",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r421",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r221",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r87",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued on stock options exercises for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r87",
      "r92",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r87",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued on stock options exercises for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r68",
      "r498",
      "r518",
      "r527",
      "r541"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r101",
      "r102",
      "r107",
      "r146",
      "r147",
      "r167",
      "r182",
      "r183",
      "r184",
      "r188",
      "r196",
      "r262",
      "r337",
      "r364",
      "r365",
      "r366",
      "r375",
      "r376",
      "r395",
      "r406",
      "r407",
      "r411",
      "r421",
      "r456",
      "r457",
      "r518",
      "r527",
      "r541"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r412",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r412",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r412",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r204",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r202",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r502": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r503": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r504": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r505": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r506": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0000719135-23-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000719135-23-000027-xbrl.zip
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MB0[RQ0=SP+@!#QN$@1PIH/ R0*2.E+03,B>S%(F4R)2>A;2QTK; >D2Q1JN
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M_'QK->/T%G.VUW\N:SOEZ@YDZR.J)\&PV@7YDXTU%$@9.!K^0P:L]2ZX .Y
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M0$2,QIH'_B?E]1]F>7F.C)TUIQN>E8IPS1"\H=FN]H3KP[*0K-1E[FLQ25/
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M] [J*QY>>S:O9LU+XOV_ 5!+ P04    " #)>*M6370@1/H$  #T%@  &0
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MUEC"ZN#[V7Z>L?$7C1V7D,NR;--QP?4,](S!ASE1& &Q!,4JJ3!X)3R3JH#
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M.M"ZOF(\1^N&-_(Y8QQ^J[OT/=0CL.4-\G=Z,QO;__<V]QF]>&WXT^V[G^:
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M<=0Q1J9-9 UST@IOC?,((S.+K)6YZ#?FF.':4JJ=IP)"@SDAE&%N@V<!X3F
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M&^_J/];^C'\& R(RGN'@I2:44J>-$$Q"1X7$@46,_9X$^?.:;N^R$476K+?
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M%IX_/:[@;52].KRJ7/UU5,'[L/)AF^[7WL?VKD>RU&CNU"H7E:MMN-^X(Y^
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MWBWM1B.E*M2C,71\MY>]L<# #(;B2KW5[D1DV!YT>0D"3P*!\<U?,=94,82
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MIGF5_##<J!!Y3,(8SIG2E!L62&#!>2FQN4&P[(K:'^][W=0:O(,UIT3UYQ5
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M1"T)1&%#6> Z2.TMURGI)%Q@7D=N(F<X%6]Q>?%K)D7 )A.3R<U[7>Y)CZU
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M .7*H@#ERJ( Y<JB .7*H@#ERJ( Y<JB .7*H@#ERJ( Y<JB .7*H@#ERJ(
MY<JB .7*H@#ERJ( Y<JB .7*&RO ;U4F+OP;6M_6_@4_QI\XEV3I8T[,77GT
M+&9:5S2]D'"ZJ,/<.XP-ZW.;;=LY;74.&IWN .YN>_!RI]&"D1WT;+MQ;'N#
MW%QJ )?[;B?$3MV=NU,EO=I!;D35ZMB.;\'%_0&\4!7'?W7E\X\&P06,\KC;
MKPKH_]Z+;3MH?8M_G+3"X'"<#G[N4Z-$7'SV$>M@!,/!U1]9E(GF%Z?B_,\\
MVBHE7!,7!4U16\8Y#]8I)30.7&F:A/'A,Q4KXP\=]L9/<&P/(G*]:+\BF^ !
M?[?M$WO:7_GMPCP<M3KC 0D.(YZ>KRMG):4'FY4Z(SI$W^U5W1]_'X)F]?)5
M,":[,&-I'/;R:8/_N5X^"@PJXU(VE=?YH$+5A\VN+1 ,J$NU<_W]_O]M;&]N
M;+U>?]=XO?/A_<Z'];VMG>:5 S^RO0/0J+/,^#\6Y5%>[S0W-IN[FQOP',W=
MG7=;&^M[\,?N'ORSO=G<VVWLO&F\7M_]=^/-NYU_=B\SRP44T"\?.W886@"T
MORZ0,ET.=;]L=6"AZ [A'J%_]7!'*I2/3X@K]*=:Y,_ OSIN 4_1ML?]^/OX
MES_&)*'5J<92?>B/BPJ:OV#JM$7U??7;9V#X"M> ..*7HV\>O?VJ>FO,5BZ\
M)^4KK>F5;^-7Y,KW?G9;PE\)SNYTVY^_)]C57WJOP8J;WO:Q_8*[MT\R-[_'
M)4<.:UU^H@-V,UB":\[7B[&Q#=<=]AN;L,R%LV*:%TY(W;=]R7T*:U]YN.J2
M\U4+/M\_K4\ZKZDH<SV>:WJ#N7Y:J%FLD\F73^1KVS]LI';WI%^W&.X>QTR,
MP4/,)RJ_@?<5KV[Y<X.Y>#BEGF,KP7D-\I'5[1EUD;K-,SZW(_^7/>)B']TO
M)?+O<B*_N3LZD?_E(]W>.&Q_>KLOFD>?ON[L??BR_<\VW_[QYY?FES];VU\.
M>'/C[Z,\EK,3^1_:^T=;M+GQGU9S _[=^^M'\^TV__3V+P;7G6S_./S:_.?#
MX?;>Q].9$_EO_V[M?]G'VT=;>/O+/FEN;.-]N/[31FA]VEO_L?/V+_+I[>9W
M>(XT*8VZBT^;/P[(]L%G[A23F@1$K8N(6VJ1<5PAS2(11D9,L5RH OES8K$%
MDIXK)"6:E$K)<6(M3\EK3E,T/$GC$^%<5I!$QY!$"R0]-23]F((D[%V0AD>4
M"%6(XV21)HH@+KVR-B:A%; JL6KD?6K:/3@D%>_D.N_D7 /FQJ#;Z$6P8]]J
MQT9GQ"/SJ_EWG]V88=ZL:G4N]6%^?]#6VXMWCX5P12I;4:^46!@UNWSQV(C'
MH%JM:D.H83NA88]R.:@?U0LOK.'M4_9;/R\'^+T=JY)<G;!^3AQE[;S%VCDI
MP7V.SEMI& L>R>A@Q:3<(6N W3LCO&/8V>1(CJ_-]GHL75N?C>7.@0$7RWUH
MRYUFO<3K8)((R&!IP7(#1=;3 "ZY=99(YI("1YS2>Q?/?QG$=UG("?B4WUK]
M;-#@40*]_09LN-L[;71S2E3L^]CQ\3YM\9XWTLV-H]CCT^^_3V3QIMO;&DMB
MYYP@+KK]J?4]!O0C]KH%^VZ#?:T9UJ(XL\E(@[B@&G'C#+),8A1#,HG8D"+#
MD_;R<ZH*ND"5E(L]SYVYW-2>B]W>QFZG.8L++#@B(C+!@O':()%QUB*5E%=$
MJ&B86%G3\^KWLZ249?&2[Q>"MRUW4"GO C0 S/)4=/NVG9.%CWLY-CDXK8),
M\;_#UG&.;98(TZ-%F-[:5B<+9J>S"["^D]Z/!/*^;3N#S;% "HN;PVJP\WJ&
MQ26LO%'!(E@6..+.)F2B$<B)7//=24J3G1N+*_&GQ;7KA]N!O:F!%T.^C2%/
MTSK)DP^1,H2C=YG6*>0\MH@XJ2T67E#A5]:H7'@;+I&H6QAXU3ZEX6Q])O#H
M.';Z=]\A>Q'>ZMSYR^ZA[<4_LP1>GQ- 23:9&];-;IC1)&"1 @9HF :L"YKE
M_#>.*-.<1T=C$FIEC:PRJ1;>BRV!IZ<//!53?C13GJ8MWG-M#9,H2F L7$F,
MK/,1&2J8C$%C)U(V92GPPIMRB<7<>0_-MMO=$]OQL?HKM_H:I&&[JH\PK$YR
MOZAPS,(D\T\B\1LCB:R/!%)@[S;ILGOKHWYZ9[U+A:0QVB21TX(@C@5%1A,
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MMZ)L=<8#/+'?8L[-.!/4SN9VPQ[T8KVBU1+OPGAZC:,1"(3X+9L1:. P63^
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M4W4T9P12[*% ZKXUV0M(S?-L#X7O8I^M=D0I*A"3AB,>E$9.)HLTUU9((HC
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MK=ISS@U%;-7@#<9_ EJ%VMWNUS%QKAWV7+BI?L:*254<NB:@X\ -,%X@G]6
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MV.2RFP1I*S0RS!N*A<4Z6#!ZNDK%TAC]LX]PO(O]_N]UEY%^U6^MVVMT\Z'
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MT;;F'9XQ,>$Y_947\89G&N5K, ?6>SW?[V5'ON6B',IZ(&V>L3?]+ZTY%[%
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M_!HJ6<W\#]^U9:]2'?VY+J+*5UF)$MT&(-?*TJEI)(_^6 @]I5N&7$\SZVF
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M_  ,T/= 5?>QH!Y$6A,6%+^>T!J^_PX&^G$XSMI^NH7NV/:&Y=N'!YIZI@.
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MR^-O%P?8TZ!S;!%U,260*QW/6##"5BH< I<8S,XWUU8Q'))EI,:3TV[9JWQ
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MUTLTTQO2B.WT^KVU;/=2E(W+BP"[#!-^ ("7PY/T,%?P5&=$4U#]K#-HN<R
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MZ#Y60+ F@0D2( =:$:-501'Q.0,L[@TR6@?$7*YR9PO8#+GRAJS-^@6 !![
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MD!2L+T_'EEE(!&G.QQ2ZWCX?H:B47N%_I #*<;6G$2%-T-F(5D^[P"I](%1
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M_,LJGGQD%(]@Y11AIFJV_=YE=[ RIG/,+8W8B2\9=,&2,OW5[#!V#ZO(<Q5
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M7"X? ]=<_A#C94P,MHI.K&@QP,,O;QI)4[!.X)L>T%>E4<=^@>3H&IP,JKR
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M$ CU3!DK92B4#)H7(#R 2!.)Y",2R6L2>682H4 B>:ZYQ29'##8.,9Q39/(
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MC1B^@$=%T>I6JU_?\):J*R9\BT:#6LN>K('KM!1+A++>=L,57ZI,^V>0;.R
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M X:\N&!KER6.'VQ9^"U'A/S$Z/KU!&/<L16,B;1F+ H('3B&_W'S_K@OWK(
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M+>H,B3=M,<QBI R!/YF\!\F(5WI)#-H83/W;)#KGB>3F<V UEJ_>7;;9(&9
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MEGR_NG_X=H9W#M.> :3_H_?C&-KUWQ]:^$]O^,?P[,<?WWL_/GT[,_X:++)
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M?Z, .;!3MGHA&5UD24@["HA0E*9QEJ;99?%Z+<<,27Z>C-0R&[^VYYW1*.)
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M/A,-DU%2E#G+BO.D)2R7'-@2L+)[&)"M&JP$K$C B@2L2,"*!*Q(P(H$K$C
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M^;/1RE_JMZDEO\,ZE]3(FU2A=75)%:V4S=O24H+7GWE+20#/O*4D@&?>4A+
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M&7";03"NS@"^5TF?J(!P<O 9V(45=_C?,FPP *D>C66\R,LQTCQ[817L)?\
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MYY>;*_T^.G$/ZFNGOI5Q)BU0%Q4(_$.37(3][:-R,/;"H.1^$[&I!0.OZ8(
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M$_>)//A>.!^2T"!P-2)C_CKK/PFFND=:"$] "EOA36N*7?;F2O;^VOC4\G&
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M]6;E!=HJA)RP++*2A?E&,8<#(=V,T IZCZAO$6('/>HOTH_1M15X B<@-JS
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MJ!_1O(_@+4S_/>J?C0?QC\^#7D)7X?!_KKKCZ]-!K_=N,/SJAZF3I5?*&T>
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MQ0W:DOK6*)$$MS92(,QI]&6<S,1SF8C5AEN9*)76_+A4N)?IL7LFK"/L%AB
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M4R#2*T."-(;X4NC(6Z8RK[V_?(AB^UYB#?T\DE*T@7!;KX8SX;20*KJ0(GI
MW)=30" 6DB4ZV B11>.JAY@>HM@76]]0OA5KF2Q&=.PO;HB]"JZ6;/TR3+NQ
M]DUU]B@%&@J\]7)(=_!%GF5@,I',C2\9C9P$7O)& N-))25PZ?JAB?"$Q=\6
M#]:1<^W.0%-;=-N":F:4,E44'!>D)"$2:2TEH=R>LI*5)/IDDEFMH/S"Q^\Z
MX+.IZ =5Y=:",;^?JSPAK)?<Z908L9/NQ\IGG%MI:RFX-33R)*L777V(8E^,
M>4/Y5BQ.M1C135'9%3"U9,@7X=F-$6^JJT=5WT#0+1CPQ=C NEC:G@<E<"DJ
MQ4^"E9F(Z+,3&AS(VB'=[2G_"<.]%=VO(=\V2FR73"I(986[:6"<7 ;#<?O(
M54G8,P+WD EP-ZDDM=9P$6H':1^ V+YE;ZZ;^:K:C03;@E$_A2^#WI=RE'2_
MO.X4G!2E#8W31"0-Z''@I*THY8U4"E0ZSSRSE;7^** ]8$ ]@==VUA?G=(\F
M"QRS(:/KF0@S#F><K"QUKCB)S*)+BFN<"9ND1-\;Y$?WXZH*L6+YR,=PS0B]
M"K+%/MUZ:MZ%RU97+2OHNH%,M_1*SQ!FGRVCW"(N[4O]HG*\4,J9TN0=Y=%+
M:/12[\!'VY6RUQ'E=I1\/O3]^!E.^C S+0D\EXX[HF/ )4V6BZ%,EMNA21H(
M6E&]21FX9>-MSU375L\*5^*:R+:B$_<TQ/.O@QE$:B(74L=2W;H07Q3O)>*/
M)MCH$P7+&EV1G!OO)U#_9K+=ZML_N9QYL]& DEH,M)PG<B(Y).*U08Y2+YWD
M4?B-RO\M'_%GH,"&\FWAX.UN1X.)I:-HS1PP0Z!$(F1FB5BT<D0K"XD; *UK
MYU/,8_C1/?HJLJU8QWL1GAF_5T'44E3V(9K=Q&2;:>D1E3<0<0NQN07(O#(B
M6Q&)D:Q4&$(C%+R*A'DKC6;69N _J-*?B,6VK?-U)%O;LD_[3T J]X-F<<.3
M+S#LE_M#MQG@!>O9R;O3F1%",Y.,Q;5-11G1S'%! I5HDX*1P@HFU(JM0388
M?/O!N:8*&VQ1VNVZ_=_K$T\+TT_3!R,5G&9#A#,,39YG:/(H)QEWO%)YX_)&
M-?X7C?6C6_HV1-IN0X=Y>#<YOBL ;!#)6SSJS@-ZS76U.@\:"+K=O=\2H,&5
MVI19$YT+T,@-L5EPXH3AQMBD.=18!9Y'L&\'1%A'OMLEP)WX5+&!F6<2HRJ-
M@+4C3O-$%"VE ZFFB6Y2X'?I@#O=^M?0T^HLV$S(V_4&[H8I(B3IDHD$;$0'
M6=E8(A3H)2LF4#K*;':2]\B0/Q$9-A7T=M>%[X%+1DO+.NH(<ZP<-XM,@A."
M1##2*)U5])N<"2P=\&>BPD9";K>[Z)UBUG?,HQ/>X]9($29PHRP-(O4L>F*Y
M$-:7!AAIM73<%0;;PWU"<Z&VVQCL ;X9[U=!V&"GL&38G6\5*JAK#2XTD'6[
M-F$9THP@DI?X4BF&5LLF2WP0F@B9K*810I@O;/?\V+#Z=F$G9%A'Q%LFP7=G
MEDI-(7@@#I=#(ITH'9$X(S%3#2DSE>(F/8:7C[A3UZ"*JM9@PF9R;G?3\ #D
M=P]&X<1SS)$$64I7I-*[ABI'M,Q41"<2^$V.CI>/^%.183,Y;WEEN+NS$2$P
M<,H2+I69EJH*T2CB# M<L*14WJ2J_V-C_ER$V%#62S</?WLU)[;W^./D#Y/?
M%[&<0GY1_OW]].A6A 7K!:1N]+U?XN#BU41\;TX/WQZ='_QV>GCXX?#X_"Q^
MAG35@Y-<+K2?SRZTOX6Q[_9&]X&-NA>7O2=#C6L]_]7W2=R?W&R0>XRH/!TH
M?3_Q%7WYHIM^?=D-SO)@'$@-7-J0K8X*7V-#-<\:HNRL-5+-.[?O;TL0)30M
M05A%LBWW$7.YBBA21L<&&68XB]'6KEJ\!$K=6\5O_'!XW>U_FG7GBPF8=5H0
M0..)&[ML2-"9XALJ\26-RNH@6YWF?3R[OI"ZF?X?OU_<0.(M7&+YO>^G]=&F
M-VN.1J.K4ECQ\-LE;@E*05^CN9XLT5JBCR4-P;5:$>JX,PI8>K"G:<R'QQ'M
M!R,J2KWUN@-WL<YJY76<TU(Z]+$X+0!QC2;6E9M[*5@J%87,:Q<M?!+4?C"C
MKNQ;2):\:W([0H#BW);NK8(3')R2@+LQHJ-##PM4S+EZP[,[X^^'RC>6: O7
MUA<%>T,4+I:JVS: (C) 0,(A..VB9NA[!L7:?=F?10W*>B_U^E)]UC4H<7-M
M/0^(7)8>>R5WT%M<E*)&NY4U=;@PM; &/.<:E&OI=I4:E.O(>'ME!U=!];/6
MH%Q+8ZO5']Q$W-LC@P"K?>"><)4TP:U\:4OD!=&!B<!-EH[1'Y@$F]2@;($#
MZTAY.S4HK0I2,,F)H.B3EA .L0P7/)8\TUQF)E5M[^ ABF=3@W(M_3Q=@W(=
MX6ZG!F6(QAN>!<E1&R*E+3<U->!\T;AE$;FUM3L9/$2Q+[:^H7RW68-R%5P_
M:PW*M72V:NW!302^S1J41F9@SE%"A<.-JD^..",=0:LF0R@!?-GNKO#YU:!L
MA0?KR'D[%A^LX#PX2VSRI82/A=*,E!'#I#56JY#G:U#NA<6OHZ&G;?XZXEUJ
M\VL>6QX=GQ^>'IZ='QW_UPE^_\_#X_/?3P^/CO^)ORO'<<>E0=>X^P4:'%VN
M/4;SX\MFTYH[P@2?C'&.A1"$C ']?N1!H*@S"!I_[JP]6K/7]D.W/QAVQ]<W
MG6._Q[$<!:03" *"EK,%IX@#S0B2&#62M6*L]@G?4C!-%Z?Y!Y]\[<-P]+E[
M^1%].GQ)_2=X?7T\Z)=P&.H<'_-I^I$.L\PH]*P)];X4=S>1A) #2<FAC^XH
M!5X[:+4QV.TO=778,[_6;4=;M3.][@.Z[<0,_W/5Q57[C;_LCGWO3?E$-UP5
MM712BDJ;[(G+L4A&*Q*,421QA9M^%)RCJ^6!KCWTC\Z4+0B\!1=I,>"C?AR"
M'\$[E-G951AU4]</KTMO=Y36[+RW@ZB38L(3KTK+BL"0V"HC?.F4T,:K +5+
M@VZ.]D=GUY;UU<+N?%X>TPB$4$I0+A41V:,$DN?X(B1.(F4^:L%!B=HAF85
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M>]55P&VAEO\#8,^JK/_Z:ER-'@UTL'6B,.L5Y'++H\0?9'(&X?)42HX[PQ1
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MI)()'O3(:X!;0$IY5IJP;]K?EOV?&?;Z_Y5E_V'8_[)K$G",XP![\CAX 5
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M"Y\LW)I$#8#)0-KMQE!RX)B<]4CVU5/>JQ"5_I\)KCXS!29^$:O\QCJ/77W
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MW+5_)1&3-^G)[ X<ZR56SF!.&;$!T25PI.:<P?G1&YE1:P-)!!,]G%V5650
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M):G\^RJZJBU,5C4"^^-N#]P#7W#QL[V$>PK9N=+G4'%2JQ/5KWXF>I1K]H.
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MMM6#V+CD=N-^JFWB _BZEW$Y/P?SX FCN>>>@PWO]/MW-X[TV[@DJDZ&U+
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M$/BKX/[D<V;'<KGSM]2*D$@/G:&M_;W(_C+]AR\4WFJZ+^"D#C@6YP)95IA
MS"J0?GU%*XR<[8W*G&M7 Z\YB3VF*GB0,%,H/87&X1Y/WI;!M;KUVO+>'L_=
MLC_*I2J^-O);&5IN,YS-K_!+S7.+I#,J&]=O_HD?!:V6 G---T/>!F;S6^R>
M$.0QXM15/@_1A8[-(:[.$<P\*Q?>%VV=AZX$LI404H3[UP\[_FL3Z>'GNPM8
M=9M!1*:K04]JGW4-3-&F27F46P<&G/_(Q0+X+V#8M)S/R*A_'BR(7]PX$^_(
MS(&W'3G!=4S;ERXHJ17!37Z-D<,=0RA_>QWZ>QJ1P8 _83B\WF9:]HFI8.K
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M,BXZ4^ 4:ACR13;,R#F Y_>43>>  7_HL<C]6JL%BNTTKD9O,.Y5'D(K]UB
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M$H>(@PKC//:HB!E8ZGY5=)>^^\\[>_^C\,_3@=R6)+]C-HU!J><+?;_7![
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MT)/U,!3A(SF#)M5H/2P1OQ+ZW2?U&5*R$N@)*T:$U;S&\$W='UDF(Q_J,]>
MX4ML-L4"[&%@@S:0*W25BER,+ZCA!32/;;(Y81Y'TN_7M$DFG)AZ2W:?FC'(
MV=_MN?OKV&N?B/G9!.9N?6R15O^<"<1,X(0QMZ7RHOHM.2KMYWVSDZD*;PC;
M<=/BKLN_&)?,+/@M;K*IE7;[N8\VAVB7Z"9L&1W^!_N'E5'"U:B4Q#)OC4[
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M^!1]VD\A^IU>'V2N /:1)D<>81YW#7G[^8?$\MAI9M=SW\LI'["3"AC"089
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M4JDJ-@I)3)P< !TP/K+C#+;&3?E]LU&>)7_WB2OVHSYE(^QF5%AU@:. %G!
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MY=4$5;7IHLM-O>/@-6MH^V3;],59LN.4DPO_3EWX'/:SEB!968-K$B:MNRN
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M-??]XOD P#[S'$G +C($ZY#X>/.^TI/KMV3U-6'"#'!FNX>YG6 B)$?@_-1
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M0E=1F, Q.)B[FQ"D<$SM-*9P(AG&!&X!P-\8SR@+)$IHY#;</")+IZEMEK-
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M%Q7:F&40G9Q#PTRPT7E@9M\3[L-/COU0XE,[*[/9E.#]> G^M?F ZF _%+6
M(QD:1)H'GG29T)6^>/)=2;E)X9YE6AUR36HF2VK^[ N\L>E=F I2KB%.LJ(T
MD8Y*]QBE2@0W*O$>=.$F+NQ3''1/)[[LQJQ,FF]B]P(:9P+7ME,VI.)KRI]A
M7-X)3VK%+F>8K P*?;==C@7K4(U"Q5_@]<QJX$7T("$3G^5K""+])",+<1KN
M%W*.-%)TII>R$G#*:"]'?:/XX6BA8],<>X9"-Q>8\*>K>5<'?\HLB\?U+;"=
MT%"6,9Q\X,9_W^V0R"NIC42*!*/\"WEZ.?Z%ZKEA#(7^(4RW;^C *4R1G-<)
M%LCS^^@O>K_L^O>AS$[]C-/09YC"-XU9$3>_A-, DH=-5OF?? ^;S (]724^
M7*<XD7AC U('[\-\PDPJUZ1SB[F]W]X**S<[I&GD^AY6H?A.V!5V$SKE3>>V
MF,#0+W(2#RYJE<0C$L=]3NG]@9F60R=[[:R<Y62X\<Q/]WN^S7L?V]7[Z7IS
M>X18W](\\C=K%B!..\D<\!M=YI^0Y;(7ELKO\E@V;2<J#9Y-K[_H=%&M1/>[
MMLA:1FH#)QFL0\_ ZC,^,B7 @:-"</$)N_CF@C=+:G#WQH$,QE Z@R>,TY-G
M@_JI_/77)N.@C%^DN4G)AG3?:0_$1*>>Z;&4]Z_2'W']ZLX>-\CZ-PZF+$>I
MHTYC$1WHPS9DK6#GJXMM:IO7GX;[I;MI\S9J\WT226F_Z]UH+37A\IM?T %&
M71\W-;B,7%(!"'7J#+;YQLY0(<?-$G!"NK&W7<=D 8]#[_3KG!Q$,*(=1KIK
M\!9]JDK>!U:STQXQ'N8L=R_A]DQ<0]_TD[L%2A$9F ?'[GFR52)>$2;9E@!#
M+FY"HC&KOK! 70Y.%$1%:U_$#?DT <?FT6REYSSB1HGNWKNU2LD&=_Z5JH/_
MV8LNS4C%38U5B2/[.[*0\Y;%L[USD"(H_=.INE4:_Z8!0RJN8@>GET:_OB,R
M(0EWVV1GA#*"$/(L4.TDE>=+QG)-8ITPN"$>F/=#$HQ6#,'#ITG%S!IWVFD>
MW"\R":-+0B+CKD%+#Y[>5_?#XT=UXY2V+C*M&3GL7JH2IR4_.W,?F7/7:^1&
M&O: 17\O=& .40,8&Y)6WY\A<<0E)A$BP-;0$4EL8R0UHC_/(\E2W>PEAA,1
MD?-LM!6KE\QY0R).BP5R'HT DS*8^Q:Z!]I_+1+[/'*O-_1[.'!O1T=./K)Y
M"QF14"),6@7HZP53LULZ$9C CZ;$Z$T;@+WV"G/M $YH/P :8FP OYR?,<I\
M+;7@MVW+/ S\*X:W!5RA+HYQ"-JSN=VNP)C!9*NV<-#Y_';AC)8V-8EFBVQJ
MAP/L,C\-.2=EK61=__<66 9@+P,Y-;;!/!;4Z$V[.=DE*.TL_#*UA72-4)<L
MV9GG4NP@FW?&P1:7P%7 =T#0Y 76!_"F7KN[]5(<UP$@40JA6]G]CK%D3X5B
MA6Y-\A?%!!BDX\?G=<(M0BM_@*\"\/<' D ?OXI]@3=;H)DR**JW2_7H#B\6
M0G)R9X'J"5T]4''"9? ZF;$TMU,,GH*YKAO0E4K'7!@<4#15ONRO#-G?OR%
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MY-#[S+JRXK52=@;_/(+,E&<;P-$''%B@!!,6R!7&*,3^RJ)O C];Q *U2;)
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M40-8()@Q<OYJ,0UBK>E)]]E!Y&RX=8SK$C;4=BO5)W__K\C[4"UH&LBF&CC
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M(>*#F4=43DW!30#&V(O.19/T4-O7!,$T=H#'S-VLPF#C(&.)X+6GUR 4[A\
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M?!6F]YZA!OSEKF.\R]8$)AECMZ_18#1.<\ LE66O1>*@D#$,;,V9@J,(%[-
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M[]2F7N+?-,)7(@0=B58CP5G6#N5!/XBP@5;*%N_:D:MN(CR/17J.:XW#?IG
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M/A8>U_H<7<\%1[X:.UM4(!MPZ281D_BY2:^I:X2][\>TRE7P%>39:1:#WA-
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ME\*= 'C(42-<HKB9A8,40K6KYUT(U;5\^K[RSKMN-=7UD#6 $O<'3K4WLS^
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MN8AKJ O4$5 "[T#C%B@H)'KO$K2G&S0SMTM*G*8^K4?"_O 1W\&CO\L*N9T
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MIVHC"B])805OTLZ2K0UAA8K0']DS,7X07OATF4QI/-6#?: C0\GI% YDFW@
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M$ [J;4\47X2X*8@.%N69XT)96)<J$6$/<UU>.S.ZF2%&HC>-X!NB.-EVM0=
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MM5F(&U03<U&#PGH\K:KZ0NWAN7K8RD&;4/<6U>GZ@,;+87V=X@3WOC;$$7X
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M=)17O=DEF/$B_!-N]IH6QB0%LY#=+FIZK6]!)F(6AXV1XMA/+B]E:Y>X]*F
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MW86L^N'L]['CP64>[U;NF+_A)Z9IOL2A-RQQ!HV'G]VR8: AL_?V:VZT@O6
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MT1'RY2')%X.H4%(D.JG@+_:-%P@PH'7E,/H^@7^?O-[<6]8C'6A-*L<AEO8
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M$@"#( 88!1#$A!(_I7&24+I2NU::3PO6\10+ALOL&S8,@HD_3UIW15[YO?I
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M=9=_OV1,IS,K;E.S;=1?6>67UV?B5U_5&R3*#YOC:[(-RQ[61X[:$ L<"LP
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MS7G]4!72.?)5_TUD7[YN!;_\)@KR1;S[(0J6E4)9$TS<YNNUS M]XRI.:1I
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M1/<P(>:MYCT*J)/"W^-&LZ\1?I5ORGR=\>KS]V$K[LNFYZ* 5$8!BP$70MF
MJ?H;3A)?;>P9]&.$*>%&I-8UR=(HZYF<7B6H93_+3DB[B<H54!/3T"",K"J&
M]X$PHF!XZ]"SU0OO4^ZX7'COM0,C,!]I*?[QJ.CDW3?U1V-W1S#A*2<,P*1J
MWD-]0*1@(.0!Y$B&+#1;[YVS+&W!'X3T*BDM0R[/ FEFCHR&9^)E_A*9"4JQ
M=4+@*LCR[!SS!E=VJ7D25-EY\?"L]]IQ]&[#WY*M6"62Q4'$(Q R1-2&!84
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M6.<4Q1!:E;'OG&UIS+(K5<;V@MIZZCNQ-73/NT)L:I_\H=V\*+V#I).VG>^
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MFL.[@M^Z'[RSB0=L&NKV!75]A*:I@:XZ_/%0-VA7J0-)SF.$U9=&)A+ $,<
ML9" A(D@D=1/>$",MP_&TR[MPU$WYR!-G8]G75!V_4^L:RY9/@B#3<0D\$[,
M[$W;DP;9G=2>$ML[DKL_QF\,M!9;C$D@GFFSX0IJNVV'-6*=&Q#ST>;;BEAK
M^&Q38G_WV .T3V)[1<JO-T7.A.!JAQW")$"<@B#5/?$"(0"!/@-1D,8\3B2/
MD#G%=\VT-%9_?GAV47F'F))7'W]7 @\] 7J)L.W!V0C<9CTVT\4(MIX6U;MQ
M#-G0([,1T+W*@9D-A"..RUI@,3\L>SG *QV5M>C1?E#6=L/08[)+SM7+4%ZI
MOUX7=_GWS8IR%'$I(V4<1R& 4>P#Y,,4Q"**41)('8]@=U)V,L?2B+,Y%FKD
M5!:#_BDO/"VK[9'9*:"FIV:C8)KGX,P.H0''9ZT8C#A!.QUSYD.T5J5.S]':
M+W75.OC#AJT?>;;Y<J,;]J@=_%%CV+N\I5DY@C(,%)T"F'*B/;4<$.030&0:
M)F'$XQ1;=:)W(Y85C<P0:WBGY_!$I<_8QL2#'I-( Q\CA@!/(@J4%2P!BF0,
MT@!SF,91FI!D]2"*+.>?MZ38+O5AO11QND?V1GS)-ILZT\ BM\#Q<Z.Q(#A5
MSXU@JM88(R&@DC) ,>%4H"0-"6J>VSNUE5KT4]L)..6WB+_V S,\T9C]$<QQ
M5OZBL_B%MU?*:[0Z:3;>TB5GRI;C8Y">K#WY(*%>N97Y&"#[VYZ/&MW.)"J+
M[:I)K&@JT&*,%<L2#F)?,  %3P$B,0?*O"%^G(18)MQDIW,R\M+V-XUP9E1Y
MBE,WVXW2?F+"VN5%]18M-F:<5FV[2$/==$08ZJ<#69R.-\MZ;U5CMV3;+W#3
MF6^%9! D*:/ 3T)=$D,D@,1)JDQ7EK)00J:LGC%M^):V!A67@>./8-;W$32#
M,610R% QEZ(R"2#%$I"$)B ,91I+K@\TJ;W)/P;,US#>=V"JOWA77[,-\?[W
M7T<"JW:T$0U\98G[<=4F4N?("0H2B5@J Q^EJ;5-/A[6V:SK"1 U,YK'8/0*
MYN_\MFX;0!.U>7S=GHYMEF3K=4/=9&1;!;'L6U>3]:XTU"75@>U,[=+#6"8X
M@L"/:L<X EB9CR#!(H2)[Z<ILVK.93+ITKYB>YEUK/E>ZGVM,N^/G>"698Z-
M'H#IKMLMK).3RFA$!VR7S2%RMADVF'+FK:XY"*<;68M[AQ[-O;L7A3)POOQ:
MY-^W7W74'=D\K<(DCG&LN <%4FU:H12 I%$$XI1#S!*8L,0H:+IGGJ413W,
MM9/5JX7U&FEM#^G.0VMZ4#<:L'D.ZVRQ&G!<UXG$B".[\^/.?&S7J=SIT5WW
MY0/KH.?W]_FFLCMO2'%=5+S#JVC:&U%4\;:K(,94\0$&4M(8P 1S0"4/@8]E
M%#/U?XC:U3KOGW-IY%"+7.>^77@/9-?I6:>_<66(DZ+TU/ZI3D RS(2S>01F
MAHEC8"<FD0;3SS6F2F!]W%^+W*0=**'K! 6'Q<G-(7)5@-Q@QGF+C)M#<%)(
MW.+6X7R4;;7AHV,ZK]0^5Q&>4.:/*-]F)5OGY6,ACC9,"2(XY2"-E)4"(1:
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MQ-%W^>A>CG>BN,\V%??<5"DXES^R<A61*.4)1LJ4B2, XT "RD(.4@I3*4E
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M@=9.3N?9'@9PN*MLU#K3W-6,^E0^4\&H]Y:QAN2->G>^JK]?JK&K3CPK!$E
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M:JJ;(M^HO[(Z(4G-V'0^_[ YOB;;L.QA+<I#+ >1@OHH12!0!@N ,I$ P80
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M98QS-ZYFEH(WM ;F@%;.K>OZ*JAD'<0'982*)U.A>ZQ1304CM0]-!;.;_)7
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MMLOZ=<2M&=SLMHW0F0BZT5&AOB\+5HCR8[$0=VOQK9Q1C!.!, 0)CG(==<(
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M+V%X4?&3M0POW^5&(VHO]DUG!2C;H;;=KU_67Y>KXE_*=E;[%TP%3D"<ICE
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MR#5R6QY:&B%N>'SI&\>A#S);"(_+FY)UT$I=9[=X/-2T0<G7\:;1F.,>=-K
M<'3D:76S&Q=M*EG\OES]\V[Q>;5DHBQG-,QI+&@(0A3I@I5Q#/*89(!C'B8A
M3###B0WYG!YF:FRCA0N*A:[XH\6SXY@S2)J12G]\!F:1C8!708M2(^15\,MJ
MV0&6-75T8^&)*\X,,BHY="MZR 87KG9;_M=E*=;ES<MJI2OI"8PXS6,)U.+7
MK:I"#$@B8V5R)%1M;",9QU9):7M/G^;I(*N%"T@EJMV*WP?/;*$[0S+P^J[E
MN@H:R?RMYI,*>UK$^\\>=>V>5.MPR9Z^J/<1Q.=5VP7O@Q!M%4R2,+59R&+
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M6.Q,8%#3"L/2'WX:5S.ZZHW6P(3D"E3OT*C' ;)T3H_QIB%-CUUY.-T7NY'
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ML#H3/ZFMTV'X_I-&.P4_J<#N\??I"WS40*R3LN*()"@F$L2I/J.F" ,:YA!
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M2\.-6P?;4/FC$MBF]SE8;@_J :5N6<?O%AJ^QE\60@:Q,M% #F-EL#%]A)I
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MZ0_/T%^3(V2<*C*?@<B&]/M#-1:7F[],EI3<#4$WTYZY=T0"[99^GQ<O7.M
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MQBVO<U;!HY(ZYZ]TK"JZ5IM6'49U+ZNP_J_+N;JY">S?6)JAB$*8)PA(3$.
M:(@ (9*#4,*8"1[)%%I5S# :=6I+?R.T+BZU*_;_W6:]N!;2,)L$,YKP#NW
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M?%EK-ZIG/;*Z9.:# 1Z\(I6'"GQ"LHBRPV@D*TZT2)IYCH;U0-)Q=+(QF_L
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MGRV9W8'O]=MX.IM?S37!Q7+DF4DF) ?!UB)+K,-NA%#@G,HN.4V'X+G&O)N
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M9V=A/!UE*9Q+#('7ABS*JP)!J)IT;H53F3'EFMO4CQ'2"6:V%_1]\VAKKG<
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M!5?GP2@17"H<A&75,W >?,@<B%=:292!;O$&X+E9<9@'C^'@LR&O._#"=F]
MUL#K(7WZ8L2BC+Q$"Z$4K&HYDEJV'@KZ4HH7(K#6KW&ON+VU,&_^$1V!WK'6
MP3'\.)\EQ+RH)59OQU]QL1PO5_7;;\X7M*?% A<C;G+6I*@@NYKKX2OKK>.
M+#'#,Q?1M6X"L099?^_9ZAM"ZF&_\*;R[0"RERRJ%:]5!N]GB\5(RQASX@I(
M%W!0B0EP(2!XEX7/V1>O6C=N>(2,O_=LP3:0W%9^+X>@OX#@%#_5-A2GS9#X
M 9?[8?&9SMC7<<;\YOOO"\R'T^L-7O98&=,9<UBXM<Z"+ZQN,$>(4M76H;Z.
M$Q=*ZO:C_-:E[N\]3:@-;G<D[6WAW.:9E39&S*Z_U8D27\-D51)(&Y[/O]/>
M:LL4LL&"2*NF;CX*4;M"1@C9*2B.R22$1X^M#8&U"/M[3P1H@]_V,NXS#O'X
M/B_%,M(\>>%\@5"[82B7'03#-42>.$]:<QWN9<6]*"3Q[.)_[T\VV^'T540Z
M-&17K^>K2^*B: =I_0_XQ^%B<4[W!J&L6*LT,(81%*=S%[(A+C)I? B1"UP/
MG,\N\_<>,&@ PW9BZL!A>G\K _'ZP3U\&Y^=G[V9S>>S/^IS?/A"?[/\/B+R
MA;"E$*CJ)'==&P5)GD'S7(HJ6"QOW?OB)?2MA5W[CXK=G4N\ S3?O2%H=[AW
M5OO^C)0N4I-A#4*84%M<D>6BF0*?9$B>'$S1O#7;4[2LA5+WCX[2)I+L )''
M6/>0ZE0/\@*G^5:[RP_G]6WFJ'R<+59,7QQ,QF?C:?WKCS@?S^JO=?;QB N)
MZ$PM>JICLA)=+C'0<2PF\H@VI^A;3\-M0/9:./?_Z#A_;7P,;N.2>?X>PP)C
M2'_[>#Y/G^GKZRJ_$;F4F3,1P8:X>JB4M!7B)S/>2*6<=R6M9^0^N\YZ[P/L
M'Q6<K275@1XF?LWK9M[BQ>^'TPLAG(9OU8Y/2(YC?4J4Z&VIN16(P9._6"3X
M[!EHKVM"F71<MWXL6).T]3#[#_^HM0M!=]KLL<Z9^G!Z='QX<+)%D\='/J7-
M:*SGB6O4U/&YR?#6<:8S5U#(. 3%C .7DZY%=>B-"SFH]JD=3Y*SO0:[_.CC
M\,=O= KGXS!9C"3MC]G:%SV&#"JO.OP(23!V(@A4S.76#6L?)63H%_<V*'BH
M3+;E>1=7W^4F_CJ;_^UPNGKU7RQ&7A<F5DDSP450QM;T0O00F8THHC6AN4O\
M."5#OXSO&#J;<[TG[+P;3\>+SYA_G<WR8F1<BJ403TJ*M LI-03N$CC!K3:U
M4-[L##MW*!GZ=7K'V-F<ZSUAAZP_0C[Y"KPVT@8>637JB@#O3 "G4M):F!A<
MZRC&70J&?@G>,59>SN7-,3);ADE;C%S/73DFL<R_XF*4E%%)90-).V)%B!("
M40 .&7V;)\RZ]:R]IZD9^G5VQ]C9COM=9*E<[^4#+D?:"Z8X-\!JKJ)*PH)7
MQ1)GN'=>HVV?\G=[_:$?47>,EI=RN)F>:>L^[YV<')R>_.7@_=MW1\<G>^\/
M]CZ\_7A\]/'@^/0_Z<N#?_O]\&.=*G0U<F)6]A8+7"[^@I-<9O,:']O"[6ZX
M>@MW?5?,:.3FD_G\!>?+[Q\G85KC3373X\NJX>!U9WIAE?">%%8H"E0,M;RN
M!#"BQB.#(.NZM7GQ0Z+:3;IY<JF+ @CM0Z#K/0,B.:-*>051D7G(@E:29R2;
MH'7+G75I&S8PT!8W3P^C:2B?#BSW)W?SYOMUES3,6#S6(ALK+2@;R#:(*H)4
MQ;&0613IU<[;#5D#-_G>"1X>5FTT%4[/>+O59BUA*N2^6"B%%U#:D_,;R,6Q
MH@1CDPRQM'8'UB"K4^VV*136A=J&<ND :N_#-%\6Q6J#6M4.Z%;65R8>D%P<
M+P M>LLU9LN;]V&]7KU3X&PJV/LY9IMQN0-\O#DGQEVD8EQ]>7CV93[[>C$(
MZ:J>FJ=B3'3@L69<,.<A9O*E3#91>+(A<G2-H;,68<.&TG>-JO:RZ0!POP7B
MZA3GWV\S['(K.5MOA%$@6>W4AZ5 3"K1'R5'YI5TKG67WF?(&3;6OFMPM9)#
M!Y!Z=SZ?KBIY:2OOQM_J5U>'@WLK# L"DK82R-8,M0ND V%=+!A1L]3:47R:
MFF$#\KL&5",I#)VP5V>UG]-GW7C.TWPR*\L_B,E7G8U$4-+$ '2=I]I:%,%G
MVAB/W&?N#"IW+]KZU&"#'ZXU;!Q^5Y#9!:,[T$.K[,'/LTE^Y)9&XW7RQ!QF
M0RTE-+05[0L4QJU/*6)NWT_\:7*&#=COW!IO)(>A5=%OM(4KNJ7GPF&)8'A4
MH)2,X)(R8.A>+E(9H>^W8GU"Y]SZT&'KAW:J7#9E70=:Y$F^O+_.%\W>I5)+
M.T42=4><0S#. )>^2)&D4++U,*8?4S7P7+E!0Y&;B:9GL%UD5RBC/?H@ 47M
MU.84[49Q"8+K0DZGT-;NH-O1,Q1U&D;:4/[KPNOEPN@ 6GLIG9^=KZI[WB(1
MD<8K.='7$[R<P[UW-ILO+V=T/[GYD=!)VDRJ7]86?HJE "[; C)F3[Z#D*)Y
MB4(KVCN-3[6!ZR "'K[AT<J^>'(SA],3G'\=)QQ%A99I8T&$^A#!Z"N?8P9K
M47%+E@OC?BV+[<=K=1JIV@YFN^!S!QF ^[/I104D26>5)OV)Q+6XT/!9,ZL\
M#U"T#J "DV2;.#H70J68HHSDH336=,^0TVFXJHWR:B6&#B[:)SFUREOC67!A
M$FAIJ@>5$WA)OVB!*F#4,836E^=S]'0:S]JQ_?92072@IFZRW=Y=9+M]F"T_
MAOGRJ-RI<=P_GU?&CU 9XRVYUTPB'9D8Z0JW@0'G2908H]+8.EOA911V&O%J
M9(GM3EB=EH*NF[[Y(<QKM>W7U\A<?;#6:^:I/K_15\M*3=85ZW($;76N5<8%
M(JL/B84;9J*(D;_:=?/J6:DE*AZ804@I5[N!7)B0> $A47*OBW2Z=5CN[R4K
M]26XV3@K]27RZ<"N.SF/"_P_YT3^P=?+L/C%N/F@#$\H02H5R>&1'J+3!FQA
MI<3BL[_?,V1[F#U.RD^2??HBN=\'5P,A](FERR>64 QW/'+(=4*/BDQ#M"F2
M;1 \%ZFHTMSG?)*8@?'40M0_AL\&?.\/0%>Y9R*9Z!V#G,ER52$:8HUUH#,R
M95.H$PQW"YX>LDL;"?EYZ&S \0Y@LX;CPY4.QOM /$KD&%MF(6KB%I?.L(!!
MIN:NX]_-8^8V-UMCT0R=+/&#]EU,(_/:91!":E#%(W@N%1C/:(M%VIS7B\:W
M:+0V8)CA12)]07NTE_"W*ZB<XOSLJ*S^.#*(41I=(.4:@T%IP)7$0:(I6KL4
M?8XO!\FM%;I_#VP#CTUYVA4PCG&*?X1)W<N(FY"MEH6N64%L89Q!Q#J+.4M%
M_JDQ[O[H]'6 <6N%[E_PV@!C4YYV!8R]Z?0\3&@KRX_A^X7R$S;77%0('BTH
M+1-X)AEH6PCFV980UTL(?GZ=[A_DVH!D._YV"I6K-HW$HQR39[4@T:\&-4MP
MM3XL<U<S'7D.2FV#E:N%NG]I:PV6C3C<%5I^"]/P:65.O4,\FMX^ 89@+A-M
M0C&Z0%7" E%*#\9END6EYBJL-WEXS06[?RYK@YY&'.\*13>CN5;##D>:.V_)
MT (?'>TF) VA)$$NH_$B:);S_4+R=:!S;Y5.4\E;XV4;WG8%DLN9+M_?XI?:
M;9T81E;9[$:9CGA*WN<4(;(0Z]@!#S$6!*8UCX:74#9!S8^6'796Q*O!J"GW
M>WVAW]\__OW@[<%_?#SX<')PLO?A[='I7PZ.]W\_/C[X</K^<._-X?O#T^U:
M.;]XC28O\EMMK-5+?/A> X"+FF.;TIQPL[AY2XT./4]D^NA:O>L5@C.ROE<D
MPJ<QQ>36+SK/D-,@C7Q^CIG.3YB/<7&5PT+WL1892=_Z4MM\" F!>P]9*!^<
M#E:IUAU9'Z=DX(A?(QP\DMN]+=<WUDM?<1YG[8H0ZC[>S*;GBUO;\,9PIA74
M\M++N8ZB"-!D\@6C=72\=57XHX0,' [<+7:VX'D'#U<W!X"V,#L[&R\6));K
MS7"%+HO:9M9DLOMD@6"B!HU2,XT^E^99M<\2-'#X<.=*:%L9=  H,B[S>5K^
MM>;I39??+QFU/PFTJ3+&?+4M&Q YKW%0[DLU_1QXK1S(K&WA,D?%6Q>*KTG:
MP.'''8%L%W+I &Z79^=PNCB?U\$UU[F_D>>4H@?O14UFL727LU! :D5V=?16
MI-:=G)X@9>  Y6YUUE9\[P<^=#@*KK1NF+S#F\M<1Q.<R!:R(K6K<JBA^2C
M1<^S2<)(W-']]P1% \<K=PNF%E+H %/[L^F*)7\=+S_OGR^6LS.<OQ^'N)K(
M>K4GXTJQ3B1 C[55D* 3XYB%%(WQIC"9E6B,K'7H&CB^N2-\-9?(T#'._SD;
M7_010G(BPX3X1I\^N=[22/ 48QVA:GTR-4NEEM#G.AU=F& $CP'OW7Y/1#5_
ML-# <<S&<&G.VJ%A\CM=S/-E&$]/P[?K::.WMB*T]9*NZ4#@!E7MO4#^!*#*
M+EGTY*FNEROV_#K##HS="4@:,K:#"VOE>-9W@&]IO*@#%2]Y=NV!RA*\5P'(
M_!>U:(6NWIH"%X*4BG ?DV@]'OX') T\YW57]U1+00RM>XZ6GW%^:=@=?/N"
MT\5J:U>'Y%:PU7$I7<X%(BKBF%4)HD4-"66P1'GRS*REAM9><N"1JSM12;OA
M]] HNMS0K5W0GE9;?61CW >MHLC@A" ++B7B'>8 41+S,&F3PWJ]XUZRZGI8
M^FF"V[OE>J<3@_:/#]X>GN[]>GQPT*J8^D<?V>*%]D5D-WJ0?8MQ^<C\*::4
M41CK@P?7H)!+" 0O"();R25'9*U?FAZG9%M;J'[JX:IERDWU23#),%\BQ$B&
MOF*:P!UE!%VB9H6EX&SK6;R/D#'L VP#N=^W=K9E=0>6\_O9]!-]VEG=RG4=
M9485O,T(R;&J=H,&QVE+W@2FN+#6-C>7'Z-C>+QL)=S[O6ZWY72':+DLGM3H
MG NI /U.=W4RH8Y_U<!<],'1Y2KNM]ENCI<>RI*WE_ /(+,!NWL S7B*1V6?
M%AY?U<9ZU(673.>HU%FP05N(REIR [6E+7!=1.OQ$0^IZ LLF\CV/ERV8W0'
M4+FK<U?G1RJ=?,RIYC"%.LYS99P[,-$E3#Q9;UOGR#VD8MCTG]8WT99<[@XG
M'\+9=1MR453D*D,1EO9AN( HC ,?N<@Z:TGG8:=HN:&E)^OEY3)^%C(;,GSH
M4,R%9KRNA+Y4D85IAIX<_Z+1@W*.0>16@%.<ON&SS7:]_/E'/[XG%&PJMEE3
M'G:@/BXV\2ZDU6/'ZG $);S)F8-;#5+2H1 OZK0)*9QE2635O#_*0RJ&30YL
M?<ULR>7N<'+5*0:=3W7D5M22L)X\8=VI C*%XJ5!CZIU+.4Q.H95+-O*]EFH
M;,#H#L"R*A6J#=;CE5;$[ M:02:WT#6T9"79W>0)1J45<\X*&9N_.MXGHB>8
M;"+7^^^+6S&Y Y0<X]?9Y.MX^NDN:RXWHV2M)?,&9#;DKCEBDI,V =,Y,N4#
M)U^P,6*>)6A8OZ<Y>MHQ?VA3]NY=O3_[BM,P72Y6BIC747U>9.#6$X>R4Q"J
M,9:X(R.-=+&-82V#]IE%ALTP;V6I-&5EIY"X/#8E%,>9<$2_(8-?ZQJ&# 82
MR\$SD8+"K4 QI%'25HQK8&,#GO:)CM.:^?X9CZ97<QPS!J&\\&!2I%.D4('G
MBGZ)65F,1C/#MH#)_?7ZP\LFHOTQ8K;B<]?0.?UC=KDE9I.0RB3PJ=1#)NL5
MG>B/-KH4,D/'Q?;0N5YO&--D,.ALQN>^H4,HN#H/B-(+@:P^=M1AGY@A&$OG
M@07EE4@RW.]&OQ%X;E8<)M0R''PVY'4''M._A_FX6GC'87GQHLKHQO;(+6!<
MU??Q#(YN<C#:8186T9C6K\WW:1BV(JYUH&XK#G>&D"LO45M9G$Q@Z]Q%A:0I
M8] )>'#*&NY<P=;%20^I&#;VLIU4GX'(!BP>^A[:R__[?'$Q4_#L,H1T]!7G
MT_&GS\MW8]*3:3S]5/=V<O3N^%)-DB+,UM$YTDFEFH J(3)%6C-:)9WD4K/U
M6LQNL'@_R-E$V+-7Y/S0R+JKBS_.\<M%5[J/.!_/\D4&4&)2L&)!>EN'9@9.
MJID)*.2#*AVL+VLF=?]XK6&+:W<8EMF:L7WCY/*411^\QF+ E+JA)"RX(@5X
M:86U+AN!+9#26:QF>]FNCYL-&-TW<FZ%%*I"+J) 2KI.L# >O!$9-&/H/3,L
ML_4J9M=<L%O\;"+C]1&T&</[!M%M[S!A5C[;!.AJW\15RTP6R%347!(WM=WL
M]>"9);N)Y+PND#9E>N=0NHY3<683B\P#][P^I\D"T4L)":VRVA2=PB:AY"<7
M[":B\\HPVHCA?8&H.@?D"ZQFS]^8 %Z&0+Z%!B[)2U66=A9XG3@OI'3!8^!Y
MO<2\-18;MFO(#@WG[5G;.52NPJ980@X*(6M.&K2.YPU1&I J.\,2QFB:@*4S
MV[F!>%^ G0UXW3EZ;JPYI@S#&! \G3!07KIJS7%(A1G,A>N<U@OWK+MBOQC:
M1,PO0-%F/.\<2#?7L"9&E5021!4"J(R9;#GMP:C"9/(RX_V.HYL!J;^7T-<&
MTF8\[QU(M]P"&2-'KQT(I2W089$0D]7@+8]"\JQU6:^]T?IK=F-%OSJ8-N1[
M!^]?=W?V_GH$@LZ!*$4/6M=389VB;0@%-AA#GH)$T[QY]A.D#-ME;;?U<YOQ
MNP/8O+]5+GJ="AN^C<_.S][,YO/9'S51-GRAOZD-P0+3"I6%4JP'A8:\5ZTR
MV959V!1UCKYU&>9+Z.NIS&I#0#Q3S-M4.AT@[RZ_:'>X=S8[GRY'RIL<)8O@
M4LF@I/?@Z" "#Y)C$MZ&^],;&VNL&UIZ*OEM@Z@F7.\./6_"8KPX(5H".1:W
M7Z[YR*EB$8E9*=;6"TG1-:YM@NRDDSZA-'FW:'J:MIXJ_7:!KD92Z<M6/YS2
MQ^)B6??Q;C*;S<ER3/3]D0PEE(0,5/#T"TNQ)F>2^2@*%YK,BJ#*!G;Z4^OU
M5'RQ'7AVQ>3.<7-Q,"Y28RXC^:LMTCV-LFCB662FUK(%<*SF?EH;O6&AQO=;
MX.B)]7O*:MP]KEH(H;O;\/8N#TK!5+OI7>XL?,*1ESQYIC44CC50PE8]-!,P
M8:RVSA<M6I>YOXC GA*8=G$OMI1/7TKN,K9;KG9X-)U\'V7K@G=<@U.2[OIB
M)7BE&!16>QFA5=%M4A/RV%H]O> U5UY;,[<OK!S43IZ+Z]#;J"#3G&L#%?R@
M5$JU/H]0GV5PUL5@-LJ0O+=,3T&HY@C9AJ5]@>/#>8W!'I7?9M/EY\GWRRG/
MBQ$R+WBV",+6&(=.##RW#NBJEMK%(A'7:[*]UG+#MOS?,5A:L/BG ,WUJ1A%
MD[@P44 LM<TK.0Q0&]&#R2P9PX.F8](./=?K#MSF?Q@<;<;UO@!UDV;U#J\,
MM%',&KDQ ;2H?>>U%N +XR"5X:D^&N!&58J/K35P@_]=VS/;<K<OL!Q\&]>-
MC*0E^YS;4L/PF5Q'K/D,.8+'FG-#3F3"3>) EQ\_<)_^G1LP+^=A7RBX*KF]
M?IYY$Q;XVWBZ>K()DSIC\#+@;H- QIB&I$2N[\NZWK,",&C) ]JDH]X )VL3
ML!Z2?HKP\ZO)H2^LO9^EO\79M[V4ZD;>G4_SXG3V!O>^?)F,,=.75WM?C(SR
M4H@80:;:EZW4W!B)EM0JB\[H%'+:Q =?GX+UT/:SQJMW)(F^X+8WG9ZO)EI>
MW=6,.QE1(^A01Z9DGB$&MYJ@8C&HK)S9I-CH_CKK0>=G#4EOQ=6^ '(KG:K.
M/1WIZ+V4UM*U76TY;CE$%CG4$@CO-5/$J>TRU^HRZ\'CIP@7-^9I7^A8XT:^
M?GU)TLI$]AYSMA::^[I)82&E&*PPW"94NS&-7J1R?M9 \HXDT<$[V/M'\J6.
ML::,UET^R)@*G&<9JH<AR. C#U.1E@T1 O<VUOK-HNX]M>XDG^UI"M?#X4\1
MKGX%$?6I[T[_P,E77$7'/N#R&.F[YW@:YI]P^9\8YD=3'/E(5F&N[=]BL603
M:@LA%PT"(U>UF[J6FZ1XKT_!>CC[62/=.Y+$3PFWTS]FHYK7K'1)U<^-H)RH
M%J95]8%(6X..<['-]?IC"M9+J_Q9 ^([DL3/";=:4#'2(F,2,4'Q4=7,9 =>
MBSI-6O @4HP$K1T"KM*P'N1^UE#ZSJ31)^CVP^+SWC37WP[^S_GX:YC4%Z=+
MTW64LM1620_<.EUK[ 5XLE4AFJ"LS88SN8UZ>W;Q]6#VLX;GV_._+WR]Q1+.
M)\M5V"[59.7;F5HC8Q7M0 6PTM8A Q+!)?K%"RF0!R[]_;2YM7#U[*+KX>EG
M#=*WXW<'ON?^)"P61^6O=7SQ='DT/Z[=[:X>QU==[R[F38?)!/.;[Y<_M[C\
MP<7(1>]5, 62T#6_.=&Q$>1J,Z89N3I)Z_O-"[8?*;,=R>N!\Z>(Z0\AQ!XP
M.SL[FTU/EK/TMX_D ,U/2'R8_SU,SFL$Z.0SR6%4C-8.N0$3K /%B9W.90U<
M(1:I@TVF]32]-<A:#WL_Q:/ KH31 [X>.TX'WW">Q@O\.!\GO/[+ZS/$1S';
ME+UBI/C1UA>02 :JUB"##"&A0)F:CV';A-#U,/A3O#R\GL Z0.75!LB$O=C!
MT?ERL0S3/)Y^JN\MHUR$BDPRJ#W2:W=] 3$J#M%9[;R((38?-_LCFM;#VD_Q
M(K$3,70 J[>7RUYT-,;]V6*Y^'4^6Y!5@(C1N'+114)QZVDC/D+6LF#D683<
M>M+UD\2L!Z2?ZDFA#>,[0-#>V6R^'/_72AI'Y;HS]FI#HV*1[,<2@.5<^R1%
M5_N1"& !@ZEU:27ZQB!ZCI[U</13/!DT9W_G4"*%^W:\6*4J+49"%$WJM:9:
MLECK_CG0E:U!^Y)8$/0_AZ\(J]NTK5<?_U,\$^Q4+,W@]B]_?L!IVO;?5G^U
M^IOZKXZQ_%)___WX\/KS:VSG#/,XA<D_I=G9Q:?O'Q^\/3S=^_7XX."W@P^G
M)^DSYO,)&9#O9Q<7?&7P6UR&\61Q=RN+\=F7R0^+O5[T^7^^V<3][5TN<P<[
MC3>$M1@B8_[3]F6^%2*3V>)\CGN1L!G2LC8.CE$'!)ND!A6#@9"%@?];WI4U
MM;4\]_=\ETYF7UY2A3%V2*[!!=R;Y$DU*U8%)$<2OB:?/CV26,PJZ<SA#/Z_
M4 ;)Y_3RFY[NGIYN)C7%OUBM6>V=X6E*ZEYC7O5H\H';4,(*XU-A+GDP%CU!
M98.B" 4O:6W[] 09P[<6ZJCWEV\D;R_J!K:XLNH6ZU5WAO]GV?4T6&X<\TBT
M*$4C9<B-,T% 4%;HK(BUL7I)SQ-T#(^73LI]6+/35=(-HF7=29 GHYQG#A=-
M5!@FI'+(X#@H3[EG.@M+2<]X:6%.5'<-OP*9'<3= FCN%:NMVT(:Z06G@@$G
MJ5P720P,Q<5$HZ.*B4R%K+T?/::B+;#LHML7J@)W$'0#4'E0U5_6#\:'3K/,
M(0>E00A3RLI40OF@T<T\,&/Z\,M^I:*E%G;==Z*.4FX.)T?N\F;Y:)$3M98
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MTS?12V.(6^>,*$??-&H"G@E;#C<#.%QXH(6PF@M',]DH1[HCLEJX7]^7OE^
MU0[";P ^^]/9]^D,F;CO3:R3A1))IMXJH%J4;#,K/F408)5RB07NS<,1A16Z
MHC]+3CN VD73C_J@UQ%[ PAZ/@ *GNB ZP<8RVBP2708B6!,(JD(7 2A\L-R
MI7^L'&V7#:V.U%N S_1'*G4TAY.'+)5@Y],JV!DY:W1*GH&)7(,P%&-IKA)D
MJLO].D6XJMVM?"/"VO*3=@3!0VA5UT@+,'O RJAT%/!HI)%@CM;;<S2PV02P
M*3"TX$K84+LIWD,:!@9/?36_8J.VDOG.F/F>9N-I/%W@3ETGC9I*WFUZF?Z8
MSN=[BU4ZN-COL^G3T? H<B4#5PHBR:GTT4&9D1(4"T7*^0-ULO:^MS61 ^^'
MO6.O7ZWM#,X?:>:G?9DT&9A@F1H0*O(R:=. 5]&"\LPY0H*R6;=@TOK+Q;^]
M2=M&YAU-VL$D]I9Q/]@[.3H\^GSZQ_'IZ=>#D]-_VSLYZ)!,?^EQ-?+D&Y-;
M*05^X&9E=/?\9D;577MJ+UBT-D 4B"#!6"J=M0@DYH3/,6K!:]?:/T=+5W-R
MU^I];[(8Q_'%52F%OIL'=_ S7%RA*,OAT_[T\OO58MWA_R%!ZP(4IHD)) ,1
M.8#0EH!)V@-/99*2#S*XVM?TZW(PK'=6!7$/K=> *FX@!.C(\X?KIQ^P*LP4
M-DHF.5CG<!M(EH)5P4/4/J!1-$953Y7UR,ZPT!\2I0]'F30"F697S[UFI)PJ
M$4J+-:U0V"))#48:77HEN$"3*T2]R1)HI<=O,^#9"-0[:K(!9!Z@1SJ]3FDY
M5?3X>Y'F.I.>*<\ZLP#<EQOIT6FP-"E(4D6768Y2U*[B?):8%K&XJ\ZG?2B@
M 22MIS7>-.<W.@J/*XN9&$$0Z<"ITAW96Z>2E-;YGB9D;H&8WE(TO2)F=T$W
M@)*.=OTN28]"XL%;"4PZ!<(8"]8(-.+,4&J9<#+5/J>O1?NPV/Q]/,3=P-#
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M#Y;4;YOT.Q[O;H65"L>[VRBN_YN2ZP_*#^_FZ5__Z?\!4$L! A0#%     @
MR7BK5@UGRVI2"   D"H  !D              ( !     &$R,#(S<3$Q,"UK
M97AH:6)I=#,Q,2YH=&U02P$"% ,4    " #)>*M6?B#QGU (  " *@  &0
M            @ &)"   83(P,C-Q,3$P+6ME>&AI8FET,S$R+FAT;5!+ 0(4
M Q0    ( ,EXJU;2VS5L[P0  '\6   9              "  1 1  !A,C R
M,W$Q,3 M:V5X:&EB:70S,C(N:'1M4$L! A0#%     @ R7BK5DUT($3Z!
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M,#(S,#,S,5]C86PN>&UL4$L! A0#%     @ R7BK5G?WKUC'-@  =RH" !4
M             ( !]Z\! &%P>7@M,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( ,EXJU9LMD@@9A$! $P\ 0 4              "  ?'F 0!A<'EX+3(P
M,C,P,S,Q7V<Q+FIP9U!+ 0(4 Q0    ( ,EXJU9T)GJLT+,  /]I!P 5
M          "  8GX @!A<'EX+3(P,C,P,S,Q7VQA8BYX;6Q02P$"% ,4
M" #)>*M649R9[PIK   )D00 %0              @ &,K , 87!Y>"TR,#(S
B,#,S,5]P<F4N>&UL4$L%!@     +  L Z (  ,D7!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
